[
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 172 cm,Body weight: 68.6 kg,BMI: 23.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 17.81,Albumin: 4.1 g/dL,Lymphocyte: 3.2,Neutrophil: 7.93,LDH level: 7155.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK1308,SNV mutations: ARAF,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 162.3 cm,Body weight: 62.8 kg,BMI: 23.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 4.39,Albumin: 3.4 g/dL,Lymphocyte: 0.83,Neutrophil: 2.96,LDH level: 283.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 171.2 cm,Body weight: 54.3 kg,BMI: 18.53,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.73,Albumin: 2.8 g/dL,Lymphocyte: 0.8,Neutrophil: 10.14,LDH level: 235.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK12(gain),CDKN2B(loss),EGFR(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 175 cm,Body weight: 70 kg,BMI: 22.92,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 7.23,Albumin: 4.0 g/dL,Lymphocyte: 0.67,Neutrophil: 5.46,LDH level: 277.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID5B,KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 162 cm,Body weight: 58 kg,BMI: 22.13,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.04,Albumin: 3.3 g/dL,Lymphocyte: 0.28,Neutrophil: 4.89,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: GATA4,NF1,PTEN,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF10(gain),FGFR1(gain),JAK2(loss),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 153.8 cm,Body weight: 49 kg,BMI: 20.71,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.9,Albumin: 4.2 g/dL,Lymphocyte: 3.43,Neutrophil: 5.63,LDH level: 164.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,NOTCH2,TP53,CNV alterations: EGFR(gain),FGF10(gain),RB1(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 169.7 cm,Body weight: 80.7 kg,BMI: 28.02,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 6.49,Albumin: 3.5 g/dL,Lymphocyte: 1.37,Neutrophil: 4.15,LDH level: 688.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: BRCA1(gain),CCND3(gain),ERBB2(gain),FGF10(gain),FGF14(gain),LAMP1(gain),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 156 cm,Body weight: 50 kg,BMI: 20.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 40%,PD-L1 (SP263): 70%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: APC,EGFR,KMT2A,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 171 cm,Body weight: 61 kg,BMI: 20.98,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 10.94,Albumin: 4.4 g/dL,Lymphocyte: 2.35,Neutrophil: 7.58,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: LATS1,TP53,CNV alterations: ERCC1(gain),ERCC2(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 171.5 cm,Body weight: 63.5 kg,BMI: 21.59,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 25%,WBC: 15.53,Albumin: 3.5 g/dL,Lymphocyte: 1.71,Neutrophil: 11.73,LDH level: 268.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK3475-C18_MK3475 SC+Paclitaxel/Carboplatin,SNV mutations: NKX2-1,RIT1,TP53,CNV alterations: AKT1(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),MYC(gain),NRG1(loss),PIK3CA(gain),PIK3CB(gain),PPP2R2A(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 153 cm,Body weight: 53.2 kg,BMI: 22.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.69,Albumin: 4.3 g/dL,Lymphocyte: 1.81,Neutrophil: 3.14,LDH level: 314.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Dostarlimab or Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 166.4 cm,Body weight: 74.3 kg,BMI: 26.83,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 5.99,Albumin: 3.5 g/dL,Lymphocyte: 1.04,Neutrophil: 4.18,LDH level: 208.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRIP1,FAT1,KRAS,MED12,CNV alterations: AKT2(gain),CDK4(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGFR1(gain),FRS2(gain),GLI1(gain),MDM2(gain),MYC(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 153 cm,Body weight: 51 kg,BMI: 21.76,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 9.16,Albumin: 3.7 g/dL,Lymphocyte: 0.36,Neutrophil: 8.25,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 171 cm,Body weight: 70 kg,BMI: 23.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.23,Albumin: 4.1 g/dL,Lymphocyte: 2.29,Neutrophil: 3.21,LDH level: 282.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CDK6(gain),EGFR(gain),ERBB2(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 149 cm,Body weight: 52 kg,BMI: 23.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.69,Albumin: 3.9 g/dL,Lymphocyte: 1.85,Neutrophil: 6.5,LDH level: 272.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 152 cm,Body weight: 56 kg,BMI: 24.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 9.82,Albumin: 3.9 g/dL,Lymphocyte: 1.0,Neutrophil: 7.7,LDH level: 392.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,NOTCH4,TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 166 cm,Body weight: 67 kg,BMI: 24.42,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Non-squamous carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.67,Albumin: 3.4 g/dL,Lymphocyte: 1.16,Neutrophil: 3.73,LDH level: 199.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FAT1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 165.9 cm,Body weight: 71.5 kg,BMI: 25.98,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.43,Albumin: 4.1 g/dL,Lymphocyte: 1.71,Neutrophil: 3.11,LDH level: 214.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 182.8 cm,Body weight: 93.8 kg,BMI: 28.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: 100%,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 8.19,Albumin: 4.4 g/dL,Lymphocyte: 2.74,Neutrophil: 4.56,LDH level: 219.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: SETD2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 165.8 cm,Body weight: 58.3 kg,BMI: 21.21,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 80%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.17,Albumin: 4.3 g/dL,Lymphocyte: 0.8,Neutrophil: 7.78,LDH level: 201.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: INPP4B,MET,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 172 cm,Body weight: 65 kg,BMI: 21.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.79,Albumin: 4.0 g/dL,Lymphocyte: 1.01,Neutrophil: 4.01,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MYC,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 168 cm,Body weight: 62.5 kg,BMI: 22.14,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 5.87,Albumin: 4.4 g/dL,Lymphocyte: 0.87,Neutrophil: 4.32,LDH level: 510.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: DNMT3A,ERBB2,GRIN2A,RB1,CNV alterations: CCNE1(gain),FOXA1(gain),NFKBIA(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 172.9 cm,Body weight: 91.8 kg,BMI: 30.71,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 6.75,Albumin: 4.3 g/dL,Lymphocyte: 2.56,Neutrophil: 3.42,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: ARID1A,NOTCH4,RB1,TP53,CNV alterations: MYCL(gain),RET(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 167.6 cm,Body weight: 55 kg,BMI: 19.58,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 16.31,Albumin: 2.5 g/dL,Lymphocyte: 1.19,Neutrophil: 13.77,LDH level: 270.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CREBBP,TP53,CNV alterations: MYC(gain),SOX2(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 153.8 cm,Body weight: 57 kg,BMI: 24.10,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.0,Albumin: 4.2 g/dL,Lymphocyte: 1.37,Neutrophil: 4.29,LDH level: 335.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 174.1 cm,Body weight: 66.8 kg,BMI: 22.04,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 8.08,Albumin: 3.3 g/dL,Lymphocyte: 0.53,Neutrophil: 7.29,LDH level: 236.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 169 cm,Body weight: 75 kg,BMI: 26.23,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 5%,WBC: 9.33,Albumin: 4.5 g/dL,Lymphocyte: 2.84,Neutrophil: 5.48,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ARID1A,PTEN,TP53,CNV alterations: CHEK2(gain),FGFR1(gain),MYCL(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 41 years old,Sex: M,Height: 172.2 cm,Body weight: 70.3 kg,BMI: 23.71,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 15.14,Albumin: 3.7 g/dL,Lymphocyte: 1.27,Neutrophil: 12.99,LDH level: 292.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TET2,CNV alterations: FGF14(gain),Fusion genes: ALK,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 154.2 cm,Body weight: 65 kg,BMI: 27.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 6.06,Albumin: 4.0 g/dL,Lymphocyte: 2.02,Neutrophil: 3.35,LDH level: 165.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.23,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 15.7,Albumin: 3.6 g/dL,Lymphocyte: 2.73,Neutrophil: 10.61,LDH level: 256.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NFE2L2,TP53,CNV alterations: BRCA2(gain),LAMP1(gain),PIK3CA(gain),PIK3CB(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 85%,WBC: 9.92,Albumin: 4.3 g/dL,Lymphocyte: 1.26,Neutrophil: 7.41,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NF2,SMARCA4,TP53,CNV alterations: CCND3(gain),FGFR1(gain),MDM2(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 10.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 163 cm,Body weight: 65 kg,BMI: 24.70,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.82,Albumin: 4.4 g/dL,Lymphocyte: 1.66,Neutrophil: 7.26,LDH level: 151.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ATM,BRAF,TGFBR2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 176 cm,Body weight: 71 kg,BMI: 22.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 13.49,Albumin: 4.3 g/dL,Lymphocyte: 3.06,Neutrophil: 9.08,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,KRAS,LZTR1,RB1,TP53,CNV alterations: FOXA1(gain),MYCN(gain),NFKBIA(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 166.1 cm,Body weight: 55.9 kg,BMI: 20.26,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 10.45,Albumin: 4.5 g/dL,Lymphocyte: 2.45,Neutrophil: 6.47,LDH level: 163.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: KRAS,TP53,CNV alterations: FGF23(gain),FGF6(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166 cm,Body weight: 78 kg,BMI: 28.31,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 20%,WBC: 8.73,Albumin: 4.7 g/dL,Lymphocyte: 2.53,Neutrophil: 5.14,LDH level: 179.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,STK11,TP53,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 35 years old,Sex: F,Height: 155.7 cm,Body weight: 67.1 kg,BMI: 27.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,PD-L1 group: 0%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib -> Gefitinib,SNV mutations: EGFR,MYOD1,NKX2-1,TP53,CNV alterations: AKT1(gain),BRAF(gain),CCND1(gain),CDK6(gain),EGFR(gain),ETV1(gain),EZH2(gain),FGF19(gain),FOXA1(gain),MET(gain),NKX2-1(gain),RB1(loss),RHEB(gain),RICTOR(gain),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 155.3 cm,Body weight: 73.9 kg,BMI: 30.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 7.24,Albumin: 4.5 g/dL,Lymphocyte: 2.76,Neutrophil: 3.97,LDH level: 294.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Mobocertinib,SNV mutations: EGFR,FUBP1,IDH1,MYCN,CNV alterations: AR(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 177 cm,Body weight: 73 kg,BMI: 23.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.01,Albumin: 4.3 g/dL,Lymphocyte: 2.06,Neutrophil: 4.12,LDH level: 135.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,BRIP1,TP53,CNV alterations: EGFR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 155 cm,Body weight: 45 kg,BMI: 18.73,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 158 cm,Body weight: 61 kg,BMI: 24.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 4.94,Albumin: 4.4 g/dL,Lymphocyte: 3.07,Neutrophil: 1.37,LDH level: 154.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: FANCI,FOXL2,MSH2,NOTCH1,NOTCH2,PALB2,PTPN11,RAD51,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 162.8 cm,Body weight: 58.2 kg,BMI: 21.96,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.87,Albumin: 4.8 g/dL,Lymphocyte: 1.57,Neutrophil: 4.65,LDH level: 279.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CREBBP,KEAP1,LRP1B,CNV alterations: CCND1(gain),CEBPA(gain),FGF19(gain),Fusion genes: None,Splice variants: None,TMB: 14.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170.2 cm,Body weight: 62.7 kg,BMI: 21.64,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 11.81,Albumin: 3.3 g/dL,Lymphocyte: 1.09,Neutrophil: 9.74,LDH level: 126.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: MGA,NOTCH4,RB1,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 164 cm,Body weight: 62.3 kg,BMI: 23.16,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.29,Albumin: 4.7 g/dL,Lymphocyte: 1.48,Neutrophil: 5.95,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Ociperlimab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: DCUN1D1(gain),KLHL6(gain),SOX2(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 168.2 cm,Body weight: 65.4 kg,BMI: 23.12,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 4.7,Albumin: 4.1 g/dL,Lymphocyte: 0.84,Neutrophil: 3.36,LDH level: 142.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: GRIN2A,PTPRT,TP53,CNV alterations: AKT2(gain),CCND1(gain),CHEK2(gain),ERCC1(gain),ERCC2(gain),FGF19(gain),FGF23(gain),FGF3(gain),FGF4(gain),FGFR1(gain),KRAS(gain),PIK3CA(gain),RPS6KB1(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 154 cm,Body weight: 56 kg,BMI: 23.61,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R or L861Q,WBC: 4.06,Albumin: 4.4 g/dL,Lymphocyte: 1.09,Neutrophil: 2.49,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 36 years old,Sex: F,Height: 157 cm,Body weight: 56.7 kg,BMI: 23.00,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 99%,PD-L1 (SP263): 60%,WBC: 6.79,Albumin: 3.4 g/dL,Lymphocyte: 1.41,Neutrophil: 6.76,LDH level: 412.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab or Tislelizumab/Ociperlimab or Placebo,SNV mutations: TP53,CNV alterations: BCL2L1(gain),INPP4A(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 155.1 cm,Body weight: 50.14 kg,BMI: 20.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 8.27,Albumin: 4.7 g/dL,Lymphocyte: 0.79,Neutrophil: 7.35,LDH level: 273.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CDKN2A,EGFR,TP53,CNV alterations: AKT2(gain),BRAF(gain),CDK6(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 152 cm,Body weight: 54 kg,BMI: 23.37,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.51,Albumin: 3.7 g/dL,Lymphocyte: 1.93,Neutrophil: 5.51,LDH level: 225.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: AKT2(gain),CCND1(gain),CCND3(gain),CDK4(gain),EGFR(gain),ETV1(gain),FGF19(gain),FGF3(gain),FGF4(gain),MDM2(gain),MYC(gain),RAC1(gain),TP53(loss),Fusion genes: FGFR3,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 149.6 cm,Body weight: 53.2 kg,BMI: 23.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E18del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.22,Albumin: 4.3 g/dL,Lymphocyte: 2.56,Neutrophil: 5.4,LDH level: 421.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,SLX4,SMAD4,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 177 cm,Body weight: 68 kg,BMI: 21.81,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 18.08,Albumin: 4.7 g/dL,Lymphocyte: 4.32,Neutrophil: 11.56,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: ERBB2(gain),ERCC1(gain),ERCC2(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 160 cm,Body weight: 53 kg,BMI: 20.70,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 4.13,Albumin: 5.0 g/dL,Lymphocyte: 1.54,Neutrophil: 2.29,LDH level: 131.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: CDK4(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 158 cm,Body weight: 79.5 kg,BMI: 31.85,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 4.27,Albumin: 4.3 g/dL,Lymphocyte: 1.45,Neutrophil: 1.99,LDH level: 216.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin/Olaparib or Placebo,SNV mutations: KRAS,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 152 cm,Body weight: 44.2 kg,BMI: 19.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 85%,PD-L1 (SP263): 90%,WBC: 33.04,Albumin: 3.2 g/dL,Lymphocyte: 1.06,Neutrophil: 30.56,LDH level: 307.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,FLT3,MET,PIK3CA,TP53,CNV alterations: BRAF(gain),EGFR(gain),LAMP1(gain),MET(gain),Fusion genes: None,Splice variants: MET,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 158 cm,Body weight: 60 kg,BMI: 24.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 40%,WBC: 14.1,Albumin: 3.4 g/dL,Lymphocyte: 1.57,Neutrophil: 11.43,LDH level: 275.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRCA2,EGFR,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF3(gain),JAK2(loss),MET(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 174 cm,Body weight: 68 kg,BMI: 22.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.65,Albumin: 4.3 g/dL,Lymphocyte: 0.8,Neutrophil: 8.29,LDH level: 252.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tremelimumab/Durvalumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 153.1 cm,Body weight: 53.3 kg,BMI: 22.74,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.25,Albumin: 3.8 g/dL,Lymphocyte: 1.06,Neutrophil: 3.65,LDH level: 219.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Dabrafenib/Trametinib,SNV mutations: BRAF,CTNNB1,KDM5C,LATS1,SETD2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 150.9 cm,Body weight: 53.4 kg,BMI: 23.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.44,Albumin: 3.1 g/dL,Lymphocyte: 1.93,Neutrophil: 8.28,LDH level: 268.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 149.7 cm,Body weight: 48.3 kg,BMI: 21.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Erlotinib/Ramucirumab -> Gefitinib,SNV mutations: EGFR,LATS2,PIK3CA,SMARCA4,CNV alterations: CCND3(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 160 cm,Body weight: 54 kg,BMI: 21.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.42,Albumin: 4.0 g/dL,Lymphocyte: 1.46,Neutrophil: 5.13,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,LZTR1,TP53,CNV alterations: CDK4(gain),KRAS(gain),MDM4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 159 cm,Body weight: 56.3 kg,BMI: 22.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.44,Albumin: 3.8 g/dL,Lymphocyte: 1.48,Neutrophil: 3.71,LDH level: 366.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: AR(gain),EGFR(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 153 cm,Body weight: 72.7 kg,BMI: 31.06,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 6.89,Albumin: 4.3 g/dL,Lymphocyte: 1.52,Neutrophil: 4.29,LDH level: 179.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,TP53,CNV alterations: CCND3(gain),EGFR(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 172.2 cm,Body weight: 77.4 kg,BMI: 26.10,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,WBC: 5.48,Albumin: 4.8 g/dL,Lymphocyte: 1.39,Neutrophil: 3.54,LDH level: 667.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: AKT1(gain),BRAF(gain),BRCA1(gain),CDK4(gain),ERBB2(gain),FGF10(gain),KIT(gain),MET(gain),MYCL(gain),MYCN(loss),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 152 cm,Body weight: 46.4 kg,BMI: 20.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.85,Albumin: 4.2 g/dL,Lymphocyte: 2.01,Neutrophil: 3.06,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/BGB-A445/pemetrexed/carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 168 cm,Body weight: 57 kg,BMI: 20.29,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.82,Albumin: 4.1 g/dL,Lymphocyte: 0.9,Neutrophil: 2.14,LDH level: 191.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: AKT2(gain),ATM(gain),CHEK1(gain),ERCC1(gain),ERCC2(gain),FGF10(gain),MDM4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 153.8 cm,Body weight: 53 kg,BMI: 22.41,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,WBC: 6.67,Albumin: 4.3 g/dL,Lymphocyte: 1.35,Neutrophil: 4.73,LDH level: 177.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 164.3 cm,Body weight: 79.1 kg,BMI: 29.30,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.71,Albumin: 4.9 g/dL,Lymphocyte: 2.18,Neutrophil: 4.75,LDH level: 393.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ATR,CDKN2A,PTEN,SMARCA4,TP53,CNV alterations: CCND3(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: M,Height: 167.7 cm,Body weight: 74 kg,BMI: 26.31,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.25,Albumin: 4.3 g/dL,Lymphocyte: 1.9,Neutrophil: 4.3,LDH level: 258.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: MGA,RB1,SMAD4,CNV alterations: FGF1(loss),FGF6(loss),FGF8(loss),FGFR3(loss),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 170 cm,Body weight: 61 kg,BMI: 21.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,PD-L1 (SP263): 40%,WBC: 5.91,Albumin: 3.6 g/dL,Lymphocyte: 0.86,Neutrophil: 3.93,LDH level: 251.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ATR,BRAF,TP53,CNV alterations: BRCA1(gain),ERCC1(gain),FGF14(loss),NRG1(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 178.1 cm,Body weight: 60.3 kg,BMI: 19.01,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.69,Albumin: 4.1 g/dL,Lymphocyte: 1.49,Neutrophil: 7.04,LDH level: 180.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Pemetrexed/Carboplatin,SNV mutations: SMARCA4,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 150 cm,Body weight: 57 kg,BMI: 25.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.47,Albumin: 4.0 g/dL,Lymphocyte: 2.35,Neutrophil: 3.24,LDH level: 243.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,ERCC2,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),FGF10(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 160 cm,Body weight: 63.5 kg,BMI: 24.80,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 6.73,Albumin: 4.6 g/dL,Lymphocyte: 2.43,Neutrophil: 3.62,LDH level: 400.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 173 cm,Body weight: 80 kg,BMI: 26.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.71,Albumin: 4.0 g/dL,Lymphocyte: 0.96,Neutrophil: 8.09,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: APC,EGFR,EPCAM,CNV alterations: CD274(gain),CDKN2A(loss),CDKN2B(loss),FANCG(gain),JAK2(gain),MDM2(gain),PDCD1LG2(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 173.5 cm,Body weight: 82.7 kg,BMI: 27.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 5.78,Albumin: 4.2 g/dL,Lymphocyte: 1.64,Neutrophil: 2.83,LDH level: 154.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),PAK1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 149.1 cm,Body weight: 51.7 kg,BMI: 23.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719X,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 90%,WBC: 8.75,Albumin: 4.3 g/dL,Lymphocyte: 1.32,Neutrophil: 5.89,LDH level: 262.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: MST1,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),GATA3(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 165.6 cm,Body weight: 81.6 kg,BMI: 29.76,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.8,Albumin: 4.3 g/dL,Lymphocyte: 1.11,Neutrophil: 3.82,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: MYCL(gain),Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 168 cm,Body weight: 68.9 kg,BMI: 24.41,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 11.1,Albumin: 4.2 g/dL,LDH level: 207.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Vinorelbine/Cisplatin,SNV mutations: STK11,TP53,CNV alterations: MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 8.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 167.5 cm,Body weight: 50.9 kg,BMI: 18.14,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 7.55,Albumin: 4.2 g/dL,Lymphocyte: 2.73,Neutrophil: 3.87,LDH level: 197.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: CDKN2A,DIS3,FAT1,NOTCH1,PIK3R2,PTEN,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 163 cm,Body weight: 57 kg,BMI: 21.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 3.46,Albumin: 4.7 g/dL,Lymphocyte: 1.63,Neutrophil: 1.37,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 165.1 cm,Body weight: 67.5 kg,BMI: 24.76,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 5.99,Albumin: 4.6 g/dL,Lymphocyte: 2.29,Neutrophil: 2.58,LDH level: 153.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Placebo/Etoposide/Carboplatin/Olapairb or Placebo,SNV mutations: CDH1,PTPRD,RB1,SMO,TP53,CNV alterations: AKT2(gain),CCNE1(gain),ERCC1(gain),ERCC2(gain),FGF6(loss),FGF7(loss),FGF8(loss),FGFR1(gain),FGFR3(loss),JAK2(gain),KRAS(loss),MGA(loss),MYC(gain),MYCN(loss),NRG1(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 160 cm,Body weight: 67 kg,BMI: 26.17,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 7.64,Albumin: 4.5 g/dL,Lymphocyte: 2.33,Neutrophil: 4.55,LDH level: 213.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: EPHA3,PTEN,TET2,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 160 cm,Body weight: 57 kg,BMI: 22.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 9.19,Albumin: 3.6 g/dL,Lymphocyte: 1.96,Neutrophil: 6.18,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,EP300,CNV alterations: BRAF(gain),CDK4(gain),CHEK1(loss),EGFR(gain),ERBB3(gain),FGF6(loss),JAK2(loss),MDM2(gain),MET(gain),NRAS(loss),NRG1(loss),PIK3CB(gain),PTEN(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 154 cm,Body weight: 44 kg,BMI: 18.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 50%,WBC: 7.48,Albumin: 4.7 g/dL,Lymphocyte: 2.49,Neutrophil: 4.34,LDH level: 195.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: MYC(gain),Fusion genes: ALK,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 167.5 cm,Body weight: 73.4 kg,BMI: 26.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 6.89,Albumin: 4.4 g/dL,Lymphocyte: 2.55,Neutrophil: 3.46,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: AMG404,SNV mutations: CDKN2A,CTCF,CNV alterations: ATM(gain),BRAF(gain),CCND3(gain),CDK6(gain),CHEK1(gain),EGFR(gain),MET(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 161 cm,Body weight: 53 kg,BMI: 20.27,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <1%,PD-L1 (SP263): 1%,WBC: 8.57,Albumin: 3.8 g/dL,Lymphocyte: 2.19,Neutrophil: 4.05,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: CCND1(gain),CDKN2A(loss),CDKN2B(loss),FGF19(gain),FGF3(gain),FGF4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 163 cm,Body weight: 68 kg,BMI: 25.48,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.06,Albumin: 4.2 g/dL,Lymphocyte: 0.67,Neutrophil: 4.11,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: TP53,CNV alterations: FGF10(gain),FGF23(gain),FGF6(gain),KRAS(gain),MDM4(gain),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 17.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 173 cm,Body weight: 68 kg,BMI: 22.72,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 40%,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 4.4,Albumin: 4.6 g/dL,Lymphocyte: 1.7,Neutrophil: 1.99,LDH level: 205.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Bevacizumab/Pemetrexed/Cisplatin,SNV mutations: ERBB2,NF2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 157 cm,Body weight: 58 kg,BMI: 23.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.66,Albumin: 4.2 g/dL,Lymphocyte: 1.72,Neutrophil: 4.07,LDH level: 186.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,FAT1,TP53,CNV alterations: CHEK1(gain),EGFR(gain),MYC(gain),RET(gain),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 164.4 cm,Body weight: 52 kg,BMI: 19.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.83,Albumin: 4.5 g/dL,Lymphocyte: 1.68,Neutrophil: 2.77,LDH level: 171.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 172 cm,Body weight: 71 kg,BMI: 24.00,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 5%,WBC: 5.95,Albumin: 4.5 g/dL,Lymphocyte: 1.79,Neutrophil: 3.5,LDH level: 187.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Ociperlimab/Paclitaxel/Carboplatin,SNV mutations: BIRC3,RB1,TP53,ZFHX3,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 172 cm,Body weight: 42.8 kg,BMI: 14.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 16.26,Albumin: 2.6 g/dL,Lymphocyte: 1.13,Neutrophil: 13.93,LDH level: 570.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 161 cm,Body weight: 61.5 kg,BMI: 23.73,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.12,Albumin: 4.5 g/dL,Lymphocyte: 1.21,Neutrophil: 4.17,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 183 cm,Body weight: 75.5 kg,BMI: 22.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 13.5,Albumin: 4.0 g/dL,Lymphocyte: 2.34,Neutrophil: 8.61,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID5B,BRAF,TP53,CNV alterations: NFKBIA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 172 cm,Body weight: 84 kg,BMI: 28.39,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.52,Albumin: 4.2 g/dL,Lymphocyte: 2.0,Neutrophil: 2.52,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: DNMT3A,EGFR,CNV alterations: CCNE1(loss),CDK4(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ERBB3(gain),LAMP1(loss),MDM2(gain),MET(gain),MYCL(gain),NRG1(loss),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 158 cm,Body weight: 51 kg,BMI: 20.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.53,Albumin: 3.1 g/dL,Lymphocyte: 0.77,Neutrophil: 9.03,LDH level: 477.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: MET,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 35 years old,Sex: F,Height: 161 cm,Body weight: 60 kg,BMI: 23.15,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.1,Albumin: 4.2 g/dL,Lymphocyte: 1.47,Neutrophil: 3.9,LDH level: 127.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),EGFR(gain),FGFR1(loss),JAK2(gain),MDM4(gain),NRG1(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 178 cm,Body weight: 74 kg,BMI: 23.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 20.28,Albumin: 3.8 g/dL,Lymphocyte: 1.15,Neutrophil: 18.78,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID1A,KIT,NFE2L2,TET2,TNFAIP3,TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 160.8 cm,Body weight: 53.9 kg,BMI: 20.85,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.65,Albumin: 3.3 g/dL,Lymphocyte: 0.87,Neutrophil: 8.12,LDH level: 134.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EP300,ERBB4,NF1,PIK3CA,TP53,CNV alterations: KAT6A(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 35.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 176 cm,Body weight: 65 kg,BMI: 20.98,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: ATRX,INPP4B,MEN1,PPP2R1A,CNV alterations: AKT2(gain),CCNE1(gain),ERCC1(gain),ERCC2(gain),FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 156 cm,Body weight: 53 kg,BMI: 21.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: 80%,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.81,Albumin: 2.6 g/dL,Lymphocyte: 0.73,Neutrophil: 5.35,LDH level: 309.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: ARID1A,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 159.8 cm,Body weight: 59.9 kg,BMI: 23.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 60%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 1%,WBC: 9.13,Albumin: 4.6 g/dL,Lymphocyte: 1.81,Neutrophil: 6.63,LDH level: 157.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 173 cm,Body weight: 72 kg,BMI: 24.06,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 6.73,Albumin: 4.1 g/dL,Lymphocyte: 1.24,Neutrophil: 4.75,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID1A,KEAP1,NOTCH1,NOTCH3,PTEN,TP53,ZFHX3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 20.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 161 cm,Body weight: 55 kg,BMI: 21.22,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.47,Albumin: 3.8 g/dL,Lymphocyte: 1.46,Neutrophil: 3.23,LDH level: 132.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ASXL1,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 171 cm,Body weight: 64 kg,BMI: 21.89,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 15.57,Albumin: 3.7 g/dL,Lymphocyte: 1.17,Neutrophil: 13.97,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ALK,CARD11,GNAS,NOTCH1,ROS1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 174 cm,Body weight: 62 kg,BMI: 20.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 80%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ALK,ERCC4,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGFR4(gain),FRS2(gain),MDM2(gain),Fusion genes: ALK,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 160 cm,Body weight: 45.4 kg,BMI: 17.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,WBC: 5.74,Albumin: 4.4 g/dL,Lymphocyte: 1.63,Neutrophil: 3.07,LDH level: 282.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 172 cm,Body weight: 88 kg,BMI: 29.81,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.56,Albumin: 4.6 g/dL,Lymphocyte: 1.69,Neutrophil: 5.91,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ASXL1,BRCA2,CDKN2A,PIK3CA,TET2,TP53,CNV alterations: EGFR(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 174.1 cm,Body weight: 59 kg,BMI: 19.47,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 56.59,Albumin: 2.0 g/dL,Lymphocyte: 1.58,Neutrophil: 52.94,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KRAS,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 176 cm,Body weight: 71.6 kg,BMI: 23.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.46,Albumin: 4.0 g/dL,Lymphocyte: 1.55,Neutrophil: 3.89,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162.7 cm,Body weight: 69.7 kg,BMI: 26.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.31,Albumin: 3.9 g/dL,Lymphocyte: 1.2,Neutrophil: 5.37,LDH level: 196.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NKX2-1,SMAD4,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 146.7 cm,Body weight: 55.9 kg,BMI: 25.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.97,Albumin: 4.2 g/dL,Lymphocyte: 2.17,Neutrophil: 2.11,LDH level: 215.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Pemetrexed/Carboplatin,SNV mutations: BRIP1,KRAS,MAP2K4,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166 cm,Body weight: 67 kg,BMI: 24.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 12.82,Albumin: 4.7 g/dL,Lymphocyte: 2.58,Neutrophil: 8.53,LDH level: 201.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KDM6A,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166 cm,Body weight: 82 kg,BMI: 29.76,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 3.92,Albumin: 4.6 g/dL,Lymphocyte: 0.44,Neutrophil: 2.64,LDH level: 203.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,CHEK2,KMT2A,SPEN,TP53,CNV alterations: AKT2(gain),CCNE1(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 164 cm,Body weight: 69 kg,BMI: 25.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 7%,WBC: 8.59,Albumin: 4.3 g/dL,Lymphocyte: 1.88,Neutrophil: 5.86,LDH level: 225.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 169.1 cm,Body weight: 66.3 kg,BMI: 23.19,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 12.01,Albumin: 3.4 g/dL,Lymphocyte: 2.0,Neutrophil: 8.63,LDH level: 182.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ASXL1,KEAP1,TET2,TP53,CNV alterations: CDK4(gain),CDK6(gain),ERBB3(gain),GLI1(gain),KDM5A(gain),KRAS(gain),MET(gain),PPP2R2A(loss),RICTOR(gain),TGFBR2(loss),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 155 cm,Body weight: 47 kg,BMI: 19.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 6.85,Albumin: 4.4 g/dL,Lymphocyte: 2.09,Neutrophil: 3.97,LDH level: 262.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 165 cm,Body weight: 80 kg,BMI: 29.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.28,Albumin: 4.0 g/dL,Lymphocyte: 1.57,Neutrophil: 6.82,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: KRAS,NKX2-1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 147.4 cm,Body weight: 50.7 kg,BMI: 23.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.67,Albumin: 4.2 g/dL,Lymphocyte: 1.6,Neutrophil: 4.48,LDH level: 223.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,PTEN,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 171.9 cm,Body weight: 76.9 kg,BMI: 26.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 60%,WBC: 7.87,Albumin: 4.7 g/dL,Lymphocyte: 1.95,Neutrophil: 5.14,LDH level: 226.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 153 cm,Body weight: 57 kg,BMI: 24.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <1%,PD-L1 (SP263): 5%,WBC: 6.82,Albumin: 4.3 g/dL,Lymphocyte: 2.33,Neutrophil: 3.83,LDH level: 292.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ANKRD11,APC,ARID1A,ATM,ATRX,CDKN2A,EGFR,NOTCH3,PTCH1,SETD2,STK11,TCF3,TP53,CNV alterations: AR(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 106.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 167.2 cm,Body weight: 70 kg,BMI: 25.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 80%,WBC: 9.86,Albumin: 4.9 g/dL,Lymphocyte: 2.36,Neutrophil: 5.95,LDH level: 180.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 184 cm,Body weight: 88 kg,BMI: 25.99,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.61,Albumin: 4.7 g/dL,Lymphocyte: 2.63,Neutrophil: 7.9,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 160 cm,Body weight: 70 kg,BMI: 27.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: BRCA1(gain),CDK4(gain),MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 149.5 cm,Body weight: 55.8 kg,BMI: 24.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.03,Albumin: 4.2 g/dL,Lymphocyte: 1.75,Neutrophil: 4.51,LDH level: 210.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 175.6 cm,Body weight: 80.3 kg,BMI: 26.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.84,Albumin: 4.0 g/dL,Lymphocyte: 2.4,Neutrophil: 6.18,LDH level: 250.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-0482/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,TP53,CNV alterations: BRAF(gain),BRCA1(gain),CCND3(gain),CD74(gain),CDK6(gain),CSF1R(gain),CSNK1A1(gain),EGFR(gain),FGFR1(gain),IRF4(gain),MYCL(gain),PDGFRB(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 173 cm,Body weight: 66.3 kg,BMI: 22.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 7.05,Albumin: 3.8 g/dL,Lymphocyte: 1.74,Neutrophil: 3.95,LDH level: 245.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EPHA7,KRAS,RBM10,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 159.3 cm,Body weight: 56 kg,BMI: 22.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 16.48,Albumin: 3.4 g/dL,Lymphocyte: 1.34,Neutrophil: 14.22,LDH level: 203.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 180 cm,Body weight: 74 kg,BMI: 22.79,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.34,Albumin: 4.4 g/dL,Lymphocyte: 1.3,Neutrophil: 2.55,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162.2 cm,Body weight: 64 kg,BMI: 24.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 8.37,Albumin: 3.1 g/dL,Lymphocyte: 1.33,Neutrophil: 6.11,LDH level: 197.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FAT1,CNV alterations: ALK(gain),CCNE1(gain),CD274(loss),CDKN2A(loss),CDKN2B(loss),DNMT3B(gain),MAPK1(gain),PDCD1LG2(loss),TP53(loss),ZRSR2(loss),Fusion genes: None,Splice variants: None,TMB: 14.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 164 cm,Body weight: 75 kg,BMI: 27.89,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 20%,WBC: 6.66,Albumin: 3.2 g/dL,Lymphocyte: 1.05,Neutrophil: 4.63,LDH level: 233.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,PIK3CA,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 148 cm,Body weight: 45 kg,BMI: 20.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 10.41,Albumin: 3.2 g/dL,Lymphocyte: 0.4,Neutrophil: 9.7,LDH level: 722.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: JAK2,MAP2K4,SPOP,TET2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 164.7 cm,Body weight: 61.9 kg,BMI: 22.82,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,WBC: 5.14,Albumin: 4.4 g/dL,Lymphocyte: 1.81,Neutrophil: 2.78,LDH level: 177.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Placebo/Etoposide/Carboplatin -> Pembrolizumab or Placebo/Olaparib or Placebo,SNV mutations: CDH1,TP53,CNV alterations: EGFR(gain),FGF6(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 156 cm,Body weight: 59.5 kg,BMI: 24.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 3.72,Albumin: 4.2 g/dL,Lymphocyte: 0.87,Neutrophil: 2.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel/Carboplatin,SNV mutations: TSC2,CNV alterations: None,Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 156 cm,Body weight: 54.5 kg,BMI: 22.39,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 50%,WBC: 6.68,Albumin: 4.7 g/dL,Lymphocyte: 1.44,Neutrophil: 4.45,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 161 cm,Body weight: 54.4 kg,BMI: 20.99,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 9.38,Albumin: 4.6 g/dL,Lymphocyte: 1.86,Neutrophil: 6.49,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: ARID1A,BRAF,DNMT3A,ERCC1,LRP1B,TP53,CNV alterations: CARD11(gain),PMS2(gain),RAC1(gain),STK11(loss),Fusion genes: None,Splice variants: None,TMB: 33.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 157 cm,Body weight: 56.6 kg,BMI: 22.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 90%,WBC: 5.75,Albumin: 4.0 g/dL,Lymphocyte: 1.41,Neutrophil: 3.71,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BAP1,MTOR,NF1,CNV alterations: BRCA1(gain),ERBB2(gain),ERCC1(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: F,Height: 159 cm,Body weight: 49 kg,BMI: 19.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib -> Pemetrexed/Cisplatin -> Repotrectinib,SNV mutations: BRCA2,EGFR,POLD1,TP53,CNV alterations: MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 155 cm,Body weight: 56 kg,BMI: 23.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,WBC: 5.8,Albumin: 3.5 g/dL,Lymphocyte: 1.41,Neutrophil: 3.27,LDH level: 240.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ANKRD11,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 175 cm,Body weight: 75 kg,BMI: 24.65,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 15.34,Albumin: 3.1 g/dL,Lymphocyte: 1.4,Neutrophil: 12.52,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID1A,FBXW7,TP53,CNV alterations: CCND3(gain),FGF23(gain),FGF6(gain),HIST1H3A(loss),HIST1H3C(loss),KRAS(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 173.9 cm,Body weight: 60.4 kg,BMI: 19.97,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 9.71,Albumin: 4.4 g/dL,Lymphocyte: 3.11,Neutrophil: 5.7,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: CREBBP,PMS1,TP53,CNV alterations: CCND1(gain),EPCAM(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGF7(gain),FGFR1(gain),MET(gain),MSH2(gain),MSH6(gain),PIK3CB(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 161 cm,Body weight: 50 kg,BMI: 19.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 7.03,Albumin: 4.0 g/dL,Lymphocyte: 1.61,Neutrophil: 4.18,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: M7824,SNV mutations: TET2,TP53,CNV alterations: CDK6(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 159 cm,Body weight: 57 kg,BMI: 22.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 7.72,Albumin: 3.5 g/dL,Lymphocyte: 1.75,Neutrophil: 5.19,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 162.9 cm,Body weight: 55.8 kg,BMI: 21.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.47,Albumin: 4.6 g/dL,Lymphocyte: 1.75,Neutrophil: 6.78,LDH level: 245.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib or Gefitinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: BRCA2(gain),EGFR(gain),FGF14(gain),FGF6(loss),FGF9(gain),FOXA1(gain),LAMP1(gain),MYCL(gain),NKX2-1(gain),PTEN(loss),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 166.5 cm,Body weight: 55.4 kg,BMI: 19.98,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.29,Albumin: 3.8 g/dL,Lymphocyte: 1.12,Neutrophil: 3.56,LDH level: 124.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: TP53,CNV alterations: FGF10(gain),FGFR1(gain),PRKCI(gain),TERC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 166.9 cm,Body weight: 68.5 kg,BMI: 24.59,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 12.16,Albumin: 2.9 g/dL,Lymphocyte: 0.93,Neutrophil: 10.42,LDH level: 462.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PTPRD,TP53,CNV alterations: EGFR(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: M,Height: 188 cm,Body weight: 79 kg,BMI: 22.35,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 14.06,Albumin: 2.7 g/dL,Lymphocyte: 0.76,Neutrophil: 12.25,LDH level: 348.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 160 cm,Body weight: 50 kg,BMI: 19.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.37,Albumin: 3.2 g/dL,Lymphocyte: 1.87,Neutrophil: 6.01,LDH level: 732.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: BRAF,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 161 cm,Body weight: 67 kg,BMI: 25.85,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 2%,WBC: 7.27,Albumin: 4.6 g/dL,Lymphocyte: 2.42,Neutrophil: 4.15,LDH level: 132.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: BRCA2,FAT1,GRIN2A,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),PIK3CA(gain),RAD51C(gain),RNF43(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 25.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: F,Height: 153 cm,Body weight: 55 kg,BMI: 23.53,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 30%,PD-L1 (SP263): >50%,WBC: 16.16,Albumin: 3.3 g/dL,Lymphocyte: 2.54,Neutrophil: 11.99,LDH level: 209.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: MET,TP53,CNV alterations: HIST1H3A(loss),MET(gain),Fusion genes: None,Splice variants: MET,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 163 cm,Body weight: 58.6 kg,BMI: 22.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.93,Albumin: 4.7 g/dL,Lymphocyte: 0.92,Neutrophil: 3.59,LDH level: 162.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: CDKN2A,SMO,TP53,CNV alterations: CCND1(gain),CCND3(gain),ERBB2(gain),ERCC2(gain),NKX2-1(loss),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 164 cm,Body weight: 58 kg,BMI: 21.56,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.32,Albumin: 4.1 g/dL,Lymphocyte: 2.44,Neutrophil: 3.68,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NRAS,TP53,CNV alterations: AR(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 16.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 164.7 cm,Body weight: 54.9 kg,BMI: 20.24,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 5.77,Albumin: 4.3 g/dL,Lymphocyte: 1.0,Neutrophil: 3.27,LDH level: 289.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RBM10,TET2,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 38 years old,Sex: F,Height: 157.3 cm,Body weight: 55.3 kg,BMI: 22.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 12.37,Albumin: 3.7 g/dL,Lymphocyte: 1.7,Neutrophil: 8.58,LDH level: 418.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: CTNNB1,SMAD4,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 172 cm,Body weight: 67 kg,BMI: 22.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 70%,WBC: 14.16,Albumin: 3.9 g/dL,Lymphocyte: 0.56,Neutrophil: 13.19,LDH level: 223.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ATM,KRAS,CNV alterations: FGF23(gain),FGF6(gain),KRAS(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165 cm,Body weight: 63 kg,BMI: 23.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 4.48,Albumin: 5.0 g/dL,Lymphocyte: 1.44,Neutrophil: 2.49,LDH level: 161.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,MSH6,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 159 cm,Body weight: 55 kg,BMI: 21.76,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 10%,WBC: 4.42,Albumin: 4.8 g/dL,Lymphocyte: 0.41,Neutrophil: 3.28,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 166 cm,Body weight: 52 kg,BMI: 18.87,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.38,Albumin: 4.1 g/dL,Lymphocyte: 0.97,Neutrophil: 4.64,LDH level: 101.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: CHEK1,FUBP1,CNV alterations: FGF1(gain),FGF10(gain),NKX2-1(gain),PDGFRB(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 174.4 cm,Body weight: 56.8 kg,BMI: 18.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 9.27,Albumin: 4.0 g/dL,Lymphocyte: 2.55,Neutrophil: 5.56,LDH level: 125.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-0482/Pembrolizumab,SNV mutations: ATR,B2M,NRAS,SMARCA4,TP53,CNV alterations: EGFR(gain),NRAS(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 156.7 cm,Body weight: 67.2 kg,BMI: 27.37,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 18.95,Albumin: 2.5 g/dL,Lymphocyte: 0.84,Neutrophil: 17.61,LDH level: 225.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: MSH6,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 12.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165 cm,Body weight: 64.6 kg,BMI: 23.73,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 8.23,Albumin: 3.9 g/dL,Lymphocyte: 2.94,Neutrophil: 3.79,LDH level: 243.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: DNMT3A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 159 cm,Body weight: 46 kg,BMI: 18.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.25,Albumin: 4.5 g/dL,Lymphocyte: 1.51,Neutrophil: 5.25,LDH level: 246.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,RBM10,TP53,CNV alterations: CCND2(loss),CCNE1(gain),ERBB2(gain),FOXA1(gain),NFKBIA(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 158 cm,Body weight: 55 kg,BMI: 22.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.53,Albumin: 4.1 g/dL,Lymphocyte: 1.28,Neutrophil: 4.85,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 156.4 cm,Body weight: 52.6 kg,BMI: 21.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,WBC: 7.29,Albumin: 4.7 g/dL,Lymphocyte: 2.45,Neutrophil: 4.26,LDH level: 228.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: CHEK2,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 162.7 cm,Body weight: 59.5 kg,BMI: 22.48,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.4,Albumin: 4.6 g/dL,Lymphocyte: 2.56,Neutrophil: 2.84,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-5890/Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ARID1A,CIC,NFE2L2,TET1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 150.6 cm,Body weight: 49.85 kg,BMI: 21.98,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 5.95,Albumin: 4.1 g/dL,Lymphocyte: 2.15,Neutrophil: 3.0,LDH level: 196.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: BRAF(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 2.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 163.2 cm,Body weight: 75 kg,BMI: 28.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 10%,WBC: 5.55,Albumin: 4.5 g/dL,Lymphocyte: 1.74,Neutrophil: 2.93,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,CNV alterations: CCND3(gain),EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 160.3 cm,Body weight: 54 kg,BMI: 21.01,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,WBC: 5.2,Albumin: 4.5 g/dL,Lymphocyte: 1.63,Neutrophil: 3.12,LDH level: 301.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: F,Height: 154.2 cm,Body weight: 56.8 kg,BMI: 23.89,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.06,Albumin: 3.6 g/dL,Lymphocyte: 2.44,Neutrophil: 8.12,LDH level: 192.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 171.1 cm,Body weight: 70 kg,BMI: 23.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 85%,WBC: 22.6,Albumin: 3.1 g/dL,Lymphocyte: 2.15,Neutrophil: 17.92,LDH level: 396.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib -> Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 147 cm,Body weight: 47 kg,BMI: 21.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 12.54,Albumin: 4.2 g/dL,Lymphocyte: 1.75,Neutrophil: 6.45,LDH level: 301.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: AMER1,CNV alterations: CDK4(gain),MDM2(gain),MYC(gain),Fusion genes: ALK,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 149.2 cm,Body weight: 58.9 kg,BMI: 26.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 30%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,CNV alterations: None,Fusion genes: BRAF,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 170 cm,Body weight: 60 kg,BMI: 20.76,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 10.88,Albumin: 4.7 g/dL,Lymphocyte: 2.56,Neutrophil: 7.34,LDH level: 147.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: EP300,FLCN,NOTCH1,NOTCH3,TP53,CNV alterations: None,Fusion genes: FGFR3,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 175 cm,Body weight: 70 kg,BMI: 22.86,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel/Cisplatin,SNV mutations: ARID1A,MAP2K1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 179.4 cm,Body weight: 88 kg,BMI: 27.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,E20ins,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,KRAS,MSH6,TP53,CNV alterations: BRAF(gain),BRCA2(loss),CDK4(gain),CDK6(gain),EGFR(gain),ERBB3(gain),FGF10(gain),FGF9(loss),JAK2(loss),KRAS(gain),LAMP1(loss),MDM2(gain),MET(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 162 cm,Body weight: 69 kg,BMI: 26.10,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 9.13,Albumin: 3.6 g/dL,Lymphocyte: 2.26,Neutrophil: 5.79,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDC73,EPHA7,KRAS,TP53,TSC1,CNV alterations: FGF10(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 158.8 cm,Body weight: 57.2 kg,BMI: 22.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.25,Albumin: 4.9 g/dL,Lymphocyte: 3.45,Neutrophil: 3.18,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 165.4 cm,Body weight: 77.9 kg,BMI: 28.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 163.6 cm,Body weight: 71.6 kg,BMI: 26.75,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 6.65,Albumin: 4.6 g/dL,Lymphocyte: 3.05,Neutrophil: 2.74,LDH level: 170.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Etoposide/Carboplatin,SNV mutations: NFKBIA,NOTCH1,RB1,TP53,CNV alterations: BRCA1(gain),FGFR1(gain),NRG1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 155 cm,Body weight: 57 kg,BMI: 23.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RBM10,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 166 cm,Body weight: 74.7 kg,BMI: 27.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.99,Albumin: 4.1 g/dL,Lymphocyte: 1.77,Neutrophil: 3.47,LDH level: 316.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 164 cm,Body weight: 53 kg,BMI: 19.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 10%,PD-L1 (SP263): 50%,WBC: 8.74,Albumin: 4.0 g/dL,Lymphocyte: 2.44,Neutrophil: 5.46,LDH level: 182.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 158 cm,Body weight: 58 kg,BMI: 23.23,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 6.88,Albumin: 3.7 g/dL,Lymphocyte: 2.43,Neutrophil: 3.4,LDH level: 199.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 159 cm,Body weight: 57 kg,BMI: 22.55,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,WBC: 7.46,Albumin: 4.5 g/dL,Lymphocyte: 3.05,Neutrophil: 3.72,LDH level: 253.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Etoposide/Cisplatin,SNV mutations: RB1,TET2,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 164 cm,Body weight: 57 kg,BMI: 21.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,WBC: 3.45,Albumin: 4.4 g/dL,Lymphocyte: 1.16,Neutrophil: 1.93,LDH level: 155.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: APC,EGFR,MED12,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 150 cm,Body weight: 52.3 kg,BMI: 23.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 7.53,Albumin: 4.4 g/dL,Lymphocyte: 3.7,Neutrophil: 2.79,LDH level: 191.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166.8 cm,Body weight: 62.3 kg,BMI: 22.39,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 25%,WBC: 8.76,Albumin: 3.2 g/dL,Lymphocyte: 1.43,Neutrophil: 6.07,LDH level: 86.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: RBM10,TERT,TP53,CNV alterations: CCND1(gain),CDK4(gain),CDKN2A(loss),EGFR(gain),ERBB2(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 160 cm,Body weight: 74 kg,BMI: 28.64,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,WBC: 13.24,Albumin: 4.8 g/dL,Lymphocyte: 4.36,Neutrophil: 6.89,LDH level: 222.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: NKX2-1,PIK3CA,RAF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 147 cm,Body weight: 36 kg,BMI: 16.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.16,Albumin: 4.0 g/dL,Lymphocyte: 1.32,Neutrophil: 10.97,LDH level: 141.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KRAS,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 159 cm,Body weight: 68.1 kg,BMI: 26.94,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.64,Albumin: 4.4 g/dL,Lymphocyte: 2.11,Neutrophil: 3.98,LDH level: 517.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-4830/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,PIK3R1,TP53,CNV alterations: BRCA2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 151 cm,Body weight: 64.9 kg,BMI: 28.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.11,Albumin: 4.5 g/dL,Lymphocyte: 2.3,Neutrophil: 3.92,LDH level: 200.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: BRCA2(loss),EGFR(gain),FGF10(gain),FGF14(loss),FGF23(loss),FGF6(loss),FGFR1(loss),FGFR3(loss),KRAS(gain),LAMP1(loss),MET(gain),MYCL(gain),NRG1(loss),RB1(loss),RICTOR(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 183.7 cm,Body weight: 92.8 kg,BMI: 27.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 4.78,Albumin: 4.4 g/dL,Lymphocyte: 1.4,Neutrophil: 2.81,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: ERBB2,TP53,CNV alterations: PHF6(gain),STAG2(gain),Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 172 cm,Body weight: 77 kg,BMI: 25.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 15%,WBC: 7.38,Albumin: 4.2 g/dL,Lymphocyte: 2.49,Neutrophil: 4.0,LDH level: 151.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 154.6 cm,Body weight: 43.9 kg,BMI: 18.37,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.28,Albumin: 3.3 g/dL,Lymphocyte: 1.66,Neutrophil: 6.48,LDH level: 194.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CASP8,EGFR,CNV alterations: BRAF(gain),CDK4(gain),EGFR(gain),JAK2(loss),MDM2(gain),MDM4(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 170 cm,Body weight: 66 kg,BMI: 22.89,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.94,Albumin: 3.8 g/dL,Lymphocyte: 2.21,Neutrophil: 4.61,LDH level: 265.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: EP300,FBXW7,PIK3CA,RHOA,SF3B1,SMO,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 164 cm,Body weight: 76 kg,BMI: 28.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CCND1(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 170.1 cm,Body weight: 64.4 kg,BMI: 22.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 6.71,Albumin: 4.1 g/dL,Lymphocyte: 2.77,Neutrophil: 3.07,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TET2,TP53,CNV alterations: KRAS(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 180 cm,Body weight: 73.4 kg,BMI: 22.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 95%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 166.1 cm,Body weight: 60.5 kg,BMI: 21.93,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.18,Albumin: 3.8 g/dL,Lymphocyte: 1.18,Neutrophil: 3.38,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: APC,AXIN1,CDKN1B,CDKN2C,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 38.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 169 cm,Body weight: 67 kg,BMI: 23.46,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 8.72,Albumin: 4.2 g/dL,Lymphocyte: 1.77,Neutrophil: 6.2,LDH level: 182.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Vinorebine/Cisplatin,SNV mutations: CDKN2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 165 cm,Body weight: 58 kg,BMI: 21.30,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.79,Albumin: 4.5 g/dL,Lymphocyte: 2.45,Neutrophil: 1.92,LDH level: 188.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: AKT2(gain),ALK(gain),CCND1(gain),CCND3(gain),EGFR(gain),FGF10(gain),KRAS(gain),MDM4(gain),MYCN(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 169 cm,Body weight: 69 kg,BMI: 24.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 2%,WBC: 4.56,Albumin: 4.4 g/dL,Lymphocyte: 1.64,Neutrophil: 2.19,LDH level: 270.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 154 cm,Body weight: 41.2 kg,BMI: 17.37,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 10%,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 4.81,Albumin: 4.4 g/dL,Lymphocyte: 1.52,Neutrophil: 2.6,LDH level: 238.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: ATRX,BCL10,BRAF,CDKN2A,IDH1,PTPRD,TP53,XPO1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 26.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 167 cm,Body weight: 73 kg,BMI: 26.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 5%,WBC: 9.64,Albumin: 4.4 g/dL,Lymphocyte: 1.39,Neutrophil: 7.66,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,ATM,BRAF,CDKN2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 162 cm,Body weight: 67 kg,BMI: 25.53,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.41,Albumin: 4.8 g/dL,Lymphocyte: 1.42,Neutrophil: 3.8,LDH level: 229.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: ARID1A,CDKN2A,NF1,TP53,CNV alterations: CHEK1(gain),JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 163 cm,Body weight: 57 kg,BMI: 21.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.29,Albumin: 3.7 g/dL,Lymphocyte: 1.08,Neutrophil: 7.0,LDH level: 958.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MGA,PIK3C2G,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: F,Height: 163.6 cm,Body weight: 62.7 kg,BMI: 23.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 60%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 17.74,Albumin: 4.0 g/dL,Lymphocyte: 1.68,Neutrophil: 14.79,LDH level: 305.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 169 cm,Body weight: 58 kg,BMI: 20.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 5.78,Albumin: 3.0 g/dL,Lymphocyte: 0.68,Neutrophil: 4.42,LDH level: 243.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin,SNV mutations: NOTCH4,PIK3CA,TP53,CNV alterations: None,Fusion genes: FGFR3,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 150 cm,Body weight: 54 kg,BMI: 24.00,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E18del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 4.33,Albumin: 4.3 g/dL,Lymphocyte: 1.75,Neutrophil: 2.22,LDH level: 245.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: CDK4(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 173 cm,Body weight: 64 kg,BMI: 21.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: 90%,WBC: 4.85,Albumin: 3.7 g/dL,Lymphocyte: 1.26,Neutrophil: 3.13,LDH level: 149.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: AKT2(gain),CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: F,Height: 159.7 cm,Body weight: 47.4 kg,BMI: 18.59,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 7.32,Albumin: 4.8 g/dL,Lymphocyte: 3.3,Neutrophil: 3.39,LDH level: 209.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 165 cm,Body weight: 61.2 kg,BMI: 22.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 9.93,Albumin: 4.0 g/dL,Lymphocyte: 2.05,Neutrophil: 6.94,LDH level: 474.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID2,B2M,MAX,PARP1,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 22.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 154 cm,Body weight: 67 kg,BMI: 28.25,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 10.47,Albumin: 3.2 g/dL,Lymphocyte: 2.27,Neutrophil: 7.21,LDH level: 194.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: MEN1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 175 cm,Body weight: 78 kg,BMI: 25.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.25,Albumin: 4.7 g/dL,Lymphocyte: 0.65,Neutrophil: 8.02,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: CDKN2A,TP53,CNV alterations: CCND1(gain),CCNE1(gain),CDK4(gain),EGFR(gain),FGF19(gain),FGF23(gain),FGF3(gain),FGF4(gain),FGF6(gain),KRAS(gain),PIK3CA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 170 cm,Body weight: 74 kg,BMI: 25.61,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del, L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.17,Albumin: 4.4 g/dL,Lymphocyte: 0.93,Neutrophil: 3.83,LDH level: 209.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: APC,EGFR,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 171.3 cm,Body weight: 68.5 kg,BMI: 23.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.93,Albumin: 3.7 g/dL,Lymphocyte: 1.22,Neutrophil: 6.84,LDH level: 3226.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CHEK2(loss),PTEN(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 158 cm,Body weight: 56 kg,BMI: 22.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 5.92,Albumin: 4.3 g/dL,Lymphocyte: 2.23,Neutrophil: 3.08,LDH level: 226.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: ARID2,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 160 cm,Body weight: 54.1 kg,BMI: 21.13,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 170.9 cm,Body weight: 74.9 kg,BMI: 25.64,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.72,Albumin: 3.9 g/dL,Lymphocyte: 2.34,Neutrophil: 3.54,LDH level: 239.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PIK3CA,TP53,CNV alterations: MYC(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 159.9 cm,Body weight: 52 kg,BMI: 20.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 30%,WBC: 7.72,Albumin: 3.8 g/dL,Lymphocyte: 1.45,Neutrophil: 4.95,LDH level: 265.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: BRAF,NF1,U2AF1,CNV alterations: None,Fusion genes: NOTCH1,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 162.5 cm,Body weight: 66 kg,BMI: 24.99,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 10.67,Albumin: 4.5 g/dL,Lymphocyte: 2.25,Neutrophil: 7.55,LDH level: 311.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 162 cm,Body weight: 53 kg,BMI: 20.20,Smoking history: Current smoker,Cancer stage: Mixed,Histology: combined small cell carcinoma and adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.6,Albumin: 2.1 g/dL,Lymphocyte: 2.49,Neutrophil: 8.03,LDH level: 1208.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: CDKN2A,FAT1,NFE2L2,RB1,SMARCA4,STK11,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 171.7 cm,Body weight: 66.6 kg,BMI: 22.59,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.07,Albumin: 4.4 g/dL,Lymphocyte: 2.09,Neutrophil: 6.35,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: TP53,CNV alterations: ATM(gain),CHEK1(gain),ESR1(loss),FGF5(loss),FGF8(loss),FGFR3(loss),JAK2(loss),NRAS(loss),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RET(loss),RICTOR(gain),SOX2(gain),TCF3(loss),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 145.4 cm,Body weight: 42 kg,BMI: 19.87,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.97,Albumin: 4.5 g/dL,Lymphocyte: 2.2,Neutrophil: 5.04,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 167.4 cm,Body weight: 62.9 kg,BMI: 22.45,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 8.27,Albumin: 4.2 g/dL,Lymphocyte: 2.73,Neutrophil: 4.45,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: PIK3R2,RB1,TP53,CNV alterations: BRCA2(loss),FGF1(loss),FGF14(loss),FGF2(loss),FGF5(loss),FGF9(loss),FGFR1(gain),FGFR3(loss),KIT(loss),LAMP1(loss),MDM4(gain),NRG1(loss),PDGFRA(loss),PDGFRB(loss),PIK3CA(gain),PIK3CB(gain),RAF1(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 155 cm,Body weight: 38 kg,BMI: 15.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 40%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: JAK3,MYC,ROS1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 163.2 cm,Body weight: 47.8 kg,BMI: 17.95,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 16%,WBC: 5.31,Albumin: 3.4 g/dL,Lymphocyte: 0.81,Neutrophil: 3.92,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ASXL1,MAP2K1,TP53,CNV alterations: CDK6(gain),FGF10(gain),FGFR1(gain),JAK2(loss),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 17.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 156 cm,Body weight: 55 kg,BMI: 22.60,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 80%,WBC: 4.88,Albumin: 4.5 g/dL,Lymphocyte: 0.97,Neutrophil: 3.47,LDH level: 182.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 172.6 cm,Body weight: 67.4 kg,BMI: 22.62,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 1%,PD-L1 (SP263): 95%,WBC: 6.69,Albumin: 4.6 g/dL,Lymphocyte: 1.85,Neutrophil: 4.03,LDH level: 185.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 173.3 cm,Body weight: 59.5 kg,BMI: 19.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 1%,WBC: 7.53,Albumin: 4.3 g/dL,Lymphocyte: 1.15,Neutrophil: 4.98,LDH level: 178.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,CDKN2A,DNMT3B,MAP2K1,MGA,TP53,CNV alterations: RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 21.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 159 cm,Body weight: 66 kg,BMI: 26.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 60%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.08,Albumin: 4.2 g/dL,Lymphocyte: 2.78,Neutrophil: 7.52,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: AR,KDR,PIK3CD,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 168 cm,Body weight: 72.4 kg,BMI: 25.65,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 8.17,Albumin: 3.7 g/dL,Lymphocyte: 1.47,Neutrophil: 5.97,LDH level: 186.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK7684A or Pembrolizumab,SNV mutations: ANKRD11,NF1,PIK3CA,RAD50,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 22.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.4 cm,Body weight: 61.3 kg,BMI: 22.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 149 cm,Body weight: 47 kg,BMI: 21.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.47,Albumin: 4.6 g/dL,Lymphocyte: 1.95,Neutrophil: 4.84,LDH level: 216.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 153 cm,Body weight: 61 kg,BMI: 26.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 5.02,Albumin: 4.1 g/dL,Lymphocyte: 1.82,Neutrophil: 2.68,LDH level: 219.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/MK4830,SNV mutations: None,CNV alterations: CDK4(gain),MDM2(gain),MYC(gain),RET(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 175.4 cm,Body weight: 77.3 kg,BMI: 25.13,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.92,Albumin: 4.7 g/dL,Lymphocyte: 2.33,Neutrophil: 4.95,LDH level: 209.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: MAX,TP53,CNV alterations: AR(gain),CCNE1(gain),FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: AR,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: F,Height: 169 cm,Body weight: 57 kg,BMI: 19.89,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.64,Albumin: 4.9 g/dL,Lymphocyte: 1.16,Neutrophil: 4.17,LDH level: 174.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA1,PIK3CA,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 165.5 cm,Body weight: 71.7 kg,BMI: 26.18,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 5%,WBC: 5.9,Albumin: 4.4 g/dL,Lymphocyte: 2.61,Neutrophil: 2.67,LDH level: 254.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: APC,KDM6A,NOTCH1,TET2,TP53,CNV alterations: FGF23(gain),FGFR1(gain),FGFR3(gain),KRAS(gain),MYB(gain),MYCL(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 155 cm,Body weight: 64 kg,BMI: 26.64,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 8.21,Albumin: 4.3 g/dL,Lymphocyte: 3.47,Neutrophil: 3.95,LDH level: 272.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: CDKN2A,NFE2L2,PTEN,TP53,CNV alterations: EGFR(gain),MYC(gain),PIK3CA(gain),Fusion genes: None,Splice variants: EGFR,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 168 cm,Body weight: 70.9 kg,BMI: 25.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.36,Albumin: 5.0 g/dL,Lymphocyte: 2.72,Neutrophil: 3.67,LDH level: 133.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 162.3 cm,Body weight: 71.4 kg,BMI: 27.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 10.71,Albumin: 4.1 g/dL,Lymphocyte: 1.67,Neutrophil: 8.1,LDH level: 204.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab/Oleclumab/Monalizumab/Placebo,SNV mutations: ERCC4,TP53,CNV alterations: KDM5A(gain),RAD52(gain),Fusion genes: NRG1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166.9 cm,Body weight: 63.5 kg,BMI: 22.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 4.52,Albumin: 4.3 g/dL,Lymphocyte: 1.55,Neutrophil: 2.41,LDH level: 187.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-4830/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RNF43,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 174 cm,Body weight: 65 kg,BMI: 21.30,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.07,Albumin: 3.8 g/dL,Lymphocyte: 1.31,Neutrophil: 5.01,LDH level: 230.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: FAT1,SHQ1,SMARCA4,SOX17,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 13.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 177 cm,Body weight: 69 kg,BMI: 22.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 10.33,Albumin: 3.7 g/dL,Lymphocyte: 1.4,Neutrophil: 8.34,LDH level: 185.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166.7 cm,Body weight: 61.7 kg,BMI: 22.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.04,Albumin: 4.5 g/dL,Lymphocyte: 2.09,Neutrophil: 4.94,LDH level: 145.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,FGFR4,KRAS,TP53,CNV alterations: ETV1(gain),KRAS(gain),MAP2K4(loss),MCL1(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 165.8 cm,Body weight: 61.6 kg,BMI: 22.41,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 13.29,Albumin: 3.9 g/dL,Lymphocyte: 1.29,Neutrophil: 10.91,LDH level: 172.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: ANKRD11,ARID2,FAT1,KRAS,TP53,CNV alterations: JAK2(gain),KRAS(gain),PIK3CA(gain),PIK3CB(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 18.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 165 cm,Body weight: 70 kg,BMI: 25.71,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.26,Albumin: 4.2 g/dL,Lymphocyte: 1.94,Neutrophil: 3.45,LDH level: 185.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: ATM(loss),CHEK2(loss),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 167.6 cm,Body weight: 60 kg,BMI: 21.36,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 9.53,Albumin: 3.8 g/dL,Lymphocyte: 3.08,Neutrophil: 5.45,LDH level: 636.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,GATA3,PTPRD,TP53,CNV alterations: FGF8(loss),MAPK1(gain),MYC(gain),NRAS(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 30.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 88 years old,Sex: M,Height: 161.1 cm,Body weight: 59.6 kg,BMI: 22.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.44,Albumin: 3.8 g/dL,Lymphocyte: 1.66,Neutrophil: 9.07,LDH level: 198.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CDKN2A,EGFR,PIK3CA,PTEN,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 164.5 cm,Body weight: 70.4 kg,BMI: 26.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 10.23,Albumin: 4.2 g/dL,Lymphocyte: 1.14,Neutrophil: 8.5,LDH level: 279.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: B2M,CDKN2A,KRAS,PTPRD,RBM10,SETD2,TET2,TP53,CNV alterations: CCND3(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 31.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 173 cm,Body weight: 78 kg,BMI: 26.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 7.21,Albumin: 4.6 g/dL,Lymphocyte: 2.39,Neutrophil: 4.01,LDH level: 136.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: DNMT3A,MSH3,NF1,PTPRD,RASA1,RB1,SF3B1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 166.3 cm,Body weight: 60.4 kg,BMI: 21.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.98,Albumin: 3.7 g/dL,Lymphocyte: 0.48,Neutrophil: 6.42,LDH level: 272.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BLM,RBM10,SMAD4,SMARCA4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 168 cm,Body weight: 60 kg,BMI: 21.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,WBC: 10.31,Albumin: 4.0 g/dL,Lymphocyte: 1.9,Neutrophil: 6.79,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BAP1,ERBB2,PBRM1,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 171.4 cm,Body weight: 84 kg,BMI: 28.59,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 8.72,Albumin: 3.6 g/dL,Lymphocyte: 1.55,Neutrophil: 5.98,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MST1,CNV alterations: BCL2L1(gain),BCL6(gain),CARD11(gain),CCNE1(gain),CDKN2A(loss),DDR2(gain),DNMT3B(gain),ETV1(gain),MCL1(gain),PIK3CA(gain),PIK3CB(gain),RAC1(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165 cm,Body weight: 64 kg,BMI: 23.51,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.33,Albumin: 4.0 g/dL,Lymphocyte: 1.02,Neutrophil: 4.45,LDH level: 186.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MEDI5752/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166 cm,Body weight: 68 kg,BMI: 24.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.69,Albumin: 5.0 g/dL,Lymphocyte: 2.47,Neutrophil: 3.61,LDH level: 205.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: B2M,NSD1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 152 cm,Body weight: 54 kg,BMI: 23.37,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.9,Albumin: 4.3 g/dL,Lymphocyte: 2.24,Neutrophil: 3.11,LDH level: 211.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin/Nivolumab or Placebo,SNV mutations: BRCA2,KRAS,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 162 cm,Body weight: 76 kg,BMI: 28.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.43,Albumin: 4.5 g/dL,Lymphocyte: 2.32,Neutrophil: 4.29,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA2,KRAS,RAD50,SMARCA4,CNV alterations: EGFR(gain),FGF14(gain),FGF23(gain),MDM4(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 40 years old,Sex: M,Height: 180.1 cm,Body weight: 84.6 kg,BMI: 26.08,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.38,Albumin: 5.0 g/dL,Lymphocyte: 1.33,Neutrophil: 7.11,LDH level: 595.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 166.3 cm,Body weight: 61.1 kg,BMI: 22.09,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 6.57,Albumin: 3.3 g/dL,Lymphocyte: 1.75,Neutrophil: 3.92,LDH level: 174.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tislelizumab or Pembrolizumab/Ociperlimab or Placebo,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 164 cm,Body weight: 57 kg,BMI: 21.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 2%,WBC: 5.89,Albumin: 4.3 g/dL,Lymphocyte: 1.6,Neutrophil: 3.58,LDH level: 255.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: NOTCH1,RB1,SOX17,CNV alterations: FGF10(gain),KIT(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166 cm,Body weight: 60 kg,BMI: 21.77,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.32,Albumin: 4.6 g/dL,Lymphocyte: 1.97,Neutrophil: 2.7,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MED12,PIK3CA,TET2,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 185 cm,Body weight: 90 kg,BMI: 26.30,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 95%,WBC: 6.83,Albumin: 3.8 g/dL,Lymphocyte: 1.95,Neutrophil: 4.1,LDH level: 198.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,KRAS,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 170 cm,Body weight: 78 kg,BMI: 26.92,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,WBC: 30.63,Albumin: 1.8 g/dL,Lymphocyte: 0.35,Neutrophil: 29.9,LDH level: 235.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID1B,ERCC4,NFE2L2,TP53,CNV alterations: ALK(gain),AR(gain),BCL6(gain),CCND3(gain),CCNE1(gain),CDK6(gain),EGFR(gain),FGF23(gain),FGF6(gain),FGFR3(loss),KDM5A(gain),KRAS(gain),MDM4(gain),MYCN(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 172.7 cm,Body weight: 87 kg,BMI: 29.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 5.99,Albumin: 4.9 g/dL,Lymphocyte: 1.83,Neutrophil: 3.34,LDH level: 178.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: AURKA(gain),BCL2L1(gain),CARD11(gain),CCND1(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ETV1(gain),FANCA(loss),FGF19(gain),FOXA1(gain),HRAS(gain),KDR(gain),KIT(gain),MYC(gain),NKX2-1(gain),PDGFRA(gain),PMS2(gain),RAC1(gain),RB1(loss),Fusion genes: None,Splice variants: AR,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: F,Height: 163 cm,Body weight: 45 kg,BMI: 16.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,WBC: 6.91,Albumin: 3.0 g/dL,Lymphocyte: 0.81,Neutrophil: 5.71,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,STK11,TP53,CNV alterations: CCNE1(gain),ERCC1(gain),ERCC2(gain),MYC(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 163.8 cm,Body weight: 50.5 kg,BMI: 18.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 15%,WBC: 24.63,Albumin: 3.6 g/dL,Lymphocyte: 2.96,Neutrophil: 16.33,LDH level: 291.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MEDI5752/Pemetrexed/Carboplatin,SNV mutations: PBRM1,TP53,VHL,CNV alterations: BRAF(gain),BRCA1(gain),CCND3(gain),CDK6(gain),ERBB2(gain),FGF10(gain),JAK2(loss),MET(gain),MYC(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 166 cm,Body weight: 67.2 kg,BMI: 24.39,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 10.58,Albumin: 4.5 g/dL,Lymphocyte: 2.72,Neutrophil: 6.69,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID1A,EGFR,KEAP1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 157 cm,Body weight: 55.5 kg,BMI: 22.52,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 4.72,Albumin: 4.9 g/dL,Lymphocyte: 1.51,Neutrophil: 2.67,LDH level: 222.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: BRCA1(gain),ERBB2(gain),FGF10(loss),FGFR3(loss),PIK3CB(gain),RICTOR(loss),Fusion genes: NRG1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 165 cm,Body weight: 75 kg,BMI: 27.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Lymphoepithelioma-like,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,WBC: 9.05,Albumin: 4.7 g/dL,Lymphocyte: 1.6,Neutrophil: 7.14,LDH level: 248.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CYLD,NFKBIA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164.2 cm,Body weight: 56.7 kg,BMI: 21.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,WBC: 6.32,Albumin: 4.5 g/dL,Lymphocyte: 1.47,Neutrophil: 4.2,LDH level: 179.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID2,DICER1,KDM5C,NF1,TP53,CNV alterations: CDKN2A(loss),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 169 cm,Body weight: 45 kg,BMI: 15.62,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 18.7,Albumin: 3.3 g/dL,Lymphocyte: 0.6,Neutrophil: 17.68,LDH level: 380.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TERT,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 159 cm,Body weight: 57 kg,BMI: 22.72,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.16,Albumin: 3.9 g/dL,Lymphocyte: 1.3,Neutrophil: 5.22,LDH level: 257.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 162 cm,Body weight: 51.5 kg,BMI: 19.62,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,WBC: 12.51,Albumin: 3.4 g/dL,Lymphocyte: 1.24,Neutrophil: 10.55,LDH level: 256.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib -> Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 160 cm,Body weight: 49 kg,BMI: 19.14,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 9.06,Albumin: 4.0 g/dL,Lymphocyte: 1.02,Neutrophil: 5.84,LDH level: 389.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: M,Height: 161.8 cm,Body weight: 52 kg,BMI: 19.86,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 3.23,Albumin: 3.9 g/dL,Lymphocyte: 1.04,Neutrophil: 1.75,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: None,CNV alterations: BRCA2(gain),CCND3(gain),CDK8(gain),DIS3(gain),EGFR(gain),FGF10(gain),FGF14(gain),FGF9(gain),FGFR1(gain),FGFR3(loss),MDM4(gain),NRAS(gain),RICTOR(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: M,Height: 173 cm,Body weight: 92 kg,BMI: 30.74,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.83,Albumin: 4.5 g/dL,Lymphocyte: 2.88,Neutrophil: 3.32,LDH level: 168.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 148.3 cm,Body weight: 51.5 kg,BMI: 23.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.04,Albumin: 4.4 g/dL,Lymphocyte: 1.62,Neutrophil: 3.68,LDH level: 210.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MEDI5752,SNV mutations: CTNNB1,DNMT3A,KDM6A,TET2,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 161 cm,Body weight: 55 kg,BMI: 21.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 7.34,Albumin: 4.5 g/dL,Lymphocyte: 0.8,Neutrophil: 5.88,LDH level: 293.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB3,NOTCH1,TP53,CNV alterations: AR(loss),CCND3(gain),ERBB2(gain),FGF10(loss),JAK2(loss),MYC(gain),NRG1(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 167.8 cm,Body weight: 78.9 kg,BMI: 28.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 7.76,Albumin: 4.4 g/dL,Lymphocyte: 1.56,Neutrophil: 5.09,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: PBRM1,RAD21,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 170 cm,Body weight: 64 kg,BMI: 22.15,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 15.77,Albumin: 4.8 g/dL,Lymphocyte: 1.37,Neutrophil: 13.03,LDH level: 169.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 163 cm,Body weight: 54 kg,BMI: 20.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.1,Albumin: 4.1 g/dL,Lymphocyte: 1.15,Neutrophil: 4.22,LDH level: 147.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 174 cm,Body weight: 81 kg,BMI: 26.75,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 5.44,Albumin: 4.7 g/dL,Lymphocyte: 1.49,Neutrophil: 3.23,LDH level: 615.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Ceritinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 165 cm,Body weight: 58 kg,BMI: 21.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.68,Albumin: 3.3 g/dL,Lymphocyte: 0.97,Neutrophil: 5.97,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: LZTR1,NF2,RBM10,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 29.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 165 cm,Body weight: 65 kg,BMI: 23.88,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 15%,WBC: 12.7,Albumin: 3.7 g/dL,Lymphocyte: 1.93,Neutrophil: 9.71,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 175 cm,Body weight: 72 kg,BMI: 23.51,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 15.42,Albumin: 3.2 g/dL,Lymphocyte: 1.7,Neutrophil: 12.39,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRCA2,EGFR,EP300,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 167 cm,Body weight: 63 kg,BMI: 22.59,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 4.06,Albumin: 4.2 g/dL,Lymphocyte: 0.74,Neutrophil: 2.86,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 155 cm,Body weight: 42 kg,BMI: 17.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 7.45,Albumin: 4.3 g/dL,Lymphocyte: 1.82,Neutrophil: 4.9,LDH level: 267.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MPL,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 151 cm,Body weight: 38 kg,BMI: 16.45,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 11.68,Albumin: 4.0 g/dL,Lymphocyte: 1.77,Neutrophil: 8.92,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/MK4830,SNV mutations: TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF10(gain),IRS2(gain),JAK2(loss),LAMP1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 168 cm,Body weight: 67.9 kg,BMI: 24.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 6.24,Albumin: 4.7 g/dL,Lymphocyte: 1.63,Neutrophil: 3.9,LDH level: 372.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 182.6 cm,Body weight: 69.1 kg,BMI: 20.72,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 30%,WBC: 6.82,Albumin: 3.6 g/dL,Lymphocyte: 1.64,Neutrophil: 4.23,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,SMARCA4,STK11,TP53,CNV alterations: CRKL(gain),ERCC1(gain),ERCC2(gain),FGF7(gain),LZTR1(gain),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 165 cm,Body weight: 65 kg,BMI: 23.96,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 12.4,Albumin: 3.8 g/dL,Lymphocyte: 1.26,Neutrophil: 10.34,LDH level: 290.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: FAT1,KEAP1,NFE2L2,TP53,CNV alterations: CCND1(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ERBB2(gain),FGF19(gain),FGF3(gain),FGF4(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 163.6 cm,Body weight: 61 kg,BMI: 22.79,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 100%,WBC: 6.56,Albumin: 4.6 g/dL,Lymphocyte: 1.89,Neutrophil: 3.86,LDH level: 159.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRCA1,CDKN2A,CEBPA,TP53,CNV alterations: ERBB2(gain),FGFR1(gain),NRG1(gain),PIK3CA(gain),Fusion genes: NOTCH3,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 169 cm,Body weight: 67 kg,BMI: 23.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 25%,WBC: 4.79,Albumin: 4.1 g/dL,Lymphocyte: 1.44,Neutrophil: 2.8,LDH level: 174.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PTEN,RB1,TP53,CNV alterations: BRCA2(gain),EGFR(gain),FGF10(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 164 cm,Body weight: 70 kg,BMI: 25.81,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 16.69,Albumin: 4.0 g/dL,Lymphocyte: 3.68,Neutrophil: 11.3,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: DNMT3B,RB1,SMARCA4,STK11,TP53,CNV alterations: CCND3(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 162 cm,Body weight: 58.7 kg,BMI: 22.37,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.59,Albumin: 4.2 g/dL,Lymphocyte: 1.29,Neutrophil: 5.57,LDH level: 180.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: FOXA1,KEAP1,LZTR1,PIK3CA,RASA1,TP53,CNV alterations: ARID1B(loss),CDKN2A(loss),CDKN2B(loss),CREBBP(loss),FGFR1(gain),PAX5(loss),PIK3CA(gain),PMAIP1(loss),PPM1D(gain),PTPRS(loss),RASA1(loss),RUNX1(loss),SOX2(gain),TGFBR2(loss),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 158 cm,Body weight: 51 kg,BMI: 20.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 2.87,Albumin: 4.4 g/dL,Lymphocyte: 1.2,Neutrophil: 1.26,LDH level: 221.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDH1,PALB2,PDGFRB,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 181 cm,Body weight: 88.8 kg,BMI: 27.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 20.29,Albumin: 3.2 g/dL,Lymphocyte: 0.68,Neutrophil: 18.76,LDH level: 370.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,KRAS,TERT,TP53,CNV alterations: AKT2(gain),JUN(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 146.2 cm,Body weight: 64.9 kg,BMI: 30.36,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RAD21,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 164 cm,Body weight: 59 kg,BMI: 21.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 14.64,Albumin: 4.1 g/dL,Lymphocyte: 2.54,Neutrophil: 10.85,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: AKT1(gain),AMER1(loss),ANKRD11(loss),CCNE1(gain),HRAS(gain),MCL1(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 159.7 cm,Body weight: 46.4 kg,BMI: 18.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 12.33,Albumin: 2.9 g/dL,Lymphocyte: 0.61,Neutrophil: 11.1,LDH level: 372.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CDKN2A,TP53,CNV alterations: MYC(gain),SMARCB1(gain),Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 163.9 cm,Body weight: 60.2 kg,BMI: 22.41,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 9.94,Albumin: 3.3 g/dL,Lymphocyte: 1.02,Neutrophil: 7.99,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: ATM(gain),BRCA1(gain),CHEK1(gain),ERBB2(gain),ERBB3(gain),FGF10(gain),FGFR1(gain),MYC(gain),MYCL(gain),NRG1(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: AR,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 177 cm,Body weight: 56.9 kg,BMI: 18.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.33,Albumin: 3.3 g/dL,Lymphocyte: 1.61,Neutrophil: 4.61,LDH level: 231.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,PIK3CA,TP53,CNV alterations: AKT2(gain),CCND3(gain),CCNE1(gain),EGFR(gain),ERCC1(gain),ERCC2(gain),FGF10(gain),FGF8(loss),FGFR3(loss),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 159.1 cm,Body weight: 51.7 kg,BMI: 20.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >95%,WBC: 7.15,Albumin: 4.0 g/dL,Lymphocyte: 0.4,Neutrophil: 6.26,LDH level: 195.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165 cm,Body weight: 48 kg,BMI: 17.55,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Large cell neuroendocrine carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.49,Albumin: 4.0 g/dL,Lymphocyte: 2.71,Neutrophil: 3.07,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,KEAP1,SMARCA4,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 157 cm,Body weight: 49 kg,BMI: 19.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): <5%,PD-L1 (SP263): <5%,WBC: 11.19,Albumin: 3.2 g/dL,Lymphocyte: 1.06,Neutrophil: 9.15,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,CNV alterations: CDK4(gain),KRAS(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 180 cm,Body weight: 70.5 kg,BMI: 21.76,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 10.39,Albumin: 3.1 g/dL,Lymphocyte: 1.11,Neutrophil: 7.33,LDH level: 254.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 161.6 cm,Body weight: 56.3 kg,BMI: 21.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 3.77,Albumin: 4.8 g/dL,Lymphocyte: 1.18,Neutrophil: 2.2,LDH level: 265.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 154 cm,Body weight: 56 kg,BMI: 23.70,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 25%,WBC: 12.61,Albumin: 4.1 g/dL,Lymphocyte: 1.85,Neutrophil: 10.02,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MET,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 163 cm,Body weight: 61.7 kg,BMI: 23.22,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 5%,WBC: 8.63,Albumin: 4.4 g/dL,Lymphocyte: 1.67,Neutrophil: 6.35,LDH level: 159.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: PTEN,PTPRS,TP53,CNV alterations: BCL6(gain),CARD11(gain),CDKN2A(loss),CDKN2B(loss),DNMT3B(gain),EGFR(gain),ETV1(gain),EZH2(loss),HRAS(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RAC1(gain),SOX2(gain),SRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 170.1 cm,Body weight: 69.9 kg,BMI: 24.16,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 98%,PD-L1 (SP263): >90%,WBC: 10.13,Albumin: 3.6 g/dL,Lymphocyte: 1.95,Neutrophil: 6.97,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: KRAS,RBM10,STK11,TERT,TP53,CNV alterations: FGF23(gain),FGF6(gain),KRAS(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 171.6 cm,Body weight: 72.5 kg,BMI: 24.62,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 4.15,Albumin: 4.7 g/dL,Lymphocyte: 0.9,Neutrophil: 2.79,LDH level: 317.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MEDI5752/Pemetrexed/Carboplatin,SNV mutations: EGFR,PMS2,RB1,TP53,CNV alterations: CARD11(gain),EGFR(gain),ETV1(gain),FGF10(gain),FGFR1(loss),FOXA1(gain),NFKBIA(gain),NKX2-1(gain),NRG1(loss),PMS2(gain),RAC1(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: M,Height: 170 cm,Body weight: 67 kg,BMI: 23.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 6.56,Albumin: 4.4 g/dL,Lymphocyte: 1.77,Neutrophil: 4.37,LDH level: 258.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: CDKN2C,CNV alterations: MDM4(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 167 cm,Body weight: 72 kg,BMI: 25.82,Smoking history: Former smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719S,L861Q,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 174 cm,Body weight: 87 kg,BMI: 28.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,WBC: 7.0,Albumin: 3.9 g/dL,Lymphocyte: 1.89,Neutrophil: 4.39,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,PIK3CA,CNV alterations: MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 150.8 cm,Body weight: 58.1 kg,BMI: 25.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 4.18,Albumin: 4.5 g/dL,Lymphocyte: 1.47,Neutrophil: 2.43,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,MGA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 167 cm,Body weight: 67 kg,BMI: 24.10,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 10%,WBC: 13.38,Albumin: 2.9 g/dL,Lymphocyte: 1.22,Neutrophil: 11.07,LDH level: 220.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: ARID5B,ATM,TP53,ZFHX3,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 144.9 cm,Body weight: 54.5 kg,BMI: 25.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.75,Albumin: 4.2 g/dL,Lymphocyte: 1.9,Neutrophil: 6.37,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: GNAS,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 171 cm,Body weight: 60 kg,BMI: 20.65,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): >95%,WBC: 14.91,Albumin: 3.9 g/dL,Lymphocyte: 1.95,Neutrophil: 10.29,LDH level: 282.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FANCA,RB1,RBM10,TBX3,CNV alterations: AKT2(gain),CCNE1(gain),CDK6(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 168.5 cm,Body weight: 63 kg,BMI: 22.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.9,Albumin: 4.6 g/dL,Lymphocyte: 0.98,Neutrophil: 3.54,LDH level: 183.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 166.4 cm,Body weight: 65 kg,BMI: 23.48,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 15%,WBC: 4.77,Albumin: 4.4 g/dL,Lymphocyte: 0.63,Neutrophil: 3.63,LDH level: 2244.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FOXA1,NOTCH1,SDHA,TET2,TP53,CNV alterations: FGF23(gain),FGF6(gain),FGFR1(gain),KRAS(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 20.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.41,Albumin: 4.3 g/dL,Lymphocyte: 1.43,Neutrophil: 5.28,LDH level: 713.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 155 cm,Body weight: 56 kg,BMI: 23.31,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 3%,WBC: 6.81,Albumin: 4.4 g/dL,Lymphocyte: 1.88,Neutrophil: 4.22,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BAP1,EGFR,FUBP1,RBM10,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 170 cm,Body weight: 62 kg,BMI: 21.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 29.67,Albumin: 2.6 g/dL,Lymphocyte: 2.03,Neutrophil: 19.11,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CDKN2A,KRAS,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 154 cm,Body weight: 52 kg,BMI: 21.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 169 cm,Body weight: 70 kg,BMI: 24.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,KRAS,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 167.9 cm,Body weight: 56.4 kg,BMI: 20.01,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 20%,WBC: 9.26,Albumin: 4.6 g/dL,Lymphocyte: 1.62,Neutrophil: 6.82,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 181 cm,Body weight: 77 kg,BMI: 23.42,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.96,Albumin: 4.2 g/dL,Lymphocyte: 1.58,Neutrophil: 5.52,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 169 cm,Body weight: 79 kg,BMI: 27.52,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.15,Albumin: 4.2 g/dL,Lymphocyte: 1.16,Neutrophil: 4.36,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),ERBB3(gain),FGF7(loss),JAK2(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 175 cm,Body weight: 75 kg,BMI: 24.49,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 4.86,Albumin: 3.9 g/dL,Lymphocyte: 0.78,Neutrophil: 3.44,LDH level: 173.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: PTEN,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 168.3 cm,Body weight: 78.6 kg,BMI: 27.75,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.14,Albumin: 4.1 g/dL,Lymphocyte: 2.24,Neutrophil: 2.37,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DIS3,RECQL4,STK11,SUZ12,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 154 cm,Body weight: 57 kg,BMI: 24.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.84,Albumin: 4.6 g/dL,Lymphocyte: 1.02,Neutrophil: 2.43,LDH level: 252.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,NF2,SMAD4,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 22.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 165 cm,Body weight: 69 kg,BMI: 25.38,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.81,Albumin: 4.0 g/dL,Lymphocyte: 0.98,Neutrophil: 4.23,LDH level: 186.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/MK4830,SNV mutations: ERBB2,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: M,Height: 170.4 cm,Body weight: 59.6 kg,BMI: 20.53,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.49,Albumin: 3.4 g/dL,Lymphocyte: 1.69,Neutrophil: 6.8,LDH level: 146.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,SMARCA4,TP53,CNV alterations: PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 15.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 170.1 cm,Body weight: 60.3 kg,BMI: 20.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 10.91,Albumin: 3.0 g/dL,Lymphocyte: 1.71,Neutrophil: 8.32,LDH level: 133.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,PMS1,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 170 cm,Body weight: 79 kg,BMI: 27.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 3.98,Albumin: 4.3 g/dL,Lymphocyte: 1.16,Neutrophil: 2.15,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,EGFR,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 178 cm,Body weight: 86.5 kg,BMI: 27.30,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: ATM(gain),CCND3(gain),EGFR(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 168 cm,Body weight: 64 kg,BMI: 22.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,WBC: 11.05,Albumin: 4.5 g/dL,Lymphocyte: 3.11,Neutrophil: 7.15,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ATM,BRAF,ERRFI1,FAT1,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 160 cm,Body weight: 48 kg,BMI: 18.75,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 11.98,Albumin: 3.8 g/dL,Lymphocyte: 0.37,Neutrophil: 10.98,LDH level: 202.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),PIK3CA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 150.8 cm,Body weight: 53.2 kg,BMI: 23.39,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 18.45,Albumin: 2.8 g/dL,Lymphocyte: 2.37,Neutrophil: 13.4,LDH level: 276.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,MET,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 163 cm,Body weight: 65 kg,BMI: 24.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 11.6,Albumin: 4.1 g/dL,Lymphocyte: 2.08,Neutrophil: 8.09,LDH level: 231.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ARID1A,KEAP1,RBM10,SMARCB1,SPEN,TP53,CNV alterations: BRCA1(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),ERBB2(gain),ERCC2(gain),FGFR4(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 33.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 168 cm,Body weight: 60 kg,BMI: 21.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 2.79,Albumin: 4.6 g/dL,Lymphocyte: 1.22,Neutrophil: 1.29,LDH level: 228.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NBN,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 161 cm,Body weight: 70 kg,BMI: 27.01,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 8.58,Albumin: 4.8 g/dL,Lymphocyte: 1.09,Neutrophil: 6.71,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: FBXW7,RB1,TP53,CNV alterations: KIT(gain),PDGFRA(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 172 cm,Body weight: 57 kg,BMI: 19.27,Smoking history: Current smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,WBC: 9.71,Albumin: 3.7 g/dL,Lymphocyte: 1.08,Neutrophil: 8.13,LDH level: 259.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BCORL1,KEAP1,LZTR1,MSH3,PTPRD,RNF43,TP53,CNV alterations: KRAS(gain),MAP2K4(loss),MCL1(gain),RAD51B(loss),RHEB(gain),RUNX1(loss),XRCC2(gain),Fusion genes: None,Splice variants: None,TMB: 46.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 174.1 cm,Body weight: 73.1 kg,BMI: 24.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 45%,PD-L1 (SP263): 60%,WBC: 14.52,Albumin: 2.9 g/dL,Lymphocyte: 1.37,Neutrophil: 9.93,LDH level: 206.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,RASA1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 164 cm,Body weight: 60 kg,BMI: 22.23,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 4.5,Albumin: 3.5 g/dL,Lymphocyte: 1.42,Neutrophil: 2.46,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,RB1,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 169.5 cm,Body weight: 70 kg,BMI: 24.36,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.69,Albumin: 4.7 g/dL,Lymphocyte: 1.34,Neutrophil: 2.83,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-5890/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 162 cm,Body weight: 68.3 kg,BMI: 26.02,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.8,Albumin: 4.3 g/dL,Lymphocyte: 2.24,Neutrophil: 4.58,LDH level: 200.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: BRCA2(loss),CHEK2(loss),PDGFRB(loss),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 174.2 cm,Body weight: 70.6 kg,BMI: 23.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 5.44,Albumin: 3.8 g/dL,Lymphocyte: 1.28,Neutrophil: 3.54,LDH level: 220.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 164 cm,Body weight: 62 kg,BMI: 23.05,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 5.3,Albumin: 3.9 g/dL,Lymphocyte: 0.67,Neutrophil: 3.92,LDH level: 212.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 155 cm,Body weight: 57.7 kg,BMI: 24.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 8.13,Albumin: 4.4 g/dL,Lymphocyte: 2.37,Neutrophil: 4.35,LDH level: 1084.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 167 cm,Body weight: 66.8 kg,BMI: 23.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,WBC: 5.12,Albumin: 4.6 g/dL,Lymphocyte: 1.43,Neutrophil: 3.15,LDH level: 189.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK1308,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 152 cm,Body weight: 47 kg,BMI: 20.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.71,Albumin: 3.9 g/dL,Lymphocyte: 0.99,Neutrophil: 9.3,LDH level: 280.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ARID1A,CTNNB1,EGFR,FGFR4,TP53,CNV alterations: BRCA2(gain),CCND3(gain),EGFR(gain),FGF1(gain),FGFR4(gain),LAMP1(gain),MDM4(gain),PDGFRB(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 159 cm,Body weight: 72 kg,BMI: 28.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 3.39,Albumin: 4.3 g/dL,Lymphocyte: 0.8,Neutrophil: 2.18,LDH level: 193.0 U/L,Treatment type: Immunotherapy,Treatment regimen: cyclophosphamide or Placebo/stimuvax or Placebo,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 173 cm,Body weight: 64 kg,BMI: 21.38,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 3%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: ERBB2,RB1,TP53,CNV alterations: BRCA1(gain),BRCA2(loss),DDR2(gain),ERBB2(gain),ESR1(gain),FGF10(gain),FGF7(loss),FGF9(loss),LAMP1(gain),NTRK1(gain),RB1(loss),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 174.4 cm,Body weight: 71.4 kg,BMI: 23.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 10%,WBC: 9.85,Albumin: 4.1 g/dL,Lymphocyte: 1.9,Neutrophil: 6.9,LDH level: 338.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 175 cm,Body weight: 74 kg,BMI: 24.29,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.7,Albumin: 2.8 g/dL,Lymphocyte: 1.39,Neutrophil: 5.22,LDH level: 400.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),EGFR(gain),ERBB2(gain),MYC(gain),Fusion genes: BRCA1,ROS1,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 61 kg,BMI: 21.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 6.88,Albumin: 4.3 g/dL,Lymphocyte: 1.24,Neutrophil: 4.78,LDH level: 149.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 163.2 cm,Body weight: 73.5 kg,BMI: 27.60,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 11.81,Albumin: 4.0 g/dL,Lymphocyte: 1.95,Neutrophil: 8.83,LDH level: 209.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: RAD50,TP53,CNV alterations: BRAF(gain),CCND3(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),CHEK1(loss),ERBB2(gain),ERBB3(gain),ESR1(gain),FGFR1(gain),FGFR3(loss),JAK2(loss),MET(gain),MYCN(gain),PIK3CA(gain),PIK3CB(gain),RPS6KB1(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 171 cm,Body weight: 67 kg,BMI: 22.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 8.88,Albumin: 3.0 g/dL,Lymphocyte: 1.33,Neutrophil: 6.58,LDH level: 300.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 161 cm,Body weight: 58 kg,BMI: 22.26,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,WBC: 9.34,Albumin: 4.1 g/dL,Lymphocyte: 1.83,Neutrophil: 6.19,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/MK7684,SNV mutations: PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 169 cm,Body weight: 77 kg,BMI: 26.87,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.81,Albumin: 4.3 g/dL,Lymphocyte: 1.21,Neutrophil: 9.33,LDH level: 162.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin or Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,KRAS,STK11,CNV alterations: FOXA1(gain),MYCN(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 157 cm,Body weight: 70 kg,BMI: 28.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.6,Albumin: 4.1 g/dL,Lymphocyte: 0.89,Neutrophil: 4.04,LDH level: 147.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 158 cm,Body weight: 64 kg,BMI: 25.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 6.97,Albumin: 4.3 g/dL,Lymphocyte: 1.65,Neutrophil: 4.68,LDH level: 266.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: BRAF,CTNNB1,EGFR,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 170 cm,Body weight: 65 kg,BMI: 22.49,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 16.8,Albumin: 4.3 g/dL,Lymphocyte: 2.3,Neutrophil: 13.41,LDH level: 173.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: ROS1,CNV alterations: CDKN2B(loss),FGFR1(gain),Fusion genes: ROS1,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 157 cm,Body weight: 61 kg,BMI: 24.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >95%,PD-L1 (SP263): >95%,WBC: 5.2,Albumin: 4.1 g/dL,Lymphocyte: 0.79,Neutrophil: 3.58,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FOXO1,KRAS,POLD1,TP53,U2AF1,CNV alterations: ERBB2(gain),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 33.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 182 cm,Body weight: 72.2 kg,BMI: 21.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.41,Albumin: 2.9 g/dL,Lymphocyte: 1.61,Neutrophil: 4.6,LDH level: 304.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: CCND1(gain),CDK4(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 35 years old,Sex: M,Height: 163.4 cm,Body weight: 49 kg,BMI: 18.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 19.84,Albumin: 4.4 g/dL,Lymphocyte: 1.58,Neutrophil: 15.27,LDH level: 365.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin/Nivolumab or Placebo,SNV mutations: ARID1A,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 173 cm,Body weight: 80 kg,BMI: 26.73,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.76,Albumin: 4.5 g/dL,Lymphocyte: 2.46,Neutrophil: 4.48,LDH level: 567.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 160.6 cm,Body weight: 62.7 kg,BMI: 24.31,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 7.53,Albumin: 3.2 g/dL,Lymphocyte: 1.71,Neutrophil: 4.77,LDH level: 303.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/CJRB-101,SNV mutations: IDH1,KEAP1,MUTYH,SMARCA4,STK11,CNV alterations: CDKN2A(loss),CDKN2B(loss),SRC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 168 cm,Body weight: 76 kg,BMI: 26.92,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 16.26,Albumin: 4.0 g/dL,Lymphocyte: 1.7,Neutrophil: 13.03,LDH level: 240.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,CYLD,TP53,CNV alterations: ARID2(loss),BRCA2(loss),FGFR1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 178.1 cm,Body weight: 81 kg,BMI: 25.54,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.87,Albumin: 3.9 g/dL,Lymphocyte: 2.5,Neutrophil: 7.95,LDH level: 266.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: ARID1A,CYLD,TP53,CNV alterations: ATRX(loss),CCNE1(gain),EGFR(gain),ERBB2(gain),JAK2(loss),KIT(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 37.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 164 cm,Body weight: 60 kg,BMI: 22.31,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 9.8,Albumin: 3.1 g/dL,Lymphocyte: 1.49,Neutrophil: 7.02,LDH level: 266.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TET2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 163 cm,Body weight: 58 kg,BMI: 21.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 6.41,Albumin: 4.8 g/dL,Lymphocyte: 2.38,Neutrophil: 3.49,LDH level: 187.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Ceritinib,SNV mutations: LATS1,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 167 cm,Body weight: 74 kg,BMI: 26.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 10.02,Albumin: 4.3 g/dL,Lymphocyte: 2.35,Neutrophil: 6.9,LDH level: 181.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,ERBB4,RB1,TP53,CNV alterations: FGF23(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 174.9 cm,Body weight: 58.5 kg,BMI: 19.12,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 3.03,Albumin: 4.1 g/dL,Lymphocyte: 1.1,Neutrophil: 1.39,LDH level: 195.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: BRCA2(loss),CCNE1(gain),FGF7(loss),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 170 cm,Body weight: 47 kg,BMI: 16.26,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 22.12,Albumin: 3.1 g/dL,Lymphocyte: 2.06,Neutrophil: 16.9,LDH level: 583.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRIP1,CDKN2A,KEAP1,STK11,TP53,CNV alterations: ERCC1(gain),ERCC2(gain),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 175 cm,Body weight: 76 kg,BMI: 24.82,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.41,Albumin: 4.3 g/dL,Lymphocyte: 1.4,Neutrophil: 3.53,LDH level: 178.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CREBBP,RB1,TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 160 cm,Body weight: 67.4 kg,BMI: 26.33,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: malignant tumor with spindle cell (or sarcomatoid) feature,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.33,Albumin: 2.5 g/dL,Lymphocyte: 0.72,Neutrophil: 11.28,LDH level: 262.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PTEN,TP53,CNV alterations: BRAF(gain),CDK6(gain),EGFR(gain),FGF23(gain),FGF6(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 169 cm,Body weight: 51.3 kg,BMI: 17.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 7.88,Albumin: 4.4 g/dL,Lymphocyte: 1.64,Neutrophil: 5.42,LDH level: 192.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: BRCA2,KRAS,TP53,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 163 cm,Body weight: 76.7 kg,BMI: 28.87,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,WBC: 5.34,Albumin: 3.8 g/dL,Lymphocyte: 1.34,Neutrophil: 3.67,LDH level: 1286.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Etoposide/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: CCND3(gain),FGF1(loss),FGF3(loss),FGF8(loss),FGFR2(loss),FGFR4(loss),MDM4(gain),NRAS(loss),PDGFRB(loss),PIK3CA(gain),PIK3CB(gain),RAF1(loss),RB1(loss),RICTOR(gain),TFRC(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 156.2 cm,Body weight: 45.3 kg,BMI: 18.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,WBC: 6.25,Albumin: 4.8 g/dL,Lymphocyte: 1.57,Neutrophil: 4.05,LDH level: 227.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,MED12,MSH3,NCOR1,TP53,CNV alterations: CHEK1(gain),MDM2(gain),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 23.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 165 cm,Body weight: 59 kg,BMI: 21.80,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 8%,WBC: 4.63,Albumin: 4.4 g/dL,Lymphocyte: 1.23,Neutrophil: 2.92,LDH level: 179.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: CDKN2C,FAT1,TP53,CNV alterations: AKT2(gain),CCND1(gain),CDK6(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),JAK2(loss),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 163.4 cm,Body weight: 68.5 kg,BMI: 25.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 6.84,Albumin: 4.4 g/dL,Lymphocyte: 2.37,Neutrophil: 3.04,LDH level: 199.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID2,BAP1,CDKN2A,CTNNB1,MAP2K1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 92 years old,Sex: F,Height: 155 cm,Body weight: 60 kg,BMI: 25.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 1%,WBC: 11.76,Albumin: 4.1 g/dL,Lymphocyte: 2.02,Neutrophil: 8.7,LDH level: 235.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/MK5890,SNV mutations: BRAF,NUP93,RBM10,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 162 cm,Body weight: 46 kg,BMI: 17.56,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 50%,WBC: 6.93,Albumin: 3.6 g/dL,Lymphocyte: 1.25,Neutrophil: 5.14,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: ARID1A(loss),FGFR3(loss),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 170.9 cm,Body weight: 73 kg,BMI: 24.99,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 10%,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 6.88,Albumin: 4.5 g/dL,Lymphocyte: 1.45,Neutrophil: 4.54,LDH level: 387.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MGA,NOTCH2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 167.3 cm,Body weight: 61.9 kg,BMI: 22.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 9.32,Albumin: 4.7 g/dL,Lymphocyte: 3.24,Neutrophil: 5.23,LDH level: 166.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Paclitaxel/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 160 cm,Body weight: 50 kg,BMI: 19.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del, L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 7.31,Albumin: 4.8 g/dL,Lymphocyte: 2.66,Neutrophil: 4.3,LDH level: 231.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),BRAF(gain),CCNE1(gain),CDK6(gain),EGFR(gain),FGF10(gain),FGFR1(loss),FGFR3(loss),INPP4B(gain),MET(gain),NRG1(loss),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 55 kg,BMI: 19.03,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.86,Albumin: 4.4 g/dL,Lymphocyte: 1.36,Neutrophil: 3.69,LDH level: 189.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: STK11,TP53,CNV alterations: CDK4(gain),FGF10(gain),MDM2(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 158 cm,Body weight: 55 kg,BMI: 22.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: SDHA(gain),Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 169 cm,Body weight: 75.4 kg,BMI: 26.40,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.71,Albumin: 4.8 g/dL,Lymphocyte: 2.31,Neutrophil: 5.68,LDH level: 476.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),FGF10(gain),FGF14(gain),FGF5(loss),FGF7(loss),FGFR1(gain),KIT(loss),LAMP1(gain),MDM4(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 163 cm,Body weight: 52 kg,BMI: 19.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,WBC: 7.33,Albumin: 4.4 g/dL,Lymphocyte: 1.35,Neutrophil: 4.94,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: FAT1,KMT2A,KRAS,RBM10,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 151 cm,Body weight: 52.7 kg,BMI: 23.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.61,Albumin: 4.2 g/dL,Lymphocyte: 1.83,Neutrophil: 2.07,LDH level: 232.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: CDKN2A,CTNNB1,EGFR,PIK3CA,CNV alterations: FGF1(gain),JAK2(loss),MDM2(gain),MDM4(gain),PDGFRB(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 54.4 kg,BMI: 18.82,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.36,Albumin: 4.2 g/dL,Lymphocyte: 0.87,Neutrophil: 8.76,LDH level: 553.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: APC,NFE2L2,TP53,CNV alterations: BRCA2(loss),CHEK2(loss),FGFR1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: F,Height: 148 cm,Body weight: 43 kg,BMI: 19.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,WBC: 7.03,Albumin: 4.9 g/dL,Lymphocyte: 0.8,Neutrophil: 5.57,LDH level: 213.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,ERRFI1,PTEN,RBM10,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 156 cm,Body weight: 73 kg,BMI: 29.98,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 85%,PD-L1 (SP263): 85%,WBC: 8.06,Albumin: 4.4 g/dL,Lymphocyte: 1.84,Neutrophil: 4.8,LDH level: 277.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KDM5C,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: F,Height: 158 cm,Body weight: 53 kg,BMI: 21.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 17.55,Albumin: 3.5 g/dL,Lymphocyte: 1.62,Neutrophil: 14.89,LDH level: 125.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ALK,DDR2,FGFR1,ROS1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 158 cm,Body weight: 54 kg,BMI: 21.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 20%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.97,Albumin: 4.4 g/dL,Lymphocyte: 2.13,Neutrophil: 3.21,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: KRAS(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 173.7 cm,Body weight: 79.4 kg,BMI: 26.32,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 6.18,Albumin: 3.8 g/dL,Lymphocyte: 2.45,Neutrophil: 2.83,LDH level: 171.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: CCND3(gain),FGF10(gain),FGF14(gain),FGF8(loss),KIT(gain),LAMP1(gain),MDM4(gain),MYCN(loss),PDGFRA(gain),RB1(loss),RET(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 160.9 cm,Body weight: 54.1 kg,BMI: 20.90,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 8.32,Albumin: 3.8 g/dL,Lymphocyte: 1.54,Neutrophil: 5.87,LDH level: 168.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel,SNV mutations: CDKN2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 151.8 cm,Body weight: 50.2 kg,BMI: 21.79,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.29,Albumin: 3.1 g/dL,Lymphocyte: 0.8,Neutrophil: 4.83,LDH level: 242.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),MDM2(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 163 cm,Body weight: 65 kg,BMI: 24.41,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.47,Albumin: 3.7 g/dL,Lymphocyte: 1.35,Neutrophil: 5.07,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 156.1 cm,Body weight: 48.8 kg,BMI: 20.03,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.19,Albumin: 4.1 g/dL,Lymphocyte: 0.95,Neutrophil: 3.58,LDH level: 212.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-0482/Pembrolizumab,SNV mutations: MGA,PIK3CA,RB1,SMAD2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 160 cm,Body weight: 58 kg,BMI: 22.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 18.75,Albumin: 4.8 g/dL,Lymphocyte: 3.81,Neutrophil: 13.71,LDH level: 215.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 173 cm,Body weight: 66 kg,BMI: 22.05,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 95%,WBC: 6.93,Albumin: 4.5 g/dL,Lymphocyte: 1.07,Neutrophil: 5.67,LDH level: 183.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 185 cm,Body weight: 62.3 kg,BMI: 18.20,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 70%,WBC: 13.97,Albumin: 3.5 g/dL,Lymphocyte: 0.76,Neutrophil: 12.91,LDH level: 287.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: EP300,TP53,CNV alterations: EGFR(gain),FGF23(gain),FGF6(gain),MYC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 161.5 cm,Body weight: 76.6 kg,BMI: 29.37,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 8.46,Albumin: 4.5 g/dL,Lymphocyte: 2.64,Neutrophil: 4.8,LDH level: 254.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-7684A or Pembrolizumab,SNV mutations: KMT2A,KRAS,RASA1,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 166.6 cm,Body weight: 80.7 kg,BMI: 29.08,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.97,Albumin: 4.0 g/dL,Lymphocyte: 1.67,Neutrophil: 3.94,LDH level: 236.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: B2M,RB1,TP53,CNV alterations: ALK(gain),CCND1(gain),CDK6(gain),CIC(loss),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),IRS2(gain),LAMP1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 29.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 159.4 cm,Body weight: 54.9 kg,BMI: 21.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 2%,WBC: 14.6,Albumin: 3.2 g/dL,Lymphocyte: 2.33,Neutrophil: 10.9,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID1A,KRAS,MGA,CNV alterations: FGF14(loss),FGF7(loss),Fusion genes: None,Splice variants: None,TMB: 15.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 173 cm,Body weight: 72 kg,BMI: 24.06,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 50%,WBC: 5.7,Albumin: 4.8 g/dL,Lymphocyte: 1.84,Neutrophil: 3.39,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin/Durvalumab,SNV mutations: CDKN2A,TP53,CNV alterations: AKT2(gain),AR(loss),CCNE1(gain),EGFR(gain),FGF10(gain),FGFR1(gain),MDM2(gain),NRAS(loss),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: F,Height: 157.8 cm,Body weight: 59.3 kg,BMI: 23.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.75,Albumin: 4.3 g/dL,Lymphocyte: 1.28,Neutrophil: 4.86,LDH level: 190.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: APC,EGFR,PIK3CB,PMS1,TP53,CNV alterations: PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 169.5 cm,Body weight: 68 kg,BMI: 23.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.22,Albumin: 4.1 g/dL,Lymphocyte: 1.18,Neutrophil: 3.57,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: KRAS,RAF1,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 172 cm,Body weight: 71.5 kg,BMI: 24.17,Smoking history: Current smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 70%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: PPM1D,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 166.6 cm,Body weight: 71.4 kg,BMI: 25.72,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 9.21,Albumin: 4.1 g/dL,Lymphocyte: 2.84,Neutrophil: 5.42,LDH level: 159.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-0482/Pembrolizumab,SNV mutations: NFE2L2,NOTCH1,PTPRT,TP53,CNV alterations: FGF23(gain),FGF6(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 169 cm,Body weight: 63 kg,BMI: 22.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 8.43,Albumin: 3.6 g/dL,Lymphocyte: 1.57,Neutrophil: 6.02,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,KRAS,NKX2-1,WT1,CNV alterations: CCND3(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 158 cm,Body weight: 43 kg,BMI: 17.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 10.21,Albumin: 4.3 g/dL,Lymphocyte: 2.77,Neutrophil: 6.2,LDH level: 203.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Dabrafenib/Trametinib,SNV mutations: BRAF,NOTCH3,PMS1,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 176 cm,Body weight: 68 kg,BMI: 21.95,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 10.32,Albumin: 3.8 g/dL,Lymphocyte: 1.86,Neutrophil: 7.5,LDH level: 221.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 160 cm,Body weight: 52 kg,BMI: 20.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: APC,ARID1A,ROS1,TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 153 cm,Body weight: 51 kg,BMI: 21.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 23.11,Albumin: 2.5 g/dL,Lymphocyte: 2.02,Neutrophil: 17.92,LDH level: 436.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 161 cm,Body weight: 68.7 kg,BMI: 26.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.87,Albumin: 4.4 g/dL,Lymphocyte: 1.82,Neutrophil: 7.06,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ARID1A,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 172.2 cm,Body weight: 68.4 kg,BMI: 23.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 70%,WBC: 5.84,Albumin: 4.0 g/dL,Lymphocyte: 2.09,Neutrophil: 2.81,LDH level: 174.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BAP1,KRAS,PTEN,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 152.7 cm,Body weight: 48.3 kg,BMI: 20.71,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.78,Albumin: 4.5 g/dL,Lymphocyte: 1.49,Neutrophil: 1.87,LDH level: 200.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,PHF6,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 169 cm,Body weight: 70 kg,BMI: 24.42,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,WBC: 12.66,Albumin: 3.7 g/dL,Lymphocyte: 1.16,Neutrophil: 10.36,LDH level: 295.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: KRAS,SETD2,TP53,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 159 cm,Body weight: 46 kg,BMI: 18.20,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 155 cm,Body weight: 47 kg,BMI: 19.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.99,Albumin: 4.0 g/dL,Lymphocyte: 1.35,Neutrophil: 6.99,LDH level: 171.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: CCNE1(gain),FGF10(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 161 cm,Body weight: 46 kg,BMI: 17.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 10%,WBC: 5.97,Albumin: 4.1 g/dL,Lymphocyte: 1.23,Neutrophil: 4.03,LDH level: 149.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: EGFR(gain),KDM6A(gain),MCL1(gain),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 173 cm,Body weight: 56 kg,BMI: 18.66,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.55,Albumin: 4.4 g/dL,Lymphocyte: 0.87,Neutrophil: 3.96,LDH level: 241.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: BCOR,BRAF,CDKN2A,CREBBP,FBXW7,GRIN2A,KDM5C,NSD1,PTEN,SMAD3,TP53,CNV alterations: MYCN(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 48.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165.3 cm,Body weight: 71 kg,BMI: 25.98,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 9.59,Albumin: 3.5 g/dL,Lymphocyte: 1.47,Neutrophil: 6.48,LDH level: 232.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 168.4 cm,Body weight: 74.2 kg,BMI: 26.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.31,Albumin: 4.0 g/dL,Lymphocyte: 1.8,Neutrophil: 2.83,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: HNF1A,KRAS,TP53,U2AF1,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 159 cm,Body weight: 57.3 kg,BMI: 22.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.31,Albumin: 4.6 g/dL,Lymphocyte: 1.06,Neutrophil: 6.75,LDH level: 523.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab or Pembrolizumab/Tiragolumab/Pemetrexed/Carboplatin,SNV mutations: NCOR1,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),KIT(gain),MYC(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 160 cm,Body weight: 49 kg,BMI: 19.14,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.7,Albumin: 4.0 g/dL,Lymphocyte: 1.32,Neutrophil: 3.02,LDH level: 156.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: CTNNB1,EGFR,TP53,CNV alterations: BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF14(gain),FGFR1(loss),LAMP1(gain),MET(gain),NKX3-1(loss),NRG1(loss),PDGFRB(gain),PPP2R2A(loss),SMAD2(loss),SMAD4(loss),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 177 cm,Body weight: 59 kg,BMI: 18.74,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 16.05,Albumin: 3.0 g/dL,Lymphocyte: 1.42,Neutrophil: 13.43,LDH level: 222.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CTNNB1,NCOR1,CNV alterations: MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 167.6 cm,Body weight: 77.4 kg,BMI: 27.55,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 20%,WBC: 6.87,Albumin: 4.7 g/dL,Lymphocyte: 1.89,Neutrophil: 4.14,LDH level: 138.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tiragolumab/Atezolizumab,SNV mutations: KRAS,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 151.9 cm,Body weight: 45.2 kg,BMI: 19.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E709A, G719C,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 15.72,Albumin: 3.5 g/dL,Lymphocyte: 2.17,Neutrophil: 12.38,LDH level: 235.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: ALK(gain),ATM(gain),BRAF(gain),CCND1(gain),CDK6(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGF8(loss),FGFR1(loss),MET(gain),MYC(gain),NRG1(loss),PIK3CB(loss),PTEN(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 159.3 cm,Body weight: 44.8 kg,BMI: 17.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 1.39,Albumin: 3.1 g/dL,Lymphocyte: 0.32,Neutrophil: 0.97,LDH level: 200.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NF1,CNV alterations: CDK4(gain),FRS2(gain),GLI1(gain),MDM2(gain),NFKBIA(gain),PRSS8(gain),ZNF703(loss),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 157.2 cm,Body weight: 57.5 kg,BMI: 23.27,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 20.2,Albumin: 3.7 g/dL,Lymphocyte: 1.47,Neutrophil: 17.76,LDH level: 246.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: ALK(gain),CCNE1(gain),KDM5C(loss),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 163 cm,Body weight: 58 kg,BMI: 21.83,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 10.15,Albumin: 3.9 g/dL,Lymphocyte: 1.46,Neutrophil: 7.15,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,EP300,NF1,RASA1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 167.6 cm,Body weight: 48.5 kg,BMI: 17.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 8.7,Albumin: 3.3 g/dL,Lymphocyte: 2.0,Neutrophil: 6.14,LDH level: 156.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID2,ERBB2,TP53,CNV alterations: AKT3(gain),APC(loss),BCL6(gain),BRAF(gain),CCND3(gain),CDK6(gain),CDKN1A(gain),DDR2(gain),EZH2(gain),MDM4(gain),MET(gain),PIK3CA(gain),PIM1(gain),PMAIP1(loss),RHEB(gain),SMAD2(loss),SMAD4(loss),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 27.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 175 cm,Body weight: 80 kg,BMI: 26.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 12.04,Albumin: 4.2 g/dL,Lymphocyte: 2.38,Neutrophil: 7.9,LDH level: 374.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA1,BRCA2,TP53,CNV alterations: CDK4(gain),ERBB2(gain),MDM2(gain),MYC(gain),RPS6KB1(gain),Fusion genes: NRG1,Splice variants: None,TMB: 51.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 167 cm,Body weight: 76 kg,BMI: 27.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 17.28,Albumin: 3.6 g/dL,Lymphocyte: 1.64,Neutrophil: 14.33,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,NF1,RBM10,TP53,CNV alterations: EGFR(gain),FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 148.8 cm,Body weight: 72.9 kg,BMI: 32.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.8,Albumin: 3.8 g/dL,Lymphocyte: 1.48,Neutrophil: 4.48,LDH level: 245.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 174.5 cm,Body weight: 84.1 kg,BMI: 27.62,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.68,Albumin: 3.7 g/dL,Lymphocyte: 3.91,Neutrophil: 3.11,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-4830/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FOXP1,GNAS,MYD88,PBRM1,PTPRT,STK11,TP53,CNV alterations: CCND3(gain),Fusion genes: None,Splice variants: None,TMB: 34.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 167 cm,Body weight: 62 kg,BMI: 22.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 1%,WBC: 6.61,Albumin: 4.7 g/dL,Lymphocyte: 2.42,Neutrophil: 3.66,LDH level: 160.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib or Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 164 cm,Body weight: 59 kg,BMI: 21.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.64,Albumin: 4.1 g/dL,Lymphocyte: 1.39,Neutrophil: 3.29,LDH level: 168.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: APC,EGFR,MGA,MSH6,SMAD4,CNV alterations: CCND3(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 174 cm,Body weight: 73 kg,BMI: 24.08,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 6.88,Albumin: 3.6 g/dL,Lymphocyte: 1.33,Neutrophil: 4.48,LDH level: 162.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,PALB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 162 cm,Body weight: 68 kg,BMI: 25.91,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,WBC: 6.44,Albumin: 4.3 g/dL,Lymphocyte: 2.35,Neutrophil: 3.13,LDH level: 268.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: TP53,CNV alterations: FGFR1(gain),LAMP1(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 160 cm,Body weight: 51.5 kg,BMI: 20.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 90%,WBC: 7.39,Albumin: 4.5 g/dL,Lymphocyte: 2.06,Neutrophil: 4.88,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 155 cm,Body weight: 40.2 kg,BMI: 16.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.23,Albumin: 4.7 g/dL,Lymphocyte: 1.13,Neutrophil: 5.81,LDH level: 189.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 151 cm,Body weight: 49 kg,BMI: 21.37,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.64,Albumin: 4.0 g/dL,Lymphocyte: 2.09,Neutrophil: 2.91,LDH level: 246.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EP300,GATA4,RB1,STK11,TP53,CNV alterations: EGFR(gain),MYC(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 164.2 cm,Body weight: 66.5 kg,BMI: 24.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 12.23,Albumin: 4.4 g/dL,Lymphocyte: 1.07,Neutrophil: 10.91,LDH level: 229.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Ociperlimab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 171.4 cm,Body weight: 67.6 kg,BMI: 23.01,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.52,Albumin: 4.5 g/dL,Lymphocyte: 2.93,Neutrophil: 3.68,LDH level: 248.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: KEAP1,TP53,CNV alterations: AKT2(gain),CCND3(gain),CCNE1(gain),FGF8(loss),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 173 cm,Body weight: 60 kg,BMI: 20.05,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.63,Albumin: 3.1 g/dL,Lymphocyte: 0.93,Neutrophil: 9.18,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,NOTCH1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 158 cm,Body weight: 62 kg,BMI: 24.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 3.52,Albumin: 4.2 g/dL,Lymphocyte: 1.1,Neutrophil: 2.02,LDH level: 184.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,KRAS,SF3B1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 70 kg,BMI: 24.22,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 9.91,Albumin: 2.8 g/dL,Lymphocyte: 1.18,Neutrophil: 7.66,LDH level: 224.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: EP300,TET2,TP53,CNV alterations: LAMP1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 162.6 cm,Body weight: 70.4 kg,BMI: 26.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.1,Albumin: 4.5 g/dL,Lymphocyte: 2.39,Neutrophil: 3.94,LDH level: 177.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 168 cm,Body weight: 69.9 kg,BMI: 24.77,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.45,Albumin: 4.4 g/dL,Lymphocyte: 1.2,Neutrophil: 9.55,LDH level: 196.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 151 cm,Body weight: 50 kg,BMI: 21.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,WBC: 7.72,Albumin: 3.6 g/dL,Lymphocyte: 1.0,Neutrophil: 6.2,LDH level: 214.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 155.6 cm,Body weight: 49 kg,BMI: 20.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.73,Albumin: 4.1 g/dL,Lymphocyte: 1.56,Neutrophil: 6.31,LDH level: 184.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168.1 cm,Body weight: 53.5 kg,BMI: 18.93,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 6.66,Albumin: 4.7 g/dL,Lymphocyte: 1.47,Neutrophil: 4.7,LDH level: 192.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin/Tislelizumab/Ociperlimab or Placebo,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: M,Height: 179.9 cm,Body weight: 69.6 kg,BMI: 21.51,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 45%,PD-L1 (SP263): 2%,WBC: 9.71,Albumin: 4.3 g/dL,Lymphocyte: 1.59,Neutrophil: 7.26,LDH level: 146.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: DS-1062a/Pembrolizumab/Carboplatin,SNV mutations: ARID1A,KEAP1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 174.1 cm,Body weight: 99 kg,BMI: 32.66,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,PD-L1 (SP263): 10%,WBC: 5.36,Albumin: 4.6 g/dL,Lymphocyte: 1.28,Neutrophil: 3.2,LDH level: 155.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BCOR,KRAS,MSH3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 157 cm,Body weight: 63 kg,BMI: 25.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 5%,WBC: 11.93,Albumin: 4.2 g/dL,Lymphocyte: 2.14,Neutrophil: 8.55,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 154.8 cm,Body weight: 41.8 kg,BMI: 17.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 50%,WBC: 10.05,Albumin: 3.1 g/dL,Lymphocyte: 1.2,Neutrophil: 7.84,LDH level: 272.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: GEN1042/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MGA,RBM10,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF23(gain),FGF3(gain),FGF4(gain),FGF6(gain),JAK2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: F,Height: 157 cm,Body weight: 52 kg,BMI: 21.02,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.95,Albumin: 4.8 g/dL,Lymphocyte: 1.13,Neutrophil: 4.33,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 174 cm,Body weight: 75 kg,BMI: 24.77,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 155.2 cm,Body weight: 56.8 kg,BMI: 23.58,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,WBC: 5.84,Albumin: 4.4 g/dL,Lymphocyte: 0.83,Neutrophil: 4.25,LDH level: 265.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: LATS1,SUZ12,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 167 cm,Body weight: 65 kg,BMI: 23.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 5.92,Albumin: 3.9 g/dL,Lymphocyte: 1.25,Neutrophil: 4.06,LDH level: 165.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 161 cm,Body weight: 56 kg,BMI: 21.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 7.02,Albumin: 3.8 g/dL,Lymphocyte: 0.95,Neutrophil: 5.37,LDH level: 137.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 171.6 cm,Body weight: 62 kg,BMI: 21.06,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 13.16,Albumin: 2.8 g/dL,Lymphocyte: 2.01,Neutrophil: 9.73,LDH level: 207.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.34,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 21.85,Albumin: 3.3 g/dL,Lymphocyte: 1.01,Neutrophil: 18.93,LDH level: 188.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,ZFHX3,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGF7(gain),LAMP1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 33.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 170.8 cm,Body weight: 74.3 kg,BMI: 25.47,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 12.29,Albumin: 4.8 g/dL,Lymphocyte: 1.49,Neutrophil: 10.11,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Pembrolizumab/Lenvatinib or placebo/Pemetraxed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 156 cm,Body weight: 73 kg,BMI: 30.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.01,Albumin: 4.2 g/dL,Lymphocyte: 2.5,Neutrophil: 5.67,LDH level: 173.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 171.2 cm,Body weight: 76.6 kg,BMI: 26.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.36,Albumin: 4.1 g/dL,Lymphocyte: 1.72,Neutrophil: 4.73,LDH level: 1253.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NKX2-1,TP53,CNV alterations: AKT2(gain),ERBB2(gain),FGFR1(gain),JAK2(loss),NKX2-1(loss),NRG1(loss),PIK3CA(gain),PIK3CB(gain),SMARCA4(loss),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 169 cm,Body weight: 67 kg,BMI: 23.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 8.1,Albumin: 3.2 g/dL,Lymphocyte: 2.95,Neutrophil: 3.97,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: APC,KEAP1,NOTCH3,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 172 cm,Body weight: 72 kg,BMI: 24.34,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 10.11,Albumin: 3.7 g/dL,Lymphocyte: 1.33,Neutrophil: 7.67,LDH level: 269.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: APC,KRAS,STK11,CNV alterations: FGF10(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 170.9 cm,Body weight: 81.6 kg,BMI: 27.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 1%,WBC: 6.85,Albumin: 4.3 g/dL,Lymphocyte: 2.74,Neutrophil: 2.96,LDH level: 203.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,NFKBIA,PTPRD,TP53,CNV alterations: ALK(gain),BRAF(gain),CDK6(gain),ERBB2(gain),ERCC2(gain),MET(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 18.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 170 cm,Body weight: 75 kg,BMI: 25.95,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 4.64,Albumin: 4.0 g/dL,Lymphocyte: 1.6,Neutrophil: 2.5,LDH level: 200.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: FGF10(gain),FGF23(gain),KRAS(gain),MYC(gain),MYCN(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 14.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 139.9 cm,Body weight: 32.2 kg,BMI: 16.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 4.68,Albumin: 4.1 g/dL,Lymphocyte: 0.74,Neutrophil: 3.24,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,LZTR1,MGA,NF1,PTEN,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 170 cm,Body weight: 85 kg,BMI: 29.41,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Vinorelbine/Cisplatin -> Vinorelbine/Carboplatin,SNV mutations: NFE2L2,RB1,TP53,CNV alterations: MET(gain),MYC(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 152.9 cm,Body weight: 42.7 kg,BMI: 18.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.13,Albumin: 3.4 g/dL,Lymphocyte: 0.53,Neutrophil: 8.18,LDH level: 139.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,ERBB2,IDH1,PIK3CA,RBM10,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 151.8 cm,Body weight: 55.9 kg,BMI: 24.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 5.21,Albumin: 4.3 g/dL,Lymphocyte: 2.27,Neutrophil: 2.21,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CCNE1(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),ERBB2(gain),FGF10(gain),FGFR3(loss),FOXA1(gain),JAK2(loss),MET(gain),MST1R(loss),NFKBIA(gain),NKX2-1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 155 cm,Body weight: 45 kg,BMI: 18.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.42,Albumin: 4.4 g/dL,Lymphocyte: 1.46,Neutrophil: 6.72,LDH level: 230.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: AKT2(gain),Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 170 cm,Body weight: 65.2 kg,BMI: 22.56,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 2.96,Albumin: 4.3 g/dL,Lymphocyte: 0.83,Neutrophil: 1.51,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 30.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 155.9 cm,Body weight: 55.5 kg,BMI: 22.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.95,Albumin: 4.1 g/dL,Lymphocyte: 2.43,Neutrophil: 10.58,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: ARID5B,EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 163 cm,Body weight: 65 kg,BMI: 24.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 7.07,Albumin: 4.4 g/dL,Lymphocyte: 1.44,Neutrophil: 4.71,LDH level: 224.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KRAS,TET2,TP53,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 154.6 cm,Body weight: 69.5 kg,BMI: 29.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.34,Albumin: 4.3 g/dL,Lymphocyte: 1.32,Neutrophil: 2.71,LDH level: 273.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Vabametkib,SNV mutations: KRAS,MET,CNV alterations: EGFR(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 163.1 cm,Body weight: 56.7 kg,BMI: 21.31,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 11.68,Albumin: 4.2 g/dL,Lymphocyte: 2.63,Neutrophil: 7.53,LDH level: 135.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 159.4 cm,Body weight: 56.7 kg,BMI: 22.32,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.72,Albumin: 3.9 g/dL,Lymphocyte: 1.26,Neutrophil: 5.62,LDH level: 198.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 153.4 cm,Body weight: 58.2 kg,BMI: 24.73,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 7.18,Albumin: 4.2 g/dL,Lymphocyte: 1.52,Neutrophil: 4.12,LDH level: 284.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: FGF1(loss),FGF7(loss),FLT4(loss),PDGFRB(loss),RB1(loss),SNCAIP(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 157.1 cm,Body weight: 63.4 kg,BMI: 25.69,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.76,Albumin: 3.6 g/dL,Lymphocyte: 1.57,Neutrophil: 2.37,LDH level: 214.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CDH1,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 169 cm,Body weight: 64 kg,BMI: 22.41,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 8.32,Albumin: 4.2 g/dL,Lymphocyte: 1.7,Neutrophil: 5.83,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ATR,CDKN2A,TP53,CNV alterations: FGFR1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 172.5 cm,Body weight: 62.9 kg,BMI: 21.14,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.51,Albumin: 4.2 g/dL,Lymphocyte: 2.39,Neutrophil: 6.67,LDH level: 144.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel,SNV mutations: STK11,CNV alterations: ARFRP1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 72.3 kg,BMI: 25.62,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,WBC: 7.09,Albumin: 2.9 g/dL,Lymphocyte: 1.37,Neutrophil: 4.42,LDH level: 371.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 170 cm,Body weight: 61 kg,BMI: 21.28,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.72,Albumin: 4.4 g/dL,Lymphocyte: 2.42,Neutrophil: 5.44,LDH level: 223.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: DNMT3A,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 18.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 171 cm,Body weight: 78 kg,BMI: 26.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 75%,PD-L1 (SP263): 80%,WBC: 4.46,Albumin: 4.1 g/dL,Lymphocyte: 1.13,Neutrophil: 2.76,LDH level: 192.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,MSH6,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 157 cm,Body weight: 61 kg,BMI: 24.74,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 9.53,Albumin: 4.2 g/dL,Lymphocyte: 0.63,Neutrophil: 8.79,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: ERBB4,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 165 cm,Body weight: 79.1 kg,BMI: 29.05,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 25%,WBC: 5.87,Albumin: 4.9 g/dL,Lymphocyte: 1.39,Neutrophil: 3.63,LDH level: 171.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: SMO,TP53,CNV alterations: CDKN2A(loss),FGFR1(gain),HIST1H3H(loss),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 158 cm,Body weight: 56 kg,BMI: 22.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.71,Albumin: 4.2 g/dL,Lymphocyte: 1.72,Neutrophil: 3.07,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165.3 cm,Body weight: 65.2 kg,BMI: 23.86,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.12,Albumin: 3.9 g/dL,Lymphocyte: 1.81,Neutrophil: 4.62,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: FH,RASA1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 173 cm,Body weight: 78.5 kg,BMI: 26.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.4,Albumin: 5.2 g/dL,Lymphocyte: 1.89,Neutrophil: 3.82,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: ERBB2,GPS2,SETD2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 159 cm,Body weight: 53.7 kg,BMI: 21.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.42,Albumin: 4.2 g/dL,Lymphocyte: 1.51,Neutrophil: 3.35,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 153 cm,Body weight: 51 kg,BMI: 21.93,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.16,Albumin: 4.8 g/dL,Lymphocyte: 1.49,Neutrophil: 2.26,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: SETD2,TET2,CNV alterations: AR(loss),BRCA1(gain),ESR1(loss),MDM4(gain),MYC(gain),NRG1(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 165.9 cm,Body weight: 62.7 kg,BMI: 22.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.06,Albumin: 3.3 g/dL,Lymphocyte: 1.06,Neutrophil: 7.44,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: APC,EGFR,PTEN,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 173.2 cm,Body weight: 85.4 kg,BMI: 28.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 5%,WBC: 10.78,Albumin: 2.4 g/dL,Lymphocyte: 1.42,Neutrophil: 7.52,LDH level: 315.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 170.1 cm,Body weight: 75.6 kg,BMI: 26.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 14.37,Albumin: 3.0 g/dL,Lymphocyte: 1.32,Neutrophil: 10.22,LDH level: 306.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: SETD2,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 170 cm,Body weight: 59.6 kg,BMI: 20.62,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 15.3,Albumin: 4.7 g/dL,Lymphocyte: 1.16,Neutrophil: 13.24,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,EP300,FANCL,NCOR1,PALB2,PIK3CA,PTPRT,SLX4,SPEN,TP53,CNV alterations: ERBB2(gain),FGF8(loss),FGFR1(loss),JAK2(gain),LAMP1(gain),MDM4(gain),MYC(gain),MYCL(gain),NRG1(loss),Fusion genes: None,Splice variants: None,TMB: 62.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 163.2 cm,Body weight: 63.1 kg,BMI: 23.69,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.67,Albumin: 4.0 g/dL,Lymphocyte: 2.7,Neutrophil: 3.25,LDH level: 224.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: NRG1,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 162 cm,Body weight: 55 kg,BMI: 20.90,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.44,Albumin: 3.7 g/dL,Lymphocyte: 1.9,Neutrophil: 4.66,LDH level: 151.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TET2,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166 cm,Body weight: 71 kg,BMI: 25.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.22,Albumin: 4.5 g/dL,Lymphocyte: 1.41,Neutrophil: 4.37,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ATM,PIK3CA,TP53,CNV alterations: AKT2(gain),CCNE1(gain),FGF10(gain),MDM4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 170 cm,Body weight: 65 kg,BMI: 22.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <50%,PD-L1 (SP263): <50%,WBC: 13.16,Albumin: 4.6 g/dL,Lymphocyte: 1.84,Neutrophil: 8.37,LDH level: 570.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MAX,TP53,CNV alterations: ERBB2(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 170 cm,Body weight: 65 kg,BMI: 22.49,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,WBC: 9.33,Albumin: 4.6 g/dL,Lymphocyte: 1.43,Neutrophil: 7.03,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: EGFR(gain),FGF10(gain),MYCL(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 154.5 cm,Body weight: 44.5 kg,BMI: 18.64,Smoking history: Former smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: BRAF,DNMT3A,KDM5C,KEAP1,NOTCH4,STK11,TP53,TP63,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 159 cm,Body weight: 57.5 kg,BMI: 22.74,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: BRAF,TP53,CNV alterations: None,Fusion genes: RPS6KB1,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 156.5 cm,Body weight: 59.7 kg,BMI: 24.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 10.49,Albumin: 4.5 g/dL,Lymphocyte: 3.13,Neutrophil: 5.24,LDH level: 209.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,NF2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 163.1 cm,Body weight: 57.8 kg,BMI: 21.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.5,Albumin: 4.0 g/dL,Lymphocyte: 3.06,Neutrophil: 3.47,LDH level: 171.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 158.9 cm,Body weight: 54.1 kg,BMI: 21.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 6.19,Albumin: 4.7 g/dL,Lymphocyte: 0.92,Neutrophil: 5.19,LDH level: 162.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 150.6 cm,Body weight: 55.5 kg,BMI: 24.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: non-squamous non-small cell carcinoma with sarcomatoid feature,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.3,Albumin: 3.2 g/dL,Lymphocyte: 1.38,Neutrophil: 5.93,LDH level: 129.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK6(gain),ERCC2(gain),Fusion genes: MET,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 170.4 cm,Body weight: 76.1 kg,BMI: 26.21,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 7.17,Albumin: 4.3 g/dL,Lymphocyte: 1.16,Neutrophil: 5.22,LDH level: 150.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tislelizumab/Ociperlimab,SNV mutations: ARAF,NOTCH4,RASA1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 166 cm,Body weight: 79 kg,BMI: 28.92,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 3%,WBC: 15.95,Albumin: 3.3 g/dL,Lymphocyte: 1.57,Neutrophil: 13.57,LDH level: 292.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PBRM1,SMARCA4,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 63 kg,BMI: 22.35,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 5%,WBC: 11.03,Albumin: 2.9 g/dL,Lymphocyte: 1.17,Neutrophil: 8.74,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/MK7684,SNV mutations: NOTCH1,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),JAK2(loss),NRG1(loss),PIK3CA(gain),PPP2R2A(loss),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 175 cm,Body weight: 86 kg,BMI: 28.08,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: NF1,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 21.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 150 cm,Body weight: 56 kg,BMI: 24.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 7.51,Albumin: 4.5 g/dL,Lymphocyte: 2.07,Neutrophil: 4.63,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 165.7 cm,Body weight: 63.3 kg,BMI: 23.05,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 2%,WBC: 4.31,Albumin: 4.4 g/dL,Lymphocyte: 1.77,Neutrophil: 2.23,LDH level: 483.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CB,TP53,CNV alterations: EGFR(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 157 cm,Body weight: 53 kg,BMI: 21.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L861Q,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.81,Albumin: 4.5 g/dL,Lymphocyte: 2.37,Neutrophil: 2.54,LDH level: 156.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: CCNE1(gain),LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 164.5 cm,Body weight: 51 kg,BMI: 18.85,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): <5%,WBC: 6.16,Albumin: 3.9 g/dL,Lymphocyte: 1.09,Neutrophil: 4.49,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ATRX,EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 171 cm,Body weight: 65 kg,BMI: 22.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.67,Albumin: 4.8 g/dL,Lymphocyte: 2.27,Neutrophil: 7.31,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: AKT3(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 172 cm,Body weight: 77 kg,BMI: 26.03,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 12.67,Albumin: 4.1 g/dL,Lymphocyte: 1.7,Neutrophil: 9.14,LDH level: 254.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,MAP2K1,TP53,CNV alterations: CCND3(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 164.5 cm,Body weight: 60 kg,BMI: 22.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: F,Height: 167 cm,Body weight: 71 kg,BMI: 25.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.47,Albumin: 4.1 g/dL,Lymphocyte: 2.74,Neutrophil: 2.95,LDH level: 295.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 90 years old,Sex: M,Height: 156 cm,Body weight: 52 kg,BMI: 21.49,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 18.72,Albumin: 2.5 g/dL,Lymphocyte: 1.75,Neutrophil: 15.96,LDH level: 311.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: IDH2,KRAS,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 168 cm,Body weight: 57 kg,BMI: 20.32,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 2.98,Albumin: 2.7 g/dL,Lymphocyte: 0.46,Neutrophil: 2.07,LDH level: 343.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MAP2K4,TP53,CNV alterations: CCNE1(gain),EGFR(gain),MYC(gain),PHOX2B(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: F,Height: 158 cm,Body weight: 49 kg,BMI: 19.63,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: 40%,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 75%,WBC: 7.37,Albumin: 4.3 g/dL,Lymphocyte: 1.92,Neutrophil: 4.68,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 158.1 cm,Body weight: 64.8 kg,BMI: 25.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.15,Albumin: 4.0 g/dL,Lymphocyte: 1.76,Neutrophil: 2.95,LDH level: 235.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 147.7 cm,Body weight: 60.9 kg,BMI: 27.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E18del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.62,Albumin: 3.9 g/dL,Lymphocyte: 1.75,Neutrophil: 4.08,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BCOR,CDKN2A,EGFR,PIK3CA,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF7(loss),FGF8(loss),JAK2(loss),PTEN(loss),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 157 cm,Body weight: 68 kg,BMI: 27.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 9.54,Albumin: 4.6 g/dL,Lymphocyte: 2.03,Neutrophil: 6.03,LDH level: 266.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: ERBB2,SETD2,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: F,Height: 155 cm,Body weight: 62 kg,BMI: 26.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.8,Albumin: 4.5 g/dL,Lymphocyte: 2.55,Neutrophil: 5.31,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BIRC3,KRAS,NKX2-1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 154 cm,Body weight: 47 kg,BMI: 19.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,WBC: 5.71,Albumin: 3.5 g/dL,Lymphocyte: 1.48,Neutrophil: 3.4,LDH level: 472.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,FAT1,KMT2A,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 159 cm,Body weight: 50.5 kg,BMI: 19.98,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.58,Albumin: 3.8 g/dL,Lymphocyte: 1.92,Neutrophil: 6.37,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,EGFR,SLX4,TP53,CNV alterations: CCNE1(gain),EGFR(gain),ERCC1(gain),ERCC2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 161.4 cm,Body weight: 47.4 kg,BMI: 18.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 3.08,Albumin: 4.9 g/dL,Lymphocyte: 1.07,Neutrophil: 1.71,LDH level: 176.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,PIK3R1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 155 cm,Body weight: 54 kg,BMI: 22.48,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.74,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: ATM,DNMT3A,EGFR,KRAS,PIK3CA,SMO,TP53,CNV alterations: SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 168 cm,Body weight: 60 kg,BMI: 21.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 36.92,Albumin: 2.8 g/dL,Lymphocyte: 3.76,Neutrophil: 30.77,LDH level: 361.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 161 cm,Body weight: 65 kg,BMI: 25.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 5.61,Albumin: 5.1 g/dL,Lymphocyte: 2.12,Neutrophil: 3.05,LDH level: 162.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: CDK4(gain),FGF23(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 166.8 cm,Body weight: 68.1 kg,BMI: 24.48,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 8.95,Albumin: 4.0 g/dL,Lymphocyte: 2.87,Neutrophil: 5.16,LDH level: 135.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Vibostolimab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,SMARCA4,TP53,CNV alterations: EGFR(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 177.5 cm,Body weight: 68.9 kg,BMI: 21.87,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 3.15,Albumin: 4.2 g/dL,Lymphocyte: 0.76,Neutrophil: 1.93,LDH level: 245.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ERBB2,TP53,TSC2,CNV alterations: CCNE1(gain),ERBB2(gain),ERCC1(gain),ERCC2(gain),FGF10(gain),FGF8(loss),FGFR4(gain),NPM1(gain),RB1(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 169 cm,Body weight: 54 kg,BMI: 18.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 21.19,Albumin: 3.7 g/dL,Lymphocyte: 3.62,Neutrophil: 16.32,LDH level: 319.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,TP53,CNV alterations: ATM(gain),CCND1(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR3(gain),JAK2(loss),MET(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 171.5 cm,Body weight: 71.8 kg,BMI: 24.41,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.95,Albumin: 4.3 g/dL,Lymphocyte: 1.38,Neutrophil: 5.73,LDH level: 210.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 172 cm,Body weight: 71 kg,BMI: 23.81,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 8.78,Albumin: 4.2 g/dL,Lymphocyte: 1.53,Neutrophil: 6.47,LDH level: 238.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: FGF23(gain),FGF6(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166 cm,Body weight: 62 kg,BMI: 22.50,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.37,Albumin: 3.7 g/dL,Lymphocyte: 1.43,Neutrophil: 7.85,LDH level: 203.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KEAP1,LATS1,TP53,CNV alterations: BRAF(gain),EGFR(gain),FGF10(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 157 cm,Body weight: 50.9 kg,BMI: 20.65,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.95,Albumin: 3.2 g/dL,Lymphocyte: 1.25,Neutrophil: 4.81,LDH level: 233.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,CNV alterations: AKT1(gain),BCL6(gain),FGFR1(gain),MYC(gain),NRG1(gain),PIK3CA(gain),PIK3CB(gain),SHQ1(loss),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 165.7 cm,Body weight: 45.5 kg,BMI: 16.57,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.39,Albumin: 3.9 g/dL,Lymphocyte: 1.67,Neutrophil: 4.81,LDH level: 221.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 5.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 170 cm,Body weight: 78 kg,BMI: 27.09,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.43,Albumin: 4.9 g/dL,Lymphocyte: 1.58,Neutrophil: 3.22,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: SDHB,STK11,TP53,CNV alterations: None,Fusion genes: NTRK2,Splice variants: None,TMB: 23.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 160 cm,Body weight: 67 kg,BMI: 26.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.69,Albumin: 3.5 g/dL,Lymphocyte: 1.39,Neutrophil: 4.14,LDH level: 226.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,CNV alterations: ERBB2(gain),JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 170 cm,Body weight: 74 kg,BMI: 25.61,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.67,Albumin: 4.5 g/dL,Lymphocyte: 1.79,Neutrophil: 3.22,LDH level: 169.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: RB1,TET2,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 12.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166.8 cm,Body weight: 62.4 kg,BMI: 22.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.23,Albumin: 3.7 g/dL,Lymphocyte: 1.25,Neutrophil: 5.5,LDH level: 638.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FBXW7,TP53,CNV alterations: FGF10(gain),FGFR2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 148 cm,Body weight: 34 kg,BMI: 15.49,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 5%,WBC: 65.69,Albumin: 3.4 g/dL,Lymphocyte: 2.26,Neutrophil: 57.13,LDH level: 226.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: KRAS,MGA,PIK3CA,RAD50,TP53,CNV alterations: MDM4(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 19.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166.5 cm,Body weight: 65.4 kg,BMI: 23.59,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 13.28,Albumin: 4.1 g/dL,Lymphocyte: 2.06,Neutrophil: 9.85,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 173 cm,Body weight: 84 kg,BMI: 28.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 5.8,Albumin: 4.8 g/dL,Lymphocyte: 1.45,Neutrophil: 3.63,LDH level: 235.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 165 cm,Body weight: 70 kg,BMI: 25.54,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 12.33,Albumin: 5.0 g/dL,Lymphocyte: 4.8,Neutrophil: 6.04,LDH level: 194.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,BRAF,PTEN,CNV alterations: CDK6(gain),CDKN2A(loss),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 169.5 cm,Body weight: 76.5 kg,BMI: 26.63,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.27,Albumin: 4.7 g/dL,Lymphocyte: 2.87,Neutrophil: 2.68,LDH level: 140.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KMT2A,KRAS,NCOR1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 174.2 cm,Body weight: 51.2 kg,BMI: 16.87,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): >95%,WBC: 7.51,Albumin: 4.2 g/dL,Lymphocyte: 1.81,Neutrophil: 4.9,LDH level: 145.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RB1,SDHA,CNV alterations: CARD11(gain),EGFR(gain),ETV1(gain),FGF14(gain),LAMP1(gain),MET(gain),RAC1(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 158 cm,Body weight: 65.7 kg,BMI: 26.32,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 8.53,Albumin: 4.4 g/dL,Lymphocyte: 1.79,Neutrophil: 5.49,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Dabrafenib/Trametinib,SNV mutations: BRAF,FBXW7,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 177.4 cm,Body weight: 74.8 kg,BMI: 23.77,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 5%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 4.69,Albumin: 4.7 g/dL,Lymphocyte: 1.84,Neutrophil: 2.43,LDH level: 145.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 171.9 cm,Body weight: 79.5 kg,BMI: 26.90,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): >10%,WBC: 7.11,Albumin: 4.1 g/dL,Lymphocyte: 0.86,Neutrophil: 5.51,LDH level: 159.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: RBM10,SMARCA4,TP53,CNV alterations: EED(loss),FGF10(gain),LAMP1(gain),MYCL(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 168 cm,Body weight: 67 kg,BMI: 23.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 7.37,Albumin: 4.4 g/dL,Lymphocyte: 1.64,Neutrophil: 5.01,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Canakinumab,SNV mutations: KRAS,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 156 cm,Body weight: 48.5 kg,BMI: 19.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 9.53,Albumin: 4.3 g/dL,Lymphocyte: 1.25,Neutrophil: 7.5,LDH level: 381.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 162 cm,Body weight: 52.5 kg,BMI: 20.00,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 10.78,Albumin: 3.6 g/dL,Lymphocyte: 1.61,Neutrophil: 8.2,LDH level: 257.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ASXL1,CDKN2A,CREBBP,KDM6A,MAP3K1,PTEN,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 69.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 167 cm,Body weight: 65 kg,BMI: 23.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.37,Albumin: 3.8 g/dL,Lymphocyte: 1.44,Neutrophil: 5.47,LDH level: 371.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CREBBP,EGFR,MTOR,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),MDM2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 158 cm,Body weight: 49 kg,BMI: 19.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,WBC: 8.56,Albumin: 4.0 g/dL,Lymphocyte: 1.72,Neutrophil: 5.49,LDH level: 182.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 158 cm,Body weight: 50 kg,BMI: 20.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 8.79,Albumin: 4.2 g/dL,Lymphocyte: 0.66,Neutrophil: 7.47,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 170 cm,Body weight: 68 kg,BMI: 23.53,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.19,Albumin: 3.9 g/dL,Lymphocyte: 1.22,Neutrophil: 4.9,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: CDKN2A,RB1,TP53,CNV alterations: ALOX12B(loss),ANKRD11(loss),BAP1(loss),CD74(loss),CDKN2A(loss),CSF1R(loss),CTNNA1(loss),FGF1(loss),FGF8(loss),FGFR2(loss),FGFR4(loss),FLT4(loss),GRIN2A(loss),H3F3A(gain),LATS2(loss),PARK2(loss),PAX5(loss),PDGFRB(loss),RAD51(loss),RB1(loss),RET(loss),SLX4(loss),SUFU(loss),TCF7L2(loss),TGFBR2(loss),TP53(loss),TRAF7(loss),TSC2(loss),ZFHX3(loss),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 169 cm,Body weight: 63 kg,BMI: 22.19,Smoking history: Current smoker,Cancer stage: Mixed,Histology: Combined small cell carcinoma and squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 6.42,Albumin: 3.8 g/dL,Lymphocyte: 1.81,Neutrophil: 3.91,LDH level: 468.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID1A,NFE2L2,TP53,CNV alterations: BRCA1(gain),FGF6(loss),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 162 cm,Body weight: 49 kg,BMI: 18.73,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,WBC: 17.25,Albumin: 2.6 g/dL,Lymphocyte: 1.34,Neutrophil: 14.65,LDH level: 216.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BCOR,KRAS,PIK3CB,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 159 cm,Body weight: 70 kg,BMI: 27.69,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.14,Albumin: 4.0 g/dL,Lymphocyte: 0.96,Neutrophil: 7.15,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Necitumumab/Paclitaxel/Carboplatin,SNV mutations: NOTCH1,SMARCA4,TP53,TP63,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGFR1(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 166 cm,Body weight: 55 kg,BMI: 19.98,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.57,Albumin: 3.7 g/dL,Lymphocyte: 1.98,Neutrophil: 6.53,LDH level: 252.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: BRCA1(gain),ERBB2(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162 cm,Body weight: 43.5 kg,BMI: 16.58,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 3%,WBC: 4.97,Albumin: 4.4 g/dL,Lymphocyte: 1.11,Neutrophil: 3.58,LDH level: 158.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EPHA7,RAD51D,SMO,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 154 cm,Body weight: 45 kg,BMI: 18.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 5.73,Albumin: 4.8 g/dL,Lymphocyte: 1.53,Neutrophil: 3.68,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: PTEN(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 155 cm,Body weight: 46.7 kg,BMI: 19.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,WBC: 6.89,Albumin: 4.6 g/dL,Lymphocyte: 0.92,Neutrophil: 5.56,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel/Carboplatin,SNV mutations: BARD1,CARD11,ERBB2,KIT,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 168.1 cm,Body weight: 65.1 kg,BMI: 23.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 9.89,Albumin: 3.9 g/dL,Lymphocyte: 1.67,Neutrophil: 6.67,LDH level: 155.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: KRAS,TP53,ZFHX3,CNV alterations: CCNE1(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 168 cm,Body weight: 64 kg,BMI: 22.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 6.42,Albumin: 3.9 g/dL,Lymphocyte: 2.72,Neutrophil: 2.84,LDH level: 217.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID2,LZTR1,NKX2-1,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166 cm,Body weight: 58 kg,BMI: 21.05,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 15%,WBC: 10.68,Albumin: 4.3 g/dL,Lymphocyte: 1.58,Neutrophil: 8.15,LDH level: 206.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TGFBR2,TP53,CNV alterations: ASXL1(gain),BCL2L1(gain),CDKN2A(loss),CDKN2B(loss),DNMT3B(gain),Fusion genes: None,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 166 cm,Body weight: 68.3 kg,BMI: 24.79,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 2.92,Albumin: 4.9 g/dL,Lymphocyte: 0.79,Neutrophil: 1.72,LDH level: 344.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: CYLD,RB1,TP53,CNV alterations: EGFR(gain),JAK2(gain),MET(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 146 cm,Body weight: 52 kg,BMI: 24.39,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.77,Albumin: 4.6 g/dL,Lymphocyte: 1.14,Neutrophil: 2.62,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: ARID5B,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 166.7 cm,Body weight: 53.9 kg,BMI: 19.40,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 9.42,Albumin: 4.5 g/dL,Lymphocyte: 2.86,Neutrophil: 5.57,LDH level: 154.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab or Tislelizumab/Ociperlimab or Placebo,SNV mutations: RAD50,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 158 cm,Body weight: 53 kg,BMI: 21.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.97,Albumin: 4.3 g/dL,Lymphocyte: 1.62,Neutrophil: 4.53,LDH level: 220.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NCOR1,SETD2,SMAD4,TET2,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 168 cm,Body weight: 67 kg,BMI: 23.74,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.96,Albumin: 4.6 g/dL,Lymphocyte: 2.31,Neutrophil: 4.61,LDH level: 268.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CB,RB1,TP53,CNV alterations: AR(gain),FGF14(gain),LAMP1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 165.2 cm,Body weight: 57 kg,BMI: 20.89,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 100%,WBC: 26.54,Albumin: 2.9 g/dL,Lymphocyte: 1.53,Neutrophil: 23.6,LDH level: 2309.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 31 years old,Sex: F,Height: 158 cm,Body weight: 62 kg,BMI: 25.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,WBC: 11.91,Albumin: 4.8 g/dL,Lymphocyte: 1.66,Neutrophil: 9.6,LDH level: 158.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,SHQ1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 166.8 cm,Body weight: 68.9 kg,BMI: 24.76,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.91,Albumin: 4.3 g/dL,Lymphocyte: 2.65,Neutrophil: 3.63,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 160 cm,Body weight: 64 kg,BMI: 25.00,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: EP300,NFE2L2,TP53,CNV alterations: CCND3(gain),FGFR1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 21.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 148 cm,Body weight: 42 kg,BMI: 19.04,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 7.43,Albumin: 2.5 g/dL,Lymphocyte: 1.02,Neutrophil: 5.65,LDH level: 140.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 165 cm,Body weight: 70 kg,BMI: 25.71,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 6.53,Albumin: 4.2 g/dL,Lymphocyte: 2.38,Neutrophil: 3.37,LDH level: 231.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 170.1 cm,Body weight: 76.4 kg,BMI: 26.40,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 12.0,Albumin: 3.2 g/dL,Lymphocyte: 0.83,Neutrophil: 10.13,LDH level: 218.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: BRAF,EGFR,TP53,CNV alterations: BRAF(gain),CCND3(gain),CCNE1(gain),CDK6(gain),EGFR(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 136 cm,Body weight: 45 kg,BMI: 24.38,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 4.3,Albumin: 4.2 g/dL,Lymphocyte: 1.0,Neutrophil: 2.69,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,FGFR3,PIK3CA,TP53,CNV alterations: JAK2(loss),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 170 cm,Body weight: 78 kg,BMI: 26.99,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 153 cm,Body weight: 59.7 kg,BMI: 25.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA2,EGFR,CNV alterations: EGFR(gain),MYC(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 150 cm,Body weight: 52 kg,BMI: 23.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Non-small cell carcinoma, NOS,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 10.26,Albumin: 4.4 g/dL,Lymphocyte: 2.74,Neutrophil: 6.14,LDH level: 138.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRCA2,MET,PIK3R3,TP53,CNV alterations: AR(gain),CDK4(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: MET,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 157 cm,Body weight: 54 kg,BMI: 21.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.18,Albumin: 4.3 g/dL,Lymphocyte: 1.7,Neutrophil: 3.71,LDH level: 181.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: PPP2R2A,RB1,TP53,CNV alterations: ERBB2(gain),NFKBIA(gain),RARA(gain),TOP2A(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 154.8 cm,Body weight: 39.6 kg,BMI: 16.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.64,Albumin: 4.7 g/dL,Lymphocyte: 2.41,Neutrophil: 5.21,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1B,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 172.3 cm,Body weight: 69.9 kg,BMI: 23.55,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 13.93,Albumin: 3.8 g/dL,Lymphocyte: 1.28,Neutrophil: 11.44,LDH level: 137.0 U/L,Treatment type: Immunotherapy,Treatment regimen: DS-1062a,SNV mutations: APC,ARID2,SMARCA4,TP53,CNV alterations: CCNE1(gain),FGFR1(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 72.5 kg,BMI: 25.69,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 27.3,Albumin: 2.7 g/dL,Lymphocyte: 0.92,Neutrophil: 25.11,LDH level: 425.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 153 cm,Body weight: 55 kg,BMI: 23.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 151.7 cm,Body weight: 64.6 kg,BMI: 28.07,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: ASXL1,FUBP1,NF2,TET2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 19.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 171.2 cm,Body weight: 58 kg,BMI: 19.79,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 6.66,Albumin: 4.2 g/dL,Lymphocyte: 2.31,Neutrophil: 3.57,LDH level: 162.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 165 cm,Body weight: 69 kg,BMI: 25.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 8.9,Albumin: 3.5 g/dL,Lymphocyte: 0.53,Neutrophil: 7.84,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK-4830,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 150 cm,Body weight: 69 kg,BMI: 30.80,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.13,Albumin: 4.0 g/dL,Lymphocyte: 1.71,Neutrophil: 8.73,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ERBB2,TP53,CNV alterations: BRCA2(gain),FGF14(gain),FGF9(gain),FGFR4(gain),LAMP1(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 167.4 cm,Body weight: 64.2 kg,BMI: 22.91,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.62,Albumin: 4.5 g/dL,Lymphocyte: 1.91,Neutrophil: 5.9,LDH level: 517.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Zimberelimab/Domvanalimab/Sacituzumab,SNV mutations: BRCA1,CHEK2,RBM10,TP53,CNV alterations: AR(gain),BRAF(gain),EGFR(gain),JAK2(loss),MDM4(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 169 cm,Body weight: 67.5 kg,BMI: 23.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.32,Albumin: 3.9 g/dL,Lymphocyte: 1.23,Neutrophil: 6.8,LDH level: 608.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FGF23(gain),FGF6(gain),NRG1(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 166 cm,Body weight: 63 kg,BMI: 22.86,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.17,Albumin: 3.8 g/dL,Lymphocyte: 1.58,Neutrophil: 4.01,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 31 years old,Sex: M,Height: 180 cm,Body weight: 104 kg,BMI: 32.10,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 8.7,Albumin: 4.3 g/dL,Lymphocyte: 4.08,Neutrophil: 3.33,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 172.7 cm,Body weight: 64 kg,BMI: 21.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 16.79,Albumin: 2.8 g/dL,Lymphocyte: 1.3,Neutrophil: 14.4,LDH level: 199.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ANKRD11,ARID1A,CDK12,GRIN2A,KEAP1,PBRM1,TP53,CNV alterations: BRAF(gain),EGFR(gain),MET(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 37.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 159.2 cm,Body weight: 53 kg,BMI: 20.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.3,Albumin: 4.3 g/dL,Lymphocyte: 0.92,Neutrophil: 5.78,LDH level: 228.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 170 cm,Body weight: 78 kg,BMI: 26.99,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.99,Albumin: 4.2 g/dL,Lymphocyte: 1.49,Neutrophil: 3.99,LDH level: 187.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: CTNNB1,EGFR,CNV alterations: CDK4(gain),ERBB3(gain),GLI1(gain),KRAS(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 176 cm,Body weight: 72 kg,BMI: 23.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,WBC: 6.6,Albumin: 4.1 g/dL,Lymphocyte: 1.68,Neutrophil: 4.29,LDH level: 236.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,NOTCH1,RBM10,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 168 cm,Body weight: 77 kg,BMI: 27.28,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 8.4,Albumin: 4.8 g/dL,Lymphocyte: 1.83,Neutrophil: 5.7,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/Olaparib or Placebo,SNV mutations: TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 152 cm,Body weight: 41.2 kg,BMI: 17.83,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 3.73,Albumin: 4.5 g/dL,Lymphocyte: 1.23,Neutrophil: 2.09,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,KRAS,LZTR1,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 157.2 cm,Body weight: 51.8 kg,BMI: 20.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.9,Albumin: 4.4 g/dL,Lymphocyte: 1.05,Neutrophil: 5.24,LDH level: 264.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: BAY2927088,SNV mutations: ANKRD11,BRCA2,CREBBP,EGFR,FAT1,GPS2,KMT2A,MSH3,NCOR1,TET1,ZFHX3,ZRSR2,CNV alterations: EGFR(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 163.1 cm,Body weight: 61.9 kg,BMI: 23.27,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.0,Albumin: 4.6 g/dL,Lymphocyte: 2.22,Neutrophil: 4.02,LDH level: 212.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 152.3 cm,Body weight: 54 kg,BMI: 23.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 7.06,Albumin: 4.3 g/dL,Lymphocyte: 1.89,Neutrophil: 4.46,LDH level: 182.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: JNJ372/Lazertinib,SNV mutations: ARID1A,ATM,EED,PIK3CA,CNV alterations: BRCA2(gain),CDK4(gain),ERBB3(gain),MDM2(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 171 cm,Body weight: 58 kg,BMI: 19.77,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 13.72,Albumin: 4.3 g/dL,Lymphocyte: 1.18,Neutrophil: 11.17,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: CCND1(gain),ERCC1(gain),ERCC2(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 167 cm,Body weight: 74 kg,BMI: 26.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.85,Albumin: 3.9 g/dL,Lymphocyte: 2.3,Neutrophil: 6.99,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: FGF10(gain),FGFR1(gain),MET(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: MET,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: F,Height: 146 cm,Body weight: 46 kg,BMI: 21.58,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 4.43,Albumin: 4.3 g/dL,Lymphocyte: 1.51,Neutrophil: 2.56,LDH level: 165.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: NOTCH2,TP53,CNV alterations: AR(gain),FGF10(gain),FGF14(gain),FGFR3(loss),IL7R(gain),MDM4(gain),PIK3CA(gain),PIK3CB(gain),RB1(loss),RICTOR(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 158 cm,Body weight: 53 kg,BMI: 21.23,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,WBC: 4.2,Albumin: 4.4 g/dL,Lymphocyte: 0.95,Neutrophil: 2.94,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: CDKN2A,NBN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 158 cm,Body weight: 59 kg,BMI: 23.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 20%,WBC: 16.95,Albumin: 3.1 g/dL,Lymphocyte: 1.13,Neutrophil: 14.64,LDH level: 201.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 152.9 cm,Body weight: 55.6 kg,BMI: 23.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 4.75,Albumin: 5.0 g/dL,Lymphocyte: 1.31,Neutrophil: 3.06,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: U2AF1,CNV alterations: CD74(gain),EMSY(loss),FGF10(gain),MAP2K4(loss),RUNX1(loss),Fusion genes: EGFR,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162.4 cm,Body weight: 67.8 kg,BMI: 25.71,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.25,Albumin: 3.8 g/dL,Lymphocyte: 1.04,Neutrophil: 5.51,LDH level: 152.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: FBXW7,NFE2L2,PTEN,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 160.5 cm,Body weight: 79.9 kg,BMI: 31.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 6.42,Albumin: 4.4 g/dL,Lymphocyte: 2.73,Neutrophil: 2.92,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: CDKN2A,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 157 cm,Body weight: 56 kg,BMI: 22.72,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,SMO,CNV alterations: BRAF(gain),CCND1(gain),CDK6(gain),EGFR(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(loss),FGFR4(gain),MDM2(gain),MDM4(gain),MET(gain),MYCL(gain),NRAS(gain),NRG1(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 156 cm,Body weight: 67 kg,BMI: 27.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 10%,WBC: 8.8,Albumin: 4.3 g/dL,Lymphocyte: 0.89,Neutrophil: 7.14,LDH level: 244.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: BIRC3,EGFR,TP53,CNV alterations: MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 162.7 cm,Body weight: 54.7 kg,BMI: 20.66,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 15%,WBC: 6.36,Albumin: 4.3 g/dL,Lymphocyte: 1.51,Neutrophil: 3.13,LDH level: 189.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: DNMT3A,MED12,NFE2L2,CNV alterations: DCUN1D1(gain),KLHL6(gain),MAP3K13(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 160.5 cm,Body weight: 52.1 kg,BMI: 20.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.62,Albumin: 4.2 g/dL,Lymphocyte: 2.52,Neutrophil: 3.95,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab or Placebo/Bevacizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: AR(loss),MYC(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 155.3 cm,Body weight: 57.5 kg,BMI: 23.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 10.33,Albumin: 4.0 g/dL,Lymphocyte: 2.39,Neutrophil: 7.3,LDH level: 425.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: BRAF(gain),CDK4(gain),GLI1(gain),MDM2(gain),MET(gain),MYC(gain),NFKBIA(gain),NKX2-1(gain),Fusion genes: ALK,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 154 cm,Body weight: 52 kg,BMI: 21.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,RB1,TP53,CNV alterations: ATM(gain),CCNE1(gain),EGFR(gain),ERCC2(gain),MDM4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 170 cm,Body weight: 77.3 kg,BMI: 26.75,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719S, S768I,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): <5%,WBC: 6.6,Albumin: 4.7 g/dL,Lymphocyte: 1.42,Neutrophil: 4.42,LDH level: 249.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: DNMT3A,EGFR,SMAD4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 149.9 cm,Body weight: 61.35 kg,BMI: 27.30,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <50%,PD-L1 (SP263): 2%,WBC: 7.41,Albumin: 3.4 g/dL,Lymphocyte: 0.87,Neutrophil: 5.88,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 162.4 cm,Body weight: 82.5 kg,BMI: 31.28,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.86,Albumin: 3.0 g/dL,Lymphocyte: 3.08,Neutrophil: 9.67,LDH level: 163.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: EPHA3,GATA3,RB1,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 25.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 163.8 cm,Body weight: 77.4 kg,BMI: 28.85,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 15.63,Albumin: 4.2 g/dL,Lymphocyte: 3.41,Neutrophil: 10.29,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,KRAS,RBM10,SETD2,TERT,CNV alterations: FGF7(loss),MDM4(gain),MYC(gain),PDGFRB(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 175 cm,Body weight: 64 kg,BMI: 20.93,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,WBC: 12.45,Albumin: 3.6 g/dL,Lymphocyte: 1.1,Neutrophil: 10.65,LDH level: 172.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,NF1,PIK3CA,RASA1,CNV alterations: BRAF(gain),CDKN2A(loss),CDKN2B(loss),MYC(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 170 cm,Body weight: 62 kg,BMI: 21.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 20%,WBC: 9.7,Albumin: 2.3 g/dL,Lymphocyte: 0.93,Neutrophil: 7.64,LDH level: 197.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: BRAF,NRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 182 cm,Body weight: 56 kg,BMI: 16.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: pleomorphic carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 9.79,Albumin: 3.3 g/dL,Lymphocyte: 0.54,Neutrophil: 7.99,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: ARID1A,BRCA1,CDKN2A,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166 cm,Body weight: 54 kg,BMI: 19.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 95%,WBC: 9.48,Albumin: 3.2 g/dL,Lymphocyte: 1.79,Neutrophil: 6.81,LDH level: 285.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 164.5 cm,Body weight: 71 kg,BMI: 26.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.48,Albumin: 4.3 g/dL,Lymphocyte: 2.11,Neutrophil: 3.52,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: BRAF,NRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 173.5 cm,Body weight: 89.7 kg,BMI: 29.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <5%,PD-L1 (SP263): 5~10%,WBC: 5.56,Albumin: 4.4 g/dL,Lymphocyte: 0.98,Neutrophil: 3.75,LDH level: 282.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: BRIP1,EGFR,RB1,TP53,CNV alterations: BRCA1(gain),EGFR(gain),ERBB2(gain),FGF1(gain),PDGFRB(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 165 cm,Body weight: 68.4 kg,BMI: 25.12,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 2%,WBC: 6.21,Albumin: 4.4 g/dL,Lymphocyte: 1.86,Neutrophil: 3.6,LDH level: 233.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Dabrafenib/Trametinib,SNV mutations: BRAF,SETD2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: EGFR,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 161 cm,Body weight: 64 kg,BMI: 24.69,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 9.52,Albumin: 4.3 g/dL,Lymphocyte: 2.47,Neutrophil: 5.04,LDH level: 294.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: CBFB,FAT1,KRAS,TP53,VHL,CNV alterations: AKT2(gain),KRAS(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 168 cm,Body weight: 62 kg,BMI: 21.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 7.73,Albumin: 4.5 g/dL,Lymphocyte: 1.36,Neutrophil: 5.27,LDH level: 286.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: F,Height: 147 cm,Body weight: 48 kg,BMI: 22.09,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 8.83,Albumin: 3.9 g/dL,Lymphocyte: 1.11,Neutrophil: 7.24,LDH level: 185.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: MET,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: F,Height: 153 cm,Body weight: 56 kg,BMI: 23.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.63,Albumin: 4.1 g/dL,Lymphocyte: 2.56,Neutrophil: 4.48,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,CDKN2A,GNAS,NKX2-1,SOCS1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162.2 cm,Body weight: 55.7 kg,BMI: 21.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 9.24,Albumin: 3.9 g/dL,Lymphocyte: 1.53,Neutrophil: 6.73,LDH level: 105.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: MET,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 154 cm,Body weight: 55 kg,BMI: 23.19,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.11,Albumin: 4.3 g/dL,Lymphocyte: 1.64,Neutrophil: 4.68,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 173 cm,Body weight: 79 kg,BMI: 26.40,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.21,Albumin: 4.2 g/dL,Lymphocyte: 1.3,Neutrophil: 3.34,LDH level: 288.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: KEAP1,SMARCA4,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 178 cm,Body weight: 82 kg,BMI: 25.88,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: NFE2L2,TP53,CNV alterations: BRCA1(gain),CCNE1(gain),CDK6(gain),EGFR(gain),ERBB2(gain),MET(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 177 cm,Body weight: 66.1 kg,BMI: 21.10,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.27,Albumin: 4.7 g/dL,Lymphocyte: 1.95,Neutrophil: 3.74,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRIP1,KRAS,STK11,TP53,TSC1,CNV alterations: AKT2(gain),ATM(gain),CCNE1(gain),CHEK1(gain),EGFR(gain),JAK2(loss),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 20.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 170.5 cm,Body weight: 60.7 kg,BMI: 20.88,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 6.15,Albumin: 4.2 g/dL,Lymphocyte: 1.18,Neutrophil: 4.03,LDH level: 142.0 U/L,Treatment type: Immunotherapy,Treatment regimen: ABL501,SNV mutations: NF1,RB1,TP53,TSC1,CNV alterations: PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 158 cm,Body weight: 48 kg,BMI: 19.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,WBC: 8.65,Albumin: 4.7 g/dL,Lymphocyte: 1.46,Neutrophil: 6.53,LDH level: 142.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: APC,EGFR,FANCD2,TP53,CNV alterations: AKT2(gain),CCND3(gain),CDK4(gain),EGFR(gain),FGFR1(gain),JAK2(loss),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 160.8 cm,Body weight: 53.2 kg,BMI: 20.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 80%,WBC: 24.71,Albumin: 4.1 g/dL,Lymphocyte: 2.01,Neutrophil: 17.92,LDH level: 524.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KRAS,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 172.9 cm,Body weight: 60.3 kg,BMI: 20.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: S768I,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRCA2,EGFR,TP53,CNV alterations: LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 156 cm,Body weight: 50.5 kg,BMI: 20.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: G719X,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 15.28,Albumin: 3.6 g/dL,Lymphocyte: 1.73,Neutrophil: 12.74,LDH level: 279.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 156.2 cm,Body weight: 35.6 kg,BMI: 14.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 20%,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 50%,WBC: 4.22,Albumin: 4.4 g/dL,Lymphocyte: 0.87,Neutrophil: 3.06,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 161 cm,Body weight: 79 kg,BMI: 30.48,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 20%,WBC: 5.48,Albumin: 4.9 g/dL,Lymphocyte: 2.59,Neutrophil: 2.32,LDH level: 262.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ARID1A,EGFR,PIK3CA,TP53,CNV alterations: FGF7(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 166 cm,Body weight: 74 kg,BMI: 26.85,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 13.93,Albumin: 4.0 g/dL,Lymphocyte: 2.33,Neutrophil: 9.66,LDH level: 196.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: ALK,CNV alterations: CDKN2A(loss),CDKN2B(loss),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 157 cm,Body weight: 58.7 kg,BMI: 23.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.1,Albumin: 4.2 g/dL,Lymphocyte: 2.72,Neutrophil: 9.58,LDH level: 874.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,ERCC4,PIK3CA,RB1,TP53,CNV alterations: MYC(gain),MYCL(gain),NRAS(gain),Fusion genes: None,Splice variants: AR,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 185 cm,Body weight: 118 kg,BMI: 34.48,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 85%,PD-L1 (SP263): 95%,WBC: 6.16,Albumin: 4.4 g/dL,Lymphocyte: 2.88,Neutrophil: 2.62,LDH level: 180.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tislelizumab or Pembrolizumab/Ociperlimab or Placebo,SNV mutations: ARID1A,BIRC3,BRCA2,CDKN2A,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 151.6 cm,Body weight: 44.8 kg,BMI: 19.49,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.77,Albumin: 4.3 g/dL,Lymphocyte: 2.65,Neutrophil: 5.31,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,TET2,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 168 cm,Body weight: 67.7 kg,BMI: 23.99,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Irrinotecan/Cisplatin,SNV mutations: FGFR3,FOXP1,KDM6A,PIK3CA,TP53,CNV alterations: FGFR1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 40.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165 cm,Body weight: 66 kg,BMI: 24.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.17,Albumin: 4.7 g/dL,Lymphocyte: 1.49,Neutrophil: 3.09,LDH level: 198.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: KRAS,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 183 cm,Body weight: 70 kg,BMI: 20.90,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,WBC: 6.3,Albumin: 4.8 g/dL,Lymphocyte: 1.51,Neutrophil: 4.09,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,SMAD4,CNV alterations: CDK4(gain),CDKN2A(loss),CDKN2B(loss),FGFR3(loss),FLCN(loss),LAMP1(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 170 cm,Body weight: 66 kg,BMI: 22.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 16.81,Albumin: 3.8 g/dL,Lymphocyte: 2.54,Neutrophil: 13.09,LDH level: 157.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,TSC2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 181 cm,Body weight: 52.8 kg,BMI: 16.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.82,Albumin: 3.9 g/dL,Lymphocyte: 2.32,Neutrophil: 3.93,LDH level: 144.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab or Placebo/Pactliaxel/Carboplatin/Bevacizumab,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 152 cm,Body weight: 57 kg,BMI: 24.79,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.75,Albumin: 4.7 g/dL,Lymphocyte: 1.53,Neutrophil: 3.75,LDH level: 294.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/M7684,SNV mutations: APC,BARD1,KMT2A,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 170 cm,Body weight: 54.7 kg,BMI: 18.93,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 11.72,Albumin: 3.6 g/dL,Lymphocyte: 1.94,Neutrophil: 8.44,LDH level: 145.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MGA,TP53,CNV alterations: CCNE1(gain),CDK4(gain),MET(gain),NFKBIA(gain),NKX2-1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 22.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 167 cm,Body weight: 66 kg,BMI: 23.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 40%,WBC: 8.99,Albumin: 2.6 g/dL,Lymphocyte: 1.42,Neutrophil: 6.69,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,FOXA1,STK11,TP53,U2AF1,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 15.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: F,Height: 154.7 cm,Body weight: 66.1 kg,BMI: 27.62,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.26,Albumin: 4.5 g/dL,Lymphocyte: 2.18,Neutrophil: 4.46,LDH level: 254.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KMT2A,MED12,TP53,CNV alterations: None,Fusion genes: NTRK1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 164 cm,Body weight: 62 kg,BMI: 23.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.43,Albumin: 4.5 g/dL,Lymphocyte: 1.25,Neutrophil: 6.59,LDH level: 153.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,PIK3CA,RB1,TP53,CNV alterations: CCNE1(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: F,Height: 166.8 cm,Body weight: 57 kg,BMI: 20.49,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 7.39,Albumin: 4.4 g/dL,Lymphocyte: 1.57,Neutrophil: 5.16,LDH level: 202.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: CUX1,EGFR,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: M,Height: 178 cm,Body weight: 67.1 kg,BMI: 21.18,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 9.8,Albumin: 4.1 g/dL,Lymphocyte: 1.33,Neutrophil: 7.3,LDH level: 188.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,EP300,FAT1,TP53,CNV alterations: ARAF(gain),CARD11(gain),CCNE1(gain),CHEK1(gain),EGFR(gain),ETV1(gain),GATA1(gain),NKX2-1(gain),RAC1(gain),RBM10(gain),TFE3(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 164 cm,Body weight: 54 kg,BMI: 20.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.04,Albumin: 4.3 g/dL,Lymphocyte: 1.59,Neutrophil: 6.26,LDH level: 637.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Cisplatin,SNV mutations: APC,KEAP1,SMARCA4,TET2,TP53,CNV alterations: BRCA1(gain),BRCA2(gain),CDK4(gain),CDK6(gain),CHEK2(gain),ERBB2(gain),ERBB3(gain),FGF6(loss),FGF8(loss),MDM2(gain),PTEN(loss),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 13.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165 cm,Body weight: 60 kg,BMI: 22.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.91,Albumin: 4.8 g/dL,Lymphocyte: 4.35,Neutrophil: 5.34,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA2,KRAS,CNV alterations: FGF6(loss),KRAS(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 160.3 cm,Body weight: 44 kg,BMI: 17.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: ERBB2,RB1,TP53,CNV alterations: ALK(gain),CCND3(gain),CDK4(gain),ERBB2(gain),ERBB3(gain),ESR1(gain),FGF10(gain),FGF8(loss),FGFR1(gain),FGFR2(loss),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 172.2 cm,Body weight: 68.9 kg,BMI: 23.24,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): <1%,PD-L1 (SP263): 90%,WBC: 5.71,Albumin: 4.5 g/dL,Lymphocyte: 1.32,Neutrophil: 3.74,LDH level: 234.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,FAM175A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 160 cm,Body weight: 59 kg,BMI: 23.05,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.68,Albumin: 4.6 g/dL,Lymphocyte: 3.58,Neutrophil: 4.38,LDH level: 175.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: NFE2L2,NOTCH4,TP53,CNV alterations: FGFR1(gain),NFE2L2(gain),PIK3CA(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 167.5 cm,Body weight: 75.6 kg,BMI: 26.95,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.15,Albumin: 4.2 g/dL,Lymphocyte: 2.68,Neutrophil: 4.47,LDH level: 203.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: APC,ATRX,TP53,CNV alterations: ATM(gain),BRAF(gain),CCND1(gain),CDKN2A(loss),CDKN2B(loss),CHEK1(gain),CHEK2(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 164.9 cm,Body weight: 47 kg,BMI: 17.28,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 5.56,Albumin: 3.8 g/dL,Lymphocyte: 1.49,Neutrophil: 2.84,LDH level: 156.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ASXL1,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 170 cm,Body weight: 73 kg,BMI: 25.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 4.39,Albumin: 4.8 g/dL,Lymphocyte: 1.38,Neutrophil: 2.43,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 42 years old,Sex: M,Height: 180.4 cm,Body weight: 81.4 kg,BMI: 25.01,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 10%,WBC: 13.08,Albumin: 3.1 g/dL,Lymphocyte: 0.89,Neutrophil: 9.15,LDH level: 313.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: LZTR1,NF1,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 159.4 cm,Body weight: 60 kg,BMI: 23.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.09,Albumin: 4.4 g/dL,Lymphocyte: 1.0,Neutrophil: 4.47,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 155.2 cm,Body weight: 54.1 kg,BMI: 22.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.05,Albumin: 3.6 g/dL,Lymphocyte: 2.35,Neutrophil: 6.81,LDH level: 161.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lorlatinib,SNV mutations: TP53,CNV alterations: AR(gain),AXL(gain),BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ETV1(gain),EZH2(gain),MET(gain),RHEB(gain),Fusion genes: ALK,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 168 cm,Body weight: 53.8 kg,BMI: 19.06,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.31,Albumin: 3.9 g/dL,Lymphocyte: 0.93,Neutrophil: 6.67,LDH level: 173.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: MET,CNV alterations: CDK4(gain),EGFR(gain),ETV1(gain),FRS2(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 164 cm,Body weight: 65 kg,BMI: 24.17,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: ARID1A,FBXW7,TP53,CNV alterations: CDK4(gain),FGFR1(gain),MET(gain),PDGFRA(gain),PDGFRB(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 178 cm,Body weight: 74 kg,BMI: 23.36,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.34,Albumin: 4.6 g/dL,Lymphocyte: 2.42,Neutrophil: 3.8,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: CCND1(gain),CDK4(gain),FGF19(gain),FGF3(gain),FGF4(gain),KRAS(gain),MDM2(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163.8 cm,Body weight: 61 kg,BMI: 22.74,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.06,Albumin: 4.2 g/dL,Lymphocyte: 2.08,Neutrophil: 4.09,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,FGFR4,CNV alterations: MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 168.7 cm,Body weight: 59.3 kg,BMI: 20.84,Smoking history: Current smoker,Cancer stage: Mixed,Histology: combined small cell carcinoma and adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.95,Albumin: 4.8 g/dL,Lymphocyte: 1.58,Neutrophil: 3.48,LDH level: 161.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: KRAS,RB1,CNV alterations: FGF1(gain),FGF10(gain),FGFR1(gain),FGFR3(loss),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165.2 cm,Body weight: 70.5 kg,BMI: 25.83,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 55%,WBC: 10.31,Albumin: 4.3 g/dL,Lymphocyte: 3.02,Neutrophil: 5.77,LDH level: 150.0 U/L,Treatment type: Immunotherapy,Treatment regimen: AZD2936,SNV mutations: KEAP1,NRAS,PBRM1,RIT1,SMARCA4,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: M,Height: 172.3 cm,Body weight: 81.1 kg,BMI: 27.32,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 9.68,Albumin: 4.5 g/dL,Lymphocyte: 2.37,Neutrophil: 6.34,LDH level: 146.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: KMT2A,RB1,TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 155 cm,Body weight: 57 kg,BMI: 23.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.72,Albumin: 4.4 g/dL,Lymphocyte: 1.39,Neutrophil: 5.9,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 154 cm,Body weight: 42 kg,BMI: 17.63,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 13.06,Albumin: 3.6 g/dL,Lymphocyte: 1.59,Neutrophil: 10.64,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 165.1 cm,Body weight: 68.7 kg,BMI: 25.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: BCOR,BRCA2,ERBB2,SMARCA4,TP53,CNV alterations: CCND1(gain),CHEK1(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 166 cm,Body weight: 66.6 kg,BMI: 24.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.43,Albumin: 4.5 g/dL,Lymphocyte: 1.54,Neutrophil: 5.19,LDH level: 183.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Entrectinib,SNV mutations: KDR,TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 163.8 cm,Body weight: 61.5 kg,BMI: 22.92,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,WBC: 4.41,Albumin: 4.3 g/dL,Lymphocyte: 1.35,Neutrophil: 2.46,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: NFE2L2,PTEN,CNV alterations: CCND3(gain),CHEK1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 159 cm,Body weight: 63 kg,BMI: 25.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.51,Albumin: 4.6 g/dL,Lymphocyte: 1.46,Neutrophil: 3.65,LDH level: 243.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: PIK3CB(gain),Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165 cm,Body weight: 50.5 kg,BMI: 18.55,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 85%,PD-L1 (SP263): 80%,WBC: 12.49,Albumin: 2.6 g/dL,Lymphocyte: 0.62,Neutrophil: 11.03,LDH level: 680.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: AKT2(gain),AR(loss),CCNE1(gain),CDK4(gain),ERBB3(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 152 cm,Body weight: 61 kg,BMI: 26.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.44,Albumin: 4.5 g/dL,Lymphocyte: 1.94,Neutrophil: 4.67,LDH level: 271.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ATRX,CDC73,CYLD,EGFR,MSH3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 38 years old,Sex: M,Height: 189 cm,Body weight: 88 kg,BMI: 24.64,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,WBC: 11.86,Albumin: 4.8 g/dL,Lymphocyte: 1.4,Neutrophil: 9.77,LDH level: 250.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 167 cm,Body weight: 75 kg,BMI: 26.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 80%,WBC: 14.16,Albumin: 2.6 g/dL,Lymphocyte: 0.6,Neutrophil: 11.66,LDH level: 530.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KRAS,MAX,TET2,CNV alterations: FGF4(gain),FGFR4(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 160 cm,Body weight: 53 kg,BMI: 20.70,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 2%,WBC: 8.91,Albumin: 5.2 g/dL,Lymphocyte: 2.38,Neutrophil: 5.45,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Ceritinib -> Crizotinib,SNV mutations: BRCA2,PDGFRA,TSC1,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 173.7 cm,Body weight: 83.4 kg,BMI: 27.64,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 10%,WBC: 9.1,Albumin: 3.9 g/dL,Lymphocyte: 3.86,Neutrophil: 4.21,LDH level: 198.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: NSD1,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 15.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 180 cm,Body weight: 72 kg,BMI: 22.22,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 11.87,Albumin: 3.2 g/dL,Lymphocyte: 1.16,Neutrophil: 9.58,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,MET,NF1,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: MET,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164 cm,Body weight: 61 kg,BMI: 22.68,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.19,Albumin: 4.3 g/dL,Lymphocyte: 0.88,Neutrophil: 4.71,LDH level: 171.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 34 years old,Sex: F,Height: 164.4 cm,Body weight: 58 kg,BMI: 21.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: 80%,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 40%,WBC: 13.0,Albumin: 4.6 g/dL,Lymphocyte: 0.93,Neutrophil: 11.54,LDH level: 345.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: SETD2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 164.3 cm,Body weight: 55.1 kg,BMI: 20.41,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.68,Albumin: 4.5 g/dL,Lymphocyte: 2.4,Neutrophil: 3.28,LDH level: 191.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: FANCA,KRAS,RBM10,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 164 cm,Body weight: 59 kg,BMI: 21.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 13.61,Albumin: 4.3 g/dL,Lymphocyte: 0.29,Neutrophil: 12.65,LDH level: 281.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NF2,RBM10,SMARCA4,STK11,TOP1,CNV alterations: NOTCH1(gain),Fusion genes: None,Splice variants: None,TMB: 16.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 161 cm,Body weight: 61 kg,BMI: 23.42,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,WBC: 16.43,Albumin: 2.6 g/dL,Lymphocyte: 1.66,Neutrophil: 12.49,LDH level: 366.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: BCORL1,NCOR1,PTPRT,RB1,SMARCA4,TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDK6(gain),FGF14(gain),FGF7(loss),LAMP1(gain),MDM4(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 26.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 156 cm,Body weight: 47 kg,BMI: 19.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 50%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.14,Albumin: 4.8 g/dL,Lymphocyte: 1.79,Neutrophil: 3.97,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,CNV alterations: CDK4(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF6(loss),FGF7(loss),JAK2(loss),MDM2(gain),MYCL(gain),NKX3-1(loss),NRG1(loss),PPP2R2A(loss),PTPRD(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 168.3 cm,Body weight: 65.1 kg,BMI: 22.98,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 12.67,Albumin: 5.2 g/dL,Lymphocyte: 1.22,Neutrophil: 10.31,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: ARID1A,BRCA2,DNMT3A,STK11,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 18.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 158.7 cm,Body weight: 51.5 kg,BMI: 20.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 11.46,Albumin: 3.8 g/dL,Lymphocyte: 2.2,Neutrophil: 8.53,LDH level: 344.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-5890/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TERT,TP53,CNV alterations: MET(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 171 cm,Body weight: 66 kg,BMI: 22.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 10.74,Albumin: 3.7 g/dL,Lymphocyte: 1.96,Neutrophil: 7.47,LDH level: 203.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 161.2 cm,Body weight: 59.1 kg,BMI: 22.74,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.73,Albumin: 3.2 g/dL,Lymphocyte: 1.69,Neutrophil: 3.27,LDH level: 202.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: CDK4(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 151.7 cm,Body weight: 68.6 kg,BMI: 29.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 7.84,Albumin: 4.2 g/dL,Lymphocyte: 0.95,Neutrophil: 6.15,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetraxed/Carboplatin,SNV mutations: CDKN2A,FUBP1,KMT2A,KRAS,NCOR1,TERT,TP53,CNV alterations: BRCA1(gain),EGFR(gain),ERBB2(gain),MET(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 34.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 171 cm,Body weight: 56 kg,BMI: 19.15,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,PD-L1 (SP263): 35%,WBC: 11.82,Albumin: 3.7 g/dL,Lymphocyte: 1.78,Neutrophil: 8.8,LDH level: 449.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: AR(loss),ATM(gain),CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGF5(loss),FGFR1(gain),KIT(loss),MDM4(gain),NRG1(loss),PIK3CA(gain),PTPRD(loss),RICTOR(gain),SMAD4(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 24.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 165 cm,Body weight: 70.5 kg,BMI: 25.90,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.12,Albumin: 4.8 g/dL,Lymphocyte: 1.7,Neutrophil: 5.46,LDH level: 181.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,SETD2,CNV alterations: BRAF(gain),CDK6(gain),CDKN2A(loss),EGFR(gain),FGFR3(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 16.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.23,Albumin: 4.7 g/dL,Lymphocyte: 2.17,Neutrophil: 4.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: LZTR1,NF1,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 163.9 cm,Body weight: 52.5 kg,BMI: 19.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 90%,WBC: 9.53,Albumin: 2.8 g/dL,Lymphocyte: 2.03,Neutrophil: 6.43,LDH level: 164.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID2,ERBB2,FOXP1,LATS1,PIK3CA,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 41.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: M,Height: 177 cm,Body weight: 82.5 kg,BMI: 26.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 6.48,Albumin: 4.3 g/dL,Lymphocyte: 1.04,Neutrophil: 4.78,LDH level: 152.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: BRCA1,MGA,PTEN,TP53,CNV alterations: BRCA1(gain),CCND3(gain),CDK6(gain),ERBB2(gain),FGF10(gain),FGF14(gain),JAK2(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 167.1 cm,Body weight: 65.5 kg,BMI: 23.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 100%,WBC: 18.41,Albumin: 3.9 g/dL,Lymphocyte: 1.69,Neutrophil: 15.28,LDH level: 239.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,BRCA1,NF1,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 167 cm,Body weight: 77 kg,BMI: 27.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,WBC: 12.84,Albumin: 3.9 g/dL,Lymphocyte: 4.65,Neutrophil: 7.2,LDH level: 146.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: BRCA1(gain),EGFR(gain),ERBB2(gain),NRAS(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 168.4 cm,Body weight: 68.6 kg,BMI: 24.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.2,Albumin: 4.0 g/dL,Lymphocyte: 2.67,Neutrophil: 4.71,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: ATM(loss),ERCC2(gain),FGF1(gain),FGF10(gain),FGFR4(gain),MDM4(gain),PDGFRB(gain),PIK3CA(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 156.6 cm,Body weight: 65.2 kg,BMI: 26.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.73,Albumin: 4.3 g/dL,Lymphocyte: 1.78,Neutrophil: 4.07,LDH level: 185.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 160 cm,Body weight: 58 kg,BMI: 22.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.63,Albumin: 4.1 g/dL,Lymphocyte: 1.37,Neutrophil: 2.72,LDH level: 180.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: CDKN2A,FAT1,SMARCA4,TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 169 cm,Body weight: 83 kg,BMI: 29.13,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Non-small cell carcinoma, NOS,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,WBC: 14.83,Albumin: 3.1 g/dL,Lymphocyte: 1.22,Neutrophil: 12.49,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: MET,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166 cm,Body weight: 55 kg,BMI: 19.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: non-squamous non-small cell carcinoma with sarcomatoid feature,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 6.0,Albumin: 3.8 g/dL,Lymphocyte: 1.16,Neutrophil: 3.92,LDH level: 226.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRAF,KRAS,RAC1,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 169 cm,Body weight: 50 kg,BMI: 17.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.95,Albumin: 3.8 g/dL,Lymphocyte: 1.31,Neutrophil: 5.61,LDH level: 196.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,MTOR,PIK3CA,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 161 cm,Body weight: 41 kg,BMI: 15.60,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 7.04,Albumin: 3.5 g/dL,Lymphocyte: 0.82,Neutrophil: 5.42,LDH level: 233.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDK12,CDKN2A,NOTCH3,TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 160 cm,Body weight: 63 kg,BMI: 24.61,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 5.34,Albumin: 4.8 g/dL,Lymphocyte: 1.74,Neutrophil: 3.11,LDH level: 150.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Ceritinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 172.5 cm,Body weight: 56.5 kg,BMI: 18.99,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.76,Albumin: 4.5 g/dL,Lymphocyte: 1.13,Neutrophil: 7.17,LDH level: 191.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 163 cm,Body weight: 58 kg,BMI: 21.83,Smoking history: Never smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,WBC: 11.45,Albumin: 3.7 g/dL,Lymphocyte: 1.05,Neutrophil: 9.95,LDH level: 224.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 172.9 cm,Body weight: 74.5 kg,BMI: 24.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 6.68,Albumin: 3.5 g/dL,Lymphocyte: 0.94,Neutrophil: 4.91,LDH level: 124.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRCA2,EGFR,PIK3CB,RB1,TP53,CNV alterations: AKT1(gain),ATM(gain),CARD11(gain),CCND3(gain),EGFR(gain),ETV1(gain),FGF10(gain),FOXA1(gain),LAMP1(gain),MYC(gain),NKX2-1(gain),PIK3CB(gain),RAC1(gain),RICTOR(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 175.4 cm,Body weight: 85.2 kg,BMI: 27.69,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 10.91,Albumin: 2.7 g/dL,Lymphocyte: 1.21,Neutrophil: 8.87,LDH level: 208.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: BRAF(gain),CCNE1(gain),CHEK2(loss),FGF10(gain),FGF2(loss),FGF5(loss),FGFR3(loss),JAK2(gain),KIT(loss),MDM4(gain),MET(gain),MYCL(gain),PDGFRA(loss),PIK3CA(gain),RAF1(loss),RICTOR(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 162 cm,Body weight: 50 kg,BMI: 19.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.17,Albumin: 3.8 g/dL,Lymphocyte: 1.76,Neutrophil: 3.92,LDH level: 313.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: AR(gain),EGFR(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 141 cm,Body weight: 57 kg,BMI: 28.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719X,ALK status: Negative,ROS1 status: 80%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.24,Albumin: 4.0 g/dL,Lymphocyte: 3.9,Neutrophil: 4.24,LDH level: 198.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CA,PTEN,SETD2,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 155 cm,Body weight: 47 kg,BMI: 19.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 11.95,Albumin: 3.5 g/dL,Lymphocyte: 0.9,Neutrophil: 10.44,LDH level: 213.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NFE2L2,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 158 cm,Body weight: 66 kg,BMI: 26.40,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 7.11,Albumin: 2.9 g/dL,Lymphocyte: 1.3,Neutrophil: 4.92,LDH level: 334.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: SMARCA4,TP53,CNV alterations: CDK6(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 168.5 cm,Body weight: 74.5 kg,BMI: 26.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 13.04,Albumin: 4.1 g/dL,Lymphocyte: 3.21,Neutrophil: 7.23,LDH level: 162.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MED12,NF1,RBM10,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 176.7 cm,Body weight: 58.1 kg,BMI: 18.61,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,WBC: 5.53,Albumin: 4.3 g/dL,Lymphocyte: 0.96,Neutrophil: 3.83,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib or Placebo/Lazertinib or Placebo,SNV mutations: EGFR,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 166 cm,Body weight: 50 kg,BMI: 18.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 13.93,Albumin: 3.6 g/dL,Lymphocyte: 2.23,Neutrophil: 10.25,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RBM10,TP53,CNV alterations: PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 172.3 cm,Body weight: 80 kg,BMI: 26.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.29,Albumin: 4.1 g/dL,Lymphocyte: 1.82,Neutrophil: 9.65,LDH level: 281.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRAF,EGFR,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 172.5 cm,Body weight: 72 kg,BMI: 24.20,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 50%,WBC: 12.63,Albumin: 3.9 g/dL,Lymphocyte: 2.81,Neutrophil: 6.7,LDH level: 220.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: MYC(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 169.6 cm,Body weight: 58.7 kg,BMI: 20.41,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 11.11,Albumin: 4.4 g/dL,Lymphocyte: 4.11,Neutrophil: 6.21,LDH level: 701.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: EPCAM,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),ESR1(gain),RAF1(loss),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164 cm,Body weight: 68 kg,BMI: 25.28,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,WBC: 9.07,Albumin: 4.8 g/dL,Lymphocyte: 2.42,Neutrophil: 5.7,LDH level: 383.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ATM,KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 151 cm,Body weight: 60 kg,BMI: 26.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 10%,WBC: 5.99,Albumin: 4.4 g/dL,Lymphocyte: 0.96,Neutrophil: 4.36,LDH level: 208.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 162 cm,Body weight: 51 kg,BMI: 19.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.65,Albumin: 3.6 g/dL,Lymphocyte: 1.69,Neutrophil: 5.02,LDH level: 524.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB4,KMT2A,MET,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 161.8 cm,Body weight: 85 kg,BMI: 32.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 7.75,Albumin: 4.6 g/dL,Lymphocyte: 2.98,Neutrophil: 4.09,LDH level: 304.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 170 cm,Body weight: 56 kg,BMI: 19.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.5,Albumin: 4.0 g/dL,Lymphocyte: 2.14,Neutrophil: 3.38,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,STK11,CNV alterations: CDK4(gain),KRAS(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 167.7 cm,Body weight: 77.8 kg,BMI: 27.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 5.67,Albumin: 4.7 g/dL,Lymphocyte: 1.04,Neutrophil: 4.53,LDH level: 208.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: BGB-A1217/Tislelizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 160 cm,Body weight: 74 kg,BMI: 28.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 167 cm,Body weight: 62 kg,BMI: 22.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 162 cm,Body weight: 65.1 kg,BMI: 24.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or sarcomatoid carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 90%,WBC: 13.84,Albumin: 4.3 g/dL,Lymphocyte: 2.0,Neutrophil: 10.12,LDH level: 356.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NRAS,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 175 cm,Body weight: 71 kg,BMI: 23.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,WBC: 10.11,Albumin: 4.2 g/dL,Lymphocyte: 1.86,Neutrophil: 7.26,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: AKT1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 170 cm,Body weight: 66 kg,BMI: 22.84,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 10%,WBC: 8.82,Albumin: 4.7 g/dL,Lymphocyte: 2.37,Neutrophil: 5.45,LDH level: 165.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),KIT(gain),MET(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 161.4 cm,Body weight: 54.3 kg,BMI: 20.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 1%,WBC: 13.1,Albumin: 4.3 g/dL,Lymphocyte: 2.01,Neutrophil: 7.54,LDH level: 218.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRAF,EGFR,FAT1,PTPRS,SMAD4,TP53,CNV alterations: CDK4(gain),ERBB3(gain),JAK2(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 156 cm,Body weight: 60 kg,BMI: 24.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: Negative,WBC: 6.01,Albumin: 4.2 g/dL,Lymphocyte: 1.88,Neutrophil: 3.73,LDH level: 154.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,FGFR4,PTEN,TBX3,TERT,TP53,CNV alterations: CDK4(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),Fusion genes: None,Splice variants: EGFR,TMB: 4.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 171 cm,Body weight: 82.3 kg,BMI: 28.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 176 cm,Body weight: 73 kg,BMI: 23.35,Smoking history: Current smoker,Cancer stage: Mixed,Histology: Combined small cell carcinoma and squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 16.33,Albumin: 3.3 g/dL,Lymphocyte: 1.71,Neutrophil: 13.35,LDH level: 207.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: RB1,SPEN,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGF8(gain),KIT(gain),MYC(gain),PDGFRA(gain),PDGFRB(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 169.3 cm,Body weight: 66.5 kg,BMI: 23.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 15.74,Albumin: 3.1 g/dL,Lymphocyte: 1.91,Neutrophil: 12.55,LDH level: 1031.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: EP300,KRAS,NRAS,TP53,CNV alterations: FGF23(gain),FGF6(gain),FGF8(gain),KDM5A(gain),MITF(gain),MYC(gain),PTEN(gain),RET(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 160.6 cm,Body weight: 71.8 kg,BMI: 27.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 2.45,Albumin: 4.2 g/dL,Lymphocyte: 0.67,Neutrophil: 1.28,LDH level: 154.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab/Oleclumab/Monalizumab/Placebo,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 171 cm,Body weight: 49 kg,BMI: 16.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 2%,WBC: 11.45,Albumin: 3.7 g/dL,Lymphocyte: 1.03,Neutrophil: 9.22,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,PTEN,RB1,TGFBR2,TP53,CNV alterations: BRCA2(gain),CCNE1(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 167.1 cm,Body weight: 62 kg,BMI: 22.20,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 20%,WBC: 5.9,Albumin: 4.4 g/dL,Lymphocyte: 1.59,Neutrophil: 2.91,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab/Oleclumab/Monalizumab,SNV mutations: CDKN2A,FAT1,PIK3CA,TP53,CNV alterations: CDK4(gain),CHEK2(loss),ERBB3(gain),ERCC2(gain),FGF10(gain),FGF23(gain),FGF6(gain),FGFR1(gain),KDM6A(loss),KRAS(gain),MDM2(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),SMARCA4(loss),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 146 cm,Body weight: 38.24 kg,BMI: 17.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): >10%,WBC: 7.32,Albumin: 4.5 g/dL,Lymphocyte: 2.39,Neutrophil: 3.73,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 170 cm,Body weight: 72 kg,BMI: 24.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 8.11,Albumin: 4.2 g/dL,Lymphocyte: 1.03,Neutrophil: 6.15,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRCA1,TP53,CNV alterations: BRAF(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 8.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.23,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: KRAS,TSC2,CNV alterations: FGFR4(gain),MDM4(gain),Fusion genes: NRG1,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 165 cm,Body weight: 78 kg,BMI: 28.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 4.88,Albumin: 4.5 g/dL,Lymphocyte: 1.72,Neutrophil: 2.73,LDH level: 187.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,SETD2,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 167.7 cm,Body weight: 57.7 kg,BMI: 20.52,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 1%,WBC: 7.51,Albumin: 4.3 g/dL,Lymphocyte: 1.98,Neutrophil: 4.56,LDH level: 155.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID2,HRAS,KDM6A,TP53,CNV alterations: AMER1(loss),BCL2L1(gain),DDR2(gain),ERBB2(gain),EZH2(gain),FGFR4(gain),FOXA1(gain),NKX2-1(gain),NTRK1(gain),PHF6(loss),RHEB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 169.4 cm,Body weight: 85.7 kg,BMI: 29.86,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 10.02,Albumin: 4.4 g/dL,Lymphocyte: 2.43,Neutrophil: 5.73,LDH level: 501.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,TP53,CNV alterations: BCL6(gain),CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),NKX2-1(loss),NKX3-1(loss),PIK3CA(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 176.8 cm,Body weight: 59.4 kg,BMI: 19.00,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carbopaltin,SNV mutations: EGFR,RBM10,TP53,CNV alterations: FGF1(gain),FGF10(gain),JUN(gain),MYC(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 12.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: M,Height: 171.6 cm,Body weight: 65 kg,BMI: 22.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.28,Albumin: 4.0 g/dL,Lymphocyte: 0.81,Neutrophil: 8.92,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 165 cm,Body weight: 66.5 kg,BMI: 24.43,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.7,Albumin: 4.5 g/dL,Lymphocyte: 2.78,Neutrophil: 3.07,LDH level: 152.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: FGF10(gain),KIT(gain),PDGFRA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 174.8 cm,Body weight: 63.1 kg,BMI: 20.65,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 0%,PD-L1 (SP263): 50%,WBC: 7.98,Albumin: 4.4 g/dL,Lymphocyte: 1.24,Neutrophil: 5.14,LDH level: 190.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: PBRM1,TCF7L2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 155 cm,Body weight: 54.7 kg,BMI: 22.77,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.34,Albumin: 4.1 g/dL,Lymphocyte: 1.94,Neutrophil: 5.74,LDH level: 205.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: BRCA2,CDH1,PPP6C,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF8(loss),MYC(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 162.7 cm,Body weight: 72.9 kg,BMI: 27.54,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.78,Albumin: 4.4 g/dL,Lymphocyte: 1.06,Neutrophil: 6.0,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Etoposide/Carboplatin,SNV mutations: ASXL1,RB1,TP53,CNV alterations: FGF10(gain),FGF3(loss),FGFR3(loss),MYCN(loss),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 168.8 cm,Body weight: 69.7 kg,BMI: 24.46,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 10%,WBC: 11.75,Albumin: 4.7 g/dL,Lymphocyte: 2.07,Neutrophil: 8.31,LDH level: 274.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: CDKN2A(loss),CDKN2B(loss),ERBB2(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 160.2 cm,Body weight: 61.65 kg,BMI: 24.02,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 17.23,Albumin: 2.9 g/dL,Lymphocyte: 1.76,Neutrophil: 13.22,LDH level: 472.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,LZTR1,CNV alterations: CDK4(gain),EGFR(gain),ERBB2(gain),FGF10(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: F,Height: 153.6 cm,Body weight: 48.8 kg,BMI: 20.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 11.6,Albumin: 4.0 g/dL,Lymphocyte: 1.44,Neutrophil: 9.08,LDH level: 193.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,NRG1,PIK3CA,RICTOR,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 171 cm,Body weight: 69 kg,BMI: 23.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 55%,PD-L1 (SP263): 80%,WBC: 8.5,Albumin: 4.5 g/dL,Lymphocyte: 1.92,Neutrophil: 5.67,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 169 cm,Body weight: 66 kg,BMI: 23.11,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 10.49,Albumin: 4.2 g/dL,Lymphocyte: 2.42,Neutrophil: 6.36,LDH level: 238.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: FGF10(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 162.8 cm,Body weight: 52.35 kg,BMI: 19.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: 100%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 11.28,Albumin: 3.5 g/dL,Lymphocyte: 0.57,Neutrophil: 9.62,LDH level: 422.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TP53,CNV alterations: FGF4(gain),Fusion genes: ALK,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 148.1 cm,Body weight: 67.6 kg,BMI: 30.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.98,Albumin: 4.8 g/dL,Lymphocyte: 2.31,Neutrophil: 3.05,LDH level: 177.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TERT,TP53,TSC2,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 37 years old,Sex: F,Height: 157.3 cm,Body weight: 47.8 kg,BMI: 19.32,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.95,Albumin: 4.7 g/dL,Lymphocyte: 1.61,Neutrophil: 5.5,LDH level: 275.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,LZTR1,RB1,TP53,CNV alterations: ARID1B(loss),B2M(loss),BRAF(gain),CDK6(gain),EGFR(gain),ETV1(gain),FOXO1(loss),MET(gain),MYC(gain),NCOR1(loss),NKX3-1(loss),RAD21(gain),SMAD2(loss),SMAD3(loss),TSC1(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165.9 cm,Body weight: 71.4 kg,BMI: 25.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,WBC: 6.87,Albumin: 4.0 g/dL,Lymphocyte: 1.52,Neutrophil: 4.71,LDH level: 327.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: EZH2,MSH6,TP53,CNV alterations: BRAF(gain),MET(gain),Fusion genes: None,Splice variants: MET,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: F,Height: 161.4 cm,Body weight: 61.7 kg,BMI: 23.69,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.28,Albumin: 3.0 g/dL,Lymphocyte: 0.91,Neutrophil: 6.39,LDH level: 230.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,ERRFI1,SH2D1A,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 180.8 cm,Body weight: 75.2 kg,BMI: 23.00,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 160.5 cm,Body weight: 46.4 kg,BMI: 18.01,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 14.44,Albumin: 4.2 g/dL,Lymphocyte: 3.54,Neutrophil: 8.71,LDH level: 456.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CDKN2A,FAT1,NFE2L2,NOTCH1,TP53,CNV alterations: CD274(gain),CRLF2(loss),FGFR1(gain),FOXO1(loss),GATA4(loss),LRP1B(loss),NKX3-1(loss),PDCD1LG2(gain),PIK3CA(gain),PPP2R2A(loss),SOX2(gain),TP63(gain),ZRSR2(loss),Fusion genes: None,Splice variants: None,TMB: 22.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 170.2 cm,Body weight: 78.2 kg,BMI: 27.00,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,WBC: 5.93,Albumin: 3.3 g/dL,Lymphocyte: 1.61,Neutrophil: 3.69,LDH level: 230.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,ATM,FOXO1,CNV alterations: ALK(gain),FGF23(gain),KRAS(gain),PDGFRA(loss),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 162 cm,Body weight: 76 kg,BMI: 28.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.81,Albumin: 3.6 g/dL,Lymphocyte: 3.43,Neutrophil: 8.46,LDH level: 799.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,RAD21,RB1,STK11,TP53,CNV alterations: ATM(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 33 years old,Sex: F,Height: 157.4 cm,Body weight: 43.2 kg,BMI: 17.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 5.96,Albumin: 4.7 g/dL,Lymphocyte: 0.95,Neutrophil: 4.44,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,PARP1,RB1,TP53,CNV alterations: CCNE1(gain),EGFR(gain),ETV1(gain),FOXO1(loss),JUN(gain),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 146.4 cm,Body weight: 64.1 kg,BMI: 29.91,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.14,Albumin: 4.4 g/dL,Lymphocyte: 0.89,Neutrophil: 4.82,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: RB1,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 165.5 cm,Body weight: 63.3 kg,BMI: 23.11,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 10.12,Albumin: 3.9 g/dL,Lymphocyte: 1.34,Neutrophil: 7.74,LDH level: 225.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CASP8,ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 160 cm,Body weight: 49 kg,BMI: 19.14,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.74,Albumin: 3.7 g/dL,Lymphocyte: 1.17,Neutrophil: 5.91,LDH level: 188.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: APC,EGFR,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 162 cm,Body weight: 49 kg,BMI: 18.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.01,Albumin: 4.1 g/dL,Lymphocyte: 1.89,Neutrophil: 6.09,LDH level: 459.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: CDC73,EGFR,FLT3,TP53,CNV alterations: CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 160.7 cm,Body weight: 64 kg,BMI: 24.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 75%,PD-L1 (SP263): 80%,WBC: 7.19,Albumin: 3.5 g/dL,Lymphocyte: 1.9,Neutrophil: 4.37,LDH level: 202.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ATR,BARD1,MSH6,NOTCH1,ROS1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 176 cm,Body weight: 58 kg,BMI: 18.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 3.93,Albumin: 2.9 g/dL,Lymphocyte: 0.5,Neutrophil: 2.68,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,CDKN1B,DIS3,MAP3K1,MET,NF2,NOTCH1,PALB2,RBM10,TP53,CNV alterations: CCNE1(gain),ERCC1(gain),ERCC2(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 64.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 165 cm,Body weight: 72 kg,BMI: 26.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: GRIN2A,NF1,PBRM1,TGFBR1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 167 cm,Body weight: 71 kg,BMI: 25.19,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 6.46,Albumin: 4.5 g/dL,Lymphocyte: 2.27,Neutrophil: 3.57,LDH level: 140.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EED,FAT1,NCOR1,SMO,TP53,CNV alterations: FGFR1(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 166.8 cm,Body weight: 72.4 kg,BMI: 26.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 6.56,Albumin: 4.2 g/dL,Lymphocyte: 1.01,Neutrophil: 4.3,LDH level: 236.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Opnurasib/Batoprotafib,SNV mutations: CHEK2,KRAS,TET2,TP53,CNV alterations: TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 178.4 cm,Body weight: 65.9 kg,BMI: 20.71,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 45%,WBC: 5.93,Albumin: 4.4 g/dL,Lymphocyte: 1.31,Neutrophil: 4.16,LDH level: 205.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Dacomitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 88 years old,Sex: F,Height: 158 cm,Body weight: 51 kg,BMI: 20.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,WBC: 4.56,Albumin: 3.9 g/dL,Lymphocyte: 1.31,Neutrophil: 2.7,LDH level: 263.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),ERBB2(gain),FGF10(gain),JAK2(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 154.8 cm,Body weight: 60.9 kg,BMI: 25.41,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.2,Albumin: 4.2 g/dL,Lymphocyte: 1.95,Neutrophil: 5.59,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: EGFR,PIK3CA,RB1,CNV alterations: BRAF(gain),CCND3(gain),FGF3(loss),FGF6(loss),FGF8(loss),FGFR1(gain),MDM2(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 150 cm,Body weight: 49 kg,BMI: 21.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.09,Albumin: 4.3 g/dL,Lymphocyte: 1.89,Neutrophil: 5.32,LDH level: 220.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,PBRM1,PIK3CA,PTPRD,SMAD4,SMO,STAG2,TERT,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: FGFR3,Splice variants: None,TMB: 14.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 173.5 cm,Body weight: 68.2 kg,BMI: 22.66,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 100%,WBC: 15.86,Albumin: 4.2 g/dL,Lymphocyte: 3.73,Neutrophil: 10.02,LDH level: 195.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 171 cm,Body weight: 49 kg,BMI: 16.76,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.94,Albumin: 4.6 g/dL,Lymphocyte: 1.0,Neutrophil: 3.55,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,NF1,TP53,CNV alterations: FGF10(gain),Fusion genes: None,Splice variants: None,TMB: 10.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 155 cm,Body weight: 47 kg,BMI: 19.56,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 12.89,Albumin: 3.9 g/dL,Lymphocyte: 0.92,Neutrophil: 11.05,LDH level: 179.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,TP53,CNV alterations: CDK12(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164.3 cm,Body weight: 65 kg,BMI: 24.08,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 6.96,Albumin: 4.1 g/dL,Lymphocyte: 1.87,Neutrophil: 3.58,LDH level: 189.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,TSC1,CNV alterations: ATM(gain),CCND1(gain),CCNE1(gain),CDK6(gain),CHEK1(gain),CHEK2(gain),FGF10(gain),FGF19(gain),FGF2(gain),FGF3(gain),FGF4(gain),FGF5(loss),FGFR1(gain),KIT(loss),NRG1(loss),PDGFRA(loss),PTEN(loss),RET(gain),RICTOR(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 159 cm,Body weight: 70 kg,BMI: 27.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,WBC: 4.22,Albumin: 4.8 g/dL,Lymphocyte: 0.76,Neutrophil: 3.34,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: MET,CNV alterations: CCND1(gain),CDK4(gain),ETV1(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 176.2 cm,Body weight: 72.8 kg,BMI: 23.45,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.18,Albumin: 4.5 g/dL,Lymphocyte: 1.79,Neutrophil: 2.93,LDH level: 162.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,KMT2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 169.3 cm,Body weight: 72 kg,BMI: 25.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 10.95,Albumin: 4.6 g/dL,Lymphocyte: 1.43,Neutrophil: 8.84,LDH level: 189.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: ERBB2,RUNX1,CNV alterations: MYCL(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 155.7 cm,Body weight: 55.5 kg,BMI: 22.89,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.56,Albumin: 4.4 g/dL,Lymphocyte: 2.52,Neutrophil: 8.01,LDH level: 269.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib or Placebo/Lazertinib or Placebo,SNV mutations: DNMT3A,EGFR,ERBB2,TP53,CNV alterations: EGFR(gain),FGF10(gain),JAK2(gain),MDM4(gain),MYCL(gain),PTEN(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 158 cm,Body weight: 58 kg,BMI: 23.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,WBC: 5.61,Albumin: 4.3 g/dL,Lymphocyte: 1.81,Neutrophil: 3.12,LDH level: 152.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ARID1A,ARID5B,BCORL1,DNMT3A,EP300,FBXW7,KRAS,MAP2K1,MAP3K1,MGA,NF1,PIK3R1,POLE,SPEN,TP63,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 90.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 170 cm,Body weight: 75 kg,BMI: 25.95,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 10.94,Albumin: 4.2 g/dL,Lymphocyte: 1.4,Neutrophil: 8.65,LDH level: 223.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,EGFR,TP53,CNV alterations: CDK4(gain),JAK2(loss),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 174 cm,Body weight: 87 kg,BMI: 28.74,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 6.89,Albumin: 5.1 g/dL,Lymphocyte: 2.78,Neutrophil: 3.48,LDH level: 177.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,SETD2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 166.6 cm,Body weight: 69.6 kg,BMI: 25.08,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 5.36,Albumin: 4.3 g/dL,Lymphocyte: 2.6,Neutrophil: 2.37,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: CREBBP,DIS3,RB1,TP53,CNV alterations: BCL2L2(loss),BRCA2(loss),CCNE1(gain),CHEK2(loss),FGF1(loss),FGF10(gain),FGF14(loss),FGF2(loss),FGF5(loss),FGF7(loss),FGF8(loss),JAK2(gain),LAMP1(loss),MAP2K4(loss),MSH3(loss),MYC(gain),NRG1(loss),PIK3CA(gain),PPP2R2A(loss),PTEN(loss),RICTOR(gain),SNCAIP(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 30.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: M,Height: 173.5 cm,Body weight: 86.1 kg,BMI: 28.60,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 7.06,Albumin: 4.4 g/dL,Lymphocyte: 2.0,Neutrophil: 4.13,LDH level: 228.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/Lenvatinib,SNV mutations: RB1,CNV alterations: MYC(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 172 cm,Body weight: 72.9 kg,BMI: 24.64,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 75%,WBC: 13.91,Albumin: 3.5 g/dL,Lymphocyte: 1.25,Neutrophil: 10.87,LDH level: 570.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: TP53,CNV alterations: CDK4(gain),FGF2(gain),FGF6(loss),JAK2(loss),RET(gain),TFRC(gain),Fusion genes: RET,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 157.1 cm,Body weight: 85.8 kg,BMI: 34.76,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.72,Albumin: 4.2 g/dL,Lymphocyte: 2.17,Neutrophil: 3.4,LDH level: 218.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 169.6 cm,Body weight: 74 kg,BMI: 25.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.09,Albumin: 4.4 g/dL,Lymphocyte: 1.65,Neutrophil: 5.87,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: F,Height: 160.7 cm,Body weight: 54.4 kg,BMI: 21.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.48,Albumin: 5.1 g/dL,Lymphocyte: 1.59,Neutrophil: 7.51,LDH level: 170.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 150.3 cm,Body weight: 40.8 kg,BMI: 18.06,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,WBC: 3.03,Albumin: 4.1 g/dL,Lymphocyte: 1.23,Neutrophil: 1.45,LDH level: 279.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 155.7 cm,Body weight: 59 kg,BMI: 24.34,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 1%,WBC: 12.02,Albumin: 3.6 g/dL,Lymphocyte: 2.0,Neutrophil: 8.84,LDH level: 192.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MED12,PTEN,RB1,TP53,CNV alterations: KDM6A(loss),PIK3CA(gain),PIK3CB(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 169 cm,Body weight: 69 kg,BMI: 24.16,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 1~49%,WBC: 10.94,Albumin: 3.6 g/dL,Lymphocyte: 1.62,Neutrophil: 8.39,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: RASA1,RB1,TP53,CNV alterations: FGF10(gain),FGF6(loss),FGF7(loss),FGF8(loss),FGFR3(loss),JAK2(loss),LAMP1(loss),MYCN(loss),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 161 cm,Body weight: 59 kg,BMI: 22.76,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.36,Albumin: 4.4 g/dL,Lymphocyte: 1.72,Neutrophil: 4.63,LDH level: 166.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA1,EGFR,PIK3CA,TP53,CNV alterations: FGF10(gain),Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 150 cm,Body weight: 51.9 kg,BMI: 23.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,WBC: 6.98,Albumin: 4.5 g/dL,Lymphocyte: 2.67,Neutrophil: 3.61,LDH level: 182.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ARID5B,CTNNB1,ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 174 cm,Body weight: 79 kg,BMI: 26.09,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 6.06,Albumin: 4.2 g/dL,Lymphocyte: 1.86,Neutrophil: 3.62,LDH level: 185.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,MYC,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 162 cm,Body weight: 67 kg,BMI: 25.53,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: KRAS,RB1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 53 kg,BMI: 18.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 4.34,Albumin: 4.2 g/dL,Lymphocyte: 1.06,Neutrophil: 2.71,LDH level: 192.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 167 cm,Body weight: 63.1 kg,BMI: 22.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 6.76,Albumin: 4.0 g/dL,Lymphocyte: 2.15,Neutrophil: 3.71,LDH level: 202.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tislelizumab or Pembrolizumab/Ociperlimab or Placebo,SNV mutations: ASXL1,MET,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 168 cm,Body weight: 58 kg,BMI: 20.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,WBC: 4.58,Albumin: 4.1 g/dL,Lymphocyte: 0.93,Neutrophil: 3.29,LDH level: 186.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,KRAS,TP53,CNV alterations: BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),DDR2(gain),EGFR(gain),ERBB2(gain),MET(gain),NTRK1(gain),PRKCI(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 164.9 cm,Body weight: 75.9 kg,BMI: 27.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Selpercatinib,SNV mutations: SHQ1,SMAD4,TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 154 cm,Body weight: 54 kg,BMI: 22.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719S,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.54,Albumin: 4.5 g/dL,Lymphocyte: 1.28,Neutrophil: 4.23,LDH level: 202.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRAF,EGFR,TP53,CNV alterations: LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 185 cm,Body weight: 66 kg,BMI: 19.28,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.73,Albumin: 4.6 g/dL,Lymphocyte: 3.12,Neutrophil: 3.88,LDH level: 230.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: SMARCA4,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 172 cm,Body weight: 58 kg,BMI: 19.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,WBC: 12.9,Albumin: 2.7 g/dL,Lymphocyte: 1.33,Neutrophil: 9.14,LDH level: 627.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,TP53,CNV alterations: BRAF(gain),CDK4(gain),CDK6(gain),EGFR(gain),ERBB3(gain),FGF23(gain),KRAS(gain),MDM2(gain),MET(gain),MYC(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: MET,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 171.1 cm,Body weight: 65.8 kg,BMI: 22.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: BCORL1,KRAS,RBM10,SMARCA4,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 17.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 174 cm,Body weight: 82 kg,BMI: 27.08,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <1%,PD-L1 (SP263): 5%,WBC: 7.68,Albumin: 4.2 g/dL,Lymphocyte: 1.99,Neutrophil: 4.78,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,ERRFI1,MET,PIK3CA,TP53,CNV alterations: CARD11(gain),EGFR(gain),ETV1(gain),FGF23(loss),FGF6(loss),KRAS(loss),MYC(gain),PDGFRA(gain),RAC1(gain),Fusion genes: None,Splice variants: MET,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 176 cm,Body weight: 72 kg,BMI: 23.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,T790M,ALK status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RB1,CNV alterations: FGF10(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 163.2 cm,Body weight: 71.8 kg,BMI: 26.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: afatinib,SNV mutations: EGFR,TGFBR2,TP53,CNV alterations: BRAF(gain),CDK6(gain),EGFR(gain),KRAS(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 160 cm,Body weight: 60 kg,BMI: 23.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.69,Albumin: 4.4 g/dL,Lymphocyte: 1.81,Neutrophil: 5.54,LDH level: 376.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,KMT2A,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 150 cm,Body weight: 51 kg,BMI: 22.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,WBC: 5.69,Albumin: 3.3 g/dL,Lymphocyte: 1.1,Neutrophil: 3.41,LDH level: 1977.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDK4(gain),ERBB3(gain),FGF10(gain),FGF2(gain),KRAS(gain),MET(gain),MYC(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 175.1 cm,Body weight: 68.9 kg,BMI: 22.47,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: CCNE1(gain),FGF19(gain),FGF3(gain),FGF4(gain),PIK3CA(gain),PIK3CB(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 14.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 172.3 cm,Body weight: 57.5 kg,BMI: 19.37,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 12.86,Albumin: 4.3 g/dL,Lymphocyte: 2.7,Neutrophil: 8.99,LDH level: 90.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MUTYH,NF2,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 166.2 cm,Body weight: 76.5 kg,BMI: 27.69,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.16,Albumin: 4.0 g/dL,Lymphocyte: 1.11,Neutrophil: 6.7,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ARID1A,ATR,EGFR,MST1,TP53,CNV alterations: CDK6(gain),FGF10(gain),Fusion genes: ALK,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 158.3 cm,Body weight: 63.75 kg,BMI: 25.44,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 11.69,Albumin: 4.0 g/dL,Lymphocyte: 2.99,Neutrophil: 7.13,LDH level: 253.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MYCN,SMARCB1,CNV alterations: CHEK2(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 158 cm,Body weight: 54 kg,BMI: 21.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: 20%,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.28,Albumin: 4.3 g/dL,Lymphocyte: 2.3,Neutrophil: 3.6,LDH level: 240.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: LAMP1(gain),Fusion genes: ALK,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 162.6 cm,Body weight: 55.8 kg,BMI: 21.11,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,PD-L1 (SP263): 25%,WBC: 5.78,Albumin: 3.5 g/dL,Lymphocyte: 2.07,Neutrophil: 2.96,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: NFE2L2,TP53,CNV alterations: CDKN2A(loss),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 173 cm,Body weight: 65 kg,BMI: 21.72,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 7.44,Albumin: 4.3 g/dL,Lymphocyte: 3.62,Neutrophil: 3.09,LDH level: 205.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165 cm,Body weight: 65 kg,BMI: 23.69,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 16.92,Albumin: 3.8 g/dL,Lymphocyte: 1.95,Neutrophil: 13.1,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: PTPRT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 162 cm,Body weight: 66 kg,BMI: 25.15,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 3%,WBC: 6.15,Albumin: 4.0 g/dL,Lymphocyte: 1.23,Neutrophil: 4.3,LDH level: 304.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,EGFR,CNV alterations: CCND3(gain),FGF10(gain),MDM4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 155 cm,Body weight: 46 kg,BMI: 19.06,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 7.11,Albumin: 4.2 g/dL,Lymphocyte: 1.63,Neutrophil: 4.34,LDH level: 197.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 164.9 cm,Body weight: 67.2 kg,BMI: 24.71,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.14,Albumin: 5.0 g/dL,Lymphocyte: 1.68,Neutrophil: 4.83,LDH level: 336.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Paclitaxel/Carboplatin -> Tiragolumab/Atezolizumab,SNV mutations: ATR,CDKN2A,FGFR3,LZTR1,TP53,ZFHX3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 166 cm,Body weight: 71 kg,BMI: 25.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 50%,WBC: 8.72,Albumin: 3.8 g/dL,Lymphocyte: 2.17,Neutrophil: 5.42,LDH level: 168.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 183 cm,Body weight: 76 kg,BMI: 22.69,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.08,Albumin: 3.4 g/dL,Lymphocyte: 1.78,Neutrophil: 4.46,LDH level: 180.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 13.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 175.7 cm,Body weight: 78.6 kg,BMI: 25.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 6.22,Albumin: 4.9 g/dL,Lymphocyte: 2.35,Neutrophil: 2.86,LDH level: 191.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 162.3 cm,Body weight: 68.3 kg,BMI: 25.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 13.79,Albumin: 3.8 g/dL,Lymphocyte: 1.27,Neutrophil: 11.63,LDH level: 695.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ERBB2,TP53,CNV alterations: AKT2(gain),CCNE1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 172 cm,Body weight: 71 kg,BMI: 24.00,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.28,Albumin: 4.9 g/dL,Lymphocyte: 1.48,Neutrophil: 3.88,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: FGFR4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 162 cm,Body weight: 61 kg,BMI: 23.24,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.19,Albumin: 3.3 g/dL,Lymphocyte: 0.73,Neutrophil: 6.59,LDH level: 671.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: B2M,CDKN2A,FGFR2,SMARCA4,TP53,CNV alterations: CCND3(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 152 cm,Body weight: 63.6 kg,BMI: 27.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 4.29,Albumin: 4.1 g/dL,Lymphocyte: 2.05,Neutrophil: 1.54,LDH level: 247.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 158 cm,Body weight: 57 kg,BMI: 22.83,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 11.59,Albumin: 3.8 g/dL,Lymphocyte: 0.92,Neutrophil: 9.84,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NFE2L2,TP53,CNV alterations: PIK3CA(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 173.8 cm,Body weight: 56.5 kg,BMI: 18.70,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <50%,PD-L1 (SP263): 10%,WBC: 4.95,Albumin: 3.6 g/dL,Lymphocyte: 1.89,Neutrophil: 2.56,LDH level: 328.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BARD1,ERBB4,FGFR2,FLT3,MPL,MYCL,MYCN,NOTCH2,PALB2,PDGFRA,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 171.5 cm,Body weight: 72.6 kg,BMI: 24.68,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 10.36,Albumin: 3.9 g/dL,Lymphocyte: 1.02,Neutrophil: 8.64,LDH level: 1602.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab or Pembrolizumab/Tiragolumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,KRAS,PTPRS,TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 13.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 146.5 cm,Body weight: 46 kg,BMI: 21.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 23.43,Albumin: 3.9 g/dL,Lymphocyte: 1.73,Neutrophil: 20.42,LDH level: 381.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 159.6 cm,Body weight: 42.46 kg,BMI: 16.67,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.97,Albumin: 3.4 g/dL,Lymphocyte: 1.12,Neutrophil: 4.93,LDH level: 326.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Paclitaxel/Carboplatin,SNV mutations: CASP8,FGFR3,LATS1,NCOR1,PARP1,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 19.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 33 years old,Sex: M,Height: 179 cm,Body weight: 80 kg,BMI: 24.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.51,Albumin: 4.8 g/dL,Lymphocyte: 1.46,Neutrophil: 1.43,LDH level: 236.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: KRAS,PBRM1,TNFAIP3,TP53,CNV alterations: FGF7(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 170 cm,Body weight: 61 kg,BMI: 21.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 9.51,Albumin: 4.1 g/dL,Lymphocyte: 2.53,Neutrophil: 5.8,LDH level: 236.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK6(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 172 cm,Body weight: 85 kg,BMI: 28.73,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.12,Albumin: 4.5 g/dL,Lymphocyte: 1.94,Neutrophil: 7.1,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine,SNV mutations: CDKN2A,TP53,TSC2,CNV alterations: AKT2(gain),AR(loss),ATM(loss),CHEK1(loss),FGF14(gain),FGF5(gain),LAMP1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 157.8 cm,Body weight: 50 kg,BMI: 20.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719X/L858R,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: ATM,EGFR,CNV alterations: MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 154 cm,Body weight: 55.2 kg,BMI: 23.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 5.32,Albumin: 3.5 g/dL,Lymphocyte: 0.61,Neutrophil: 1.25,LDH level: 189.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab -> Dabrafenib/Trametinib,SNV mutations: BRAF,PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 158 cm,Body weight: 54.7 kg,BMI: 21.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.19,Albumin: 3.0 g/dL,Lymphocyte: 1.22,Neutrophil: 4.66,LDH level: 325.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: DNMT3A,TET2,TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 167 cm,Body weight: 56.2 kg,BMI: 20.15,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 168.5 cm,Body weight: 70.1 kg,BMI: 24.69,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 5.74,Albumin: 4.3 g/dL,Lymphocyte: 2.44,Neutrophil: 2.86,LDH level: 137.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,CNV alterations: AKT2(gain),CCND3(gain),CDK12(gain),ERBB2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 169 cm,Body weight: 64 kg,BMI: 22.41,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 7.2,Albumin: 4.6 g/dL,Lymphocyte: 1.92,Neutrophil: 2.72,LDH level: 343.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 156 cm,Body weight: 58 kg,BMI: 23.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 12.04,Albumin: 4.6 g/dL,Lymphocyte: 2.5,Neutrophil: 8.84,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: CCND3(gain),EGFR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 164.3 cm,Body weight: 54.6 kg,BMI: 20.23,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 6.88,Albumin: 3.5 g/dL,Lymphocyte: 1.01,Neutrophil: 5.41,LDH level: 143.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: MDM2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 34 years old,Sex: F,Height: 159.6 cm,Body weight: 49.5 kg,BMI: 19.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.05,Albumin: 4.5 g/dL,Lymphocyte: 1.67,Neutrophil: 3.0,LDH level: 104.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 169 cm,Body weight: 67.2 kg,BMI: 23.53,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 40%,PD-L1 (SP263): 55%,WBC: 7.89,Albumin: 4.9 g/dL,Lymphocyte: 1.93,Neutrophil: 4.88,LDH level: 209.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 144.1 cm,Body weight: 44.5 kg,BMI: 21.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 65%,WBC: 5.11,Albumin: 4.1 g/dL,Lymphocyte: 1.62,Neutrophil: 3.01,LDH level: 311.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK3475A/Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: BRCA1(gain),CCNE1(gain),EGFR(gain),ERBB2(gain),FGF10(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 173 cm,Body weight: 71.9 kg,BMI: 24.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 8.62,Albumin: 2.6 g/dL,Lymphocyte: 0.45,Neutrophil: 6.58,LDH level: 372.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NF1,NRAS,TP53,CNV alterations: RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 155.2 cm,Body weight: 77.3 kg,BMI: 32.09,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 5.8,Albumin: 4.3 g/dL,Lymphocyte: 0.23,Neutrophil: 4.99,LDH level: 279.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 160 cm,Body weight: 46 kg,BMI: 17.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: 40%,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 9.99,Albumin: 3.7 g/dL,Lymphocyte: 2.46,Neutrophil: 6.76,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TP53,CNV alterations: FGF1(gain),KRAS(gain),MET(gain),Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 177.7 cm,Body weight: 91.3 kg,BMI: 28.91,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 6.71,Albumin: 4.3 g/dL,Lymphocyte: 1.54,Neutrophil: 4.12,LDH level: 141.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: SETD2,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: ROS1,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 166.6 cm,Body weight: 54.2 kg,BMI: 19.53,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.03,Albumin: 3.1 g/dL,Lymphocyte: 0.78,Neutrophil: 9.6,LDH level: 262.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 147.5 cm,Body weight: 41.7 kg,BMI: 19.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.46,Albumin: 3.5 g/dL,Lymphocyte: 1.2,Neutrophil: 4.7,LDH level: 225.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,CHEK2,RB1,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 164 cm,Body weight: 61 kg,BMI: 22.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 8.04,Albumin: 3.9 g/dL,Lymphocyte: 1.77,Neutrophil: 5.48,LDH level: 184.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: PBRM1,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 168.3 cm,Body weight: 62.5 kg,BMI: 22.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 80%,WBC: 22.29,Albumin: 3.8 g/dL,Lymphocyte: 1.54,Neutrophil: 18.84,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: CCND1(gain),CDK4(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),MYC(gain),PDGFRA(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 183 cm,Body weight: 72 kg,BMI: 21.50,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.9,Albumin: 4.4 g/dL,Lymphocyte: 2.67,Neutrophil: 3.24,LDH level: 353.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 178 cm,Body weight: 75 kg,BMI: 23.80,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.18,Albumin: 3.9 g/dL,Lymphocyte: 2.01,Neutrophil: 5.21,LDH level: 320.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK4(gain),FGF9(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 167.2 cm,Body weight: 66 kg,BMI: 23.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 30%,WBC: 10.99,Albumin: 4.7 g/dL,Lymphocyte: 3.17,Neutrophil: 6.95,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-5890/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 160.7 cm,Body weight: 58.3 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 70%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.81,Albumin: 3.7 g/dL,Lymphocyte: 2.7,Neutrophil: 5.32,LDH level: 207.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KRAS,CNV alterations: ERBB3(gain),MDM2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 172 cm,Body weight: 60 kg,BMI: 20.28,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,WBC: 10.02,Albumin: 4.1 g/dL,Lymphocyte: 2.01,Neutrophil: 6.84,LDH level: 222.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,RET,STK11,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: F,Height: 153 cm,Body weight: 69 kg,BMI: 29.48,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.58,Albumin: 4.5 g/dL,Lymphocyte: 2.33,Neutrophil: 4.6,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 157 cm,Body weight: 46 kg,BMI: 18.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CDK6(gain),CHEK1(gain),EGFR(gain),JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 162 cm,Body weight: 55 kg,BMI: 20.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 70%,WBC: 6.06,Albumin: 3.7 g/dL,Lymphocyte: 0.78,Neutrophil: 4.68,LDH level: 185.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FOXA1(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 157 cm,Body weight: 66 kg,BMI: 26.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.31,Albumin: 4.4 g/dL,Lymphocyte: 2.79,Neutrophil: 2.78,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,ERBB2,LZTR1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 159 cm,Body weight: 53.8 kg,BMI: 21.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.24,Albumin: 4.2 g/dL,Lymphocyte: 1.9,Neutrophil: 5.85,LDH level: 210.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,SMO,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 159 cm,Body weight: 45 kg,BMI: 17.80,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 4.92,Albumin: 4.4 g/dL,Lymphocyte: 1.89,Neutrophil: 2.39,LDH level: 185.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,NSD1,CNV alterations: CDK4(gain),ERBB3(gain),FGF23(gain),FGF6(gain),FGFR3(loss),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 163.1 cm,Body weight: 61.9 kg,BMI: 23.27,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.77,Albumin: 4.6 g/dL,Lymphocyte: 2.3,Neutrophil: 5.67,LDH level: 197.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CUL3,TP53,CNV alterations: CCND3(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGFR1(gain),H3F3C(gain),KRAS(gain),LAMP1(gain),PIK3CA(gain),RICTOR(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166 cm,Body weight: 61 kg,BMI: 22.14,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,PD-L1 (SP263): 25%,WBC: 6.01,Albumin: 4.3 g/dL,Lymphocyte: 1.85,Neutrophil: 3.48,LDH level: 277.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NF1,NFE2L2,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: F,Height: 166 cm,Body weight: 58 kg,BMI: 21.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 55%,WBC: 7.44,Albumin: 4.3 g/dL,Lymphocyte: 1.46,Neutrophil: 5.42,LDH level: 184.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 165 cm,Body weight: 67 kg,BMI: 24.55,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.99,Albumin: 4.6 g/dL,Lymphocyte: 3.15,Neutrophil: 4.03,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: TET2,TP53,CNV alterations: AKT2(gain),EGFR(gain),ERCC2(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 169.8 cm,Body weight: 57.4 kg,BMI: 19.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 11.51,Albumin: 4.1 g/dL,Lymphocyte: 1.67,Neutrophil: 8.66,LDH level: 286.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 165 cm,Body weight: 54.9 kg,BMI: 20.17,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 25.71,Albumin: 3.1 g/dL,Lymphocyte: 0.73,Neutrophil: 23.37,LDH level: 145.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: BCL2L1(gain),CCNE1(gain),ERBB2(gain),FGF10(gain),KRAS(gain),LATS2(loss),MYB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 165 cm,Body weight: 61.8 kg,BMI: 22.70,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 12.89,Albumin: 4.0 g/dL,Lymphocyte: 1.52,Neutrophil: 10.38,LDH level: 189.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 166.1 cm,Body weight: 90 kg,BMI: 32.62,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): >10%,WBC: 20.27,Albumin: 3.6 g/dL,Lymphocyte: 1.04,Neutrophil: 17.2,LDH level: 189.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BAP1,CDKN2A,EP300,NF2,TP53,CNV alterations: BCL2L1(gain),CCND1(gain),DNMT3B(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),SRC(gain),TOP1(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 159 cm,Body weight: 67.5 kg,BMI: 26.70,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.56,Albumin: 4.0 g/dL,Lymphocyte: 2.5,Neutrophil: 5.34,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: CDKN1B(loss),FGF14(loss),FGF9(loss),FGFR2(loss),FGFR3(loss),LAMP1(loss),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 170 cm,Body weight: 68 kg,BMI: 23.54,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 6.24,Albumin: 4.0 g/dL,Lymphocyte: 2.45,Neutrophil: 3.04,LDH level: 258.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CREBBP,KDM6A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 147.7 cm,Body weight: 58 kg,BMI: 26.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 0%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: ARID2,BRAF,IDH1,RHOA,TP53,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 150 cm,Body weight: 46 kg,BMI: 20.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,WBC: 10.88,Albumin: 4.4 g/dL,Lymphocyte: 1.14,Neutrophil: 8.59,LDH level: 188.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 167 cm,Body weight: 50 kg,BMI: 17.93,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 9.83,Albumin: 3.5 g/dL,Lymphocyte: 1.07,Neutrophil: 7.59,LDH level: 173.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,BRCA2,KRAS,TBX3,TERT,TP53,CNV alterations: KRAS(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.7 cm,Body weight: 66.25 kg,BMI: 24.72,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 10.59,Albumin: 4.2 g/dL,Lymphocyte: 1.97,Neutrophil: 7.53,LDH level: 251.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: BRCA2,CUX1,TET1,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),KIT(gain),KRAS(gain),PDGFRA(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 172.1 cm,Body weight: 65.5 kg,BMI: 22.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.1,Albumin: 4.1 g/dL,Lymphocyte: 1.97,Neutrophil: 4.25,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Selpercatinib,SNV mutations: None,CNV alterations: PTEN(loss),Fusion genes: RET,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 165.1 cm,Body weight: 59.2 kg,BMI: 21.72,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 95%,WBC: 13.54,Albumin: 4.7 g/dL,Lymphocyte: 1.85,Neutrophil: 10.41,LDH level: 186.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: DNMT3A,FAT1,RB1,TP53,CNV alterations: CCND1(gain),FGF4(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 164.8 cm,Body weight: 68.3 kg,BMI: 25.15,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 20%,WBC: 10.28,Albumin: 4.3 g/dL,Lymphocyte: 1.83,Neutrophil: 7.49,LDH level: 277.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-0482/Pembrolizumab,SNV mutations: BLM,NFE2L2,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 178 cm,Body weight: 80 kg,BMI: 25.25,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.56,Albumin: 4.8 g/dL,Lymphocyte: 2.25,Neutrophil: 3.35,LDH level: 173.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 153.9 cm,Body weight: 56 kg,BMI: 23.64,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,WBC: 6.63,Albumin: 3.9 g/dL,Lymphocyte: 2.72,Neutrophil: 3.26,LDH level: 288.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: PTEN,RB1,TP53,CNV alterations: MYCL(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 175 cm,Body weight: 91 kg,BMI: 29.75,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.96,Albumin: 4.7 g/dL,Lymphocyte: 1.14,Neutrophil: 3.21,LDH level: 248.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Canakinumab,SNV mutations: BAP1,BCL2L1,CNV alterations: ATM(loss),BRCA1(gain),CCND1(gain),CDK4(gain),CHEK1(loss),ERBB2(gain),ERBB3(gain),FGF10(loss),FGFR4(gain),JAK2(loss),KRAS(gain),MDM2(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 169 cm,Body weight: 65 kg,BMI: 22.76,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.06,Albumin: 4.5 g/dL,Lymphocyte: 1.57,Neutrophil: 3.91,LDH level: 178.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TET2,TP53,CNV alterations: None,Fusion genes: BRAF,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 155 cm,Body weight: 59 kg,BMI: 24.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 12.41,Albumin: 4.1 g/dL,Lymphocyte: 1.54,Neutrophil: 9.99,LDH level: 192.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Selpercatinib,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 164.5 cm,Body weight: 55 kg,BMI: 20.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 11.55,Albumin: 3.7 g/dL,Lymphocyte: 0.6,Neutrophil: 10.28,LDH level: 625.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: M,Height: 176.1 cm,Body weight: 85.1 kg,BMI: 27.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: 60%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.38,Albumin: 4.7 g/dL,Lymphocyte: 1.99,Neutrophil: 2.97,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,TP63,CNV alterations: BRAF(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 167.8 cm,Body weight: 60.3 kg,BMI: 21.42,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.27,Albumin: 4.1 g/dL,Lymphocyte: 1.59,Neutrophil: 2.03,LDH level: 234.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK3475A/Paclitaxel/Carboplatin,SNV mutations: NSD1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),FGFR1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 156 cm,Body weight: 50 kg,BMI: 20.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.16,Albumin: 4.3 g/dL,Lymphocyte: 2.09,Neutrophil: 5.28,LDH level: 236.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ARID1A,BRCA1,EGFR,MSH6,PTCH1,TP53,CNV alterations: CDK4(gain),KRAS(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 157.6 cm,Body weight: 56 kg,BMI: 22.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 5.06,Albumin: 4.2 g/dL,Lymphocyte: 1.82,Neutrophil: 2.63,LDH level: 153.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,SETD2,TP53,CNV alterations: EGFR(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 161 cm,Body weight: 51 kg,BMI: 19.49,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.34,Albumin: 4.4 g/dL,Lymphocyte: 1.79,Neutrophil: 4.42,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: SHQ1,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 158 cm,Body weight: 57.3 kg,BMI: 22.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 7.06,Albumin: 4.3 g/dL,Lymphocyte: 2.34,Neutrophil: 4.06,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: APC,FANCI,FGFR4,GNAQ,RAD51B,TSC2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 142 cm,Body weight: 47 kg,BMI: 23.49,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,WBC: 15.94,Albumin: 3.5 g/dL,Lymphocyte: 0.67,Neutrophil: 14.35,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KEAP1,TP53,CNV alterations: FGF10(gain),KEAP1(loss),PIK3CA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 154.5 cm,Body weight: 54.1 kg,BMI: 22.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 165 cm,Body weight: 71 kg,BMI: 26.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): >10%50%,WBC: 4.89,Albumin: 4.2 g/dL,Lymphocyte: 1.41,Neutrophil: 2.65,LDH level: 219.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 164.5 cm,Body weight: 59.9 kg,BMI: 22.14,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.85,Albumin: 4.8 g/dL,Lymphocyte: 1.23,Neutrophil: 5.34,LDH level: 224.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: ARID2,FGFR4,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 150 cm,Body weight: 54 kg,BMI: 24.00,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 16.2,Albumin: 2.5 g/dL,Lymphocyte: 0.93,Neutrophil: 13.89,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 176 cm,Body weight: 76 kg,BMI: 24.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 4.92,Albumin: 4.9 g/dL,Lymphocyte: 1.66,Neutrophil: 2.77,LDH level: 245.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: TP53,CNV alterations: CDK4(gain),FGF1(gain),PDGFRB(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 151 cm,Body weight: 61.4 kg,BMI: 26.93,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 5.49,Albumin: 4.2 g/dL,Lymphocyte: 1.64,Neutrophil: 3.19,LDH level: 147.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Oleclumab/Durvalumab/Pemetrexated/Carboplatin,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 153 cm,Body weight: 50 kg,BMI: 21.36,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.85,Albumin: 3.9 g/dL,Lymphocyte: 1.44,Neutrophil: 11.86,LDH level: 263.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CTNNB1,PTEN,TP53,CNV alterations: AKT2(gain),AR(loss),CCND1(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),ERCC1(loss),ERCC2(loss),FGF1(loss),FGF10(gain),FGF19(gain),FGF2(loss),FGF3(gain),FGF4(gain),FGF5(loss),FGF9(loss),FGFR3(loss),FGFR4(loss),KIT(loss),MDM4(gain),MET(loss),MYC(gain),MYCL(loss),NRAS(loss),PDGFRA(loss),PDGFRB(loss),PIK3CA(gain),PTEN(loss),RAF1(loss),RICTOR(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 175 cm,Body weight: 77 kg,BMI: 24.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.61,Albumin: 4.8 g/dL,Lymphocyte: 2.26,Neutrophil: 2.46,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 166 cm,Body weight: 60 kg,BMI: 21.77,Smoking history: Current smoker,Cancer stage: Mixed,Histology: Adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 9.13,Albumin: 4.1 g/dL,Lymphocyte: 1.45,Neutrophil: 6.27,LDH level: 342.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATRX,TP53,CNV alterations: CHEK1(gain),JAK2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 156.8 cm,Body weight: 75 kg,BMI: 30.50,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 8.08,Albumin: 4.3 g/dL,Lymphocyte: 2.14,Neutrophil: 5.77,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: CREBBP,RAD21,TP53,CNV alterations: FGF7(loss),MYCL(gain),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 36 years old,Sex: F,Height: 157.5 cm,Body weight: 52.7 kg,BMI: 21.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 16.71,Albumin: 3.8 g/dL,Lymphocyte: 1.05,Neutrophil: 14.26,LDH level: 212.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Atezolizumab/Paclitaxel/Carboplatin,SNV mutations: ARID1A,BRCA2,CDKN2A,EGFR,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 172.7 cm,Body weight: 81 kg,BMI: 27.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 35%,PD-L1 (SP263): 25%,WBC: 7.2,Albumin: 4.3 g/dL,Lymphocyte: 1.05,Neutrophil: 5.61,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MEDI5752/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 172 cm,Body weight: 67 kg,BMI: 22.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 5.88,Albumin: 4.4 g/dL,Lymphocyte: 2.18,Neutrophil: 2.92,LDH level: 159.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Atezolizumab/Cobimetinib,SNV mutations: ARID1A,PAX5,RBM10,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 174 cm,Body weight: 84 kg,BMI: 27.74,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 70%,WBC: 5.63,Albumin: 4.5 g/dL,Lymphocyte: 1.06,Neutrophil: 3.37,LDH level: 253.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,LZTR1,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 43 years old,Sex: M,Height: 168 cm,Body weight: 62 kg,BMI: 21.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Bevacizumab/Nivolumab,SNV mutations: MAP2K1,SMARCB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 173 cm,Body weight: 60 kg,BMI: 20.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.92,Albumin: 3.0 g/dL,Lymphocyte: 2.14,Neutrophil: 7.01,LDH level: 243.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDH1,MAX,PTEN,STK11,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 153.3 cm,Body weight: 45.6 kg,BMI: 19.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.12,Albumin: 4.4 g/dL,Lymphocyte: 1.84,Neutrophil: 4.04,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FGF10(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 171.4 cm,Body weight: 79.8 kg,BMI: 27.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.1,Albumin: 4.3 g/dL,Lymphocyte: 2.54,Neutrophil: 4.83,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CHEK1,CTNNB1,STK11,CNV alterations: ARID1A(loss),EGFL7(gain),FRS2(gain),JAK2(gain),KDR(gain),MAP2K4(loss),MDM2(gain),MYC(gain),NOTCH1(gain),RUNX1(loss),TRAF2(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 173.2 cm,Body weight: 66.1 kg,BMI: 22.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.33,Albumin: 4.1 g/dL,Lymphocyte: 3.56,Neutrophil: 4.63,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CTNNB1,KEAP1,MGA,MSH3,PBRM1,RBM10,RIT1,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 167 cm,Body weight: 57 kg,BMI: 20.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 17.0,Albumin: 2.5 g/dL,Lymphocyte: 1.44,Neutrophil: 14.15,LDH level: 194.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,TP53,CNV alterations: CCND1(gain),CCND3(gain),EGFR(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: F,Height: 162 cm,Body weight: 62 kg,BMI: 23.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.51,Albumin: 4.4 g/dL,Lymphocyte: 1.46,Neutrophil: 3.56,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: AKT1,PIK3R2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 170 cm,Body weight: 68 kg,BMI: 23.36,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,WBC: 16.28,Albumin: 3.4 g/dL,Lymphocyte: 0.91,Neutrophil: 14.84,LDH level: 521.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATRX,CBL,EP300,ERCC4,KRAS,LATS1,MLH1,NOTCH2,SETD2,TCF3,CNV alterations: ATM(gain),FGF23(gain),FGFR1(gain),KRAS(gain),NRG1(loss),Fusion genes: None,Splice variants: None,TMB: 59.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 159.1 cm,Body weight: 59.1 kg,BMI: 23.35,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 70%,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 7.15,Albumin: 4.8 g/dL,Lymphocyte: 2.18,Neutrophil: 4.23,LDH level: 193.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 172.5 cm,Body weight: 69.2 kg,BMI: 23.26,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 8.24,Albumin: 4.2 g/dL,Lymphocyte: 1.9,Neutrophil: 5.6,LDH level: 109.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 165.7 cm,Body weight: 51 kg,BMI: 18.57,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,WBC: 13.07,Albumin: 2.1 g/dL,Lymphocyte: 1.36,Neutrophil: 10.28,LDH level: 344.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,BRAF,STK11,TP53,CNV alterations: CCNE1(gain),CDKN2A(loss),CDKN2B(loss),KIT(gain),KRAS(gain),MDM2(gain),MYC(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 19.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,WBC: 6.43,Albumin: 4.6 g/dL,Lymphocyte: 2.18,Neutrophil: 3.81,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 160 cm,Body weight: 44.2 kg,BMI: 17.27,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 1%,WBC: 4.02,Albumin: 4.3 g/dL,Lymphocyte: 1.36,Neutrophil: 2.19,LDH level: 196.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: TP53,CNV alterations: ATM(gain),CHEK1(gain),FGFR3(loss),FGFR4(loss),MYCL(gain),PDGFRB(loss),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 172 cm,Body weight: 66.7 kg,BMI: 22.55,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,T790M,C797S,ALK status: Positive,WBC: 6.98,Albumin: 4.7 g/dL,Lymphocyte: 1.77,Neutrophil: 4.25,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EGFR,TGFBR2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 163.2 cm,Body weight: 66.5 kg,BMI: 24.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.49,Albumin: 3.0 g/dL,Lymphocyte: 1.79,Neutrophil: 4.02,LDH level: 1306.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: IDH1(gain),MYB(gain),NOTCH1(gain),Fusion genes: NOTCH1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 170 cm,Body weight: 72 kg,BMI: 24.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 5.97,Albumin: 3.1 g/dL,Lymphocyte: 0.95,Neutrophil: 4.5,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: AKT1,APC,ARID5B,DNMT3B,FH,MAP2K1,NCOR1,PPM1D,TERT,TP53,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 62.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 38 years old,Sex: F,Height: 168 cm,Body weight: 51 kg,BMI: 18.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 5.61,Albumin: 4.1 g/dL,Lymphocyte: 1.78,Neutrophil: 3.32,LDH level: 378.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: None,Fusion genes: NRG1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 181.2 cm,Body weight: 70.8 kg,BMI: 21.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 21.28,Albumin: 3.8 g/dL,Lymphocyte: 1.59,Neutrophil: 17.1,LDH level: 168.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Ociperlimab/Pemetrexed/Carboplatin,SNV mutations: PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 88 years old,Sex: F,Height: 156 cm,Body weight: 64 kg,BMI: 26.30,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719X/L861Q/T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,WBC: 6.57,Albumin: 4.6 g/dL,Lymphocyte: 2.24,Neutrophil: 3.88,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 152.8 cm,Body weight: 53.5 kg,BMI: 22.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.71,Albumin: 4.4 g/dL,Lymphocyte: 2.3,Neutrophil: 3.09,LDH level: 180.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Ociperlimab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 162 cm,Body weight: 58 kg,BMI: 21.95,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 6.16,Albumin: 4.2 g/dL,Lymphocyte: 2.69,Neutrophil: 2.85,LDH level: 170.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NKX2-1,TP53,CNV alterations: MET(gain),PIK3CA(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 149 cm,Body weight: 61 kg,BMI: 27.48,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 9.18,Albumin: 4.2 g/dL,Lymphocyte: 1.91,Neutrophil: 6.49,LDH level: 192.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: ARID2,B2M,CHEK2,NF1,NOTCH1,RB1,TP53,CNV alterations: AKT2(gain),ERCC2(gain),FGF1(loss),FGF2(loss),FGF5(loss),FGF7(loss),FGFR3(loss),FGFR4(loss),KIT(loss),MYCL(gain),PDGFRA(loss),PDGFRB(loss),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 148.1 cm,Body weight: 51.5 kg,BMI: 23.48,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 60%,WBC: 4.96,Albumin: 4.2 g/dL,Lymphocyte: 1.35,Neutrophil: 3.01,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),DDR2(gain),EGFR(gain),NRG1(loss),NTRK1(gain),RICTOR(gain),RIT1(gain),RPS6KB1(gain),SDHC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 168 cm,Body weight: 71 kg,BMI: 25.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: large cell neuroendocrine carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.24,Albumin: 4.2 g/dL,Lymphocyte: 0.94,Neutrophil: 4.01,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: APC,FBXW7,RB1,TP53,CNV alterations: BRCA2(gain),PIK3CA(gain),PTEN(loss),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 158.9 cm,Body weight: 58 kg,BMI: 22.97,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.12,Albumin: 4.4 g/dL,Lymphocyte: 2.49,Neutrophil: 4.67,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: KDM6A,SMARCA4,TP53,CNV alterations: BRCA2(loss),CDK4(gain),ERBB3(gain),FGF7(loss),JAK2(loss),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 150 cm,Body weight: 51 kg,BMI: 22.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 9.08,Albumin: 3.8 g/dL,Lymphocyte: 1.88,Neutrophil: 6.16,LDH level: 387.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 173.5 cm,Body weight: 75.6 kg,BMI: 25.11,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.34,Albumin: 4.0 g/dL,Lymphocyte: 1.23,Neutrophil: 7.14,LDH level: 167.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: ROS1,TP53,CNV alterations: AKT2(loss),CHEK2(loss),FGF14(loss),FGF8(loss),MYC(gain),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RB1(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 159 cm,Body weight: 55 kg,BMI: 21.76,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: NF2,NFE2L2,NOTCH4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 178 cm,Body weight: 90 kg,BMI: 28.41,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.62,Albumin: 4.9 g/dL,Lymphocyte: 2.93,Neutrophil: 2.96,LDH level: 218.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: FGF1(gain),RICTOR(gain),Fusion genes: RET,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 150.8 cm,Body weight: 53.2 kg,BMI: 23.39,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.22,Albumin: 4.3 g/dL,Lymphocyte: 1.4,Neutrophil: 4.4,LDH level: 295.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NOTCH1,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 174 cm,Body weight: 71 kg,BMI: 23.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.29,Albumin: 4.7 g/dL,Lymphocyte: 1.51,Neutrophil: 4.19,LDH level: 198.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: EZH2(loss),FGFR1(gain),MDM2(gain),MDM4(gain),MYC(gain),RASA1(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 164.6 cm,Body weight: 66.2 kg,BMI: 24.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 6.56,Albumin: 4.2 g/dL,Lymphocyte: 1.06,Neutrophil: 4.77,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 163 cm,Body weight: 56 kg,BMI: 21.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 15.86,Albumin: 4.1 g/dL,Lymphocyte: 0.81,Neutrophil: 14.24,LDH level: 334.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CREBBP,CNV alterations: AR(gain),FGF10(gain),Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 159.3 cm,Body weight: 59.2 kg,BMI: 23.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 8.44,Albumin: 4.1 g/dL,Lymphocyte: 3.13,Neutrophil: 4.73,LDH level: 203.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,EGFR,PIK3CA,SETD2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 182 cm,Body weight: 57 kg,BMI: 17.30,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): >50%,WBC: 6.18,Albumin: 4.3 g/dL,Lymphocyte: 0.73,Neutrophil: 4.79,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NFE2L2,PIK3CA,TP53,CNV alterations: CCND3(gain),FGFR1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 9.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 171.5 cm,Body weight: 67.3 kg,BMI: 22.88,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: BRAF,EP300,CNV alterations: AR(gain),BCORL1(loss),CDKN2A(loss),CDKN2B(loss),FGF10(gain),RICTOR(gain),SH2D1A(gain),SMARCA4(loss),Fusion genes: ROS1,Splice variants: None,TMB: 9.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 158 cm,Body weight: 55 kg,BMI: 22.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 166 cm,Body weight: 79 kg,BMI: 28.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 13.65,Albumin: 3.3 g/dL,Lymphocyte: 1.43,Neutrophil: 10.17,LDH level: 266.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,NFE2L2,PIK3CA,SF3B1,TP53,CNV alterations: BRAF(gain),EGFR(gain),FGF10(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 84.5 kg,BMI: 29.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.79,Albumin: 4.6 g/dL,Lymphocyte: 4.22,Neutrophil: 4.78,LDH level: 241.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,PBRM1,SF3B1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 160 cm,Body weight: 75 kg,BMI: 29.30,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel/Carboplatin,SNV mutations: EGFR,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165.8 cm,Body weight: 57.7 kg,BMI: 20.99,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 10.21,Albumin: 3.8 g/dL,Lymphocyte: 2.01,Neutrophil: 6.33,LDH level: 238.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 178.9 cm,Body weight: 75 kg,BMI: 23.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.48,Albumin: 4.3 g/dL,Lymphocyte: 2.1,Neutrophil: 4.63,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Docetaxel/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 176 cm,Body weight: 73 kg,BMI: 23.57,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 6.47,Albumin: 4.8 g/dL,Lymphocyte: 1.78,Neutrophil: 4.13,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: BRCA1(gain),CCND1(gain),ERBB2(gain),FGF19(gain),Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 161 cm,Body weight: 77 kg,BMI: 29.55,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.01,Albumin: 3.6 g/dL,Lymphocyte: 0.72,Neutrophil: 5.65,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ASXL1,KMT2A,NFE2L2,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.34,Albumin: 4.3 g/dL,Lymphocyte: 1.88,Neutrophil: 6.83,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 153 cm,Body weight: 56 kg,BMI: 23.92,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: ARID1B,EGFR,SMO,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 173.58 cm,Body weight: 73.5 kg,BMI: 24.39,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,T790M,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: APC,ARID1A,ARID1B,ARID5B,BBC3,EGFR,FBXW7,MPL,NCOR1,PIK3CA,PTCH1,PTEN,TP53,CNV alterations: CCND3(gain),ESR1(gain),FGF14(gain),FGF3(gain),FGF4(gain),FGFR1(gain),LAMP1(gain),MYC(gain),NRG1(gain),Fusion genes: None,Splice variants: None,TMB: 22.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: F,Height: 152 cm,Body weight: 43.5 kg,BMI: 18.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 5.43,Albumin: 4.1 g/dL,Lymphocyte: 1.76,Neutrophil: 3.32,LDH level: 152.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),ETV1(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 156 cm,Body weight: 53 kg,BMI: 21.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.36,Albumin: 4.4 g/dL,Lymphocyte: 2.34,Neutrophil: 4.63,LDH level: 179.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,SMAD4,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 168 cm,Body weight: 57 kg,BMI: 20.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,TP53,CNV alterations: CDK6(gain),FGF10(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 173 cm,Body weight: 70 kg,BMI: 23.35,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 8.01,Albumin: 4.5 g/dL,Lymphocyte: 1.49,Neutrophil: 5.73,LDH level: 220.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERCC3,STK11,TP53,CNV alterations: FGF10(gain),KRAS(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 177 cm,Body weight: 73 kg,BMI: 23.30,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 0%,WBC: 7.03,Albumin: 4.7 g/dL,Lymphocyte: 1.97,Neutrophil: 4.41,LDH level: 205.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib -> Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CDK6(gain),EGFR(gain),FOXA1(gain),MET(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 170 cm,Body weight: 64 kg,BMI: 22.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 90%,WBC: 7.94,Albumin: 4.4 g/dL,Lymphocyte: 1.5,Neutrophil: 4.98,LDH level: 273.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,CNV alterations: MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: F,Height: 161.2 cm,Body weight: 68.6 kg,BMI: 26.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 10.52,Albumin: 3.9 g/dL,Lymphocyte: 2.99,Neutrophil: 6.25,LDH level: 332.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: MUTYH,RAD51B,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 155 cm,Body weight: 63 kg,BMI: 26.22,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.44,Albumin: 4.6 g/dL,Lymphocyte: 3.09,Neutrophil: 3.09,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 157.7 cm,Body weight: 53.8 kg,BMI: 21.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.87,Albumin: 4.4 g/dL,Lymphocyte: 1.56,Neutrophil: 4.63,LDH level: 403.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 153 cm,Body weight: 62.7 kg,BMI: 26.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 90%,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 4.3,Albumin: Unknown g/dL,Lymphocyte: 0.69,Neutrophil: 3.1,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 170 cm,Body weight: 58 kg,BMI: 20.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <1%,PD-L1 (SP263): 2%,WBC: 7.72,Albumin: 3.5 g/dL,Lymphocyte: 1.74,Neutrophil: 5.07,LDH level: 166.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ASXL1,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 168.1 cm,Body weight: 59.9 kg,BMI: 21.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 60%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 178 cm,Body weight: 66 kg,BMI: 20.83,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.52,Albumin: 3.8 g/dL,Lymphocyte: 1.31,Neutrophil: 7.85,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TET1,TP53,CNV alterations: CCND3(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 164 cm,Body weight: 65.4 kg,BMI: 24.32,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.42,Albumin: 3.8 g/dL,Lymphocyte: 1.36,Neutrophil: 7.13,LDH level: 589.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RAF1,TP53,CNV alterations: ATM(gain),BCL2L1(gain),BIRC3(gain),CCND1(gain),CDK4(gain),CDKN2A(loss),CDKN2B(loss),CRKL(gain),DAXX(gain),EED(gain),EGFR(gain),EIF4E(loss),EMSY(gain),ERCC2(gain),ERG(gain),FGF19(gain),FGF23(gain),FGF3(gain),FGF4(gain),FGF6(gain),FGF9(gain),HIST1H1C(gain),ICOSLG(gain),KAT6A(gain),KDM5A(gain),KRAS(gain),LATS2(gain),LZTR1(gain),MALT1(loss),MRE11A(gain),PAK1(gain),PAK7(gain),PDGFRA(loss),PGR(gain),PIK3C2G(gain),PREX2(gain),RAD21(gain),RECQL4(gain),RPS6KB2(gain),RUNX1(gain),SMAD4(loss),TMPRSS2(gain),U2AF1(gain),YAP1(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 165 cm,Body weight: 66 kg,BMI: 24.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.78,Albumin: 4.1 g/dL,Lymphocyte: 3.79,Neutrophil: 7.14,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PAX5,RB1,TNFRSF14,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),FGF10(gain),FGF6(loss),FGFR3(loss),FOXA1(gain),MYC(gain),NKX2-1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 160 cm,Body weight: 50 kg,BMI: 19.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 20%,WBC: 6.74,Albumin: 4.6 g/dL,Lymphocyte: 2.13,Neutrophil: 3.58,LDH level: 234.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 159.3 cm,Body weight: 61.8 kg,BMI: 24.35,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.33,Albumin: 4.0 g/dL,Lymphocyte: 1.05,Neutrophil: 11.6,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: GRIN2A,PIK3CA,CNV alterations: CCNE1(gain),ESR1(loss),FGF23(gain),FGF6(gain),FGF8(loss),KRAS(gain),MDM4(gain),MYC(gain),PIK3CA(gain),PTEN(loss),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 164 cm,Body weight: 62 kg,BMI: 23.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.08,Albumin: 3.7 g/dL,Lymphocyte: 1.64,Neutrophil: 9.23,LDH level: 276.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,GRIN2A,SMARCA4,TP53,CNV alterations: CCNE1(gain),CDK6(gain),EGFR(gain),PIK3CA(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 22.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 167 cm,Body weight: 65 kg,BMI: 23.31,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 9.37,Albumin: 4.3 g/dL,Lymphocyte: 2.83,Neutrophil: 5.59,LDH level: 275.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRAF,CYLD,MSH3,NOTCH4,NSD1,SPEN,CNV alterations: EGFR(gain),FGF1(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 26.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 161.6 cm,Body weight: 59.6 kg,BMI: 22.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 12.36,Albumin: 3.2 g/dL,Lymphocyte: 1.74,Neutrophil: 8.78,LDH level: 1302.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,ATR,CDKN2A,TP53,CNV alterations: CDK6(gain),FGF23(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 157 cm,Body weight: 64 kg,BMI: 25.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.99,Albumin: 4.9 g/dL,Lymphocyte: 2.55,Neutrophil: 3.56,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib -> Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 167.2 cm,Body weight: 65.6 kg,BMI: 23.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 30%,PD-L1 (SP263): 80%,WBC: 17.46,Albumin: 4.0 g/dL,Lymphocyte: 2.58,Neutrophil: 13.11,LDH level: 225.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: MET,MGA,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: MET,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 154 cm,Body weight: 44 kg,BMI: 18.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 5.77,Albumin: 3.4 g/dL,Lymphocyte: 0.6,Neutrophil: 4.55,LDH level: 229.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,CNV alterations: MDM2(gain),MYC(gain),Fusion genes: None,Splice variants: MET,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 158.7 cm,Body weight: 54.3 kg,BMI: 21.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.18,Albumin: 3.9 g/dL,Lymphocyte: 1.18,Neutrophil: 5.37,LDH level: 338.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TERT,TP53,CNV alterations: FGFR1(gain),Fusion genes: ROS1,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 169 cm,Body weight: 75 kg,BMI: 26.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 8.81,Albumin: 3.5 g/dL,Lymphocyte: 1.26,Neutrophil: 6.67,LDH level: 260.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,PPM1D,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 160 cm,Body weight: 57 kg,BMI: 22.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: 20%,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 8.86,Albumin: 4.3 g/dL,Lymphocyte: 1.72,Neutrophil: 6.19,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,SMO,TP53,CNV alterations: ALK(gain),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 162 cm,Body weight: 61 kg,BMI: 23.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,NF2,PIK3CA,CNV alterations: ATM(gain),BRCA2(gain),CCND1(gain),EGFR(gain),FGF10(gain),FGF14(gain),FGF4(gain),FGF8(loss),FGF9(gain),FGFR3(loss),FGFR4(gain),LAMP1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 174 cm,Body weight: 65 kg,BMI: 21.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.86,Albumin: 3.7 g/dL,Lymphocyte: 1.52,Neutrophil: 6.46,LDH level: 1470.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PBRM1,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: Unknown cm,Body weight: Unknown kg,BMI: #VALUE!,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (SP263): 80%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ARID1A,CDKN2A,MST1,NFE2L2,TP53,CNV alterations: ALK(gain),FGFR1(gain),LAMP1(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 167.2 cm,Body weight: 78.5 kg,BMI: 28.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 80%,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 5.36,Albumin: 4.3 g/dL,Lymphocyte: 1.44,Neutrophil: 3.25,LDH level: 245.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,RB1,RBM10,TP53,CNV alterations: CARD11(gain),EGFR(gain),ETV1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 172 cm,Body weight: 74.5 kg,BMI: 25.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: DNMT3A,EGFR,TP53,CNV alterations: BRAF(gain),CCND3(gain),CDK6(gain),EGFR(gain),FGF10(gain),KIT(gain),MET(gain),MYC(gain),NKX2-1(gain),PDGFRA(gain),Fusion genes: None,Splice variants: EGFR,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,WBC: 16.71,Albumin: 3.7 g/dL,Lymphocyte: 2.6,Neutrophil: 12.91,LDH level: 219.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CTNNB1,FANCA,PTEN,RB1,TP53,CNV alterations: ERBB2(gain),FGF10(gain),FGFR1(gain),FGFR3(gain),MYC(gain),NRG1(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 171 cm,Body weight: 73 kg,BMI: 24.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 15.51,Albumin: 4.9 g/dL,Lymphocyte: 2.17,Neutrophil: 11.17,LDH level: 201.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: RICTOR(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 159 cm,Body weight: 49 kg,BMI: 19.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.75,Albumin: 4.7 g/dL,Lymphocyte: 1.24,Neutrophil: 4.8,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MED12,RBM10,SMARCA4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 88 years old,Sex: F,Height: 150 cm,Body weight: 62.5 kg,BMI: 27.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.32,Albumin: 4.8 g/dL,Lymphocyte: 2.38,Neutrophil: 3.37,LDH level: 479.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CDK4(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: F,Height: 165 cm,Body weight: 60.2 kg,BMI: 22.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 4.91,Albumin: 4.6 g/dL,Lymphocyte: 0.85,Neutrophil: 3.59,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 163 cm,Body weight: 50 kg,BMI: 18.89,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 14.89,Albumin: 4.0 g/dL,Lymphocyte: 3.48,Neutrophil: 9.72,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MITF,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 160 cm,Body weight: 67 kg,BMI: 26.33,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 30%,WBC: 5.35,Albumin: 3.5 g/dL,Lymphocyte: 0.96,Neutrophil: 3.82,LDH level: 318.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: ALK(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 20.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 158 cm,Body weight: 58 kg,BMI: 23.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.03,Albumin: 4.4 g/dL,Lymphocyte: 1.52,Neutrophil: 2.74,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BIRC3,KRAS,NKX2-1,PBRM1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 160.8 cm,Body weight: 50.6 kg,BMI: 19.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.09,Albumin: 5.2 g/dL,Lymphocyte: 1.75,Neutrophil: 2.84,LDH level: 206.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,MSH3,NCOR1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 155 cm,Body weight: 56 kg,BMI: 23.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 9.91,Albumin: 4.4 g/dL,Lymphocyte: 3.07,Neutrophil: 5.88,LDH level: 214.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CDKN2A,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 166 cm,Body weight: 65.5 kg,BMI: 23.77,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,MET,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 156 cm,Body weight: 49 kg,BMI: 20.25,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,WBC: 9.23,Albumin: 4.1 g/dL,Lymphocyte: 1.88,Neutrophil: 6.36,LDH level: 191.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CCND1(gain),ERBB2(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: NRG1,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 164.1 cm,Body weight: 67.4 kg,BMI: 25.03,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.72,Albumin: 3.2 g/dL,Lymphocyte: 1.85,Neutrophil: 10.68,LDH level: 512.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KDM5C,SMARCA4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 170 cm,Body weight: 61 kg,BMI: 21.11,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.57,Albumin: 3.9 g/dL,Lymphocyte: 0.84,Neutrophil: 6.0,LDH level: 207.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: APC,BIRC3,EGFR,MSH3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 166 cm,Body weight: 48 kg,BMI: 17.42,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 12.63,Albumin: 3.4 g/dL,Lymphocyte: 1.69,Neutrophil: 9.63,LDH level: 373.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: CREBBP,PTEN,RB1,TP53,CNV alterations: ALK(gain),BRCA1(gain),ERBB2(gain),FGF10(gain),KIT(gain),MYC(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: F,Height: 144.9 cm,Body weight: 53 kg,BMI: 25.24,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1-4%,WBC: 8.37,Albumin: 4.3 g/dL,Lymphocyte: 2.0,Neutrophil: 5.77,LDH level: 183.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Larotrectinib,SNV mutations: KRAS,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 180 cm,Body weight: 60.9 kg,BMI: 18.80,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 5.24,Albumin: 3.9 g/dL,Lymphocyte: 0.76,Neutrophil: 3.71,LDH level: 467.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 170 cm,Body weight: 82 kg,BMI: 28.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 6.58,Albumin: 3.8 g/dL,Lymphocyte: 1.15,Neutrophil: 4.15,LDH level: 291.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,PRKAR1A,TET2,TP53,CNV alterations: FGF10(gain),HIST1H3A(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 19.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 167.2 cm,Body weight: 52.3 kg,BMI: 18.71,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 9.65,Albumin: 3.7 g/dL,Lymphocyte: 1.94,Neutrophil: 6.58,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: GRIN2A,STK11,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 20.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 154 cm,Body weight: 61 kg,BMI: 25.72,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.76,Albumin: 4.8 g/dL,Lymphocyte: 1.36,Neutrophil: 5.72,LDH level: 257.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lorlatinib,SNV mutations: None,CNV alterations: FGF1(gain),FGF10(gain),PDGFRB(gain),Fusion genes: ALK,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 178.4 cm,Body weight: 80.3 kg,BMI: 25.23,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 5.47,Albumin: 4.3 g/dL,Lymphocyte: 2.16,Neutrophil: 2.59,LDH level: 149.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: CCND1(gain),CDKN2A(loss),CDKN2B(loss),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 182.6 cm,Body weight: 91.6 kg,BMI: 27.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 8.84,Albumin: 4.4 g/dL,Lymphocyte: 1.64,Neutrophil: 6.59,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,MGA,RBM10,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 35.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 165 cm,Body weight: 59 kg,BMI: 21.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 12.7,Albumin: 3.2 g/dL,Lymphocyte: 1.2,Neutrophil: 10.92,LDH level: 430.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF2,TP53,CNV alterations: CCND1(gain),FGF3(gain),FGF4(gain),MET(gain),Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 154 cm,Body weight: 49 kg,BMI: 20.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.1,Albumin: 4.3 g/dL,Lymphocyte: 1.41,Neutrophil: 4.2,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CD274(loss),CDKN2A(loss),CDKN2B(loss),EGFR(gain),EZH2(gain),FGFR3(gain),JAK2(loss),KEL(gain),LYN(gain),MAGI2(gain),MET(gain),NBN(gain),PDCD1LG2(loss),PREX2(gain),PRKDC(gain),RAD21(gain),RECQL4(gain),RUNX1T1(gain),SMAD4(loss),SOX17(gain),TCEB1(gain),XRCC2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 172 cm,Body weight: 62 kg,BMI: 21.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Poorly differentiated adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.7,Albumin: 3.6 g/dL,Lymphocyte: 1.74,Neutrophil: 3.37,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FANCA,FLT3,RAD52,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 172.5 cm,Body weight: 63.8 kg,BMI: 21.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 60%,WBC: 5.1,Albumin: 4.2 g/dL,LDH level: 224.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RBM10,TP53,CNV alterations: ARAF(gain),EGFR(gain),RBM10(gain),SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 155 cm,Body weight: 66 kg,BMI: 27.50,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 18.32,Albumin: 3.5 g/dL,Lymphocyte: 2.88,Neutrophil: 13.2,LDH level: 313.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,NRAS,TGFBR2,CNV alterations: NRAS(gain),Fusion genes: None,Splice variants: None,TMB: 22.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 150.5 cm,Body weight: 51 kg,BMI: 22.52,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 10.71,Albumin: 4.2 g/dL,Lymphocyte: 2.16,Neutrophil: 7.83,LDH level: 165.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRCA2,EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 150.6 cm,Body weight: 51.2 kg,BMI: 22.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 10.89,Albumin: 3.5 g/dL,Lymphocyte: 1.27,Neutrophil: 8.82,LDH level: 297.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 154 cm,Body weight: 61 kg,BMI: 25.72,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.38,Albumin: 4.2 g/dL,Lymphocyte: 1.35,Neutrophil: 4.62,LDH level: 198.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ASXL1,BRCA1,EP300,PIK3CA,SETD2,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 167 cm,Body weight: 61 kg,BMI: 21.88,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): >5% <10%,WBC: 8.29,Albumin: 4.6 g/dL,Lymphocyte: 1.94,Neutrophil: 5.52,LDH level: 428.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: CRKL(gain),LZTR1(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 149.3 cm,Body weight: 43.1 kg,BMI: 19.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 6.29,Albumin: 3.4 g/dL,Lymphocyte: 0.49,Neutrophil: 5.33,LDH level: 269.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 157 cm,Body weight: 57 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): <1%,PD-L1 (SP263): 1%,WBC: 6.57,Albumin: 4.5 g/dL,Lymphocyte: 0.74,Neutrophil: 5.27,LDH level: 157.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: BRAF,EGFR,ERRFI1,TP53,CNV alterations: CCND1(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 175 cm,Body weight: 58 kg,BMI: 18.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: ERCC1(gain),ERCC2(gain),FGF14(gain),LAMP1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 38 years old,Sex: F,Height: 161 cm,Body weight: 46.5 kg,BMI: 17.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: BAP1,CNV alterations: FGF10(gain),Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 165 cm,Body weight: 53 kg,BMI: 19.47,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,PD-L1 (SP263): 100%,WBC: 6.32,Albumin: 4.0 g/dL,Lymphocyte: 1.31,Neutrophil: 4.05,LDH level: 353.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: SMO,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 165 cm,Body weight: 63 kg,BMI: 23.14,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 8.02,Albumin: 3.2 g/dL,Lymphocyte: 1.42,Neutrophil: 5.56,LDH level: 230.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,EP300,KRAS,RNF43,TET2,CNV alterations: CDK6(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 154.9 cm,Body weight: 78.8 kg,BMI: 32.84,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 40%,WBC: 5.18,Albumin: 3.6 g/dL,Lymphocyte: 0.86,Neutrophil: 3.25,LDH level: 119.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,DNMT3A,ERBB2,TP53,CNV alterations: ERBB2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 155 cm,Body weight: 51 kg,BMI: 21.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 70%,WBC: 20.2,Albumin: 3.5 g/dL,Lymphocyte: 2.52,Neutrophil: 13.09,LDH level: 367.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: MET,RHEB,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 168.1 cm,Body weight: 81.1 kg,BMI: 28.70,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.98,Albumin: 3.8 g/dL,Lymphocyte: 0.95,Neutrophil: 5.85,LDH level: 260.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: KRAS,SMARCB1,TERT,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 171 cm,Body weight: 64 kg,BMI: 22.10,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 5%,PD-L1 (SP263): 60%,WBC: 16.58,Albumin: 3.7 g/dL,Lymphocyte: 0.98,Neutrophil: 13.94,LDH level: 329.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,TP53,CNV alterations: CCND3(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 170 cm,Body weight: 68.4 kg,BMI: 23.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 20%,WBC: 6.39,Albumin: 4.8 g/dL,Lymphocyte: 2.84,Neutrophil: 2.89,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FGFR4(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 149.6 cm,Body weight: 64.5 kg,BMI: 28.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719X, S768I,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.26,Albumin: 4.7 g/dL,Lymphocyte: 2.28,Neutrophil: 3.42,LDH level: 222.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PTEN,SETD2,SLX4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163.9 cm,Body weight: 67.9 kg,BMI: 25.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 2.99,Albumin: 4.8 g/dL,Lymphocyte: 0.84,Neutrophil: 1.95,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MGA,PHF6,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: ROS1,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 175 cm,Body weight: 74 kg,BMI: 24.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.72,Albumin: 4.6 g/dL,Lymphocyte: 1.94,Neutrophil: 4.15,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 176 cm,Body weight: 68 kg,BMI: 22.00,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 19.64,Albumin: 4.2 g/dL,Lymphocyte: 1.13,Neutrophil: 17.79,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: KRAS,RB1,TP53,CNV alterations: CDK4(gain),ERBB3(gain),FGF10(gain),FGF23(gain),KRAS(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 171.4 cm,Body weight: 90 kg,BMI: 30.64,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 80%,WBC: 6.85,Albumin: 4.5 g/dL,Lymphocyte: 2.7,Neutrophil: 3.29,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 162.8 cm,Body weight: 59 kg,BMI: 22.26,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 30%,WBC: 20.53,Albumin: 3.8 g/dL,Lymphocyte: 1.15,Neutrophil: 18.58,LDH level: 440.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Pembrolizumab,SNV mutations: FANCL,PIK3CA,RB1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),FGF10(gain),FGF23(gain),FGF6(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 20.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 176 cm,Body weight: 61 kg,BMI: 19.69,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.94,Albumin: 3.6 g/dL,Lymphocyte: 1.6,Neutrophil: 6.17,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: BRCA1(gain),CCNE1(gain),ERBB2(gain),ERCC1(gain),ERCC2(gain),FGFR1(gain),JAK2(gain),MYCL(gain),NRG1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 162 cm,Body weight: 80 kg,BMI: 30.48,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.24,Albumin: 3.8 g/dL,Lymphocyte: 1.06,Neutrophil: 8.7,LDH level: 196.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDK6(gain),ERCC1(gain),ERCC2(gain),FGFR1(gain),MET(gain),MYC(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 160 cm,Body weight: 52 kg,BMI: 20.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 5.31,Albumin: 3.4 g/dL,Lymphocyte: 2.61,Neutrophil: 2.03,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CTNNB1,EGFR,RB1,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 164 cm,Body weight: 66.1 kg,BMI: 24.58,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.58,Albumin: 4.6 g/dL,Lymphocyte: 1.9,Neutrophil: 5.11,LDH level: 236.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: FLCN,MAX,TP53,CNV alterations: LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 147 cm,Body weight: 54.4 kg,BMI: 25.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.94,Albumin: 4.1 g/dL,Lymphocyte: 1.25,Neutrophil: 2.98,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),NRG1(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 175 cm,Body weight: 65.9 kg,BMI: 21.52,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 10.65,Albumin: 3.5 g/dL,Lymphocyte: 0.87,Neutrophil: 8.8,LDH level: 172.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin/Durvalumab,SNV mutations: MGA,TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 165.7 cm,Body weight: 64.1 kg,BMI: 23.35,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.53,Albumin: 4.4 g/dL,Lymphocyte: 1.84,Neutrophil: 4.07,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DIS3,FAT1,SMARCA4,TET2,TP53,CNV alterations: JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 37.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 164.5 cm,Body weight: 64.3 kg,BMI: 23.76,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 3.16,Albumin: 4.0 g/dL,Lymphocyte: 0.99,Neutrophil: 1.81,LDH level: 229.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,MAP3K1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 169 cm,Body weight: 69.5 kg,BMI: 24.33,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.35,Albumin: 4.2 g/dL,Lymphocyte: 1.6,Neutrophil: 4.03,LDH level: 481.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: F,Height: 162 cm,Body weight: 55 kg,BMI: 20.72,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 9.0,Albumin: 3.0 g/dL,Lymphocyte: 0.84,Neutrophil: 7.17,LDH level: 376.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab or Tislelizumab/Ociperlimab,SNV mutations: TERT,TP53,CNV alterations: MET(gain),Fusion genes: RET,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 178 cm,Body weight: 69 kg,BMI: 21.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.26,Albumin: 4.9 g/dL,Lymphocyte: 2.49,Neutrophil: 5.13,LDH level: 212.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA1,BRCA2,ERBB2,SHQ1,CNV alterations: AR(loss),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 150 cm,Body weight: 57.4 kg,BMI: 25.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 30%,WBC: 8.24,Albumin: 4.8 g/dL,Lymphocyte: 2.29,Neutrophil: 5.15,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 161 cm,Body weight: 38 kg,BMI: 14.71,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 11.49,Albumin: 3.1 g/dL,Lymphocyte: 2.42,Neutrophil: 7.89,LDH level: 232.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KDM6A,CNV alterations: FGFR3(gain),FGFR4(loss),MYC(gain),Fusion genes: FGFR3,Splice variants: None,TMB: 6.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 148 cm,Body weight: 47 kg,BMI: 21.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 9.4,Albumin: 3.9 g/dL,Lymphocyte: 2.47,Neutrophil: 5.76,LDH level: 739.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 169 cm,Body weight: 75 kg,BMI: 26.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.79,Albumin: 4.2 g/dL,Lymphocyte: 1.41,Neutrophil: 5.51,LDH level: 235.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,KRAS,STK11,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 163 cm,Body weight: 63 kg,BMI: 23.71,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.61,Albumin: 3.7 g/dL,Lymphocyte: 2.75,Neutrophil: 7.69,LDH level: 816.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Erlotinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),FGF10(gain),KRAS(gain),RICTOR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 181 cm,Body weight: 60 kg,BMI: 18.31,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 9.67,Albumin: 4.1 g/dL,Lymphocyte: 1.62,Neutrophil: 5.59,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ARID1A,CDKN2A,NRAS,TP53,CNV alterations: FGF23(gain),FGF6(gain),MET(gain),NRAS(gain),Fusion genes: None,Splice variants: None,TMB: 32.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 170 cm,Body weight: 49 kg,BMI: 16.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 7.94,Albumin: 4.5 g/dL,Lymphocyte: 0.81,Neutrophil: 6.6,LDH level: 553.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 171 cm,Body weight: 68 kg,BMI: 23.26,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 7.21,Albumin: 4.5 g/dL,Lymphocyte: 1.38,Neutrophil: 4.9,LDH level: 471.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: CREBBP,FAT1,NOTCH1,PBRM1,PTEN,TP53,CNV alterations: ATM(gain),BRCA2(loss),CHEK1(gain),CHEK2(loss),FGF1(loss),FGF14(loss),FGF2(loss),FGF5(loss),FGF7(loss),FGF8(loss),FGF9(loss),KIT(loss),LAMP1(loss),MYCL(gain),PDGFRA(loss),PDGFRB(loss),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RAF1(loss),RB1(loss),RET(loss),RICTOR(gain),TFRC(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 88 years old,Sex: M,Height: 168.1 cm,Body weight: 45.7 kg,BMI: 16.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 9.79,Albumin: 3.2 g/dL,Lymphocyte: 2.07,Neutrophil: 6.46,LDH level: 438.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: CTNNB1,EGFR,MGA,NSD1,TP53,CNV alterations: CD79B(gain),PPM1D(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 73 kg,BMI: 23.57,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 10%,WBC: 10.23,Albumin: 4.0 g/dL,Lymphocyte: 1.17,Neutrophil: 8.54,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BARD1,PTPN11,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 167 cm,Body weight: 56 kg,BMI: 20.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 1%,WBC: 5.61,Albumin: 4.4 g/dL,Lymphocyte: 2.15,Neutrophil: 2.22,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 175 cm,Body weight: 79 kg,BMI: 25.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.67,Albumin: 5.2 g/dL,Lymphocyte: 0.85,Neutrophil: 3.75,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: BCOR,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 156 cm,Body weight: 54 kg,BMI: 22.19,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 80%,WBC: 7.0,Albumin: 4.7 g/dL,Lymphocyte: 0.9,Neutrophil: 5.6,LDH level: 185.0 U/L,Treatment type: Immunotherapy,Treatment regimen: M7824,SNV mutations: TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 169.1 cm,Body weight: 65.4 kg,BMI: 22.87,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.48,Albumin: 3.9 g/dL,Lymphocyte: 3.49,Neutrophil: 4.78,LDH level: 119.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,STK11,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 158 cm,Body weight: 60 kg,BMI: 24.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 8.81,Albumin: 4.0 g/dL,Lymphocyte: 1.91,Neutrophil: 6.16,LDH level: 390.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 174.6 cm,Body weight: 70.6 kg,BMI: 23.16,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.88,Albumin: 4.7 g/dL,Lymphocyte: 3.05,Neutrophil: 4.09,LDH level: 139.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: NKX2-1,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 172 cm,Body weight: 61 kg,BMI: 20.62,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 11.05,Albumin: 4.3 g/dL,Lymphocyte: 1.44,Neutrophil: 8.36,LDH level: 364.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: FANCA,NF1,PTPRT,TP53,CNV alterations: BRAF(gain),FGF10(gain),MET(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 163 cm,Body weight: 68 kg,BMI: 25.50,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 30%,PD-L1 (SP263): 50%,WBC: 6.97,Albumin: 4.2 g/dL,Lymphocyte: 2.61,Neutrophil: 2.92,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/MK5890,SNV mutations: SETD2,TP53,CNV alterations: FGF1(gain),FGF10(gain),PDGFRB(gain),Fusion genes: RET,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 160.8 cm,Body weight: 54.6 kg,BMI: 21.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 6.62,Albumin: 4.6 g/dL,Lymphocyte: 2.42,Neutrophil: 3.48,LDH level: 283.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,CDKN2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 143 cm,Body weight: 53.5 kg,BMI: 26.16,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.06,Albumin: 4.4 g/dL,Lymphocyte: 2.21,Neutrophil: 2.39,LDH level: 236.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: SMAD4,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 149 cm,Body weight: 45 kg,BMI: 20.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 11.5,Albumin: 4.1 g/dL,Lymphocyte: 1.93,Neutrophil: 8.57,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATRX,CTNNB1,EGFR,MED12,PIK3CA,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(loss),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 182 cm,Body weight: 78 kg,BMI: 23.55,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 17.59,Albumin: 4.1 g/dL,Lymphocyte: 4.09,Neutrophil: 12.06,LDH level: 299.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: SMARCA4,TP53,CNV alterations: None,Fusion genes: NOTCH3,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: F,Height: 147 cm,Body weight: 52.8 kg,BMI: 24.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 4.49,Albumin: 4.1 g/dL,Lymphocyte: 1.37,Neutrophil: 2.43,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 156 cm,Body weight: 55 kg,BMI: 22.60,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 12.7,Albumin: 3.1 g/dL,Lymphocyte: 0.51,Neutrophil: 11.63,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: DNMT3A,CNV alterations: CDK6(gain),FGF10(gain),Fusion genes: RET,Splice variants: None,TMB: 8.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 173.8 cm,Body weight: 60.3 kg,BMI: 19.96,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.65,Albumin: 4.4 g/dL,Lymphocyte: 2.34,Neutrophil: 3.54,LDH level: 230.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,EIF1AX,KRAS,PHF6,CNV alterations: ERCC1(gain),ERCC2(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 169 cm,Body weight: 77 kg,BMI: 26.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.42,Albumin: 3.7 g/dL,Lymphocyte: 2.33,Neutrophil: 5.13,LDH level: 345.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK6(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 159 cm,Body weight: 68 kg,BMI: 26.90,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.31,Albumin: 3.7 g/dL,Lymphocyte: 1.72,Neutrophil: 4.94,LDH level: 1136.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ALK,ROS1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 173.4 cm,Body weight: 70.2 kg,BMI: 23.35,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 6.47,Albumin: 3.9 g/dL,Lymphocyte: 0.58,Neutrophil: 5.26,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: EP300,NF1,TGFBR2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 170 cm,Body weight: 65.6 kg,BMI: 22.70,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 10.42,Albumin: 3.8 g/dL,Lymphocyte: 1.63,Neutrophil: 7.53,LDH level: 191.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,EP300,KMT2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 166 cm,Body weight: 63 kg,BMI: 22.86,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.34,Albumin: 3.8 g/dL,Lymphocyte: 1.46,Neutrophil: 5.98,LDH level: 208.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 167 cm,Body weight: 70.2 kg,BMI: 25.17,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.99,Albumin: 3.6 g/dL,Lymphocyte: 1.26,Neutrophil: 4.84,LDH level: 205.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Paclitaxel/Carboplatin,SNV mutations: ASXL1,FAT1,TP53,CNV alterations: FGF10(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 166 cm,Body weight: 68 kg,BMI: 24.68,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.82,Albumin: 3.9 g/dL,Lymphocyte: 1.98,Neutrophil: 5.14,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 176.1 cm,Body weight: 97.4 kg,BMI: 31.41,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 4.38,Albumin: 4.2 g/dL,Lymphocyte: 1.64,Neutrophil: 2.16,LDH level: 226.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: TP53,CNV alterations: BRAF(gain),FGF8(loss),FGFR3(loss),KIT(gain),LAMP1(loss),MDM4(gain),MYCL(gain),MYCN(loss),PDGFRA(gain),PIK3CA(gain),PIK3CB(gain),RAF1(loss),RET(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 170 cm,Body weight: 67 kg,BMI: 23.18,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.94,Albumin: 4.4 g/dL,Lymphocyte: 2.04,Neutrophil: 5.28,LDH level: 243.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: FANCA,TP53,CNV alterations: CDK6(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 148 cm,Body weight: 56 kg,BMI: 25.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.81,Albumin: 4.4 g/dL,Lymphocyte: 2.24,Neutrophil: 4.05,LDH level: 284.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,BRAF,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 157.2 cm,Body weight: 65 kg,BMI: 26.30,Smoking history: Never smoker,Cancer stage: Mixed,Histology: adenocarcinoma -> squamous cell carcinoma transformation,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 7.34,Albumin: 4.1 g/dL,Lymphocyte: 1.41,Neutrophil: 5.46,LDH level: 195.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,SMARCA4,TP53,CNV alterations: CCND1(gain),CD274(gain),CDKN2A(loss),CDKN2B(loss),FGF19(gain),JAK2(gain),KLF4(loss),MET(gain),PAK1(gain),PDCD1LG2(gain),YAP1(gain),Fusion genes: None,Splice variants: MET,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 188 cm,Body weight: 66.6 kg,BMI: 18.84,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 21.73,Albumin: 3.1 g/dL,Lymphocyte: 1.58,Neutrophil: 18.11,LDH level: 132.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 159 cm,Body weight: 60 kg,BMI: 23.68,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.74,Albumin: 4.4 g/dL,Lymphocyte: 2.34,Neutrophil: 4.18,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KRAS,NF1,RB1,TP53,TSC1,CNV alterations: BRCA1(gain),ERBB2(gain),FGF14(gain),LAMP1(gain),MDM4(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 149 cm,Body weight: 58 kg,BMI: 25.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.58,Albumin: 4.8 g/dL,Lymphocyte: 3.12,Neutrophil: 5.67,LDH level: 179.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: NKX2-1,PIK3CA,CNV alterations: FGFR2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 38 years old,Sex: M,Height: 178 cm,Body weight: 88 kg,BMI: 27.77,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.67,Albumin: 5.1 g/dL,Lymphocyte: 2.9,Neutrophil: 5.17,LDH level: 309.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,ASXL1,EPHA3,EPHA7,TP53,CNV alterations: AKT2(gain),AURKA(gain),AXIN1(loss),CCNE1(gain),CDKN1B(loss),CDKN2A(loss),CDKN2B(loss),FGF10(gain),FGFR1(loss),KDM5A(gain),MYC(gain),NRG1(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 25.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 174 cm,Body weight: 74 kg,BMI: 24.44,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: KRAS,ZFHX3,CNV alterations: FGF6(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: F,Height: 152 cm,Body weight: 59 kg,BMI: 25.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.18,Albumin: 4.5 g/dL,Lymphocyte: 1.31,Neutrophil: 3.04,LDH level: 182.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PTEN,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),FGF10(gain),FGF14(gain),FGF7(loss),LAMP1(gain),MYC(gain),PTEN(loss),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 168 cm,Body weight: 61.3 kg,BMI: 21.72,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 9.06,Albumin: 4.4 g/dL,Lymphocyte: 2.26,Neutrophil: 5.72,LDH level: 186.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 150 cm,Body weight: 38 kg,BMI: 16.89,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 9.4,Albumin: 2.8 g/dL,Lymphocyte: 0.76,Neutrophil: 7.62,LDH level: 431.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,NOTCH2,TP53,CNV alterations: FGF10(gain),FGFR3(gain),MDM4(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 166.8 cm,Body weight: 68 kg,BMI: 24.44,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.13,Albumin: 4.1 g/dL,Lymphocyte: 1.1,Neutrophil: 4.31,LDH level: 167.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 167.5 cm,Body weight: 55.5 kg,BMI: 19.78,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.51,Albumin: 3.5 g/dL,Lymphocyte: 1.0,Neutrophil: 5.67,LDH level: 141.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: HRAS,RB1,STK11,TP53,CNV alterations: AMER1(loss),NKX2-1(gain),PHF6(loss),PIK3CB(gain),RAC1(gain),RICTOR(gain),SH2D1A(loss),Fusion genes: None,Splice variants: None,TMB: 14.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 158 cm,Body weight: 54 kg,BMI: 21.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.2,Albumin: 4.2 g/dL,Lymphocyte: 1.65,Neutrophil: 5.06,LDH level: 140.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: BCOR,EGFR,TP53,CNV alterations: BRCA1(gain),ERBB2(gain),FGF1(gain),FGF6(loss),FGFR4(gain),MYCL(gain),PDGFRB(gain),PIK3CA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 184.4 cm,Body weight: 86.6 kg,BMI: 25.47,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.94,Albumin: 4.3 g/dL,Lymphocyte: 1.43,Neutrophil: 3.56,LDH level: 151.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 165.1 cm,Body weight: 53 kg,BMI: 19.44,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 9.47,Albumin: 4.0 g/dL,Lymphocyte: 1.99,Neutrophil: 6.42,LDH level: 390.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCND3(gain),LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 160 cm,Body weight: 49 kg,BMI: 19.14,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CCND1(gain),CDK4(gain),FGF19(gain),FGF4(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 172 cm,Body weight: 72 kg,BMI: 24.34,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 9.61,Albumin: 4.0 g/dL,Lymphocyte: 1.18,Neutrophil: 6.74,LDH level: 235.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 168 cm,Body weight: 58 kg,BMI: 20.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.51,Albumin: 3.8 g/dL,Lymphocyte: 1.39,Neutrophil: 4.54,LDH level: 178.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRAF,EGFR,CNV alterations: MDM4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 159 cm,Body weight: 66 kg,BMI: 26.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 6.83,Albumin: 4.2 g/dL,Lymphocyte: 1.76,Neutrophil: 4.37,LDH level: 166.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Capmatinib,SNV mutations: MET,CNV alterations: CCNE1(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 172 cm,Body weight: 74.6 kg,BMI: 25.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.22,Albumin: 4.1 g/dL,Lymphocyte: 1.76,Neutrophil: 2.88,LDH level: 297.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 167.1 cm,Body weight: 63.3 kg,BMI: 22.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 12.3,Albumin: 3.8 g/dL,Lymphocyte: 2.45,Neutrophil: 8.61,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,NOTCH2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 14.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 149.8 cm,Body weight: 63.3 kg,BMI: 28.21,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 90%,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 60%,WBC: 6.47,Albumin: 3.8 g/dL,Lymphocyte: 1.03,Neutrophil: 4.83,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin/Durvalumab,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 171.5 cm,Body weight: 72 kg,BMI: 24.48,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: ASXL1,EPHA3,FAT1,KMT2A,MED12,MSH2,NOTCH4,POLE,TP53,CNV alterations: ALK(gain),FGF2(gain),FGFR3(gain),MDM4(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),PTEN(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 18.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 160.3 cm,Body weight: 54.6 kg,BMI: 21.25,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.41,Albumin: 3.2 g/dL,Lymphocyte: 1.63,Neutrophil: 7.33,LDH level: 174.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),CHEK1(gain),PIK3CA(gain),PIK3CB(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 156.8 cm,Body weight: 55.7 kg,BMI: 22.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1~49%,PD-L1 (SP263): 0%,WBC: 7.84,Albumin: 4.5 g/dL,Lymphocyte: 1.65,Neutrophil: 5.27,LDH level: 162.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,SMARCA4,TP53,CNV alterations: EGFR(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 154 cm,Body weight: 65 kg,BMI: 27.41,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.06,Albumin: 4.3 g/dL,Lymphocyte: 1.03,Neutrophil: 3.5,LDH level: 155.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 176 cm,Body weight: 60 kg,BMI: 19.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 7.52,Albumin: 4.1 g/dL,Lymphocyte: 2.01,Neutrophil: 4.64,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/M7684,SNV mutations: APC,PTPRT,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 23.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 166 cm,Body weight: 59 kg,BMI: 21.41,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 5.11,Albumin: 4.0 g/dL,Lymphocyte: 1.04,Neutrophil: 3.03,LDH level: 434.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: MET(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 162 cm,Body weight: 69 kg,BMI: 26.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 18.19,Albumin: 4.8 g/dL,Lymphocyte: 2.58,Neutrophil: 12.96,LDH level: 265.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: ARID2,IDH1,KRAS,PIK3R1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 164 cm,Body weight: 56 kg,BMI: 20.82,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 6.5,Albumin: 3.0 g/dL,Lymphocyte: 0.73,Neutrophil: 4.87,LDH level: 200.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: FGFR1(gain),PIK3CA(gain),Fusion genes: FGFR3,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 168.5 cm,Body weight: 68 kg,BMI: 23.95,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.37,Albumin: 4.0 g/dL,Lymphocyte: 1.78,Neutrophil: 3.01,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ATM,CYLD,EPHA7,GRIN2A,KMT2A,KRAS,PTPRT,STK11,CNV alterations: FGF5(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 153 cm,Body weight: 59 kg,BMI: 25.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 9.23,Albumin: 4.6 g/dL,Lymphocyte: 1.06,Neutrophil: 7.59,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TET2,TP53,CNV alterations: MYC(gain),RET(gain),Fusion genes: RET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 167.5 cm,Body weight: 70.5 kg,BMI: 25.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.02,Albumin: 4.0 g/dL,Lymphocyte: 1.97,Neutrophil: 6.2,LDH level: 217.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: STK11,SUZ12,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166.2 cm,Body weight: 79.2 kg,BMI: 28.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.35,Albumin: 4.5 g/dL,Lymphocyte: 1.55,Neutrophil: 4.74,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 156 cm,Body weight: 56 kg,BMI: 23.07,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,WBC: 11.87,Albumin: 4.4 g/dL,Lymphocyte: 1.6,Neutrophil: 8.54,LDH level: 380.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDKN2A,TP53,CNV alterations: FGF10(gain),Fusion genes: None,Splice variants: None,TMB: 4.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 164 cm,Body weight: 63 kg,BMI: 23.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 1%,WBC: 4.3,Albumin: 3.9 g/dL,Lymphocyte: 0.87,Neutrophil: 2.94,LDH level: 352.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,SPEN,CNV alterations: AURKA(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 164.6 cm,Body weight: 56 kg,BMI: 20.67,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 9.22,Albumin: 3.4 g/dL,Lymphocyte: 1.17,Neutrophil: 6.95,LDH level: 148.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,CTCF,DNMT3A,GPS2,TP53,CNV alterations: FGFR1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 176 cm,Body weight: 70 kg,BMI: 22.60,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: pleomorphic carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,PD-L1 group: 1~49%,PD-L1 (22C3): 12%,PD-L1 (SP263): 15%,WBC: 4.66,Albumin: 4.4 g/dL,Lymphocyte: 0.65,Neutrophil: 3.63,LDH level: 192.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 158 cm,Body weight: 54.8 kg,BMI: 21.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 15.84,Albumin: 4.2 g/dL,Lymphocyte: 4.48,Neutrophil: 10.17,LDH level: 182.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-4830/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FGFR3,KRAS,NKX2-1,SMAD4,TET2,TP53,CNV alterations: CCND3(gain),CDKN2A(loss),CDKN2B(loss),PIK3CB(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 168 cm,Body weight: 63 kg,BMI: 22.45,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.47,Albumin: 4.3 g/dL,Lymphocyte: 2.01,Neutrophil: 6.72,LDH level: 170.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin or Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 159.5 cm,Body weight: 54 kg,BMI: 21.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 5%,WBC: 5.49,Albumin: 4.1 g/dL,Lymphocyte: 1.9,Neutrophil: 3.21,LDH level: 168.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 149.6 cm,Body weight: 53 kg,BMI: 23.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.81,Albumin: 4.5 g/dL,Lymphocyte: 1.76,Neutrophil: 4.34,LDH level: 166.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CTNNB1,EGFR,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: F,Height: 150.5 cm,Body weight: 39.5 kg,BMI: 17.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 7.91,Albumin: 3.8 g/dL,Lymphocyte: 1.49,Neutrophil: 5.66,LDH level: 257.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,KEAP1,PIK3CA,SETD2,TET2,TP53,VHL,CNV alterations: CDK4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 160 cm,Body weight: 60.5 kg,BMI: 23.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 15%,WBC: 10.89,Albumin: 4.0 g/dL,Lymphocyte: 1.52,Neutrophil: 8.57,LDH level: 301.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 173 cm,Body weight: 65 kg,BMI: 21.71,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.46,Albumin: 4.2 g/dL,Lymphocyte: 1.64,Neutrophil: 5.3,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,STK11,TP53,CNV alterations: FGF14(gain),LAMP1(gain),MDM4(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 146 cm,Body weight: 48 kg,BMI: 22.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 30%,WBC: 8.48,Albumin: 4.5 g/dL,Lymphocyte: 1.68,Neutrophil: 5.77,LDH level: 300.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CTNNB1,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 162.3 cm,Body weight: 69.2 kg,BMI: 26.27,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.22,Albumin: 4.5 g/dL,Lymphocyte: 1.69,Neutrophil: 4.7,LDH level: 150.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: PTEN,TP53,CNV alterations: AKT2(gain),AR(loss),ATM(loss),BRCA1(loss),BRCA2(loss),CCNE1(gain),CHEK1(loss),ERCC1(loss),ERCC2(loss),FGF1(loss),FGF14(loss),FGF2(loss),FGF5(loss),FGF7(loss),FGF8(loss),FGFR4(loss),JAK2(loss),MDM4(gain),MYC(gain),PDGFRB(loss),PIK3CA(gain),PIK3CB(gain),PTEN(loss),RAF1(loss),RB1(loss),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 175 cm,Body weight: 71 kg,BMI: 23.18,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 20%,PD-L1 group: >50%,PD-L1 (22C3): 100%,WBC: 10.63,Albumin: 4.2 g/dL,Lymphocyte: 2.67,Neutrophil: 6.94,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 170 cm,Body weight: 55 kg,BMI: 19.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,T790M,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 65%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),ERBB2(gain),MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 173.7 cm,Body weight: 82 kg,BMI: 27.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 9.01,Albumin: 4.8 g/dL,Lymphocyte: 2.65,Neutrophil: 5.36,LDH level: 224.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: None,CNV alterations: CDK6(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 168 cm,Body weight: 68 kg,BMI: 23.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,WBC: 10.71,Albumin: 4.1 g/dL,Lymphocyte: 2.18,Neutrophil: 7.15,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ATM,KRAS,NFE2L2,NKX2-1,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 170 cm,Body weight: 75 kg,BMI: 25.95,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 10%,PD-L1 (SP263): 80%,WBC: 2.05,Albumin: 4.6 g/dL,Lymphocyte: 0.21,Neutrophil: 1.51,LDH level: 238.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: HRAS,RAD51B,RECQL4,SHQ1,CNV alterations: FGFR1(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 180 cm,Body weight: 77 kg,BMI: 23.77,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR3(loss),MYC(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 153 cm,Body weight: 45 kg,BMI: 19.22,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 8.68,Albumin: 4.3 g/dL,Lymphocyte: 1.9,Neutrophil: 5.89,LDH level: 293.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 172 cm,Body weight: 80 kg,BMI: 27.04,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 6.07,Albumin: 3.8 g/dL,Lymphocyte: 0.32,Neutrophil: 5.36,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CHEK1,FOXL2,KRAS,MGA,NKX2-1,NOTCH3,PALB2,PTPRD,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 45.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 167.6 cm,Body weight: 60 kg,BMI: 21.36,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 10.89,Albumin: 3.7 g/dL,Lymphocyte: 0.98,Neutrophil: 8.88,LDH level: 135.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: NOTCH1,RB1,TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 167 cm,Body weight: 69 kg,BMI: 24.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 95%,WBC: 18.19,Albumin: 2.7 g/dL,Lymphocyte: 1.1,Neutrophil: 15.78,LDH level: 374.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TERT,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: M,Height: 165 cm,Body weight: 72 kg,BMI: 26.45,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 40%,WBC: 12.32,Albumin: 4.8 g/dL,Lymphocyte: 1.47,Neutrophil: 9.73,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: BRAF,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 168 cm,Body weight: 75.6 kg,BMI: 26.79,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 10%,WBC: 5.89,Albumin: 4.3 g/dL,Lymphocyte: 1.52,Neutrophil: 3.61,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 168.6 cm,Body weight: 64.2 kg,BMI: 22.58,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 3.87,Albumin: 4.4 g/dL,Lymphocyte: 0.97,Neutrophil: 2.2,LDH level: 244.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CREBBP,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 173 cm,Body weight: 64 kg,BMI: 21.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.39,Albumin: 4.0 g/dL,Lymphocyte: 2.14,Neutrophil: 4.5,LDH level: 309.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: ALK(gain),ERBB2(gain),ERCC2(gain),FGFR4(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 42 years old,Sex: M,Height: 177 cm,Body weight: 69 kg,BMI: 22.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.05,Albumin: 4.0 g/dL,Lymphocyte: 1.15,Neutrophil: 4.23,LDH level: 342.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FLCN,PALB2,RB1,SMARCA4,TP53,CNV alterations: CDK4(gain),E2F3(gain),EGFR(gain),ERBB3(gain),KRAS(gain),NTRK1(gain),PIK3CA(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 167 cm,Body weight: 69.95 kg,BMI: 25.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.08,Albumin: 4.5 g/dL,Lymphocyte: 1.83,Neutrophil: 3.41,LDH level: 333.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 168.4 cm,Body weight: 52.1 kg,BMI: 18.37,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.27,Albumin: 3.7 g/dL,Lymphocyte: 1.37,Neutrophil: 9.2,LDH level: 180.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 161.7 cm,Body weight: 54 kg,BMI: 20.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 3.34,Albumin: 4.7 g/dL,Lymphocyte: 1.34,Neutrophil: 1.8,LDH level: 177.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,CNV alterations: CDKN2A(loss),JAK2(loss),MDM2(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 167 cm,Body weight: 64 kg,BMI: 22.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 15%,WBC: 4.64,Albumin: 2.7 g/dL,Lymphocyte: 0.68,Neutrophil: 3.15,LDH level: 152.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 178 cm,Body weight: 55 kg,BMI: 17.36,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 18.02,Albumin: 3.8 g/dL,Lymphocyte: 1.24,Neutrophil: 16.09,LDH level: 327.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: MGA,CNV alterations: CCND3(gain),CDK4(gain),ERBB2(gain),ERBB3(gain),ERCC1(gain),ERCC2(gain),MDM2(gain),MDM4(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 34.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 148 cm,Body weight: 59 kg,BMI: 26.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.59,Albumin: 4.6 g/dL,Lymphocyte: 2.41,Neutrophil: 4.33,LDH level: 219.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CTNNB1,EGFR,PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 174 cm,Body weight: 70 kg,BMI: 23.12,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 4.97,Albumin: 3.3 g/dL,Lymphocyte: 0.95,Neutrophil: 3.48,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,PTEN,TP53,CNV alterations: MYCN(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 172.5 cm,Body weight: 79.4 kg,BMI: 26.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.3,Albumin: 4.1 g/dL,Lymphocyte: 1.56,Neutrophil: 6.67,LDH level: 197.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: EGFR(gain),LAMP1(gain),MET(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 147.4 cm,Body weight: 49.9 kg,BMI: 22.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.35,Albumin: 5.2 g/dL,Lymphocyte: 1.64,Neutrophil: 5.14,LDH level: 336.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,ERBB2,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 160.3 cm,Body weight: 63 kg,BMI: 24.52,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 8.51,Albumin: 4.4 g/dL,Lymphocyte: 2.34,Neutrophil: 5.15,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: BRAF,MGA,NFKBIA,TP53,CNV alterations: CDK4(gain),EGFR(gain),JAK2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 26.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 174 cm,Body weight: 82 kg,BMI: 27.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 55%,PD-L1 (SP263): 95%,WBC: 4.83,Albumin: 4.0 g/dL,Lymphocyte: 1.78,Neutrophil: 2.13,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRAF,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 179 cm,Body weight: 64 kg,BMI: 19.97,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,WBC: 9.04,Albumin: 4.4 g/dL,Lymphocyte: 1.35,Neutrophil: 6.88,LDH level: 212.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: ATM,NRAS,TP53,CNV alterations: BRAF(gain),CCNE1(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),EZH2(gain),MDM4(gain),MET(gain),NRAS(gain),RHEB(gain),TFRC(loss),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 163 cm,Body weight: 53 kg,BMI: 19.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 4.47,Albumin: 3.7 g/dL,Lymphocyte: 0.88,Neutrophil: 3.15,LDH level: 444.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 172 cm,Body weight: 54 kg,BMI: 18.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.97,Albumin: 4.5 g/dL,Lymphocyte: 2.35,Neutrophil: 5.65,LDH level: 207.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB4,KEAP1,PTPRT,RAD51B,SMARCA4,SPEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: F,Height: 150.1 cm,Body weight: 37 kg,BMI: 16.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.76,Albumin: 3.5 g/dL,Lymphocyte: 1.38,Neutrophil: 8.49,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,CDKN2A,TP53,CNV alterations: ARAF(gain),ERBB3(gain),FGF10(gain),RBM10(gain),RICTOR(gain),Fusion genes: NRG1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 170 cm,Body weight: 77 kg,BMI: 26.64,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,WBC: 9.18,Albumin: 4.4 g/dL,Lymphocyte: 1.76,Neutrophil: 5.85,LDH level: 296.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 168 cm,Body weight: 72 kg,BMI: 25.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,WBC: 5.33,Albumin: 4.4 g/dL,Lymphocyte: 0.92,Neutrophil: 3.93,LDH level: 376.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: ALK(loss),CCND1(gain),CDK4(loss),CHEK1(loss),ERBB2(gain),FGF10(gain),FGF14(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),JAK2(gain),LAMP1(gain),MDM2(gain),MYC(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 39 years old,Sex: F,Height: 160 cm,Body weight: 54 kg,BMI: 21.09,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,PD-L1 group: >50%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib -> Erlotinib,SNV mutations: EGFR,MAP2K4,PBRM1,TP53,CNV alterations: CDK6(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 170.9 cm,Body weight: 73.2 kg,BMI: 25.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 9.85,Albumin: 4.0 g/dL,Lymphocyte: 1.4,Neutrophil: 7.45,LDH level: 241.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 160 cm,Body weight: 57 kg,BMI: 22.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,WBC: 8.6,Albumin: 3.6 g/dL,Lymphocyte: 1.13,Neutrophil: 6.84,LDH level: 183.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 150 cm,Body weight: 49 kg,BMI: 21.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 50%,WBC: 13.84,Albumin: 3.0 g/dL,Lymphocyte: 1.67,Neutrophil: 10.13,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: BRAF(gain),EGFR(gain),MDM2(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: MET,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 168 cm,Body weight: 47 kg,BMI: 16.75,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 95%,WBC: 11.8,Albumin: 3.3 g/dL,Lymphocyte: 0.74,Neutrophil: 10.28,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KDM6A,NFE2L2,TP53,CNV alterations: AKT3(gain),ALK(gain),BCL2L1(gain),BCL6(gain),CHEK2(gain),DDR2(gain),EGFR(gain),ESR1(loss),FGF10(gain),FGF5(loss),FGFR1(gain),FGFR3(loss),FGFR4(gain),IKBKE(gain),MAPK1(gain),MDM4(gain),MYC(gain),NTRK1(gain),PDGFRA(gain),PIK3CA(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 168.1 cm,Body weight: 65 kg,BMI: 23.00,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 2%,WBC: 5.85,Albumin: 4.6 g/dL,Lymphocyte: 1.99,Neutrophil: 2.96,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,PTEN,TP53,CNV alterations: ALK(gain),MYC(gain),MYCN(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 25.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 179.3 cm,Body weight: 77.9 kg,BMI: 24.23,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 8.04,Albumin: 4.0 g/dL,Lymphocyte: 1.04,Neutrophil: 5.89,LDH level: 268.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PTPRD,RB1,SMARCA4,STK11,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 18.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 175 cm,Body weight: 58 kg,BMI: 18.94,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.55,Albumin: 3.7 g/dL,Lymphocyte: 1.98,Neutrophil: 8.25,LDH level: 147.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 167.9 cm,Body weight: 60.5 kg,BMI: 21.46,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (22C3): >50%,WBC: 7.01,Albumin: 4.5 g/dL,Lymphocyte: 1.34,Neutrophil: 4.7,LDH level: 156.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: FANCC,TP53,CNV alterations: AKT2(gain),ALK(gain),AR(loss),BRAF(gain),CCND3(gain),CCNE1(gain),CDK6(gain),EGFR(gain),FGF23(gain),FGF6(gain),FGFR1(gain),JAK2(loss),KRAS(gain),MET(gain),MYC(gain),NRG1(gain),PIK3CA(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 181 cm,Body weight: 70 kg,BMI: 21.37,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 6.32,Albumin: 4.7 g/dL,Lymphocyte: 1.47,Neutrophil: 4.06,LDH level: 227.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 173.7 cm,Body weight: 67.6 kg,BMI: 22.41,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 70%,WBC: 7.42,Albumin: 3.9 g/dL,Lymphocyte: 1.53,Neutrophil: 4.97,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: AMG404,SNV mutations: CDKN2A,SMO,TP53,CNV alterations: NRG1(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 20.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 154.8 cm,Body weight: 51.9 kg,BMI: 21.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 1.75,Albumin: 3.3 g/dL,Lymphocyte: 0.45,Neutrophil: 0.92,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RBM10,TP53,CNV alterations: CCND3(gain),EGFR(gain),FGF23(gain),FGF6(gain),JAK2(loss),KRAS(gain),MAPK1(gain),MYC(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 157.6 cm,Body weight: 65 kg,BMI: 26.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 6.7,Albumin: 4.4 g/dL,Lymphocyte: 2.25,Neutrophil: 3.64,LDH level: 118.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NFE2L2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157 cm,Body weight: 57 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.44,Albumin: 4.9 g/dL,Lymphocyte: 1.99,Neutrophil: 5.81,LDH level: 143.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,MSH3,NF2,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 169 cm,Body weight: 55 kg,BMI: 19.26,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.24,Albumin: 3.9 g/dL,Lymphocyte: 1.56,Neutrophil: 4.41,LDH level: 215.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MEDI5752,SNV mutations: BIRC3,CDKN2A,MAPK1,PPM1D,STK11,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 14.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 183.9 cm,Body weight: 80.8 kg,BMI: 23.89,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 1%,WBC: 5.51,Albumin: 3.7 g/dL,Lymphocyte: 1.57,Neutrophil: 2.89,LDH level: 228.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,RBM10,RIT1,TP53,CNV alterations: FGF10(gain),IL7R(gain),PMS2(gain),STAG1(gain),Fusion genes: None,Splice variants: MET,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 171 cm,Body weight: 82 kg,BMI: 28.04,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 2.98,Albumin: 4.5 g/dL,Lymphocyte: 0.89,Neutrophil: 1.63,LDH level: 212.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CHEK2,TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 177 cm,Body weight: 75 kg,BMI: 23.91,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.53,Albumin: 4.6 g/dL,Lymphocyte: 2.6,Neutrophil: 8.21,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID1A,KEAP1,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 169 cm,Body weight: 70 kg,BMI: 24.69,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.27,Albumin: 4.4 g/dL,Lymphocyte: 0.57,Neutrophil: 4.02,LDH level: 192.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: RASA1,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 150 cm,Body weight: 48 kg,BMI: 21.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 90%,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 8.0,Albumin: 4.4 g/dL,Lymphocyte: 1.79,Neutrophil: 5.23,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 159 cm,Body weight: 60 kg,BMI: 23.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 8.55,Albumin: 4.4 g/dL,Lymphocyte: 1.26,Neutrophil: 6.82,LDH level: 204.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: ARID1A,ARID1B,EGFR,TP53,CNV alterations: EGFR(gain),FGF10(gain),JAK2(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 164.2 cm,Body weight: 64 kg,BMI: 23.74,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 5.13,Albumin: 4.0 g/dL,Lymphocyte: 1.23,Neutrophil: 3.21,LDH level: 225.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: AXIN1,EGFR,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 167 cm,Body weight: 63.2 kg,BMI: 22.66,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 11.01,Albumin: 4.2 g/dL,Lymphocyte: 1.07,Neutrophil: 9.02,LDH level: 196.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 33 years old,Sex: F,Height: 162 cm,Body weight: 54 kg,BMI: 20.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.16,Albumin: 3.8 g/dL,Lymphocyte: 0.69,Neutrophil: 3.32,LDH level: 380.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Amivantamab/Pemetrexed/Carboplatin,SNV mutations: EGFR,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: F,Height: 155 cm,Body weight: 60 kg,BMI: 24.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 20%,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 8.64,Albumin: 4.5 g/dL,Lymphocyte: 2.7,Neutrophil: 5.2,LDH level: 222.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin/Nivolumab or Placebo,SNV mutations: ERBB2,TP53,CNV alterations: FGF14(gain),FGFR4(gain),LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 162 cm,Body weight: 49 kg,BMI: 18.60,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 80%,WBC: 15.69,Albumin: 3.9 g/dL,Lymphocyte: 2.21,Neutrophil: 12.58,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 170 cm,Body weight: 57 kg,BMI: 19.79,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 24.18,Albumin: 3.7 g/dL,Lymphocyte: 1.7,Neutrophil: 20.8,LDH level: 232.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: None,CNV alterations: BRCA1(gain),CCND1(gain),CDK4(gain),CHEK2(gain),ERBB3(gain),ESR1(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(loss),MDM4(gain),NRG1(gain),PIK3CA(gain),RICTOR(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 167 cm,Body weight: 72 kg,BMI: 25.82,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: BRAF,PIK3CA,TP53,CNV alterations: EGFR(gain),FGF10(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 149.8 cm,Body weight: 50.64 kg,BMI: 22.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.88,Albumin: 3.7 g/dL,Lymphocyte: 1.44,Neutrophil: 7.69,LDH level: 235.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib -> Gefitinib,SNV mutations: ALK,AMER1,ARID1A,ARID1B,ATM,B2M,FBXW7,MAP3K1,MGA,NOTCH3,RNF43,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 54.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 174 cm,Body weight: 68 kg,BMI: 22.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> dabrafenib/trametinib,SNV mutations: BRAF,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 155 cm,Body weight: 63 kg,BMI: 26.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 5.64,Albumin: 3.5 g/dL,Lymphocyte: 1.26,Neutrophil: 3.88,LDH level: 183.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: NF1,RB1,STK11,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 167.7 cm,Body weight: 73 kg,BMI: 25.96,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 6.59,Albumin: 4.8 g/dL,Lymphocyte: 1.76,Neutrophil: 4.06,LDH level: 196.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: MGA,NFE2L2,TP53,CNV alterations: AKT2(gain),EGFR(gain),FGFR1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 168 cm,Body weight: 70 kg,BMI: 24.72,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.04,Albumin: 4.4 g/dL,Lymphocyte: 2.09,Neutrophil: 6.02,LDH level: 183.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NKX2-1,PMS1,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 171 cm,Body weight: 58 kg,BMI: 19.85,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 13.8,Albumin: 4.5 g/dL,Lymphocyte: 3.11,Neutrophil: 9.33,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/M7684,SNV mutations: STK11,TP53,CNV alterations: FGF23(gain),FGF6(gain),FGFR1(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 152.7 cm,Body weight: 50.4 kg,BMI: 21.61,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 75%,PD-L1 (SP263): 75%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 162 cm,Body weight: 66.9 kg,BMI: 25.49,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 20%,WBC: 6.79,Albumin: 4.5 g/dL,Lymphocyte: 2.84,Neutrophil: 3.16,LDH level: 225.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,FGFR4,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 151.8 cm,Body weight: 53.4 kg,BMI: 23.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 5.98,Albumin: 4.5 g/dL,Lymphocyte: 2.95,Neutrophil: 2.56,LDH level: 260.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: ARID1A,PIK3CA,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 168 cm,Body weight: 75 kg,BMI: 26.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: ATM(loss),CHEK1(loss),CHEK2(loss),Fusion genes: NRG1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 167.4 cm,Body weight: 64.1 kg,BMI: 22.87,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 2%,WBC: 10.29,Albumin: 4.4 g/dL,Lymphocyte: 2.73,Neutrophil: 6.69,LDH level: 206.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,NFKBIA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 163 cm,Body weight: 66 kg,BMI: 24.92,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.08,Albumin: 4.3 g/dL,Lymphocyte: 1.91,Neutrophil: 3.16,LDH level: 354.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: BAP1,CDKN2A,FBXW7,RB1,STK11,TP53,CNV alterations: MDM2(gain),PTEN(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 168 cm,Body weight: 64 kg,BMI: 22.64,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 10.03,Albumin: 4.5 g/dL,Lymphocyte: 1.71,Neutrophil: 7.26,LDH level: 372.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,TP53,CNV alterations: FGF10(gain),FGFR1(gain),MET(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 37 years old,Sex: F,Height: 165.4 cm,Body weight: 60.1 kg,BMI: 21.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 5.09,Albumin: 3.3 g/dL,Lymphocyte: 1.03,Neutrophil: 3.67,LDH level: 804.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: EGFR(gain),ERBB2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 160 cm,Body weight: 59 kg,BMI: 23.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.36,Albumin: 4.8 g/dL,Lymphocyte: 2.07,Neutrophil: 3.73,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: CARD11,NOTCH3,SMO,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 169.7 cm,Body weight: 73.1 kg,BMI: 25.38,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.21,Albumin: 3.4 g/dL,Lymphocyte: 2.0,Neutrophil: 8.32,LDH level: 155.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: CDK6(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 161 cm,Body weight: 64 kg,BMI: 24.69,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,WBC: 5.0,Albumin: 3.8 g/dL,Lymphocyte: 1.36,Neutrophil: 3.2,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: TP53,CNV alterations: FGFR3(gain),KIT(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 165 cm,Body weight: 67 kg,BMI: 24.61,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 4.41,Albumin: 4.4 g/dL,Lymphocyte: 1.29,Neutrophil: 2.69,LDH level: 264.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 160.3 cm,Body weight: 50.6 kg,BMI: 19.69,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,WBC: 12.76,Albumin: 3.7 g/dL,Lymphocyte: 3.41,Neutrophil: 6.97,LDH level: 164.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Capmatinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157 cm,Body weight: 62 kg,BMI: 25.15,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 16.19,Albumin: 3.6 g/dL,Lymphocyte: 0.47,Neutrophil: 15.27,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: BARD1,FANCD2,MGA,PIK3CA,TP53,CNV alterations: BRCA1(gain),BRCA2(gain),CCND3(gain),FGF14(gain),FGF8(loss),FGF9(loss),FGFR1(gain),FOXA1(gain),FOXO1(loss),LAMP1(gain),LATS2(loss),NKX2-1(gain),NRAS(loss),NRG1(gain),PIK3CA(gain),PTEN(loss),RB1(loss),RET(loss),SOX2(gain),Fusion genes: NOTCH3,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 176 cm,Body weight: 71 kg,BMI: 22.92,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 10.3,Albumin: 4.4 g/dL,Lymphocyte: 2.63,Neutrophil: 5.12,LDH level: 133.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NOTCH3,NPM1,SMO,TP53,TSC1,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 179 cm,Body weight: 61.7 kg,BMI: 19.26,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 1%,WBC: 18.53,Albumin: 3.2 g/dL,Lymphocyte: 1.94,Neutrophil: 15.18,LDH level: 1703.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: PDGFRB(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 156.5 cm,Body weight: 62.5 kg,BMI: 25.52,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 6.1,Albumin: 4.9 g/dL,Lymphocyte: 1.9,Neutrophil: 2.88,LDH level: 249.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Vinorelbine,SNV mutations: CDKN2A,CUX1,TP53,TSC1,CNV alterations: DCUN1D1(gain),FGFR1(gain),KLHL6(gain),PIK3CA(gain),PRKCI(gain),SOX2(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 173 cm,Body weight: 67.9 kg,BMI: 22.69,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 8.46,Albumin: 3.3 g/dL,Lymphocyte: 1.19,Neutrophil: 6.21,LDH level: 349.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,RASA1,TP53,CNV alterations: BRAF(loss),CDKN2A(loss),CDKN2B(loss),MET(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 156.6 cm,Body weight: 45.2 kg,BMI: 18.43,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719X,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,WBC: 5.11,Albumin: 4.0 g/dL,Lymphocyte: 0.85,Neutrophil: 3.75,LDH level: 159.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: DNMT3A,EGFR,FANCA,PIK3CA,TERT,TP53,CNV alterations: YAP1(gain),Fusion genes: FGFR3,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 168 cm,Body weight: 62 kg,BMI: 21.97,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 7.65,Albumin: 3.9 g/dL,Lymphocyte: 1.87,Neutrophil: 5.09,LDH level: 293.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: SMARCA4,STK11,TP53,CNV alterations: CDK6(gain),CRKL(gain),LZTR1(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 167.9 cm,Body weight: 67.1 kg,BMI: 23.80,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.61,Albumin: 3.7 g/dL,Lymphocyte: 0.97,Neutrophil: 7.35,LDH level: 145.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: CHEK2,EGFR,PIK3CA,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 157 cm,Body weight: 54 kg,BMI: 21.76,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.97,Albumin: 4.4 g/dL,Lymphocyte: 1.45,Neutrophil: 5.03,LDH level: 175.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ARID1A,CDK12,NOTCH1,PIK3CA,TP53,CNV alterations: ALK(gain),CDK4(gain),CHEK1(gain),EGFR(gain),ESR1(gain),KIT(gain),MYC(gain),PDGFRA(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: EGFR,TMB: 19.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: F,Height: 147 cm,Body weight: 55 kg,BMI: 25.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.39,Albumin: 4.4 g/dL,Lymphocyte: 3.16,Neutrophil: 5.11,LDH level: 176.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,ATM,DIS3,KRAS,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 177 cm,Body weight: 54 kg,BMI: 17.18,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 30%,PD-L1 (SP263): 60%,WBC: 7.09,Albumin: 3.3 g/dL,Lymphocyte: 1.2,Neutrophil: 5.09,LDH level: 248.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 173 cm,Body weight: 79 kg,BMI: 26.40,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 70%,WBC: 9.16,Albumin: 4.3 g/dL,Lymphocyte: 1.78,Neutrophil: 6.22,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ATM,CTCF,KRAS,NF2,TP53,U2AF1,CNV alterations: CDK6(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 168 cm,Body weight: 66 kg,BMI: 23.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,WBC: 4.07,Albumin: 4.7 g/dL,Lymphocyte: 1.95,Neutrophil: 1.68,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CHEK2,FGFR2,SMAD4,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 66 kg,BMI: 23.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,WBC: 6.21,Albumin: 4.4 g/dL,Lymphocyte: 1.47,Neutrophil: 4.26,LDH level: 179.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ASXL1,CHEK2,EPHA3,FAT1,ID3,INPP4B,KMT2A,MGA,NF2,NOTCH4,SH2B3,SPEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 151 cm,Body weight: 54.2 kg,BMI: 23.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.34,Albumin: 4.3 g/dL,Lymphocyte: 2.42,Neutrophil: 2.29,LDH level: 173.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib or Placebo/Lazertinib or Placebo,SNV mutations: AXIN2,EGFR,NSD1,PPM1D,TP53,CNV alterations: CDK4(gain),ETV1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 156 cm,Body weight: 68 kg,BMI: 27.97,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.88,Albumin: 4.4 g/dL,Lymphocyte: 1.51,Neutrophil: 5.67,LDH level: 191.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDH1,KRAS,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 159.3 cm,Body weight: 51 kg,BMI: 20.10,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 10.46,Albumin: 4.4 g/dL,Lymphocyte: 1.48,Neutrophil: 8.13,LDH level: 191.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib -> Gefitinib,SNV mutations: BIRC3,EGFR,PIK3CA,TERT,TP53,CNV alterations: AKT2(gain),CCNE1(gain),EGFR(gain),MDM4(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 166 cm,Body weight: 65 kg,BMI: 23.70,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 40%,WBC: 13.55,Albumin: 3.8 g/dL,Lymphocyte: 1.73,Neutrophil: 10.59,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ARID5B,KRAS,TP53,CNV alterations: AKT2(gain),MDM4(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 153 cm,Body weight: 54 kg,BMI: 22.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 5.89,Albumin: 4.4 g/dL,Lymphocyte: 1.92,Neutrophil: 2.69,LDH level: 189.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: LATS1,CNV alterations: FGF14(gain),LAMP1(gain),RET(gain),Fusion genes: RET,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 157.7 cm,Body weight: 74.9 kg,BMI: 30.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 35.92,Albumin: 3.0 g/dL,Lymphocyte: 1.47,Neutrophil: 26.89,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NF1,TP53,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 14.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 163 cm,Body weight: 52 kg,BMI: 19.57,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 5.03,Albumin: 4.3 g/dL,Lymphocyte: 1.28,Neutrophil: 2.92,LDH level: 202.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: NFE2L2,TP53,CNV alterations: ALK(gain),CCND3(gain),FGF14(loss),FGFR1(gain),MYC(gain),PIK3CA(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 16.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 42 years old,Sex: F,Height: 160 cm,Body weight: 61.5 kg,BMI: 24.02,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Positive,WBC: 9.5,Albumin: 4.6 g/dL,Lymphocyte: 1.74,Neutrophil: 6.97,LDH level: 165.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: BRCA2,TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 172 cm,Body weight: 89 kg,BMI: 29.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.82,Albumin: 4.0 g/dL,Lymphocyte: 1.67,Neutrophil: 3.15,LDH level: 281.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BTG1,ERBB2,MGA,SMARCA4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 151 cm,Body weight: 65.95 kg,BMI: 28.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.61,Albumin: 4.9 g/dL,Lymphocyte: 2.32,Neutrophil: 4.84,LDH level: 515.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 157.1 cm,Body weight: 47.7 kg,BMI: 19.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.28,Albumin: 3.3 g/dL,Lymphocyte: 1.79,Neutrophil: 3.81,LDH level: 211.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 173 cm,Body weight: 60 kg,BMI: 19.83,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.48,Albumin: 4.1 g/dL,Lymphocyte: 1.62,Neutrophil: 5.38,LDH level: 168.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,KEAP1,MSH2,NSD1,TP53,CNV alterations: CHEK2(gain),FGF4(loss),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 155 cm,Body weight: 64 kg,BMI: 26.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,WBC: 9.87,Albumin: 4.7 g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: BRAF(gain),CCND1(gain),CDK6(gain),FGF19(gain),FGFR4(gain),MET(gain),MYC(gain),PIK3CA(gain),PTEN(gain),RICTOR(gain),Fusion genes: None,Splice variants: MET,TMB: 7.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: F,Height: 159.7 cm,Body weight: 54.4 kg,BMI: 21.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 8.71,Albumin: 2.7 g/dL,Lymphocyte: 1.45,Neutrophil: 6.35,LDH level: 210.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 131.5 cm,Body weight: 50.5 kg,BMI: 29.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 0%,WBC: 5.21,Albumin: 4.5 g/dL,Lymphocyte: 1.58,Neutrophil: 3.08,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: BCOR,EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 172.8 cm,Body weight: 65.8 kg,BMI: 22.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 7.22,Albumin: 3.9 g/dL,Lymphocyte: 0.99,Neutrophil: 6.11,LDH level: 245.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 162 cm,Body weight: 70 kg,BMI: 26.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.17,Albumin: 4.6 g/dL,Lymphocyte: 2.98,Neutrophil: 4.45,LDH level: 146.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: KEAP1,PIK3CA,TP53,CNV alterations: JAK2(loss),Fusion genes: None,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 168 cm,Body weight: 64 kg,BMI: 22.50,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 7.11,Albumin: 3.0 g/dL,Lymphocyte: 0.77,Neutrophil: 5.31,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,NF2,NFE2L2,PPP2R1A,PTPRT,TP53,CNV alterations: BRAF(gain),CCNE1(gain),CDK6(gain),CHEK1(gain),EGFR(gain),MDM4(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 18.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 165 cm,Body weight: 42.6 kg,BMI: 15.65,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: AKT1,ARID1A,GRIN2A,MEN1,PTPRD,PTPRT,RB1,STK11,TP53,CNV alterations: CCNE1(gain),EGFR(gain),ERCC2(gain),MDM4(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 41.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 163 cm,Body weight: 67 kg,BMI: 25.39,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.67,Albumin: 3.9 g/dL,Lymphocyte: 1.61,Neutrophil: 8.66,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/MK7684,SNV mutations: CDKN2A,STK11,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 19.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 154.4 cm,Body weight: 72.2 kg,BMI: 30.29,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.52,Albumin: 4.4 g/dL,Lymphocyte: 1.63,Neutrophil: 3.28,LDH level: 141.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: KRAS,SHQ1,STK11,TGFBR1,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 168 cm,Body weight: 65 kg,BMI: 23.03,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 97%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: EP300,NCOR1,CNV alterations: CDK4(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),CHEK1(gain),ERBB3(gain),FGF10(gain),FGF7(loss),FGFR1(gain),JAK2(gain),MDM2(gain),MET(gain),MYC(gain),NFKBIA(loss),PAX5(gain),PDGFRA(gain),PIK3CB(gain),RICTOR(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 173 cm,Body weight: 62 kg,BMI: 20.72,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.1,Albumin: 4.2 g/dL,Lymphocyte: 1.38,Neutrophil: 4.92,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: PTEN,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),MDM2(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 151.7 cm,Body weight: 63 kg,BMI: 27.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.4,Albumin: 4.4 g/dL,Lymphocyte: 2.97,Neutrophil: 5.11,LDH level: 159.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 177 cm,Body weight: 78 kg,BMI: 24.90,Smoking history: Former smoker,Cancer stage: Mixed,Histology: Adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 13.54,Albumin: 3.2 g/dL,Lymphocyte: 0.86,Neutrophil: 11.87,LDH level: 196.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 167.6 cm,Body weight: 59.2 kg,BMI: 21.08,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 13.95,Albumin: 3.4 g/dL,Lymphocyte: 2.66,Neutrophil: 10.34,LDH level: 272.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KEAP1,MGA,TP53,CNV alterations: AR(gain),CCNE1(gain),CDK4(gain),CDKN2A(loss),CDKN2B(loss),JAK2(gain),MET(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 24.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 160 cm,Body weight: 70 kg,BMI: 27.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 8.46,Albumin: 4.1 g/dL,Lymphocyte: 1.8,Neutrophil: 5.61,LDH level: 240.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: HOXB13,RET,CNV alterations: AKT2(loss),BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),CHEK2(loss),EGFR(gain),ERCC1(loss),ERCC2(loss),FGF1(gain),FGF10(gain),FGF4(gain),FGF7(loss),JAK2(loss),MET(gain),MYCL(gain),NRAS(loss),PDGFRB(gain),RICTOR(gain),Fusion genes: RET,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 173 cm,Body weight: 64 kg,BMI: 21.38,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 11.07,Albumin: 5.3 g/dL,Lymphocyte: 2.22,Neutrophil: 8.08,LDH level: 208.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ATM,PARP1,SMAD2,TP53,TP63,CNV alterations: None,Fusion genes: None,Splice variants: EGFR,TMB: 23.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 170.2 cm,Body weight: 63 kg,BMI: 21.75,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,Negative,PD-L1 group: 0%,>50%,PD-L1 (22C3): 0%,95%,PD-L1 (SP263): 0%,7%,WBC: 7.45,Albumin: 4.2 g/dL,Lymphocyte: 1.61,Neutrophil: 5.17,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: MET,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 165 cm,Body weight: 69 kg,BMI: 25.34,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PTCH1,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 158 cm,Body weight: 56 kg,BMI: 22.43,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: BRCA2,EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164 cm,Body weight: 59 kg,BMI: 22.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.76,Albumin: 3.3 g/dL,Lymphocyte: 1.3,Neutrophil: 4.62,LDH level: 325.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: SMARCA4,TP53,CNV alterations: ERBB2(gain),FGF10(gain),FGFR1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 158 cm,Body weight: 56 kg,BMI: 22.43,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 15.63,Albumin: 3.2 g/dL,Lymphocyte: 3.16,Neutrophil: 10.54,LDH level: 149.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Ociperlimab/Tislelizumab/Pemetrexed/Carboplatin,SNV mutations: PTPN11,RBM10,TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),ERCC1(gain),ERCC2(gain),PDGFRB(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 164 cm,Body weight: 75 kg,BMI: 27.89,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 156 cm,Body weight: 62 kg,BMI: 25.48,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,WBC: 10.1,Albumin: 4.7 g/dL,Lymphocyte: 2.0,Neutrophil: 6.65,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 163.4 cm,Body weight: 60.3 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,WBC: 6.55,Albumin: 4.3 g/dL,Lymphocyte: 1.76,Neutrophil: 4.19,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ATM,EGFR,TP53,CNV alterations: EGFR(gain),FGF19(gain),FGF4(gain),FRS2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 149 cm,Body weight: 64 kg,BMI: 28.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.67,Albumin: 4.2 g/dL,Lymphocyte: 1.19,Neutrophil: 2.74,LDH level: 239.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 157.3 cm,Body weight: 57.6 kg,BMI: 23.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.59,Albumin: 4.8 g/dL,Lymphocyte: 1.86,Neutrophil: 3.26,LDH level: 184.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: APC,EGFR,PIK3CA,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 169.6 cm,Body weight: 93.3 kg,BMI: 32.44,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,EGFR,MGA,TP53,CNV alterations: CCND3(gain),EGFR(gain),FGF10(gain),MET(gain),MYC(gain),MYCL(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 163 cm,Body weight: 57.5 kg,BMI: 21.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 8.01,Albumin: 4.7 g/dL,Lymphocyte: 2.26,Neutrophil: 5.01,LDH level: 200.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: BRCA2(loss),CCND3(gain),CDK4(gain),EGFR(gain),ERBB2(gain),ETV1(gain),FGF14(loss),FGF9(loss),LAMP1(loss),MYC(gain),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 44 years old,Sex: M,Height: 173 cm,Body weight: 67 kg,BMI: 22.39,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib -> Afatinib,SNV mutations: RB1,TP53,CNV alterations: MYC(gain),Fusion genes: ALK,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164.4 cm,Body weight: 55.6 kg,BMI: 20.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: ALK,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 162.4 cm,Body weight: 70 kg,BMI: 26.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 7.68,Albumin: 4.4 g/dL,Lymphocyte: 1.95,Neutrophil: 4.57,LDH level: 167.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ATM,CUL3,KRAS,SLX4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 156.1 cm,Body weight: 61 kg,BMI: 25.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L861Q,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.27,Albumin: 4.5 g/dL,Lymphocyte: 1.37,Neutrophil: 5.41,LDH level: 159.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ATRX,EGFR,PIK3CA,TP53,CNV alterations: AKT2(gain),BRAF(gain),CCND3(gain),CCNE1(gain),CDK6(gain),EGFR(gain),ERBB2(gain),ERCC1(gain),ERCC2(gain),FGFR3(gain),GATA4(loss),MET(gain),MYC(gain),MYCL(gain),NKX3-1(loss),PIK3CA(gain),PIK3CB(gain),PPP2R2A(loss),RAF1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 152.9 cm,Body weight: 46.5 kg,BMI: 19.89,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 21.06,Albumin: 3.6 g/dL,Lymphocyte: 2.84,Neutrophil: 16.94,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FGF23(gain),FGF6(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 146 cm,Body weight: 63 kg,BMI: 29.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.99,Albumin: 4.8 g/dL,Lymphocyte: 1.72,Neutrophil: 3.84,LDH level: 167.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 167 cm,Body weight: 63 kg,BMI: 22.59,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 6.56,Albumin: 4.4 g/dL,Lymphocyte: 1.84,Neutrophil: 3.83,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CDKN2A,TP53,CNV alterations: ALK(gain),CDK6(gain),CHEK2(gain),FGF6(loss),JAK2(gain),LAMP1(gain),MYC(gain),NFE2L2(gain),PIK3CA(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: M,Height: 177 cm,Body weight: 63.5 kg,BMI: 20.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 10.38,Albumin: 4.2 g/dL,Lymphocyte: 1.66,Neutrophil: 7.96,LDH level: 162.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 168.5 cm,Body weight: 69.9 kg,BMI: 24.62,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 7.53,Albumin: 4.4 g/dL,Lymphocyte: 2.81,Neutrophil: 3.6,LDH level: 179.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 177 cm,Body weight: 60 kg,BMI: 19.15,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 70%,WBC: 21.33,Albumin: 3.1 g/dL,Lymphocyte: 0.71,Neutrophil: 19.89,LDH level: 267.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,TP53,CNV alterations: BCL6(gain),CHEK1(loss),FGF23(gain),FGF6(gain),FGFR1(gain),FOXA1(loss),KDM5A(gain),KDR(gain),KIT(gain),KRAS(gain),MDM2(gain),MYC(gain),NRG1(gain),PDGFRA(gain),PIK3CA(gain),PIK3CB(gain),RAD51B(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 22.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 175.1 cm,Body weight: 75.8 kg,BMI: 24.72,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 5.3,Albumin: 4.2 g/dL,Lymphocyte: 1.23,Neutrophil: 3.05,LDH level: 595.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: BRCA2(loss),FGF7(loss),FGFR1(gain),KRAS(loss),MYC(gain),NRG1(gain),RB1(loss),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 64 kg,BMI: 22.15,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.4,Albumin: 4.6 g/dL,Lymphocyte: 1.99,Neutrophil: 4.3,LDH level: 231.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: BRCA2(gain),FGF10(gain),FGF5(gain),FGF9(gain),KIT(gain),LAMP1(gain),MDM4(gain),MYC(gain),NRAS(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 179 cm,Body weight: 59.6 kg,BMI: 18.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 80%,WBC: 8.47,Albumin: 4.2 g/dL,Lymphocyte: 2.29,Neutrophil: 5.39,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 157 cm,Body weight: 50 kg,BMI: 20.28,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.53,Albumin: 4.4 g/dL,Lymphocyte: 1.97,Neutrophil: 2.95,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,RBM10,SHQ1,CNV alterations: MYC(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 158 cm,Body weight: 51 kg,BMI: 20.48,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 5.77,Albumin: 3.9 g/dL,Lymphocyte: 2.04,Neutrophil: 3.05,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 16.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 92 years old,Sex: M,Height: 166 cm,Body weight: 56 kg,BMI: 20.32,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine,SNV mutations: ERBB2,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 160 cm,Body weight: 63 kg,BMI: 24.66,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 8.02,Albumin: 4.6 g/dL,Lymphocyte: 2.25,Neutrophil: 4.89,LDH level: 211.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: CDKN2A,NFE2L2,TP53,TP63,CNV alterations: EGFR(gain),MYC(gain),PDGFRA(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 36 years old,Sex: M,Height: 174.5 cm,Body weight: 83 kg,BMI: 27.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.75,Albumin: 4.0 g/dL,Lymphocyte: 1.71,Neutrophil: 7.19,LDH level: 207.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: SETD2,TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 164.7 cm,Body weight: 61.2 kg,BMI: 22.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 4.97,Albumin: 4.8 g/dL,Lymphocyte: 1.38,Neutrophil: 2.74,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,BRAF,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 165 cm,Body weight: 57 kg,BMI: 20.94,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 10~20%,PD-L1 (SP263): 100%,WBC: 7.28,Albumin: 3.9 g/dL,Lymphocyte: 2.38,Neutrophil: 3.92,LDH level: 173.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NOTCH4,TP53,CNV alterations: ALK(gain),CDK6(gain),FGF10(gain),FGFR1(gain),JAK2(gain),PIK3CA(gain),RPS6KB1(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 159 cm,Body weight: 53 kg,BMI: 20.96,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 14.92,Albumin: 3.4 g/dL,Lymphocyte: 2.42,Neutrophil: 10.88,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NF2,TERT,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166.6 cm,Body weight: 66.8 kg,BMI: 24.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 8.11,Albumin: 4.3 g/dL,Lymphocyte: 1.24,Neutrophil: 4.75,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATM,KRAS,SF3B1,CNV alterations: RAC1(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 163 cm,Body weight: 67 kg,BMI: 25.22,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: KEAP1,KRAS,STK11,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 170.2 cm,Body weight: 60.2 kg,BMI: 20.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719X,ALK status: Negative,ROS1 status: Positive,WBC: 10.54,Albumin: 4.6 g/dL,Lymphocyte: 3.25,Neutrophil: 6.26,LDH level: 225.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,CNV alterations: MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 156 cm,Body weight: 56 kg,BMI: 23.01,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.85,Albumin: 4.1 g/dL,Lymphocyte: 2.02,Neutrophil: 2.92,LDH level: 212.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 158 cm,Body weight: 61.5 kg,BMI: 24.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,WBC: 6.81,Albumin: 4.2 g/dL,Lymphocyte: 2.23,Neutrophil: 4.29,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: AKT1,BRAF,NF1,RB1,TP53,CNV alterations: FGF10(gain),IL7R(gain),KDM5A(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 153.7 cm,Body weight: 50.4 kg,BMI: 21.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 6.16,Albumin: 4.3 g/dL,Lymphocyte: 1.52,Neutrophil: 3.77,LDH level: 140.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,KMT2A,MED12,NCOR1,RAD50,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 156.7 cm,Body weight: 70.4 kg,BMI: 28.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.5,Albumin: 4.7 g/dL,Lymphocyte: 1.98,Neutrophil: 2.94,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 90 years old,Sex: M,Height: 164 cm,Body weight: 57 kg,BMI: 21.19,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 5%,WBC: 4.42,Albumin: 4.3 g/dL,Lymphocyte: 1.2,Neutrophil: 2.48,LDH level: 194.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 162 cm,Body weight: 53.7 kg,BMI: 20.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.71,Albumin: 4.0 g/dL,Lymphocyte: 1.34,Neutrophil: 5.39,LDH level: 263.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),EGFR(gain),FOXA1(gain),JAK2(gain),NKX2-1(gain),PIK3CA(gain),RICTOR(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 12.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 160 cm,Body weight: 59 kg,BMI: 23.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.76,Albumin: 5.1 g/dL,Lymphocyte: 2.89,Neutrophil: 2.35,LDH level: 186.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 157 cm,Body weight: 67 kg,BMI: 27.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: MDM4(gain),MYCN(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 165 cm,Body weight: 59 kg,BMI: 21.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 5.07,Albumin: 4.5 g/dL,Lymphocyte: 1.12,Neutrophil: 3.47,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRCA1,SMARCA4,STK11,TP53,CNV alterations: CCND3(gain),CCNE1(gain),KIT(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.25,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): <1%,WBC: 14.23,Albumin: 4.2 g/dL,Lymphocyte: 2.69,Neutrophil: 10.16,LDH level: 313.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab or MK7684,SNV mutations: ERBB2,PIK3R2,RB1,STK11,TP53,CNV alterations: AKT2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 174 cm,Body weight: 70 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: APC,CDKN2A,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 176 cm,Body weight: 78 kg,BMI: 25.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 12.59,Albumin: 2.9 g/dL,Lymphocyte: 2.32,Neutrophil: 8.99,LDH level: 136.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: SH2B3,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 171 cm,Body weight: 74 kg,BMI: 25.31,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 10.35,Albumin: 4.4 g/dL,Lymphocyte: 1.07,Neutrophil: 8.33,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: FGF2(loss),FGF5(loss),FGFR3(loss),MDM4(gain),MYCL(gain),NRAS(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 177.7 cm,Body weight: 72.7 kg,BMI: 23.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 3%,WBC: 4.19,Albumin: 3.8 g/dL,Lymphocyte: 1.24,Neutrophil: 1.95,LDH level: 229.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Cisplatin,SNV mutations: GRIN2A,RB1,TP53,CNV alterations: FGF10(gain),FGFR1(gain),RICTOR(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 23.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 175.3 cm,Body weight: 69.9 kg,BMI: 22.75,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.6,Albumin: 4.4 g/dL,Lymphocyte: 0.57,Neutrophil: 4.18,LDH level: 188.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ARID1B,RB1,RECQL4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 157.9 cm,Body weight: 57.2 kg,BMI: 22.94,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: poorly differentiated carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 31.84,Albumin: 3.5 g/dL,Lymphocyte: 2.25,Neutrophil: 23.64,LDH level: 376.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Pembrolizumab/Sacituzumab,SNV mutations: KRAS,RASA1,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF23(gain),KRAS(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 28 years old,Sex: M,Height: 173.5 cm,Body weight: 68 kg,BMI: 22.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 12.95,Albumin: 4.4 g/dL,Lymphocyte: 0.7,Neutrophil: 11.97,LDH level: 143.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: LATS1,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 173.7 cm,Body weight: 53.2 kg,BMI: 17.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.13,Albumin: 3.3 g/dL,Lymphocyte: 1.02,Neutrophil: 7.21,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NF1,PTCH1,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 15.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165.8 cm,Body weight: 62.6 kg,BMI: 22.77,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.98,Albumin: 4.6 g/dL,Lymphocyte: 0.96,Neutrophil: 6.63,LDH level: 160.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MGA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 170.5 cm,Body weight: 60 kg,BMI: 20.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.98,Albumin: 4.9 g/dL,Lymphocyte: 2.89,Neutrophil: 5.42,LDH level: 163.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: ERBB2(gain),Fusion genes: NRG1,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 164 cm,Body weight: 54 kg,BMI: 20.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: malignant tumor with spindle cell (or sarcomatoid) feature,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 10.74,Albumin: 4.4 g/dL,Lymphocyte: 1.9,Neutrophil: 7.58,LDH level: 233.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PTEN,RAF1,TP53,CNV alterations: AMER1(loss),ARID2(loss),CHEK2(gain),ERCC2(gain),FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 171 cm,Body weight: 54 kg,BMI: 18.57,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma or Large cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 9.9,Albumin: 3.8 g/dL,Lymphocyte: 1.27,Neutrophil: 8.36,LDH level: 267.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: EP300,KEAP1,SETD2,SMARCA4,SOX17,STK11,CNV alterations: PTEN(loss),RET(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 20.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 160 cm,Body weight: 65 kg,BMI: 25.41,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.19,Albumin: 4.2 g/dL,Lymphocyte: 1.09,Neutrophil: 1.79,LDH level: 430.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 171.4 cm,Body weight: 73.8 kg,BMI: 25.12,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 20%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 2%,WBC: 7.41,Albumin: 3.9 g/dL,Lymphocyte: 1.34,Neutrophil: 5.23,LDH level: 204.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 159.4 cm,Body weight: 52.1 kg,BMI: 20.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 20.47,Albumin: 3.9 g/dL,Lymphocyte: 2.67,Neutrophil: 16.48,LDH level: 593.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RET,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 180 cm,Body weight: 65 kg,BMI: 20.06,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 5.72,Albumin: 3.7 g/dL,Lymphocyte: 1.93,Neutrophil: 2.83,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: AR(gain),Fusion genes: None,Splice variants: None,TMB: 5.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 166.3 cm,Body weight: 66.1 kg,BMI: 23.90,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.59,Albumin: 4.3 g/dL,Lymphocyte: 1.53,Neutrophil: 5.44,LDH level: 214.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 162 cm,Body weight: 63 kg,BMI: 24.01,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib -> Afatinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 168 cm,Body weight: 65 kg,BMI: 23.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 8.81,Albumin: 3.0 g/dL,Lymphocyte: 1.56,Neutrophil: 6.31,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: PBRM1,TP53,CNV alterations: ALK(gain),BRCA2(gain),CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 171.5 cm,Body weight: 71.1 kg,BMI: 24.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 5%,WBC: 4.47,Albumin: 3.4 g/dL,Lymphocyte: 2.02,Neutrophil: 1.1,LDH level: 133.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 156 cm,Body weight: 68.9 kg,BMI: 28.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.88,Albumin: 4.5 g/dL,Lymphocyte: 2.19,Neutrophil: 3.01,LDH level: 196.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CTNNB1,KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 160 cm,Body weight: 56 kg,BMI: 21.88,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.93,Albumin: 4.8 g/dL,Lymphocyte: 2.2,Neutrophil: 6.42,LDH level: 330.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: CDKN2A,FAT1,SMARCA4,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 19.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163 cm,Body weight: 57 kg,BMI: 21.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 11.5,Albumin: 4.2 g/dL,Lymphocyte: 2.72,Neutrophil: 7.49,LDH level: 195.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KMT2A,KRAS,PTPRS,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 164.9 cm,Body weight: 70.9 kg,BMI: 26.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 20%,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 35%,WBC: 5.54,Albumin: 4.1 g/dL,Lymphocyte: 1.52,Neutrophil: 3.06,LDH level: 142.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,MGA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 171.1 cm,Body weight: 61 kg,BMI: 20.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.65,Albumin: 4.3 g/dL,Lymphocyte: 1.39,Neutrophil: 4.34,LDH level: 114.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PIK3CA,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 171 cm,Body weight: 72 kg,BMI: 24.62,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 10.68,Albumin: 3.7 g/dL,Lymphocyte: 2.69,Neutrophil: 6.43,LDH level: 148.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: GNAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 172.3 cm,Body weight: 69.9 kg,BMI: 23.55,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 8.06,Albumin: 4.7 g/dL,Lymphocyte: 2.85,Neutrophil: 4.19,LDH level: 233.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 170.3 cm,Body weight: 54 kg,BMI: 18.62,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 18.15,Albumin: 3.1 g/dL,Lymphocyte: 1.59,Neutrophil: 15.16,LDH level: 279.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KEAP1,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF10(gain),PIK3CA(gain),PTEN(loss),RICTOR(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 168 cm,Body weight: 57 kg,BMI: 20.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 12.53,Albumin: 3.7 g/dL,Lymphocyte: 2.52,Neutrophil: 9.02,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 25.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 165 cm,Body weight: 71 kg,BMI: 26.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.77,Albumin: 4.2 g/dL,Lymphocyte: 1.56,Neutrophil: 3.85,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,SF3B1,TP53,CNV alterations: ERBB2(gain),NKX2-1(loss),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 146 cm,Body weight: 50 kg,BMI: 23.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,T790M,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 145.6 cm,Body weight: 50.2 kg,BMI: 23.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 40%,PD-L1 (SP263): 50%,WBC: 5.41,Albumin: 4.3 g/dL,Lymphocyte: 1.41,Neutrophil: 3.51,LDH level: 232.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib or Gefitinib,SNV mutations: EGFR,PTPN11,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164 cm,Body weight: 75 kg,BMI: 28.00,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.39,Albumin: 4.6 g/dL,Lymphocyte: 2.98,Neutrophil: 3.5,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,BAP1,CHEK2,NF1,NKX2-1,PPM1D,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 145.6 cm,Body weight: 48.8 kg,BMI: 23.02,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 8.26,Albumin: 4.2 g/dL,Lymphocyte: 2.19,Neutrophil: 5.08,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163 cm,Body weight: 55 kg,BMI: 20.70,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 7.89,Albumin: 4.1 g/dL,Lymphocyte: 2.09,Neutrophil: 4.46,LDH level: 155.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: EPHA3,EPHA7,NCOR1,CNV alterations: ALK(gain),BRAF(gain),EGFR(gain),ERCC2(gain),FGF10(gain),MET(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 20.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 159 cm,Body weight: 58.9 kg,BMI: 23.30,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 6.48,Albumin: 4.2 g/dL,Lymphocyte: 1.51,Neutrophil: 4.03,LDH level: 695.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: TP53,CNV alterations: CCNE1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 41 years old,Sex: F,Height: 162 cm,Body weight: 69 kg,BMI: 26.07,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.76,Albumin: 4.0 g/dL,Lymphocyte: 2.34,Neutrophil: 3.85,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: RET,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 160 cm,Body weight: 73 kg,BMI: 28.52,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.18,Albumin: 4.5 g/dL,Lymphocyte: 1.55,Neutrophil: 4.12,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 170 cm,Body weight: 59 kg,BMI: 20.24,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (22C3): <3%,PD-L1 (SP263): <3%,WBC: 8.76,Albumin: 4.2 g/dL,Lymphocyte: 1.06,Neutrophil: 6.96,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Sasanlimab,SNV mutations: CDKN2A,FBXW7,TP53,CNV alterations: CHEK2(gain),EGFR(gain),FGF10(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 172 cm,Body weight: 74 kg,BMI: 25.20,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 6.66,Albumin: 4.7 g/dL,Lymphocyte: 2.0,Neutrophil: 3.86,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NF1,TP53,ZFHX3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 173 cm,Body weight: 64.7 kg,BMI: 21.62,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.31,Albumin: 4.6 g/dL,Lymphocyte: 1.12,Neutrophil: 3.56,LDH level: 204.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: RB1,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 168 cm,Body weight: 74.4 kg,BMI: 26.36,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 5.07,Albumin: 4.1 g/dL,Lymphocyte: 1.67,Neutrophil: 2.95,LDH level: 237.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: ERBB2,NF1,PALB2,TP53,CNV alterations: BRAF(gain),CDK4(gain),MET(gain),MYC(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 160.5 cm,Body weight: 49.3 kg,BMI: 19.14,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.64,Albumin: 4.4 g/dL,Lymphocyte: 1.27,Neutrophil: 4.27,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: TP53,CNV alterations: PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 172.2 cm,Body weight: 79.5 kg,BMI: 26.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 2%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,SPEN,TP53,CNV alterations: EGFR(gain),ERCC1(gain),MET(gain),MYC(gain),NFKBIA(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 163 cm,Body weight: 64 kg,BMI: 24.09,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.96,Albumin: 4.0 g/dL,Lymphocyte: 2.36,Neutrophil: 4.55,LDH level: 166.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: CDK4(gain),FGFR1(gain),FRS2(gain),MDM2(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 178 cm,Body weight: 68 kg,BMI: 21.46,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 12.87,Albumin: 3.9 g/dL,Lymphocyte: 2.13,Neutrophil: 9.6,LDH level: 262.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,CDKN2A,CREBBP,PIK3CA,SMARCA4,CNV alterations: EGFR(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166 cm,Body weight: 59 kg,BMI: 21.29,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 15%,WBC: 8.47,Albumin: 4.0 g/dL,Lymphocyte: 2.05,Neutrophil: 5.18,LDH level: 168.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: TP53,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 156.5 cm,Body weight: 54.3 kg,BMI: 22.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 5.68,Albumin: 4.5 g/dL,Lymphocyte: 1.55,Neutrophil: 3.41,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 154.1 cm,Body weight: 54.5 kg,BMI: 22.95,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.39,Albumin: 4.2 g/dL,Lymphocyte: 1.87,Neutrophil: 3.8,LDH level: 165.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: None,Fusion genes: MET,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 170 cm,Body weight: 63 kg,BMI: 21.88,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.8,Albumin: 3.3 g/dL,Lymphocyte: 2.52,Neutrophil: 7.15,LDH level: 166.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: SOX9,STK11,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 159 cm,Body weight: 58 kg,BMI: 22.94,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.33,Albumin: 4.1 g/dL,Lymphocyte: 1.56,Neutrophil: 10.45,LDH level: 225.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: AKT2(gain),AR(gain),CDKN2A(loss),CDKN2B(loss),RAC1(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 164 cm,Body weight: 64 kg,BMI: 23.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,WBC: 11.48,Albumin: 2.4 g/dL,Lymphocyte: 2.02,Neutrophil: 8.5,LDH level: 451.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,STK11,TP53,CNV alterations: EGFR(gain),ERCC1(gain),ERCC2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 173 cm,Body weight: 62 kg,BMI: 20.72,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.58,Albumin: 4.5 g/dL,Lymphocyte: 0.77,Neutrophil: 4.1,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 157 cm,Body weight: 61 kg,BMI: 24.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.16,Albumin: 4.0 g/dL,Lymphocyte: 1.28,Neutrophil: 4.43,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: FGFR1,CNV alterations: None,Fusion genes: NRG1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 159.5 cm,Body weight: 54.5 kg,BMI: 21.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 6.28,Albumin: 4.1 g/dL,Lymphocyte: 2.1,Neutrophil: 3.49,LDH level: 155.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: F,Height: 168 cm,Body weight: 70.3 kg,BMI: 24.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 4.99,Albumin: 4.8 g/dL,Lymphocyte: 1.27,Neutrophil: 3.19,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Ceritinib,SNV mutations: AR,BRAF,BRCA1,CDKN2A,LAMP1,PTCH1,RICTOR,SLX4,TSC1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 174.1 cm,Body weight: 74.6 kg,BMI: 24.61,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.94,Albumin: 4.5 g/dL,Lymphocyte: 1.66,Neutrophil: 2.51,LDH level: 342.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Pembrolizumab/Sacituzumab/Carboplatin,SNV mutations: FGFR4,MITF,TP53,CNV alterations: ARAF(gain),GATA1(gain),RBM10(gain),TFE3(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 149 cm,Body weight: 71 kg,BMI: 32.02,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.56,Albumin: 3.0 g/dL,Lymphocyte: 1.97,Neutrophil: 4.57,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TCF3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 147 cm,Body weight: 53 kg,BMI: 24.30,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,WBC: 10.0,Albumin: 4.5 g/dL,Lymphocyte: 2.4,Neutrophil: 6.51,LDH level: 180.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: EZH2,FAT1,KRAS,MSH3,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 178 cm,Body weight: 82 kg,BMI: 25.70,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 4.94,Albumin: 4.0 g/dL,Lymphocyte: 0.79,Neutrophil: 4.92,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ASXL1,SDHA,TP53,CNV alterations: AKT2(gain),ERCC1(gain),ERCC2(gain),FGF8(loss),MDM2(gain),MYOD1(loss),Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166 cm,Body weight: 60 kg,BMI: 21.88,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 15.49,Albumin: 4.1 g/dL,Lymphocyte: 0.98,Neutrophil: 14.26,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,CYLD,MGA,NF1,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 168 cm,Body weight: 61 kg,BMI: 21.61,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 10.86,Albumin: 4.5 g/dL,Lymphocyte: 1.63,Neutrophil: 8.04,LDH level: 728.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,PTEN,TP53,CNV alterations: CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ERCC2(gain),FGF8(loss),FGFR4(gain),NKX2-1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 155 cm,Body weight: 64.5 kg,BMI: 26.85,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 5.3,Albumin: 3.3 g/dL,Lymphocyte: 1.75,Neutrophil: 2.78,LDH level: 281.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ATM,TP53,CNV alterations: ALK(gain),CHEK1(gain),ERBB2(gain),FGF10(gain),FGFR1(gain),FGFR3(gain),JAK2(gain),MYC(gain),MYCN(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 171 cm,Body weight: 78.6 kg,BMI: 26.88,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 95%,WBC: 8.31,Albumin: 4.3 g/dL,Lymphocyte: 2.11,Neutrophil: 5.33,LDH level: 123.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: M7824 or Placebo/Paclitaxel/Carboplatin,SNV mutations: ARID1A,EPCAM,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 164.2 cm,Body weight: 60.9 kg,BMI: 22.59,Smoking history: Current smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.0,Albumin: 4.9 g/dL,Lymphocyte: 2.01,Neutrophil: 5.2,LDH level: 175.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KEAP1,RPS6KA4,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 155 cm,Body weight: 64 kg,BMI: 26.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 30%,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.45,Albumin: 4.8 g/dL,Lymphocyte: 1.79,Neutrophil: 4.14,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 158 cm,Body weight: 43 kg,BMI: 17.10,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 8.03,Albumin: 4.9 g/dL,Lymphocyte: 2.39,Neutrophil: 5.04,LDH level: 252.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: AMER1,GPS2,TP53,CNV alterations: LAMP1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 37 years old,Sex: M,Height: 178 cm,Body weight: 78 kg,BMI: 24.62,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.87,Albumin: 4.3 g/dL,Lymphocyte: 1.92,Neutrophil: 6.21,LDH level: 198.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: SUZ12,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: ALK,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 167.9 cm,Body weight: 71.2 kg,BMI: 25.26,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: AKT2(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 35 years old,Sex: F,Height: 167 cm,Body weight: 55 kg,BMI: 19.72,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TP53,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 155.4 cm,Body weight: 64.1 kg,BMI: 26.54,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 5.33,Albumin: 4.4 g/dL,Lymphocyte: 0.97,Neutrophil: 4.13,LDH level: 202.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: FANCD2,TP53,CNV alterations: AR(gain),Fusion genes: ROS1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 158.3 cm,Body weight: 67.2 kg,BMI: 26.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,WBC: 6.17,Albumin: 4.4 g/dL,Lymphocyte: 2.01,Neutrophil: 3.42,LDH level: 322.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib or Placebo/Lazertinib or Placebo,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 159 cm,Body weight: 50 kg,BMI: 19.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CCND3(gain),CDK4(gain),ERBB3(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 167 cm,Body weight: 69 kg,BMI: 24.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,PD-L1 (SP263): 70-80%,WBC: 7.01,Albumin: 4.2 g/dL,Lymphocyte: 1.85,Neutrophil: 4.12,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: M7824,SNV mutations: CDKN2A,ERBB2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 149 cm,Body weight: 52 kg,BMI: 23.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 9.68,Albumin: 4.5 g/dL,Lymphocyte: 3.46,Neutrophil: 5.2,LDH level: 239.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: PTEN(gain),Fusion genes: ALK,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 34 years old,Sex: F,Height: 158.3 cm,Body weight: 47 kg,BMI: 18.76,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,ROS1 status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,RB1,TP53,CNV alterations: FGF23(gain),FGF6(gain),KRAS(gain),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 164.8 cm,Body weight: 64.6 kg,BMI: 23.79,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 18.32,Albumin: 4.2 g/dL,Lymphocyte: 1.35,Neutrophil: 15.08,LDH level: 190.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Lazertinib/Pemetrexed/Carboplatin,SNV mutations: EGFR,MAP2K4,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 170.6 cm,Body weight: 68.4 kg,BMI: 23.50,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.46,Albumin: 4.0 g/dL,Lymphocyte: 1.16,Neutrophil: 9.42,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: APC,BRCA2,CUX1,KMT2A,PARP1,SMAD4,TP53,WT1,CNV alterations: AKT2(gain),CCND3(gain),CCNE1(gain),CDKN2A(loss),CDKN2B(loss),ERCC2(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 69.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 160 cm,Body weight: 50 kg,BMI: 19.53,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: APC,CREBBP,MAP2K4,PTEN,RB1,TP53,CNV alterations: AKT1(gain),AKT3(gain),APC(loss),BCL6(gain),BRCA2(loss),FAT1(loss),MCL1(gain),MGA(loss),MYC(gain),MYCL(gain),PIK3CA(gain),PTEN(loss),RB1(loss),SETD2(loss),SOX2(gain),TP63(gain),WT1(loss),ZFHX3(loss),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 166 cm,Body weight: 75.1 kg,BMI: 27.25,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 14.38,Albumin: 1.9 g/dL,Lymphocyte: 0.33,Neutrophil: 13.81,LDH level: 552.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: DNMT3B,NOTCH1,RB1,TP53,CNV alterations: BRCA2(loss),CCND3(gain),CHEK2(loss),ERBB3(loss),FGF2(loss),FGF23(loss),FGF5(loss),FGF6(loss),FGF9(loss),FGFR1(gain),FGFR3(loss),KIT(loss),KRAS(loss),MYC(gain),MYCN(loss),NRG1(gain),PDGFRA(loss),PIK3CA(gain),PIK3CB(gain),RB1(loss),TFRC(gain),TP53(loss),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 170 cm,Body weight: 76 kg,BMI: 26.30,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 95%,WBC: 9.73,Albumin: 4.4 g/dL,Lymphocyte: 1.75,Neutrophil: 6.68,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin->Lenvatinib,SNV mutations: ERBB2,CNV alterations: CDK4(gain),FGF7(gain),Fusion genes: None,Splice variants: None,TMB: 2.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 172 cm,Body weight: 68.5 kg,BMI: 23.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,RBM10,CNV alterations: CDK4(gain),EGFR(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 166 cm,Body weight: 63 kg,BMI: 22.86,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 166 cm,Body weight: 60.1 kg,BMI: 21.81,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 20%,WBC: 9.68,Albumin: 3.7 g/dL,Lymphocyte: 2.51,Neutrophil: 6.22,LDH level: 166.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRCA1,BRCA2,KDM6A,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 161 cm,Body weight: 60 kg,BMI: 22.96,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.86,Albumin: 3.8 g/dL,Lymphocyte: 0.95,Neutrophil: 6.42,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: DNMT3A,KEAP1,PBRM1,SF3B1,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 31.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 162.6 cm,Body weight: 64.5 kg,BMI: 24.40,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 8.85,Albumin: 4.2 g/dL,Lymphocyte: 1.92,Neutrophil: 6.02,LDH level: 199.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Oleclumab/Durvalumab/Pemetrexated/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 170 cm,Body weight: 67 kg,BMI: 23.31,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 15.89,Albumin: 3.8 g/dL,Lymphocyte: 1.79,Neutrophil: 10.99,LDH level: 653.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: BRAF,KRAS,PTPRD,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 19.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 168 cm,Body weight: 65 kg,BMI: 23.03,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 7.51,Albumin: 3.4 g/dL,Lymphocyte: 1.31,Neutrophil: 5.68,LDH level: 460.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CDH1,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 173 cm,Body weight: 79 kg,BMI: 26.40,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 9.24,Albumin: 4.5 g/dL,Lymphocyte: 2.2,Neutrophil: 5.75,LDH level: 199.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB3,KRAS,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 142 cm,Body weight: 43.9 kg,BMI: 21.77,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 40%,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 15%,WBC: 6.79,Albumin: 5.0 g/dL,Lymphocyte: 2.51,Neutrophil: 3.23,LDH level: 134.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab or Placebo/Pactliaxel/Carboplatin/Bevacizumab,SNV mutations: ERBB4,NTRK3,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 171 cm,Body weight: 68 kg,BMI: 23.26,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 6.58,Albumin: 3.8 g/dL,Lymphocyte: 1.34,Neutrophil: 4.09,LDH level: 279.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: NFE2L2,TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 179 cm,Body weight: 76.3 kg,BMI: 23.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 7.29,Albumin: 4.6 g/dL,Lymphocyte: 2.67,Neutrophil: 3.86,LDH level: 193.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CA,TP53,ZFHX3,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF10(gain),FGF6(loss),FGFR3(loss),FGFR4(gain),PIK3CA(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 159.7 cm,Body weight: 61.7 kg,BMI: 24.19,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.85,Albumin: 4.0 g/dL,Lymphocyte: 2.38,Neutrophil: 4.34,LDH level: 137.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,ERRFI1,FAT1,MSH3,NF1,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 67 kg,BMI: 23.72,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 4.3,Albumin: 4.5 g/dL,Lymphocyte: 0.92,Neutrophil: 2.85,LDH level: 166.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 167 cm,Body weight: 67 kg,BMI: 24.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 6.56,Albumin: 4.7 g/dL,Lymphocyte: 1.01,Neutrophil: 4.78,LDH level: 139.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: PTPRD,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 172 cm,Body weight: 47.4 kg,BMI: 16.02,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 50%,WBC: 13.82,Albumin: 2.1 g/dL,Lymphocyte: 1.18,Neutrophil: 11.74,LDH level: 179.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: M,Height: 168 cm,Body weight: 63 kg,BMI: 22.32,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.0,Albumin: 4.4 g/dL,Lymphocyte: 1.86,Neutrophil: 4.62,LDH level: 189.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: EPHA3,TP53,CNV alterations: FGFR1(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 183 cm,Body weight: 73 kg,BMI: 21.80,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >95%,PD-L1 (SP263): >95%,WBC: 7.09,Albumin: 4.0 g/dL,Lymphocyte: 0.67,Neutrophil: 5.94,LDH level: 204.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: CDKN2A,LATS2,NF2,STK11,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 154 cm,Body weight: 55 kg,BMI: 23.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TET1,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 173.1 cm,Body weight: 65.7 kg,BMI: 21.93,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.15,Albumin: 4.6 g/dL,Lymphocyte: 2.41,Neutrophil: 6.99,LDH level: 233.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK-4830,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 157 cm,Body weight: 84 kg,BMI: 34.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 7.68,Albumin: 4.3 g/dL,Lymphocyte: 1.66,Neutrophil: 5.12,LDH level: 188.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 150.5 cm,Body weight: 53.2 kg,BMI: 23.49,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 4.25,Albumin: 4.0 g/dL,Lymphocyte: 1.2,Neutrophil: 2.71,LDH level: 367.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Pemetrexed/Carboplatin/Amivantamab,SNV mutations: EGFR,EZH2,NCOR1,NOTCH2,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 168.1 cm,Body weight: 80.3 kg,BMI: 28.42,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizuamb/Pemetrexed/Carbopaltin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 163.2 cm,Body weight: 70.4 kg,BMI: 26.43,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 8.51,Albumin: 4.4 g/dL,Lymphocyte: 1.61,Neutrophil: 5.81,LDH level: 264.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,RBM10,TP53,CNV alterations: AR(loss),BRAF(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ERBB2(gain),FGF4(gain),FGF7(loss),FGFR1(loss),MET(gain),MYC(gain),NRG1(loss),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 160.3 cm,Body weight: 60.4 kg,BMI: 23.51,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 100%,WBC: 6.84,Albumin: 4.7 g/dL,Lymphocyte: 1.78,Neutrophil: 3.74,LDH level: 174.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/CJRB-101,SNV mutations: ATRX,BCOR,PTPRD,TGFBR2,TP53,CNV alterations: EGFR(gain),FGF10(gain),MYC(gain),MYCL(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 20.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 164 cm,Body weight: 68 kg,BMI: 25.28,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 11.12,Albumin: 4.4 g/dL,Lymphocyte: 1.67,Neutrophil: 8.02,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KEAP1,SMARCA4,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 93 years old,Sex: M,Height: 167 cm,Body weight: 56 kg,BMI: 20.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.71,Albumin: 4.0 g/dL,Lymphocyte: 2.81,Neutrophil: 2.95,LDH level: 267.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK1308/Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 154 cm,Body weight: 63.6 kg,BMI: 26.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 100%,WBC: 4.68,Albumin: 4.6 g/dL,Lymphocyte: 1.97,Neutrophil: 2.23,LDH level: 200.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Etoposide/Cisplatin,SNV mutations: BCOR,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 162.7 cm,Body weight: 69 kg,BMI: 26.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.31,Albumin: 4.7 g/dL,Lymphocyte: 1.33,Neutrophil: 4.33,LDH level: 144.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NOTCH4,CNV alterations: STK11(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 157.6 cm,Body weight: 52.1 kg,BMI: 20.98,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.51,Albumin: 3.9 g/dL,Lymphocyte: 2.82,Neutrophil: 3.61,LDH level: 157.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 164 cm,Body weight: 67 kg,BMI: 24.91,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,WBC: 8.05,Albumin: 4.1 g/dL,Lymphocyte: 2.49,Neutrophil: 4.48,LDH level: 161.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,EP300,RBM10,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 156.9 cm,Body weight: 53.1 kg,BMI: 21.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.37,Albumin: 2.4 g/dL,Lymphocyte: 1.31,Neutrophil: 4.55,LDH level: 138.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Enhertu/MEDI5752,SNV mutations: ERBB2,ERCC4,TP53,CNV alterations: AKT1(gain),CDKN1B(loss),DNMT3B(gain),FOXA1(gain),GATA3(gain),NF2(loss),NKX2-1(gain),PAX5(gain),RUNX1(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 163.5 cm,Body weight: 61.3 kg,BMI: 22.93,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.65,Albumin: 3.8 g/dL,Lymphocyte: 0.93,Neutrophil: 4.78,LDH level: 327.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Paclitaxel/Carboplatin,SNV mutations: AXIN2,TP53,CNV alterations: AKT2(gain),CCNE1(gain),MYC(gain),Fusion genes: FGFR3,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 56.5 kg,BMI: 19.55,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 16.89,Albumin: 3.5 g/dL,Lymphocyte: 2.45,Neutrophil: 12.16,LDH level: 112.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab or Tislelizumab/Ociperlimab or Placebo,SNV mutations: ATM,BRAF,HNF1A,TP53,CNV alterations: ATM(gain),BRAF(gain),CCND1(gain),CDKN2A(loss),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 173 cm,Body weight: 54 kg,BMI: 17.96,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma or Large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 7.9,Albumin: 3.9 g/dL,Lymphocyte: 1.88,Neutrophil: 5.31,LDH level: 224.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,TP53,TP63,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF23(gain),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 31.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 178 cm,Body weight: 86 kg,BMI: 27.14,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 5.87,Albumin: 4.4 g/dL,Lymphocyte: 0.96,Neutrophil: 4.23,LDH level: 191.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FOXA1(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 158 cm,Body weight: 66 kg,BMI: 26.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.33,Albumin: 4.4 g/dL,Lymphocyte: 2.62,Neutrophil: 3.85,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NKX2-1,CNV alterations: CDKN2A(loss),CDKN2B(loss),MYC(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 154 cm,Body weight: 58 kg,BMI: 24.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 3.48,Albumin: 4.1 g/dL,Lymphocyte: 1.02,Neutrophil: 2.09,LDH level: 383.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 156 cm,Body weight: 42 kg,BMI: 17.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 15%,WBC: 8.61,Albumin: 4.1 g/dL,Lymphocyte: 2.24,Neutrophil: 5.58,LDH level: 172.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: NKX2-1,SMARCB1,TGFBR1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 165 cm,Body weight: 72 kg,BMI: 26.45,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.41,Albumin: 4.8 g/dL,Lymphocyte: 2.76,Neutrophil: 4.92,LDH level: 171.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NBN,TP53,CNV alterations: None,Fusion genes: NRG1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 159 cm,Body weight: 45.7 kg,BMI: 18.08,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 7.16,Albumin: 4.5 g/dL,Lymphocyte: 1.86,Neutrophil: 4.55,LDH level: 192.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: RICTOR,TSC1,TSC2,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 70 kg,BMI: 24.50,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,WBC: 4.91,Albumin: 4.0 g/dL,Lymphocyte: 1.21,Neutrophil: 3.18,LDH level: 221.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tislelizumab/Pemetrexed/Carboplatin->ociperlimab,SNV mutations: CDKN2A,SMARCA4,STK11,TP53,CNV alterations: MAPK1(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 164 cm,Body weight: 67 kg,BMI: 24.91,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 7.09,Albumin: 4.0 g/dL,Lymphocyte: 1.36,Neutrophil: 4.97,LDH level: 158.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165.8 cm,Body weight: 76.4 kg,BMI: 27.79,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 10%,WBC: 10.14,Albumin: 4.5 g/dL,Lymphocyte: 3.37,Neutrophil: 5.78,LDH level: 520.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: HRAS,NF1,NF2,SMARCA4,TP53,CNV alterations: ALK(gain),FGFR1(gain),MYCN(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 175.5 cm,Body weight: 58.7 kg,BMI: 19.06,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 3.66,Albumin: 4.7 g/dL,Lymphocyte: 1.24,Neutrophil: 1.82,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 165.3 cm,Body weight: 61.6 kg,BMI: 22.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.97,Albumin: 4.2 g/dL,Lymphocyte: 1.61,Neutrophil: 5.7,LDH level: 180.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib or Placebo/Lazertinib or Placebo,SNV mutations: APC,EGFR,SMAD4,CNV alterations: CCNE1(gain),EGFR(gain),FGF10(gain),FGFR1(loss),MYCL(gain),PDGFRB(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 171.4 cm,Body weight: 67 kg,BMI: 22.81,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 4.54,Albumin: 4.3 g/dL,Lymphocyte: 1.56,Neutrophil: 2.57,LDH level: 164.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: CDKN2A,RAD51B,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 166 cm,Body weight: 63.4 kg,BMI: 23.01,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 7.32,Albumin: 4.4 g/dL,Lymphocyte: 2.46,Neutrophil: 4.41,LDH level: 201.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ATRX,DNMT3A,KRAS,LRP1B,TP53,WT1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 163 cm,Body weight: 70 kg,BMI: 26.35,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 15.68,Albumin: 3.0 g/dL,Lymphocyte: 1.47,Neutrophil: 11.49,LDH level: 187.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: NF1,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 155 cm,Body weight: 51 kg,BMI: 21.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 3.62,Albumin: 4.0 g/dL,Lymphocyte: 0.64,Neutrophil: 2.5,LDH level: 188.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,ERBB2,TET2,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: None,Splice variants: None,TMB: 8.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 173 cm,Body weight: 86 kg,BMI: 28.73,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 13.3,Albumin: 5.1 g/dL,Lymphocyte: 1.6,Neutrophil: 11.44,LDH level: 178.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Pemetrexed/Carboplatin or Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: SMAD4,TP53,CNV alterations: CCND1(gain),FGF10(gain),FGF6(loss),JAK2(loss),MYC(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 161 cm,Body weight: 47 kg,BMI: 17.89,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 11.9,Albumin: 3.4 g/dL,Lymphocyte: 1.86,Neutrophil: 8.73,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: FANCL,KRAS,MET,PPM1D,CNV alterations: AURKA(gain),CDK4(gain),GLI1(gain),Fusion genes: None,Splice variants: MET,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 26 years old,Sex: M,Height: 174.4 cm,Body weight: 72.7 kg,BMI: 23.90,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.8,Albumin: 5.1 g/dL,Lymphocyte: 2.85,Neutrophil: 4.24,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ATRX,AXIN1,KRAS,SMAD4,CNV alterations: STK11(loss),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 161.1 cm,Body weight: 45.8 kg,BMI: 17.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.06,Albumin: 4.4 g/dL,Lymphocyte: 1.49,Neutrophil: 4.92,LDH level: 165.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 150 cm,Body weight: 55 kg,BMI: 24.31,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 16.14,Albumin: 3.9 g/dL,Lymphocyte: 2.05,Neutrophil: 13.37,LDH level: 265.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 167 cm,Body weight: 78 kg,BMI: 27.97,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 3.67,Albumin: 4.4 g/dL,Lymphocyte: 1.56,Neutrophil: 1.28,LDH level: 176.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Cisplatin,SNV mutations: RASA1,SMARCA4,TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 13.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 161 cm,Body weight: 67 kg,BMI: 25.85,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 100%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,BRAF,NCOR1,NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 11.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 51 years old,Sex: M,Height: 163 cm,Body weight: 52 kg,BMI: 19.57,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,WBC: 7.22,Albumin: 4.8 g/dL,Lymphocyte: 1.69,Neutrophil: 4.54,LDH level: 231.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: ARID1A,FANCI,FLT3,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 174 cm,Body weight: 56 kg,BMI: 18.50,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 14.19,Albumin: 3.9 g/dL,Lymphocyte: 1.9,Neutrophil: 10.89,LDH level: 187.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: KRAS,LRP1B,TP53,CNV alterations: CARD11(gain),EGFR(gain),ETV1(gain),MAP3K13(gain),MYC(gain),RAC1(gain),RICTOR(gain),SMAD4(loss),STAG1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 164 cm,Body weight: 56 kg,BMI: 20.82,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 7.21,Albumin: 4.1 g/dL,Lymphocyte: 1.55,Neutrophil: 4.51,LDH level: 322.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CDKN2A,KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 180.6 cm,Body weight: 77.8 kg,BMI: 23.85,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 12.04,Albumin: 4.0 g/dL,Lymphocyte: 1.77,Neutrophil: 8.89,LDH level: 214.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: ASXL1,CDKN2A,NFE2L2,PIK3CA,TP53,CNV alterations: SOX2(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 40 years old,Sex: M,Height: 170 cm,Body weight: 62 kg,BMI: 21.45,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 50%,WBC: 11.54,Albumin: 4.8 g/dL,Lymphocyte: 2.01,Neutrophil: 7.87,LDH level: 266.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: TP53,CNV alterations: MYC(gain),Fusion genes: ROS1,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 174.7 cm,Body weight: 81.4 kg,BMI: 26.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.1,Albumin: 4.5 g/dL,Lymphocyte: 2.38,Neutrophil: 4.05,LDH level: 185.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,NFE2L2,TP53,CNV alterations: BRAF(gain),CDK6(gain),EZH2(gain),FGFR1(gain),MYC(gain),RHEB(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163 cm,Body weight: 75 kg,BMI: 28.23,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 8.85,Albumin: 4.2 g/dL,Lymphocyte: 0.76,Neutrophil: 7.38,LDH level: 313.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: ERCC2(gain),FGF10(gain),LAMP1(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 163.7 cm,Body weight: 58 kg,BMI: 21.64,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 5%,WBC: 5.21,Albumin: 4.6 g/dL,Lymphocyte: 0.95,Neutrophil: 3.59,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: PTEN,RASA1,TP53,CNV alterations: RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 153.5 cm,Body weight: 56.9 kg,BMI: 24.15,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.53,Albumin: 4.0 g/dL,Lymphocyte: 0.99,Neutrophil: 8.71,LDH level: 183.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: KLHL6(gain),MYCL(gain),SOX2(gain),SPTA1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 171.1 cm,Body weight: 43.8 kg,BMI: 14.96,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 70%,WBC: 9.13,Albumin: 4.1 g/dL,Lymphocyte: 2.79,Neutrophil: 5.66,LDH level: 117.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1B,CDKN2A,DNMT3A,NOTCH1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 34.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: M,Height: 167.3 cm,Body weight: 67.8 kg,BMI: 24.22,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 5.22,Albumin: 4.2 g/dL,Lymphocyte: 2.21,Neutrophil: 2.45,LDH level: 200.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: BRIP1,MAP3K1,NFE2L2,TP53,CNV alterations: CCNE1(gain),EGFR(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 20.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: F,Height: 152 cm,Body weight: 47.8 kg,BMI: 20.69,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 15.98,Albumin: 3.2 g/dL,Lymphocyte: 1.45,Neutrophil: 13.55,LDH level: 275.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: DNMT3A,SLX4,CNV alterations: SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 42 years old,Sex: F,Height: 158 cm,Body weight: 50 kg,BMI: 20.03,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 0%,WBC: 7.92,Albumin: 4.9 g/dL,Lymphocyte: 2.29,Neutrophil: 4.99,LDH level: 144.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CDK6(gain),EGFR(gain),FOXA1(gain),MDM4(gain),MET(gain),MYC(gain),NKX2-1(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 158 cm,Body weight: 53 kg,BMI: 21.23,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719A,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.28,Albumin: 4.2 g/dL,Lymphocyte: 1.12,Neutrophil: 4.72,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RBM10,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 169 cm,Body weight: 70 kg,BMI: 24.51,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BRIP1,FGFR1,FOXL2,MYC,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 160 cm,Body weight: 44.2 kg,BMI: 17.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 164 cm,Body weight: 65 kg,BMI: 24.09,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.17,Albumin: 5.0 g/dL,Lymphocyte: 1.3,Neutrophil: 4.3,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDKN2A,NF1,TP53,TSC1,CNV alterations: EGFR(gain),FGF2(gain),Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 168.3 cm,Body weight: 55.4 kg,BMI: 19.56,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 70%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.35,Albumin: 4.2 g/dL,Lymphocyte: 1.95,Neutrophil: 4.61,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: AR(loss),BRCA1(gain),CDK4(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF14(loss),FGF5(loss),FGFR3(loss),FGFR4(gain),KIT(loss),KRAS(gain),MET(gain),NRG1(loss),PDGFRA(loss),RICTOR(gain),Fusion genes: MET,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 79.6 kg,BMI: 27.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,WBC: 9.14,Albumin: 4.5 g/dL,Lymphocyte: 2.49,Neutrophil: 5.61,LDH level: 222.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: ROS1,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 165.5 cm,Body weight: 54.5 kg,BMI: 19.90,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 6.62,Albumin: 4.6 g/dL,Lymphocyte: 1.38,Neutrophil: 4.66,LDH level: 210.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: BCL2L1(gain),Fusion genes: None,Splice variants: None,TMB: 11.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: F,Height: 164 cm,Body weight: 58 kg,BMI: 21.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.03,Albumin: 4.4 g/dL,Lymphocyte: 1.7,Neutrophil: 2.47,LDH level: 148.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,RUNX1,TP53,CNV alterations: CDK4(gain),EGFR(gain),ETV1(gain),IKZF1(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 11.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 170 cm,Body weight: 77 kg,BMI: 26.64,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.03,Albumin: 4.3 g/dL,Lymphocyte: 2.54,Neutrophil: 3.7,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Erlotinib,SNV mutations: EGFR,PIK3CA,RBM10,CNV alterations: AKT2(gain),CCND3(gain),CCNE1(gain),EGFR(gain),ERBB2(gain),FGF10(gain),KIT(gain),MDM2(gain),MYC(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 142.8 cm,Body weight: 47.6 kg,BMI: 23.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: BAP1,CTNNB1,MAP2K1,CNV alterations: FGF6(loss),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 151 cm,Body weight: 54 kg,BMI: 23.68,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 8.52,Albumin: 4.3 g/dL,Lymphocyte: 1.1,Neutrophil: 6.68,LDH level: 166.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: CCND3(gain),CCNE1(gain),EGFR(gain),ESR1(gain),MYCN(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 177 cm,Body weight: 72 kg,BMI: 22.98,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,WBC: 11.19,Albumin: 3.9 g/dL,Lymphocyte: 1.0,Neutrophil: 9.15,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed,SNV mutations: CYLD,EPHA3,KMT2A,SETD2,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 160 cm,Body weight: 54 kg,BMI: 21.04,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 4.14,Albumin: 4.3 g/dL,Lymphocyte: 1.7,Neutrophil: 1.89,LDH level: 170.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,SMO,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 168 cm,Body weight: 42 kg,BMI: 14.70,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 2.94,Albumin: 4.0 g/dL,Lymphocyte: 1.32,Neutrophil: 1.23,LDH level: 213.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: NRG1,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 163.7 cm,Body weight: 56.1 kg,BMI: 20.93,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.9,Albumin: 3.7 g/dL,Lymphocyte: 2.88,Neutrophil: 5.09,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NF1,RNF43,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 170 cm,Body weight: 78 kg,BMI: 26.99,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 50%,WBC: 11.41,Albumin: 4.2 g/dL,Lymphocyte: 2.81,Neutrophil: 6.94,LDH level: 191.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 181 cm,Body weight: 71 kg,BMI: 21.67,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,WBC: 4.02,Albumin: 4.2 g/dL,Lymphocyte: 1.04,Neutrophil: 2.49,LDH level: 200.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: SUZ12,TP53,CNV alterations: FGFR1(loss),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 171 cm,Body weight: 68 kg,BMI: 23.26,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 5.06,Albumin: 4.5 g/dL,Lymphocyte: 1.36,Neutrophil: 3.08,LDH level: 222.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Cisplatin,SNV mutations: KEAP1,RB1,TET2,TP53,CNV alterations: AKT2(gain),CCNE1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 172 cm,Body weight: 72 kg,BMI: 24.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: BRAF,EGFR,TP53,CNV alterations: EGFR(gain),ERBB2(gain),FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 170 cm,Body weight: 79 kg,BMI: 27.37,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 40%,WBC: 10.17,Albumin: 3.1 g/dL,Lymphocyte: 1.46,Neutrophil: 7.61,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CYLD,PTPRT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 25.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 162 cm,Body weight: 57 kg,BMI: 21.72,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.02,Albumin: 4.1 g/dL,Lymphocyte: 1.4,Neutrophil: 4.73,LDH level: 198.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: CHEK1,DICER1,PTEN,TGFBR2,TP53,CNV alterations: BIRC3(gain),CDKN2A(loss),CDKN2B(loss),FGFR1(gain),MYC(gain),RICTOR(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 176 cm,Body weight: 75 kg,BMI: 24.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 9.93,Albumin: 3.9 g/dL,Lymphocyte: 1.22,Neutrophil: 7.78,LDH level: 268.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 156 cm,Body weight: 45 kg,BMI: 18.49,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.84,Albumin: 4.4 g/dL,Lymphocyte: 1.66,Neutrophil: 3.67,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: TP53,CNV alterations: ALK(gain),BCL6(gain),CCND1(gain),CDK6(gain),CHEK1(gain),FGF19(gain),FGF23(gain),FGF3(gain),FGF4(gain),FGF6(gain),FGFR1(gain),GATA3(gain),KDM5A(gain),KRAS(gain),MYCL(gain),MYCN(gain),PDGFRA(gain),PDGFRB(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 171 cm,Body weight: 59 kg,BMI: 20.18,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.19,Albumin: 4.0 g/dL,Lymphocyte: 1.76,Neutrophil: 3.84,LDH level: 268.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,NF1,TP53,CNV alterations: CCNE1(gain),Fusion genes: NOTCH1,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 167 cm,Body weight: 58 kg,BMI: 20.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <5%,WBC: 12.04,Albumin: 3.4 g/dL,Lymphocyte: 1.39,Neutrophil: 9.83,LDH level: 1149.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NFE2L2,SMAD3,TP53,CNV alterations: ATM(loss),BRCA2(loss),CCND1(gain),CDKN2A(loss),CDKN2B(loss),FGF1(loss),FGF19(gain),FGF2(loss),FGF3(gain),FGF4(gain),FGF9(loss),FGFR1(gain),JAK2(loss),KIT(loss),NRAS(loss),PDGFRA(loss),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 148.5 cm,Body weight: 51.6 kg,BMI: 23.40,Smoking history: Former smoker,Cancer stage: Mixed,Histology: adenocarcinoma/mucinous bronchioloalveolar,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 11.61,Albumin: 4.2 g/dL,Lymphocyte: 2.89,Neutrophil: 7.77,LDH level: 226.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: BRCA2,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 158 cm,Body weight: 39 kg,BMI: 15.60,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 11.95,Albumin: 3.2 g/dL,Lymphocyte: 1.54,Neutrophil: 9.77,LDH level: 146.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: MET,PIK3CA,CNV alterations: ATM(gain),CDK4(gain),CHEK1(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166.6 cm,Body weight: 60.9 kg,BMI: 21.94,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.28,Albumin: 4.9 g/dL,Lymphocyte: 1.17,Neutrophil: 3.51,LDH level: 197.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,RECQL4,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 148.5 cm,Body weight: 59.4 kg,BMI: 26.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 25%,PD-L1 (SP263): 20%,WBC: 10.4,Albumin: 4.0 g/dL,Lymphocyte: 2.07,Neutrophil: 7.54,LDH level: 246.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 153.6 cm,Body weight: 61.4 kg,BMI: 26.02,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 5.8,Albumin: 4.3 g/dL,Lymphocyte: 2.36,Neutrophil: 2.8,LDH level: 244.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Placebo/Etoposide/Carboplatin,SNV mutations: CDKN2A,NF1,PPP6C,RB1,SPEN,TP53,CNV alterations: BRCA2(loss),FGFR4(loss),PDGFRB(loss),Fusion genes: None,Splice variants: None,TMB: 20.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 148 cm,Body weight: 53.5 kg,BMI: 24.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: large cell neuroendocrine carcinoma+adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E18del,G179A,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.8,Albumin: 4.6 g/dL,Lymphocyte: 1.52,Neutrophil: 2.81,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 176 cm,Body weight: 73 kg,BMI: 23.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDKN2A,TP53,CNV alterations: ERBB2(gain),MYCN(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 173.4 cm,Body weight: 67.3 kg,BMI: 22.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.4,Albumin: 4.7 g/dL,Lymphocyte: 2.63,Neutrophil: 4.19,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.04,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 80%,WBC: 10.53,Albumin: 4.2 g/dL,Lymphocyte: 2.8,Neutrophil: 6.63,LDH level: 169.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,ERBB4,NCOR1,NFE2L2,TP53,CNV alterations: FGFR1(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 168 cm,Body weight: 73 kg,BMI: 25.86,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 10%,WBC: 7.86,Albumin: 4.8 g/dL,Lymphocyte: 2.83,Neutrophil: 4.25,LDH level: 180.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: ARID1A,FANCE,KEAP1,TP53,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 159 cm,Body weight: 56 kg,BMI: 22.15,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 3.44,Albumin: 4.6 g/dL,Lymphocyte: 0.71,Neutrophil: 2.43,LDH level: 180.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: ARID1A,EGFR,PIK3CA,TP53,CNV alterations: BRCA1(gain),EGFR(gain),ERBB2(gain),FGF14(gain),FGF6(loss),LAMP1(gain),RB1(loss),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: M,Height: 163 cm,Body weight: 56 kg,BMI: 21.06,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.39,Albumin: 4.1 g/dL,Lymphocyte: 2.33,Neutrophil: 6.97,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: FGFR1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 169.3 cm,Body weight: 64 kg,BMI: 22.33,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.05,Albumin: 3.5 g/dL,Lymphocyte: 1.41,Neutrophil: 4.66,LDH level: 130.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 165.3 cm,Body weight: 61.7 kg,BMI: 22.58,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 5%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.43,Albumin: 3.8 g/dL,Lymphocyte: 2.02,Neutrophil: 2.94,LDH level: 232.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,KRAS,PIK3R2,TBX3,TP53,CNV alterations: CCND3(gain),CDK6(gain),MDM4(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 19.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 148 cm,Body weight: 56 kg,BMI: 25.46,Smoking history: Never smoker,Cancer stage: Mixed,Histology: Adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 25%,WBC: 8.2,Albumin: 4.1 g/dL,Lymphocyte: 2.06,Neutrophil: 5.21,LDH level: 206.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: EGFR,PIK3CA,TP53,CNV alterations: None,Fusion genes: FGFR3,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 165 cm,Body weight: 67 kg,BMI: 24.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 4.3,Albumin: 3.9 g/dL,Lymphocyte: 1.17,Neutrophil: 2.52,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: CTNNB1,TET2,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 172 cm,Body weight: 67 kg,BMI: 22.85,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.42,Albumin: 3.0 g/dL,Lymphocyte: 1.46,Neutrophil: 4.99,LDH level: 209.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: SMAD4,STK11,CNV alterations: MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 168.5 cm,Body weight: 52.7 kg,BMI: 18.56,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 15.36,Albumin: 3.4 g/dL,Lymphocyte: 1.48,Neutrophil: 12.63,LDH level: 150.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: BRIP1,NFE2L2,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: F,Height: 158 cm,Body weight: 49 kg,BMI: 19.63,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,TP53,CNV alterations: ATM(gain),CCND3(gain),CDK6(gain),EGFR(gain),FGF10(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 168 cm,Body weight: 66 kg,BMI: 23.24,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Non-small cell carcinoma with sarcomatoid feature,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 14.63,Albumin: 3.7 g/dL,Lymphocyte: 2.05,Neutrophil: 9.65,LDH level: 174.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: BRAF,DNMT3A,PBRM1,RB1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 172 cm,Body weight: 86 kg,BMI: 29.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 10.2,Albumin: 3.8 g/dL,Lymphocyte: 1.19,Neutrophil: 7.48,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,PALB2,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 162 cm,Body weight: 57 kg,BMI: 21.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,WBC: 8.17,Albumin: 3.5 g/dL,Lymphocyte: 1.68,Neutrophil: 4.27,LDH level: 191.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: B2M,CBL,EGFR,PDGFRA,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),KIT(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 16.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 87 years old,Sex: M,Height: 164 cm,Body weight: 65 kg,BMI: 24.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 7.52,Albumin: 3.2 g/dL,Lymphocyte: 1.84,Neutrophil: 4.92,LDH level: 167.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KMT2A,NF1,SETD2,TP53,CNV alterations: FGF4(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: M,Height: 172.2 cm,Body weight: 68.4 kg,BMI: 23.07,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: AKT2(gain),EGFR(gain),FGF10(gain),MYC(gain),RET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 173 cm,Body weight: 58 kg,BMI: 19.38,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 4.1,Albumin: 4.2 g/dL,Lymphocyte: 1.13,Neutrophil: 2.55,LDH level: 190.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: PIK3CA,SHQ1,TET2,TP53,CNV alterations: AKT2(gain),BRCA2(gain),CCND3(gain),FGF10(gain),FGF14(gain),FGF8(loss),FGFR3(loss),FGFR4(loss),JAK2(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 164 cm,Body weight: 47 kg,BMI: 17.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.16,Albumin: 4.4 g/dL,Lymphocyte: 2.33,Neutrophil: 7.25,LDH level: 222.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,PTEN,RB1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 170 cm,Body weight: 68 kg,BMI: 23.36,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 12.31,Albumin: 3.1 g/dL,Lymphocyte: 2.92,Neutrophil: 8.35,LDH level: 371.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin or Dostarlimab/Pemetrexed/Carboplatin,SNV mutations: NF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 173.3 cm,Body weight: 68 kg,BMI: 22.64,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 7.33,Albumin: 4.9 g/dL,Lymphocyte: 1.28,Neutrophil: 5.2,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID2,RBM10,TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 170 cm,Body weight: 61 kg,BMI: 21.11,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Canakinumab/Paclitaxel/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: AKT2(gain),AR(loss),ERCC1(gain),ERCC2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 157.9 cm,Body weight: 64.4 kg,BMI: 25.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: invasive carcinoma with squamoid feature,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.68,Albumin: 3.6 g/dL,Lymphocyte: 1.5,Neutrophil: 6.73,LDH level: 190.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: PTEN,CNV alterations: ARID2(loss),CDKN2A(loss),CDKN2B(loss),FGFR1(gain),MCL1(gain),Fusion genes: ALK,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 150.7 cm,Body weight: 48.5 kg,BMI: 21.36,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 2.93,Albumin: 4.4 g/dL,Lymphocyte: 0.72,Neutrophil: 1.64,LDH level: 409.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 159.9 cm,Body weight: 42.7 kg,BMI: 16.70,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): >50%,PD-L1 (SP263): 30%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin -> Pemetrexed,SNV mutations: ERBB2,TP53,CNV alterations: EGFR(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166 cm,Body weight: 58.2 kg,BMI: 21.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: 30,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 3%,WBC: 8.6,Albumin: 4.8 g/dL,Lymphocyte: 1.26,Neutrophil: 6.85,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: ATM(loss),CDKN2A(loss),CDKN2B(loss),CHEK1(loss),FGF4(gain),MET(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 167.6 cm,Body weight: 67 kg,BMI: 23.85,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 8.03,Albumin: 2.9 g/dL,Lymphocyte: 1.46,Neutrophil: 5.56,LDH level: 458.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MEN1,SMAD4,SMARCA4,TP53,CNV alterations: ALK(gain),AR(loss),ATM(gain),BRAF(gain),CCND1(gain),CCND3(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),CHEK1(gain),EGFR(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR2(gain),JAK2(loss),MDM4(gain),MET(gain),MYCL(gain),NRG1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 162 cm,Body weight: 53 kg,BMI: 20.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: PTEN,CNV alterations: MDM2(gain),Fusion genes: RET,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 164 cm,Body weight: 71 kg,BMI: 26.40,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 1%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 164.5 cm,Body weight: 61.5 kg,BMI: 22.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 11.0,Albumin: 4.6 g/dL,Lymphocyte: 1.68,Neutrophil: 8.64,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 177.4 cm,Body weight: 80.5 kg,BMI: 25.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 97%,PD-L1 (SP263): 60%,WBC: 10.99,Albumin: 3.3 g/dL,Lymphocyte: 1.37,Neutrophil: 7.92,LDH level: 214.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDC73,KDM5C,MET,SMO,TP53,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166 cm,Body weight: 67 kg,BMI: 24.16,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.27,Albumin: 4.7 g/dL,Lymphocyte: 2.54,Neutrophil: 4.66,LDH level: 156.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: NF2,SDHB,TP53,CNV alterations: CCNE1(gain),ERBB2(gain),ERCC1(gain),ERCC2(gain),MDM4(gain),PTEN(loss),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 154 cm,Body weight: 62 kg,BMI: 26.14,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 90%,WBC: 10.22,Albumin: 4.7 g/dL,Lymphocyte: 3.15,Neutrophil: 5.92,LDH level: 268.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),BCL2L1(gain),BRCA2(loss),CCNE1(gain),CD274(gain),CDKN2A(loss),CDKN2B(loss),FGF9(loss),JAK2(loss),MET(gain),MYC(gain),PDCD1LG2(gain),RAF1(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 182.1 cm,Body weight: 87 kg,BMI: 26.24,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 11.01,Albumin: 3.4 g/dL,Lymphocyte: 1.01,Neutrophil: 8.93,LDH level: 144.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: FGFR4,SMO,CNV alterations: CDKN2A(loss),CDKN2B(loss),HRAS(gain),Fusion genes: ROS1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 152 cm,Body weight: 64.8 kg,BMI: 28.05,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 20%,WBC: 3.88,Albumin: 4.5 g/dL,Lymphocyte: 1.42,Neutrophil: 2.17,LDH level: 239.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: BRCA2,EGFR,NBN,RBM10,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 156 cm,Body weight: 60 kg,BMI: 24.65,Smoking history: Never smoker,Cancer stage: Mixed,Histology: adenosquamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 5.04,Albumin: 4.6 g/dL,Lymphocyte: 1.48,Neutrophil: 3.04,LDH level: 213.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Tremelimumab/Durvalumab,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 151 cm,Body weight: 43 kg,BMI: 18.86,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 6.36,Albumin: 4.0 g/dL,Lymphocyte: 1.35,Neutrophil: 4.22,LDH level: 155.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Bevacizumab/Erlotinib,SNV mutations: BRCA1,EGFR,NCOR1,RUNX1,TP53,CNV alterations: EGFR(gain),ERBB2(gain),FGF10(gain),FGFR3(loss),KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166.8 cm,Body weight: 56.8 kg,BMI: 20.42,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 6.07,Albumin: 3.9 g/dL,Lymphocyte: 1.34,Neutrophil: 3.91,LDH level: 169.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: NOTCH1,PIK3R1,TP53,TSC2,CNV alterations: BRCA2(loss),Fusion genes: ALK,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 164.4 cm,Body weight: 61 kg,BMI: 22.57,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 5.45,Albumin: 4.3 g/dL,Lymphocyte: 1.37,Neutrophil: 3.72,LDH level: 182.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CREBBP,EGFR,TP53,CNV alterations: EGFR(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 167 cm,Body weight: 48.5 kg,BMI: 17.39,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 5.66,Albumin: 4.1 g/dL,Lymphocyte: 0.73,Neutrophil: 4.46,LDH level: 193.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NF1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 13.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: F,Height: 146 cm,Body weight: 75 kg,BMI: 35.28,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.31,Albumin: 3.7 g/dL,Lymphocyte: 0.82,Neutrophil: 3.1,LDH level: 282.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 162 cm,Body weight: 60.2 kg,BMI: 22.94,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 50%,WBC: 6.8,Albumin: 4.6 g/dL,Lymphocyte: 2.9,Neutrophil: 3.32,LDH level: 176.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Bevacizuma/Nivolumab/Pactliaxel/Carboplatin,SNV mutations: ANKRD11,BIRC3,EZH2,FAT1,ID3,LATS2,MED12,MSH3,NCOR1,CNV alterations: FGF1(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 165 cm,Body weight: 72 kg,BMI: 26.31,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,WBC: 8.71,Albumin: 4.4 g/dL,Lymphocyte: 1.26,Neutrophil: 6.42,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: CCND3(gain),CCNE1(gain),RPS6KB1(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 174 cm,Body weight: 94 kg,BMI: 31.06,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,WBC: 13.04,Albumin: 2.9 g/dL,Lymphocyte: 1.68,Neutrophil: 9.79,LDH level: 330.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,SMARCA4,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 17.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 170 cm,Body weight: 71 kg,BMI: 24.57,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 9.73,Albumin: 4.4 g/dL,Lymphocyte: 4.08,Neutrophil: 4.23,LDH level: 261.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: ATM,EGFR,ERBB2,RBM10,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: F,Height: 159 cm,Body weight: 51 kg,BMI: 20.17,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 6.37,Albumin: 2.3 g/dL,Lymphocyte: 1.74,Neutrophil: 3.84,LDH level: 249.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: ATM,CTNNB1,EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 10.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: F,Height: 151.6 cm,Body weight: 47.4 kg,BMI: 20.62,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 8.64,Albumin: 4.5 g/dL,Lymphocyte: 2.17,Neutrophil: 5.64,LDH level: 192.0 U/L,Treatment type: Chemotherapy + Targeted Therapy,Treatment regimen: Lazertinib/Pemetrexed/Carboplatin,SNV mutations: EGFR,EP300,RBM10,TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 150.4 cm,Body weight: 54.9 kg,BMI: 24.27,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 30%,PD-L1 (SP263): 50%,WBC: 7.44,Albumin: 4.0 g/dL,Lymphocyte: 2.25,Neutrophil: 4.38,LDH level: 233.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: MK-0482/Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 165 cm,Body weight: 55 kg,BMI: 20.20,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 8.2,Albumin: 4.4 g/dL,Lymphocyte: 1.83,Neutrophil: 5.55,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin/Olaparib or Placebo,SNV mutations: CDKN2A,FOXP1,NOTCH1,PTPRT,TP53,CNV alterations: MDM4(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 169.7 cm,Body weight: 70.2 kg,BMI: 24.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 5.11,Albumin: 4.4 g/dL,Lymphocyte: 0.88,Neutrophil: 3.57,LDH level: 228.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ARID2,EGFR,TP53,CNV alterations: AR(gain),BRAF(gain),CCNE1(gain),CDK6(gain),EGFR(gain),MDM4(gain),MET(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 48 years old,Sex: M,Height: 170.7 cm,Body weight: 56.7 kg,BMI: 19.46,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 5.05,Albumin: 4.7 g/dL,Lymphocyte: 1.08,Neutrophil: 3.35,LDH level: 214.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: ALK(gain),CCND3(gain),CCNE1(gain),EGFR(gain),FGF10(gain),FGFR4(gain),JAK2(gain),MET(gain),MYC(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: F,Height: 158 cm,Body weight: 52 kg,BMI: 20.83,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,WBC: 4.75,Albumin: 4.1 g/dL,Lymphocyte: 1.36,Neutrophil: 2.5,LDH level: 202.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 162 cm,Body weight: 64 kg,BMI: 24.39,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 5%,WBC: 7.38,Albumin: 3.6 g/dL,Lymphocyte: 1.43,Neutrophil: 5.07,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 182.1 cm,Body weight: 85.1 kg,BMI: 25.66,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 9.3,Albumin: 4.4 g/dL,Lymphocyte: 2.06,Neutrophil: 6.28,LDH level: 646.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/cobimetinib,SNV mutations: BRAF,TP53,CNV alterations: MET(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: F,Height: 144 cm,Body weight: 41 kg,BMI: 19.77,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,WBC: 10.25,Albumin: 3.5 g/dL,Lymphocyte: 2.05,Neutrophil: 7.87,LDH level: 550.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: CDK4(gain),EGFR(gain),MYC(gain),RPS6KB1(gain),Fusion genes: EGFR,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 166 cm,Body weight: 69 kg,BMI: 25.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: ERCC1(gain),MYC(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 164.6 cm,Body weight: 61.3 kg,BMI: 22.63,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: CCND3(gain),FGF10(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 162 cm,Body weight: 53 kg,BMI: 20.20,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719X,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.69,Albumin: 4.5 g/dL,Lymphocyte: 1.17,Neutrophil: 3.77,LDH level: 172.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 143 cm,Body weight: 68 kg,BMI: 33.54,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): <1%,WBC: 10.46,Albumin: 4.0 g/dL,Lymphocyte: 2.58,Neutrophil: 6.82,LDH level: 238.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CREBBP,FBXW7,CNV alterations: CHEK2(loss),MDM4(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 174 cm,Body weight: 66 kg,BMI: 21.72,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.45,Albumin: 3.9 g/dL,Lymphocyte: 1.27,Neutrophil: 4.67,LDH level: 248.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BARD1,KMT2A,NKX2-1,PTEN,STK11,TP53,CNV alterations: ERBB2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 160 cm,Body weight: 58 kg,BMI: 22.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 50%,WBC: 6.5,Albumin: 3.0 g/dL,Lymphocyte: 1.56,Neutrophil: 4.18,LDH level: 274.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,TP53,CNV alterations: CCNE1(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166 cm,Body weight: 53 kg,BMI: 19.27,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 15.4,Albumin: 4.5 g/dL,Lymphocyte: 6.31,Neutrophil: 7.83,LDH level: 199.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CBFB,FBXW7,RB1,TP53,CNV alterations: AKT2(gain),CCNE1(gain),Fusion genes: None,Splice variants: None,TMB: 13.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 166 cm,Body weight: 64 kg,BMI: 23.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 5.75,Albumin: 3.8 g/dL,Lymphocyte: 2.08,Neutrophil: 2.99,LDH level: 285.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: NOTCH2,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 164 cm,Body weight: 46 kg,BMI: 17.10,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 7%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: ATM,MET,TP53,CNV alterations: BRAF(gain),CCND1(gain),CDK6(gain),CDKN2A(loss),CDKN2B(loss),FGF19(gain),FGF3(gain),FGF4(gain),MET(gain),PIK3CA(gain),YAP1(gain),Fusion genes: ALK,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 163.4 cm,Body weight: 71 kg,BMI: 26.59,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 7.56,Albumin: 3.8 g/dL,Lymphocyte: 0.88,Neutrophil: 5.62,LDH level: 207.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ATRX,EGFR,TP53,CNV alterations: CCND1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),MDM4(gain),MYC(gain),RICTOR(gain),Fusion genes: RET,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: M,Height: 165.8 cm,Body weight: 54.7 kg,BMI: 19.90,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 14.75,Albumin: 3.8 g/dL,Lymphocyte: 2.56,Neutrophil: 10.39,LDH level: 149.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: CIC,NKX2-1,SUZ12,TP53,CNV alterations: CDK4(gain),GLI1(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 168 cm,Body weight: 63 kg,BMI: 22.35,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 4.44,Albumin: 5.0 g/dL,Lymphocyte: 1.1,Neutrophil: 2.87,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/ACZ885,SNV mutations: TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDK6(gain),FGF14(gain),LAMP1(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 159 cm,Body weight: 65 kg,BMI: 25.71,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.91,Albumin: 4.1 g/dL,Lymphocyte: 2.16,Neutrophil: 4.86,LDH level: 240.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: ARID1A,CDK12,FAT1,FBXW7,KMT2A,LRP1B,PTEN,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 29.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 159 cm,Body weight: 69 kg,BMI: 27.29,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.82,Albumin: 4.4 g/dL,Lymphocyte: 1.29,Neutrophil: 6.38,LDH level: 343.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab/Tiragolumab,SNV mutations: ARID2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 165 cm,Body weight: 52 kg,BMI: 19.10,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.67,Albumin: 4.4 g/dL,Lymphocyte: 1.61,Neutrophil: 3.11,LDH level: 297.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 91 years old,Sex: M,Height: 167 cm,Body weight: 53.5 kg,BMI: 19.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.56,Albumin: 3.1 g/dL,Lymphocyte: 1.27,Neutrophil: 8.6,LDH level: 293.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: M,Height: 176.3 cm,Body weight: 53.2 kg,BMI: 17.12,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 10.57,Albumin: 3.8 g/dL,Lymphocyte: 1.31,Neutrophil: 7.76,LDH level: 338.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: RB1,TP53,TSC2,CNV alterations: AURKA(gain),EGFR(gain),FGF10(gain),FGFR1(gain),MYC(gain),PIK3CA(gain),PTEN(loss),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 168 cm,Body weight: 73 kg,BMI: 25.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 13.06,Albumin: 2.9 g/dL,Lymphocyte: 1.28,Neutrophil: 9.79,LDH level: 207.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,TET2,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 182.4 cm,Body weight: 63.7 kg,BMI: 19.15,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 76.97,Albumin: 3.8 g/dL,Lymphocyte: 2.38,Neutrophil: 70.74,LDH level: 309.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: ERBB2,TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 170 cm,Body weight: 63 kg,BMI: 21.80,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 90%,WBC: 11.31,Albumin: 4.6 g/dL,Lymphocyte: 2.89,Neutrophil: 7.13,LDH level: 149.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 41 years old,Sex: F,Height: 159.8 cm,Body weight: 50.6 kg,BMI: 19.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,WBC: 9.82,Albumin: 3.8 g/dL,Lymphocyte: 1.13,Neutrophil: 6.76,LDH level: 232.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib/Amivantamab,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: F,Height: 157 cm,Body weight: 48 kg,BMI: 19.59,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,WBC: 15.56,Albumin: 4.3 g/dL,Lymphocyte: 2.06,Neutrophil: 11.92,LDH level: 146.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TERT,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 47 years old,Sex: M,Height: 179.3 cm,Body weight: 93.8 kg,BMI: 29.18,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 10%,WBC: 9.55,Albumin: 2.9 g/dL,Lymphocyte: 1.68,Neutrophil: 6.59,LDH level: 200.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: EGFR(gain),FGF10(gain),FGFR1(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 171.9 cm,Body weight: 57 kg,BMI: 19.29,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 10.16,Albumin: 3.7 g/dL,Lymphocyte: 3.32,Neutrophil: 5.33,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab,SNV mutations: BRCA2,ZFHX3,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(loss),PIK3CA(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 175 cm,Body weight: 64 kg,BMI: 20.90,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (SP263): 95%,WBC: 6.68,Albumin: 4.3 g/dL,Lymphocyte: 1.51,Neutrophil: 4.4,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: CDKN2A,TET2,TP53,CNV alterations: AKT2(gain),BRAF(gain),CCND1(gain),CCNE1(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(gain),KIT(gain),MET(gain),MYC(gain),PDGFRA(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: M,Height: 162.5 cm,Body weight: 60.8 kg,BMI: 23.02,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 80%,WBC: 6.46,Albumin: 3.3 g/dL,Lymphocyte: 0.99,Neutrophil: 3.29,LDH level: 156.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Durvalumab/Oleclumab/Monalizumab/Placebo,SNV mutations: CDKN2A,DAXX,TP53,CNV alterations: BCL6(gain),FGFR3(loss),PIK3CA(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 13.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 62 years old,Sex: F,Height: 157 cm,Body weight: 45 kg,BMI: 18.26,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,WBC: 5.81,Albumin: 3.9 g/dL,Lymphocyte: 0.67,Neutrophil: 4.27,LDH level: 212.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,PTPRT,TP53,CNV alterations: CCNE1(gain),EGFR(gain),MDM4(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 166 cm,Body weight: 68 kg,BMI: 24.68,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.82,Albumin: 4.2 g/dL,Lymphocyte: 1.54,Neutrophil: 7.86,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,SETBP1,CNV alterations: BRCA2(gain),MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 152.6 cm,Body weight: 51.5 kg,BMI: 22.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.17,Albumin: 3.9 g/dL,Lymphocyte: 1.21,Neutrophil: 5.53,LDH level: 172.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Tiragolumab/Atezolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: ERCC2(gain),MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 154.8 cm,Body weight: 41.7 kg,BMI: 17.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Positive,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 20.78,Albumin: 2.6 g/dL,Lymphocyte: 0.75,Neutrophil: 18.43,LDH level: 3366.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Crizotinib,SNV mutations: AMER1,EP300,NF2,CNV alterations: None,Fusion genes: ROS1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 160.8 cm,Body weight: 53.1 kg,BMI: 20.54,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,WBC: 4.11,Albumin: 3.4 g/dL,Lymphocyte: 0.64,Neutrophil: 2.72,LDH level: 216.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Belotecan,SNV mutations: NOTCH1,TP53,CNV alterations: FGFR4(loss),PDGFRB(loss),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 172 cm,Body weight: 60 kg,BMI: 20.28,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: L858R,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 11.35,Albumin: 3.5 g/dL,Lymphocyte: 1.39,Neutrophil: 8.9,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: APC,EGFR,CNV alterations: BRAF(gain),CDK4(gain),EGFR(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 165 cm,Body weight: 56.5 kg,BMI: 20.75,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.2,Albumin: 4.2 g/dL,Lymphocyte: 1.0,Neutrophil: 8.21,LDH level: 891.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,RB1,TP53,U2AF1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 179 cm,Body weight: 72 kg,BMI: 22.47,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.39,Albumin: 4.6 g/dL,Lymphocyte: 1.83,Neutrophil: 5.65,LDH level: 202.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 159 cm,Body weight: 57 kg,BMI: 22.62,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 9.24,Albumin: 3.8 g/dL,Lymphocyte: 1.18,Neutrophil: 6.57,LDH level: 226.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: PMS1,TP53,CNV alterations: MYC(gain),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 164 cm,Body weight: 48 kg,BMI: 17.80,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 100%,WBC: 6.78,Albumin: 3.2 g/dL,Lymphocyte: 0.54,Neutrophil: 5.42,LDH level: 213.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/SAR442720,SNV mutations: MET,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 169.4 cm,Body weight: 64 kg,BMI: 22.30,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 13.69,Albumin: 3.3 g/dL,Lymphocyte: 2.41,Neutrophil: 9.95,LDH level: 124.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,KRAS,NKX2-1,PTPRD,STK11,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 18.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 170 cm,Body weight: 53 kg,BMI: 18.34,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 8.86,Albumin: 4.2 g/dL,Lymphocyte: 4.7,Neutrophil: 3.27,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,MAX,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 171 cm,Body weight: 58 kg,BMI: 19.84,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5~10%,WBC: 5.73,Albumin: 4.7 g/dL,Lymphocyte: 1.52,Neutrophil: 3.68,LDH level: 213.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,ERBB2,PIK3CA,RB1,TP53,CNV alterations: AKT2(gain),ERBB2(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 160 cm,Body weight: 71.7 kg,BMI: 28.01,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: non-squamous non-small cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 90%,WBC: 5.31,Albumin: 4.5 g/dL,Lymphocyte: 1.71,Neutrophil: 2.77,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: MET,TP53,XRCC2,CNV alterations: ALK(gain),KIT(gain),KRAS(gain),MYC(gain),Fusion genes: None,Splice variants: MET,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: F,Height: 165 cm,Body weight: 61 kg,BMI: 22.41,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 3.84,Albumin: 4.5 g/dL,Lymphocyte: 1.16,Neutrophil: 2.17,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 168 cm,Body weight: 73.6 kg,BMI: 26.08,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 50%,PD-L1 (SP263): 15%,WBC: 8.59,Albumin: 4.4 g/dL,Lymphocyte: 3.61,Neutrophil: 3.78,LDH level: 241.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin/Nivolumab or Placebo,SNV mutations: DNMT3A,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: ALK,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 178 cm,Body weight: 81 kg,BMI: 25.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.53,Albumin: 4.9 g/dL,Lymphocyte: 2.58,Neutrophil: 3.27,LDH level: 157.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,EGFR,U2AF1,CNV alterations: FGF10(gain),RICTOR(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 160 cm,Body weight: 49 kg,BMI: 19.24,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Non-squamous carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 70%,PD-L1 (SP263): 70%,WBC: 12.62,Albumin: 4.0 g/dL,Lymphocyte: 3.93,Neutrophil: 7.24,LDH level: 150.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NOTCH1,PBRM1,TCF3,TP53,CNV alterations: FGF10(gain),JAK2(gain),PIK3CB(gain),Fusion genes: None,Splice variants: None,TMB: 33.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 180.4 cm,Body weight: 67.5 kg,BMI: 20.74,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 7.28,Albumin: 4.8 g/dL,Lymphocyte: 0.49,Neutrophil: 6.66,LDH level: 234.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CTNNB1,KRAS,MSH2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 167.3 cm,Body weight: 58.9 kg,BMI: 21.04,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 9.37,Albumin: 4.0 g/dL,Lymphocyte: 1.94,Neutrophil: 6.62,LDH level: 376.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,SMARCA4,STK11,TP53,CNV alterations: CCND1(gain),CDK6(gain),EGFR(gain),FGF19(gain),FGF3(gain),FGF4(gain),PAK1(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 157 cm,Body weight: 44.7 kg,BMI: 18.13,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 7.6,Albumin: 3.8 g/dL,Lymphocyte: 0.85,Neutrophil: 6.24,LDH level: 241.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lorlatinib,SNV mutations: CDKN2A,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 5.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 164.2 cm,Body weight: 82 kg,BMI: 30.41,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 7.26,Albumin: 4.5 g/dL,Lymphocyte: 1.08,Neutrophil: 5.47,LDH level: 112.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Gemcitabine/Carboplatin,SNV mutations: CDKN2A,NFE2L2,CNV alterations: CCND1(gain),CHEK2(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(gain),PIK3CA(gain),SOX2(gain),TFRC(gain),TP63(gain),Fusion genes: None,Splice variants: None,TMB: 12.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: F,Height: 150 cm,Body weight: 66 kg,BMI: 29.04,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,WBC: 9.22,Albumin: 4.7 g/dL,Lymphocyte: 2.31,Neutrophil: 6.19,LDH level: 177.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 158 cm,Body weight: 55 kg,BMI: 21.87,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 16.15,Albumin: 3.7 g/dL,Lymphocyte: 2.68,Neutrophil: 11.66,LDH level: 192.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID1A,EZH2,SMAD4,SMARCB1,SOCS1,TP53,CNV alterations: PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 23.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 86 years old,Sex: F,Height: 152 cm,Body weight: 50 kg,BMI: 21.76,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 8.1,Albumin: 4.7 g/dL,Lymphocyte: 1.45,Neutrophil: 6.09,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ARID5B,KRAS,RNF43,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 162.3 cm,Body weight: 63.8 kg,BMI: 24.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: 50%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 8.67,Albumin: 4.8 g/dL,Lymphocyte: 2.4,Neutrophil: 5.51,LDH level: 194.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 164 cm,Body weight: 64.5 kg,BMI: 23.98,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 4.65,Albumin: 4.5 g/dL,Lymphocyte: 1.33,Neutrophil: 2.98,LDH level: 192.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: FGFR4(gain),RICTOR(gain),Fusion genes: EWSR1,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 170.2 cm,Body weight: 66 kg,BMI: 22.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 5.99,Albumin: 2.9 g/dL,Lymphocyte: 1.07,Neutrophil: 4.25,LDH level: 202.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab,SNV mutations: KRAS,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 54 years old,Sex: M,Height: 171 cm,Body weight: 93 kg,BMI: 31.80,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,WBC: 8.93,Albumin: 4.2 g/dL,Lymphocyte: 2.19,Neutrophil: 5.24,LDH level: 205.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NF1,PDGFRA,SOX17,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: M,Height: 176 cm,Body weight: 81.2 kg,BMI: 26.21,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.93,Albumin: 4.5 g/dL,Lymphocyte: 0.61,Neutrophil: 7.12,LDH level: 242.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: GRIN2A,MET,NF1,SMAD4,TP53,CNV alterations: BCL2L1(gain),EGFR(gain),NOTCH2(gain),Fusion genes: None,Splice variants: MET,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 152 cm,Body weight: 59 kg,BMI: 25.54,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,WBC: 9.01,Albumin: 3.8 g/dL,Lymphocyte: 1.54,Neutrophil: 6.6,LDH level: 153.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,PIK3CA,SMAD4,CNV alterations: AR(gain),FGF7(loss),FGF9(loss),FGFR1(loss),MYC(loss),NRG1(loss),PMAIP1(loss),SMAD2(loss),SMAD4(loss),Fusion genes: None,Splice variants: None,TMB: 25.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 83 years old,Sex: F,Height: 150 cm,Body weight: 54 kg,BMI: 24.00,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 7.28,Albumin: 4.0 g/dL,Lymphocyte: 2.28,Neutrophil: 4.33,LDH level: 183.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,CNV alterations: MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: F,Height: 156.7 cm,Body weight: 53 kg,BMI: 21.58,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): <1%,WBC: 8.27,Albumin: 4.1 g/dL,Lymphocyte: 1.37,Neutrophil: 6.02,LDH level: 231.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Tepotinib,SNV mutations: MET,CNV alterations: EGFR(gain),FGF2(gain),FGFR4(gain),Fusion genes: None,Splice variants: MET,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: F,Height: 158 cm,Body weight: 56 kg,BMI: 22.43,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 3.88,Albumin: 3.4 g/dL,Lymphocyte: 1.04,Neutrophil: 2.19,LDH level: 485.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: PIK3CA,RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 163 cm,Body weight: 60.6 kg,BMI: 22.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 75%,WBC: 6.54,Albumin: 4.2 g/dL,Lymphocyte: 1.92,Neutrophil: 3.66,LDH level: 180.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 163 cm,Body weight: 63 kg,BMI: 23.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 0%,WBC: 9.88,Albumin: 3.6 g/dL,Lymphocyte: 1.71,Neutrophil: 6.93,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,NKX2-1,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 153 cm,Body weight: 56 kg,BMI: 23.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.82,Albumin: 4.2 g/dL,Lymphocyte: 1.86,Neutrophil: 5.18,LDH level: 131.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: CTNNB1,EGFR,PTEN,RB1,CNV alterations: CCND3(gain),FGFR3(loss),FRS2(gain),MDM2(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 168 cm,Body weight: 55.3 kg,BMI: 19.59,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 90%,WBC: 18.64,Albumin: 4.6 g/dL,Lymphocyte: 2.13,Neutrophil: 15.25,LDH level: 162.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Atezolizumab+/-Tiragolumab,SNV mutations: MET,RBM10,SMAD4,TP53,CNV alterations: MYC(gain),RECQL4(gain),Fusion genes: None,Splice variants: MET,TMB: 7.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 164.3 cm,Body weight: 66.6 kg,BMI: 24.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 5.81,Albumin: 4.4 g/dL,Lymphocyte: 1.47,Neutrophil: 3.9,LDH level: 240.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,SETD2,CNV alterations: None,Fusion genes: FGFR3,Splice variants: None,TMB: 1.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 167.7 cm,Body weight: 63.5 kg,BMI: 22.58,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.01,Albumin: 4.7 g/dL,Lymphocyte: 1.44,Neutrophil: 2.82,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: JNJ372/Lazertinib,SNV mutations: EGFR,MITF,TP53,CNV alterations: MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 160.6 cm,Body weight: 58 kg,BMI: 22.49,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: 70%,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 80%,WBC: 11.21,Albumin: 3.7 g/dL,Lymphocyte: 1.9,Neutrophil: 7.93,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: CCND3(gain),EGFR(gain),JAK2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 164 cm,Body weight: 62 kg,BMI: 23.05,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.11,Albumin: 3.9 g/dL,Lymphocyte: 2.39,Neutrophil: 6.96,LDH level: 172.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Erlotinib,SNV mutations: CTNNB1,EGFR,PTEN,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 167 cm,Body weight: 57 kg,BMI: 20.44,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,T790M,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: APC,EGFR,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 177 cm,Body weight: 74.8 kg,BMI: 23.88,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 8.28,Albumin: 2.8 g/dL,Lymphocyte: 0.98,Neutrophil: 6.77,LDH level: 259.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: APC,EPHA3,NOTCH1,RB1,TP53,CNV alterations: FGF14(gain),FGFR1(gain),LAMP1(gain),MYCN(loss),NF1(gain),PIK3CA(gain),SUZ12(gain),Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 168 cm,Body weight: 62 kg,BMI: 21.97,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 8.75,Albumin: 4.4 g/dL,Lymphocyte: 2.5,Neutrophil: 4.91,LDH level: 604.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Durvalumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 171.4 cm,Body weight: 64 kg,BMI: 21.79,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 21.7,Albumin: 3.5 g/dL,Lymphocyte: 2.02,Neutrophil: 18.35,LDH level: 241.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: AR(loss),CCND3(gain),FGFR3(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 173 cm,Body weight: 60 kg,BMI: 20.05,Smoking history: Never smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 60%,WBC: 7.41,Albumin: 4.2 g/dL,Lymphocyte: 1.36,Neutrophil: 5.46,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: TP53,CNV alterations: CCND1(gain),FGF19(gain),FGF3(gain),FGF4(gain),FGFR1(gain),KRAS(gain),NRG1(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 10.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 45 years old,Sex: F,Height: 165 cm,Body weight: 94.7 kg,BMI: 34.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 10.59,Albumin: 4.0 g/dL,Lymphocyte: 1.14,Neutrophil: 8.33,LDH level: 212.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: APC,EGFR,TGFBR1,CNV alterations: CCND3(gain),CDK6(loss),FGF1(loss),FGF3(gain),MDM4(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 82 years old,Sex: M,Height: 163.2 cm,Body weight: 71.8 kg,BMI: 26.96,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 70%,WBC: 6.75,Albumin: 4.1 g/dL,Lymphocyte: 1.86,Neutrophil: 3.93,LDH level: 216.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-7684A or Pembrolizumab,SNV mutations: CREBBP,MET,TP53,CNV alterations: CDK6(gain),EGFR(gain),MET(gain),MYC(gain),Fusion genes: None,Splice variants: MET,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: F,Height: 151 cm,Body weight: 68 kg,BMI: 29.82,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 6.76,Albumin: 3.9 g/dL,Lymphocyte: 0.9,Neutrophil: 5.02,LDH level: 218.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,TP53,CNV alterations: ARAF(gain),BRAF(gain),EGFR(gain),FGF10(gain),GATA1(gain),MYC(gain),NKX2-1(gain),RBM10(gain),TFE3(gain),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 158.6 cm,Body weight: 86 kg,BMI: 34.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 6.83,Albumin: 4.3 g/dL,Lymphocyte: 2.01,Neutrophil: 4.01,LDH level: 256.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: IDH1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: M,Height: 165 cm,Body weight: 73 kg,BMI: 26.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.08,Albumin: 5.2 g/dL,Lymphocyte: 1.88,Neutrophil: 5.29,LDH level: 156.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRAF,NFE2L2,PIK3CA,SETD2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: F,Height: 160 cm,Body weight: 70 kg,BMI: 27.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.09,Albumin: 4.7 g/dL,Lymphocyte: 2.12,Neutrophil: 2.41,LDH level: 252.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ERBB2,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 175 cm,Body weight: 82 kg,BMI: 26.93,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): >50%,WBC: 10.0,Albumin: 3.7 g/dL,Lymphocyte: 1.73,Neutrophil: 6.29,LDH level: 587.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,CDKN2A,DNMT3A,INPP4B,KRAS,TP53,CNV alterations: AR(loss),ERBB3(gain),FGFR4(gain),NRAS(loss),Fusion genes: None,Splice variants: None,TMB: 22.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 157.3 cm,Body weight: 53.1 kg,BMI: 21.46,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 161 cm,Body weight: 49.5 kg,BMI: 19.10,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): <1%,WBC: 6.52,Albumin: 3.5 g/dL,Lymphocyte: 2.68,Neutrophil: 3.1,LDH level: 204.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: CREBBP,NF1,SMAD4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: F,Height: 148.6 cm,Body weight: 51.2 kg,BMI: 23.19,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 100%,PD-L1 (SP263): 100%,WBC: 7.65,Albumin: 4.6 g/dL,Lymphocyte: 3.81,Neutrophil: 3.16,LDH level: 308.0 U/L,Treatment type: Immunotherapy,Treatment regimen: MK-4830/Pembrolizumab,SNV mutations: CDKN2A,RASA1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 0.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 170 cm,Body weight: 70 kg,BMI: 24.22,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 10.35,Albumin: 4.7 g/dL,Lymphocyte: 1.61,Neutrophil: 8.15,LDH level: 206.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: None,CNV alterations: AKT2(gain),BRD4(gain),CCND1(gain),CCND3(gain),CCNE1(gain),FGF19(gain),FGF3(gain),FGF4(gain),GEN1(gain),MYCN(gain),RPS6KB2(gain),STAT4(loss),TERC(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 40 years old,Sex: M,Height: 170 cm,Body weight: 63 kg,BMI: 21.80,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 8.81,Albumin: 4.8 g/dL,Lymphocyte: 3.35,Neutrophil: 3.96,LDH level: 181.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: BGB-A445/Docetaxel,SNV mutations: CHEK2,FAT1,KEAP1,SMARCA4,STK11,TP53,CNV alterations: CCND3(gain),JAK2(loss),PAK1(gain),VEGFA(gain),Fusion genes: None,Splice variants: None,TMB: 34.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 85 years old,Sex: M,Height: 158 cm,Body weight: 56.4 kg,BMI: 22.59,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,WBC: 9.8,Albumin: 3.6 g/dL,Lymphocyte: 1.88,Neutrophil: 6.35,LDH level: 201.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: ARID1A,TP53,CNV alterations: AKT2(gain),BCL2L1(gain),BRAF(gain),CCND3(gain),EGFR(gain),ERCC2(gain),FGF8(loss),MYC(gain),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 178.3 cm,Body weight: 88.6 kg,BMI: 27.87,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 6.45,Albumin: 4.3 g/dL,Lymphocyte: 2.02,Neutrophil: 3.53,LDH level: 142.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: MAP2K4,NF1,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 158.9 cm,Body weight: 54.7 kg,BMI: 21.66,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 10%,WBC: 6.77,Albumin: 3.8 g/dL,Lymphocyte: 1.32,Neutrophil: 4.83,LDH level: 206.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: ARID5B,EGFR,TP53,CNV alterations: EGFR(gain),MDM4(gain),MYC(gain),PIK3CA(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 155.3 cm,Body weight: 53.5 kg,BMI: 22.18,Smoking history: Never smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 6.81,Albumin: 4.4 g/dL,Lymphocyte: 1.8,Neutrophil: 4.35,LDH level: 245.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab or Placebo/Etoposide/Carboplatin,SNV mutations: RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: M,Height: 167 cm,Body weight: 66 kg,BMI: 23.67,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 20%,WBC: 13.84,Albumin: 3.3 g/dL,Lymphocyte: 2.54,Neutrophil: 10.03,LDH level: 212.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab/MK4830,SNV mutations: NOTCH1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 16.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 156 cm,Body weight: 50 kg,BMI: 20.55,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 10.59,Albumin: 3.5 g/dL,Lymphocyte: 2.42,Neutrophil: 7.44,LDH level: 147.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: FGF14(gain),KRAS(gain),LAMP1(gain),MDM4(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 89 years old,Sex: M,Height: 166 cm,Body weight: 66 kg,BMI: 23.89,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 80%,WBC: 6.59,Albumin: 3.8 g/dL,Lymphocyte: 1.64,Neutrophil: 4.23,LDH level: 164.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: MET,CNV alterations: None,Fusion genes: None,Splice variants: MET,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 140.9 cm,Body weight: 42.5 kg,BMI: 21.41,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 5.76,Albumin: 4.0 g/dL,Lymphocyte: 1.53,Neutrophil: 3.65,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: APC,EGFR,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 163 cm,Body weight: 69 kg,BMI: 26.10,Smoking history: Current smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 7.87,Albumin: 4.8 g/dL,Lymphocyte: 2.2,Neutrophil: 5.08,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KDM6A,TP53,CNV alterations: AKT2(gain),ALK(gain),CCNE1(gain),FGFR1(gain),MYC(gain),NRG1(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 23.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 158 cm,Body weight: 48 kg,BMI: 19.23,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: G719X,ALK status: Negative,WBC: 5.01,Albumin: 4.3 g/dL,Lymphocyte: 2.75,Neutrophil: 1.75,LDH level: 178.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CCND1(gain),CCND3(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),ERBB2(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),MDM4(gain),MET(gain),MPL(gain),MYCN(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 11.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 158 cm,Body weight: 65 kg,BMI: 26.04,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 7.53,Albumin: 4.5 g/dL,Lymphocyte: 1.88,Neutrophil: 5.15,LDH level: 211.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,CNV alterations: ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 155 cm,Body weight: 50 kg,BMI: 20.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 11.44,Albumin: 4.1 g/dL,Lymphocyte: 1.62,Neutrophil: 9.1,LDH level: 187.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 80 years old,Sex: M,Height: 167.3 cm,Body weight: 62.7 kg,BMI: 22.40,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (SP263): >50%,WBC: 5.35,Albumin: 3.8 g/dL,Lymphocyte: 1.41,Neutrophil: 2.89,LDH level: 343.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: B2M,TP53,CNV alterations: ATM(gain),CCND1(gain),CHEK1(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 163 cm,Body weight: 62.6 kg,BMI: 23.56,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 9.41,Albumin: 4.3 g/dL,Lymphocyte: 1.53,Neutrophil: 6.75,LDH level: 270.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 46 years old,Sex: M,Height: 169.2 cm,Body weight: 57 kg,BMI: 19.91,Smoking history: Never smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 27.07,Albumin: 3.6 g/dL,Lymphocyte: 1.55,Neutrophil: 22.02,LDH level: 96.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: EGFR,PIK3CA,RBM10,CNV alterations: CDK6(gain),EGFR(gain),GRM3(gain),MDM2(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 165 cm,Body weight: 75 kg,BMI: 27.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: Wild,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.29,Albumin: 4.7 g/dL,Lymphocyte: 0.94,Neutrophil: 4.4,LDH level: 210.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin/MK4830,SNV mutations: ERBB2,CNV alterations: CDKN2A(loss),CDKN2B(loss),FGF23(gain),FGF6(gain),MYC(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: F,Height: 144 cm,Body weight: 50 kg,BMI: 24.11,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.28,Albumin: 4.5 g/dL,Lymphocyte: 2.14,Neutrophil: 3.56,LDH level: 326.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 77 years old,Sex: M,Height: 170.2 cm,Body weight: 72 kg,BMI: 24.85,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.02,Albumin: 5.0 g/dL,Lymphocyte: 1.34,Neutrophil: 2.98,LDH level: 250.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: CTNNB1,EGFR,MGA,SMAD4,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 9.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 167 cm,Body weight: 75 kg,BMI: 26.89,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.27,Albumin: 4.9 g/dL,Lymphocyte: 1.83,Neutrophil: 3.95,LDH level: 205.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin+Canakinumab,SNV mutations: BRAF,MGA,MTOR,TET2,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: F,Height: 164 cm,Body weight: 61 kg,BMI: 22.64,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 90%,WBC: 13.14,Albumin: 4.6 g/dL,Lymphocyte: 3.06,Neutrophil: 8.31,LDH level: 202.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CHEK2,KRAS,MGA,SMARCA4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 170 cm,Body weight: 62 kg,BMI: 21.45,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Sarcomatoid carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 11.77,Albumin: 4.4 g/dL,Lymphocyte: 2.0,Neutrophil: 7.75,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: KRAS,CNV alterations: KRAS(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 169 cm,Body weight: 73 kg,BMI: 25.56,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: >50%,PD-L1 (22C3): 90%,PD-L1 (SP263): 90%,WBC: 5.91,Albumin: 4.5 g/dL,Lymphocyte: 1.57,Neutrophil: 3.51,LDH level: 175.0 U/L,Treatment type: Immunotherapy,Treatment regimen: Pembrolizumab,SNV mutations: CDKN2A,DNMT3A,NSD1,TP53,CNV alterations: EGFR(gain),FGF3(loss),FGF4(loss),MYCL(gain),PIK3CA(gain),PIK3CB(gain),PIK3CD(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 22.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: F,Height: 156 cm,Body weight: 57 kg,BMI: 23.52,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 99%,PD-L1 (SP263): 100%,WBC: 10.16,Albumin: 4.1 g/dL,Lymphocyte: 2.59,Neutrophil: 6.12,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 70 years old,Sex: F,Height: 161 cm,Body weight: 61 kg,BMI: 23.53,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,WBC: 11.13,Albumin: 4.3 g/dL,Lymphocyte: 1.48,Neutrophil: 8.96,LDH level: 215.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Bevacizumab+Erlotinib,SNV mutations: DDX41,DIS3,EGFR,EPCAM,SHQ1,SPEN,TP53,CNV alterations: CD274(gain),CDK4(gain),CEBPA(gain),EGFR(gain),EPCAM(gain),FANCL(gain),JAK2(gain),KAT6A(gain),MDM4(gain),MET(gain),MSH2(gain),PDCD1LG2(gain),PIK3C2B(gain),PPP2R1A(gain),SDHA(gain),Fusion genes: None,Splice variants: MET,TMB: 24.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 180 cm,Body weight: 70 kg,BMI: 21.60,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 1%,WBC: 9.7,Albumin: 4.1 g/dL,Lymphocyte: 2.16,Neutrophil: 5.88,LDH level: 211.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Alectinib,SNV mutations: None,CNV alterations: None,Fusion genes: ALK,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 49 years old,Sex: F,Height: 158.8 cm,Body weight: 64.1 kg,BMI: 25.42,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 5.74,Albumin: 4.6 g/dL,Lymphocyte: 2.04,Neutrophil: 3.21,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: DIS3,EGFR,TP53,CNV alterations: EGFR(gain),MYC(gain),Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 52 years old,Sex: F,Height: 165.1 cm,Body weight: 61.5 kg,BMI: 22.56,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 5%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Osimertinib,SNV mutations: EGFR,PIK3CA,RB1,TP53,CNV alterations: AKT2(gain),BRAF(gain),CCNE1(gain),CDK6(gain),EGFR(gain),JAK2(gain),LAMP1(gain),MDM4(gain),MET(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 165.1 cm,Body weight: 59 kg,BMI: 21.65,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 11.3,Albumin: 4.8 g/dL,Lymphocyte: 0.73,Neutrophil: 10.12,LDH level: 179.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetraxed/Carboplatin,SNV mutations: FOXO1,MET,CNV alterations: CDK4(gain),MDM2(gain),Fusion genes: None,Splice variants: MET,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 157.5 cm,Body weight: 37 kg,BMI: 14.92,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 1%,WBC: 5.2,Albumin: 4.2 g/dL,Lymphocyte: 0.92,Neutrophil: 3.65,LDH level: 158.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib -> Erlotinib,SNV mutations: AKT1,EGFR,LATS1,PTEN,TP53,CNV alterations: EGFR(gain),FGFR3(loss),Fusion genes: None,Splice variants: None,TMB: 4.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 169 cm,Body weight: 58.9 kg,BMI: 20.62,Smoking history: Former smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.43,Albumin: 4.2 g/dL,Lymphocyte: 1.15,Neutrophil: 2.8,LDH level: 129.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: ADGRA2(gain),CDKN2A(loss),CDKN2B(loss),FGFR1(gain),MYC(gain),PIK3CA(gain),PIK3CB(gain),RAD51B(loss),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 15.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: M,Height: 169 cm,Body weight: 56 kg,BMI: 19.71,Smoking history: Former smoker,Cancer stage: SqCC,Histology: Squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,WBC: 11.82,Albumin: 3.8 g/dL,Lymphocyte: 0.95,Neutrophil: 9.87,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: CDKN2A,EP300,KMT2A,NF2,NFE2L2,PPM1D,TP53,TSC1,CNV alterations: CCNE1(gain),EGFR(gain),PIK3CA(gain),PIK3CB(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 21.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: M,Height: 174 cm,Body weight: 66 kg,BMI: 21.80,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: G719X,S768I,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 10%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 159 cm,Body weight: 50 kg,BMI: 19.78,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 6.78,Albumin: 3.6 g/dL,Lymphocyte: 0.81,Neutrophil: 5.76,LDH level: 248.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: CDKN2A(loss),CDKN2B(loss),MAP3K4(loss),Fusion genes: RET,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 72 years old,Sex: M,Height: 161 cm,Body weight: 69.5 kg,BMI: 26.81,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.58,Albumin: 4.1 g/dL,Lymphocyte: 1.48,Neutrophil: 3.51,LDH level: 165.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,EED,RASA1,TP53,CNV alterations: CCNE1(gain),CDK12(gain),ERBB2(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: M,Height: 160 cm,Body weight: 49.5 kg,BMI: 19.34,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 75%,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 2%,WBC: 4.02,Albumin: 3.6 g/dL,Lymphocyte: 0.45,Neutrophil: 2.97,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,TP53,CNV alterations: BCL6(gain),EGFR(gain),ERBB2(gain),ETV1(gain),FGF8(loss),NKX2-1(gain),NTRK1(gain),PIK3CA(gain),PIK3CB(gain),RAC1(gain),RICTOR(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 157.6 cm,Body weight: 64.1 kg,BMI: 25.81,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.18,Albumin: 4.2 g/dL,Lymphocyte: 2.44,Neutrophil: 2.91,LDH level: 168.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: BAP1,CNV alterations: BRCA1(gain),FGF7(loss),FGFR1(gain),RICTOR(gain),Fusion genes: NRG1,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 159 cm,Body weight: 63 kg,BMI: 24.92,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 15%,WBC: 12.83,Albumin: 4.1 g/dL,Lymphocyte: 1.84,Neutrophil: 9.97,LDH level: 324.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: TP53,CNV alterations: EGFR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 157 cm,Body weight: 70 kg,BMI: 28.21,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,WBC: 9.41,Albumin: 4.8 g/dL,Lymphocyte: 2.31,Neutrophil: 6.4,LDH level: 226.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ERBB2,CNV alterations: FGFR3(loss),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 162.1 cm,Body weight: 68.9 kg,BMI: 26.22,Smoking history: Current smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: No,WBC: 7.12,Albumin: 4.3 g/dL,Lymphocyte: 2.08,Neutrophil: 4.39,LDH level: 379.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Etoposide/Carboplatin,SNV mutations: EP300,TP53,CNV alterations: ATM(gain),CCNE1(gain),CHEK1(gain),FGF9(gain),JAK2(gain),MYC(gain),PIK3CA(gain),PTEN(loss),RB1(loss),Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 78 years old,Sex: F,Height: 153.5 cm,Body weight: 46.3 kg,BMI: 19.65,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (22C3): <1%,PD-L1 (SP263): 0%,WBC: 5.73,Albumin: 3.7 g/dL,Lymphocyte: 1.16,Neutrophil: 3.94,LDH level: 249.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: NOTCH4,TP53,CNV alterations: CCND3(gain),FGFR1(gain),Fusion genes: NRG1,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: M,Height: 166.9 cm,Body weight: 72.9 kg,BMI: 26.17,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): <1%,WBC: 7.43,Albumin: 4.3 g/dL,Lymphocyte: 2.73,Neutrophil: 4.03,LDH level: 142.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RB1,RBM10,CNV alterations: MDM2(gain),Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 164 cm,Body weight: 63 kg,BMI: 23.42,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: Adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 5%,WBC: 7.36,Albumin: 4.9 g/dL,Lymphocyte: 1.69,Neutrophil: 4.9,LDH level: Unknown U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,SMAD4,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 170 cm,Body weight: 70 kg,BMI: 24.22,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,WBC: 6.93,Albumin: 5.2 g/dL,Lymphocyte: 1.06,Neutrophil: 5.3,LDH level: 174.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,LZTR1,RB1,TP53,CNV alterations: BRAF(gain),CHEK1(loss),FGF10(gain),FGF8(loss),FGFR3(loss),MDM4(gain),PIK3CA(gain),PIK3CB(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 56 years old,Sex: M,Height: 168 cm,Body weight: 64 kg,BMI: 22.68,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 5.2,Albumin: 4.2 g/dL,Lymphocyte: 2.57,Neutrophil: 1.97,LDH level: 189.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: F,Height: 162 cm,Body weight: 50.2 kg,BMI: 19.13,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 40%,PD-L1 (SP263): 10%,WBC: 4.73,Albumin: 4.9 g/dL,Lymphocyte: 1.0,Neutrophil: 3.19,LDH level: Unknown U/L,Treatment type: Immunotherapy,Treatment regimen: Nivolumab,SNV mutations: None,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 73 years old,Sex: M,Height: 167 cm,Body weight: 67 kg,BMI: 24.02,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 6.04,Albumin: 4.0 g/dL,Lymphocyte: 1.6,Neutrophil: 3.33,LDH level: 182.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: BRCA2,MGA,NF1,PTPRD,RAD50,TP53,CNV alterations: BCOR(loss),BRAF(gain),FGFR3(loss),KIT(gain),STK11(loss),TCF3(loss),ZRSR2(loss),Fusion genes: None,Splice variants: None,TMB: 11.8 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 75 years old,Sex: M,Height: 160 cm,Body weight: 53 kg,BMI: 20.70,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 2%,PD-L1 (SP263): 2%,WBC: 4.86,Albumin: 4.2 g/dL,Lymphocyte: 1.02,Neutrophil: 3.38,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: AKT1,AKT2,CARD11,PIK3R1,RAD51C,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 168.6 cm,Body weight: 52.7 kg,BMI: 18.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 3.92,Albumin: 4.1 g/dL,Lymphocyte: 0.69,Neutrophil: 2.74,LDH level: 184.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: AKT2(gain),AR(gain),BCL2L1(gain),CCNE1(gain),CDK4(gain),CDKN2A(loss),CDKN2B(loss),DNMT3B(gain),ERBB3(gain),ERCC1(gain),ERCC2(gain),FGF10(gain),JAK2(loss),KRAS(gain),MYC(gain),PIK3CA(gain),RAF1(gain),RET(loss),RICTOR(gain),SMAD2(loss),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 81 years old,Sex: F,Height: 155 cm,Body weight: 66 kg,BMI: 27.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 20%,PD-L1 (SP263): 15%,WBC: 7.45,Albumin: 4.5 g/dL,Lymphocyte: 2.53,Neutrophil: 4.21,LDH level: 227.0 U/L,Treatment type: Immunotherapy + Chemotherapy + Targeted Therapy,Treatment regimen: Bevacizumab/Paclitaxel/Carboplatin/Nivolumab or Placebo,SNV mutations: KRAS,CNV alterations: FGF5(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 178.9 cm,Body weight: 74.4 kg,BMI: 23.25,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 5.54,Albumin: 4.5 g/dL,Lymphocyte: 1.33,Neutrophil: 3.76,LDH level: 196.0 U/L,Treatment type: Immunotherapy + Targeted Therapy,Treatment regimen: Amivantamab/Lazertinib,SNV mutations: EGFR,CNV alterations: AKT2(gain),BRCA2(gain),CCND1(gain),CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF10(gain),FGF19(gain),FGF3(gain),FGF4(gain),JAK2(loss),MDM2(gain),PAK1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 71 years old,Sex: F,Height: 167 cm,Body weight: 66 kg,BMI: 23.67,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: E19del,T790M,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,RBM10,TP53,CNV alterations: EGFR(gain),MET(gain),Fusion genes: None,Splice variants: None,TMB: 4.0 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 55 years old,Sex: M,Height: 170 cm,Body weight: 55 kg,BMI: 19.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: large cell carcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 3%,PD-L1 (SP263): 3%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Etoposide/Carboplatin,SNV mutations: ARID1B,CDKN2A,SMARCA4,TP53,CNV alterations: BRCA2(gain),CCND1(loss),CCNE1(gain),ERBB2(gain),ERCC2(gain),FGF10(gain),FGF4(loss),GATA6(gain),LAMP1(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 14.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: F,Height: 161.6 cm,Body weight: 63.9 kg,BMI: 24.47,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,PD-L1 group: 1~49%,PD-L1 (22C3): 0%,PD-L1 (SP263): 1%,WBC: 6.6,Albumin: 4.7 g/dL,Lymphocyte: 1.63,Neutrophil: 4.39,LDH level: 172.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,KMT2A,PIK3CA,TP53,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),FGF10(gain),RICTOR(gain),Fusion genes: None,Splice variants: None,TMB: 9.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: M,Height: 166.6 cm,Body weight: 64 kg,BMI: 23.06,Smoking history: Former smoker,Cancer stage: SCLC,Histology: small cell carcinoma,Liver metastasis: No,Brain metastasis: Yes,WBC: 6.84,Albumin: 3.9 g/dL,Lymphocyte: 1.59,Neutrophil: 4.58,LDH level: 175.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Atezolizumab/Tiragolumab/Etoposide/Cisplatin,SNV mutations: RB1,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 8.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 178.7 cm,Body weight: 80.7 kg,BMI: 25.27,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 60%,PD-L1 (SP263): 60%,WBC: 6.22,Albumin: 3.4 g/dL,Lymphocyte: 1.65,Neutrophil: 4.09,LDH level: 212.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib -> Osimertinib,SNV mutations: EGFR,PIK3CA,CNV alterations: AR(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 53 years old,Sex: M,Height: 170 cm,Body weight: 81 kg,BMI: 28.03,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: E19del,ALK status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,TP53,CNV alterations: AKT2(gain),CCNE1(gain),CDK6(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 6.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 63 years old,Sex: M,Height: 174.6 cm,Body weight: 70.5 kg,BMI: 23.13,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 8.6,Albumin: 3.5 g/dL,Lymphocyte: 1.79,Neutrophil: 5.7,LDH level: 154.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,MAX,ZFHX3,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 3.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 175.3 cm,Body weight: 71.9 kg,BMI: 23.40,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E20ins,ALK status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 80%,PD-L1 (SP263): 20%,WBC: 3.62,Albumin: 4.5 g/dL,Lymphocyte: 0.49,Neutrophil: 2.66,LDH level: 151.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Carboplatin,SNV mutations: EGFR,FANCA,CNV alterations: CDKN2A(loss),CDKN2B(loss),EGFR(gain),MDM4(gain),RICTOR(gain),SDHA(gain),Fusion genes: None,Splice variants: None,TMB: 3.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157.7 cm,Body weight: 65.6 kg,BMI: 26.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: E19del,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 2.86,Albumin: 4.1 g/dL,Lymphocyte: 0.84,Neutrophil: 1.52,LDH level: 175.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,TP53,CNV alterations: BRAF(gain),CCNE1(gain),CDK6(gain),EGFR(gain),Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "A",
    "answer": "CR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 168.1 cm,Body weight: 63.7 kg,BMI: 22.54,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (22C3): 95%,PD-L1 (SP263): 90%,Albumin: Unknown g/dL,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: None,CNV alterations: None,Fusion genes: RET,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 61 years old,Sex: F,Height: 153 cm,Body weight: 58 kg,BMI: 24.78,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 6.93,Albumin: 4.4 g/dL,Lymphocyte: 2.17,Neutrophil: 3.92,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: AR,NBN,PTCH1,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 74 years old,Sex: F,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 6.93,Albumin: 3.9 g/dL,Lymphocyte: 2.03,Neutrophil: 4.13,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: F,Height: 162 cm,Body weight: 54.4 kg,BMI: 20.73,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,WBC: 8.65,Albumin: 4.5 g/dL,Lymphocyte: 2.24,Neutrophil: 5.79,LDH level: Unknown U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: ALK,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 60 years old,Sex: M,Height: 178.7 cm,Body weight: 71.4 kg,BMI: 22.36,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 6.19,Albumin: 4.8 g/dL,Lymphocyte: 1.41,Neutrophil: 4.05,LDH level: 343.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetrexed/Cisplatin,SNV mutations: NBN,TP53,CNV alterations: FGF19(gain),FGFR1(gain),FGFR3(gain),MYC(loss),MYCN(gain),PIK3CA(gain),RPS6KB1(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 76 years old,Sex: F,Height: 154.5 cm,Body weight: 58.5 kg,BMI: 24.51,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: 10%,PD-L1 group: 1~49%,PD-L1 (22C3): 30%,PD-L1 (SP263): 30%,WBC: 11.36,Albumin: 3.7 g/dL,Lymphocyte: 2.46,Neutrophil: 8.23,LDH level: 190.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Gefitinib,SNV mutations: EGFR,EP300,CNV alterations: CDK4(gain),EGFR(gain),FGFR1(gain),MDM2(gain),Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 172 cm,Body weight: 69 kg,BMI: 23.32,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 10%,PD-L1 (SP263): 0%,WBC: 5.28,Albumin: 4.3 g/dL,Lymphocyte: 1.08,Neutrophil: 3.64,LDH level: 124.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Pemetraxed/Carboplatin,SNV mutations: CREBBP,GRIN2A,KRAS,RB1,STK11,TP53,VHL,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 14.9 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 169 cm,Body weight: 62 kg,BMI: 21.71,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma or large cell carcinoma,Liver metastasis: Yes,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 12.36,Albumin: 2.7 g/dL,Lymphocyte: 1.08,Neutrophil: 10.21,LDH level: 482.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,ARID2,FGFR4,KEAP1,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 64 years old,Sex: M,Height: 172.4 cm,Body weight: 75.1 kg,BMI: 25.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 10%,WBC: 9.6,Albumin: 4.4 g/dL,Lymphocyte: 1.77,Neutrophil: 6.56,LDH level: 182.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Lazertinib,SNV mutations: EGFR,MITF,PTPRS,TP53,U2AF1,CNV alterations: CDK4(gain),GLI1(gain),Fusion genes: None,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 172.5 cm,Body weight: 61 kg,BMI: 20.50,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Positive,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 80%,WBC: 8.03,Albumin: 3.9 g/dL,Lymphocyte: 0.77,Neutrophil: 6.93,LDH level: 319.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Brigatinib,SNV mutations: EP300,CNV alterations: CDKN2A(loss),CDKN2B(loss),Fusion genes: ALK,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "B",
    "answer": "PR"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 79 years old,Sex: M,Height: 163.6 cm,Body weight: 74.3 kg,BMI: 27.76,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (22C3): 0%,PD-L1 (SP263): 0%,WBC: 5.71,Albumin: 4.6 g/dL,Lymphocyte: 1.97,Neutrophil: 3.2,LDH level: 188.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Nivolumab/Ipilimumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,KRAS,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 7.1 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 59 years old,Sex: M,Height: 174.1 cm,Body weight: 69.9 kg,BMI: 23.06,Smoking history: Current smoker,Cancer stage: SqCC,Histology: squamous cell carcinoma,Liver metastasis: No,Brain metastasis: No,PD-L1 group: 1~49%,PD-L1 (SP263): 1%,WBC: 13.69,Albumin: 4.0 g/dL,Lymphocyte: 2.03,Neutrophil: 10.43,LDH level: 158.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin/Durvalumab,SNV mutations: TP53,CNV alterations: MYC(gain),PIK3CA(gain),TFRC(gain),Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 57 years old,Sex: F,Height: 164.6 cm,Body weight: 65.5 kg,BMI: 24.18,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: L858R,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 15%,PD-L1 (SP263): 20%,WBC: 5.94,Albumin: 4.4 g/dL,Lymphocyte: 2.09,Neutrophil: 3.28,LDH level: 139.0 U/L,Treatment type: Targeted Therapy,Treatment regimen: Afatinib,SNV mutations: EGFR,MUTYH,TP53,CNV alterations: None,Fusion genes: None,Splice variants: None\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 84 years old,Sex: F,Height: 163 cm,Body weight: 51.5 kg,BMI: 19.38,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 20%,WBC: 5.8,Albumin: 3.9 g/dL,Lymphocyte: 1.37,Neutrophil: 3.34,LDH level: 332.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: None,CNV alterations: MDM2(gain),MITF(gain),Fusion genes: RET,Splice variants: None,TMB: 4.7 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 69 years old,Sex: M,Height: 175.7 cm,Body weight: 67.4 kg,BMI: 21.83,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: NSCLC, NOS,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 5%,PD-L1 (SP263): 5%,WBC: 5.43,Albumin: 2.9 g/dL,Lymphocyte: 0.72,Neutrophil: 3.9,LDH level: 186.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: ARID1A,CDKN2A,GRIN2A,MAP3K1,TP53,CNV alterations: CHEK1(gain),Fusion genes: None,Splice variants: None,TMB: 24.4 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 68 years old,Sex: M,Height: 163.7 cm,Body weight: 70.4 kg,BMI: 26.27,Smoking history: Former smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 30%,WBC: 5.55,Albumin: 4.1 g/dL,Lymphocyte: 1.57,Neutrophil: 3.27,LDH level: 186.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Paclitaxel/Carboplatin,SNV mutations: AMER1,KRAS,SMARCA4,STK11,CNV alterations: CD274(gain),CDKN2A(loss),FGF7(gain),JAK2(gain),NRG1(gain),PDCD1LG2(gain),Fusion genes: None,Splice variants: None,TMB: 8.6 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 67 years old,Sex: M,Height: 156.9 cm,Body weight: 60.3 kg,BMI: 24.49,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 0%,PD-L1 (SP263): 0%,WBC: 14.52,Albumin: 4.5 g/dL,Lymphocyte: 2.16,Neutrophil: 11.37,LDH level: 186.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: TP53,CNV alterations: AKT2(gain),ERCC1(gain),FGF10(gain),LAMP1(gain),PDGFRA(gain),Fusion genes: None,Splice variants: None,TMB: 16.3 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "C",
    "answer": "SD"
  },
  {
    "question": "Patient Clinical Profile:\nAge: 65 years old,Sex: M,Height: 159.3 cm,Body weight: 49.5 kg,BMI: 19.51,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: 1~49%,PD-L1 (22C3): 1%,PD-L1 (SP263): 0%,WBC: 10.87,Albumin: 3.6 g/dL,Lymphocyte: 2.35,Neutrophil: 7.25,LDH level: 625.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: CDKN2A,LATS1,SMARCA4,TP53,CNV alterations: H3F3A(gain),Fusion genes: None,Splice variants: None,TMB: 3.2 mutations/Mb\nWhat is the most likely treatment response?",
    "options": {
      "A": "Complete Response",
      "B": "Partial Response",
      "C": "Stable Disease",
      "D": "Progressive Disease"
    },
    "answer_idx": "D",
    "answer": "PD"
  }
]